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ABSTRACT 
As life expectancy increases due to better diagnosis and treatments for chronic diseases, the 
ageing population and the number of people suffering from incontinence will increase. Thus, 
although non-life threatening, there is a need for better treatments for these conditions.  
Correct functioning of the urethra and the anorectum is reliant on the smooth muscle of these 
tissues. The internal anal sphincter of the anorectum provides most of the resting anal 
pressure, while the urethral circular smooth muscle provides the resting urethral pressure. 
Loss of tone in these smooth muscles is associated with faecal incontinence and stress urinary 
incontinence respectively. Presently, there are no effective pharmacological treatments for 
stress urinary incontinence or faecal incontinence. Adverse side effects have hampered the 
development and use of pharmacotherapies for these conditions, mainly due to a poor 
understanding of urethral and anorectal function.  
The aim of this PhD project was to increase our understanding of the pharmacology of the 
urethra and the anorectum. Specifically, the intent was to elucidate the pharmacology of the 
smooth muscle of the urethra and the anorectum; to establish the influence of the urothelial 
lining on urethral contraction; to investigate the mediators and neurotransmitters involved in 
the regulation of these tissues and to characterise the intracellular signalling pathways 
involved in contraction and relaxation. 
Regional differences, age-related differences and signalling pathways in response to G-
protein-coupled receptor activation were investigated directly in the urethra, using an in vitro 
organ bath technique with isolated porcine tissues (Large white-Landrace), whilst the 
neurotransmitters of the internal anal sphincter were investigated using  electrically field 
stimulated porcine tissues.  
Using these techniques, a role for cellular Ca
2+
, protein kinase C and Rho kinase in 
influencing the basal tone and receptor-mediated responses of the urethra was investigated. 
Experiments investigating urethral α1-adrenoceptor-mediated responses showed the proximal 
urethra to be the region with the greatest contractile response, and this was similar in tissues 
from young (6 months) and older (36 months) pigs. The urothelium/lamina propria of the 
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urethra had an inhibitory effect on the underlying smooth muscle that did not involve 
prostaglandins or nitric oxide.  
Ca
2+
-sensitization which is the increase in Ca
2+
-sensitivity of the contractile apparatus, 
prostaglandins and Ca
2+
 influx via L-type Ca
2+
 channels all contributed to the basal tone 
developed by the urethra. Likewise, pharmacological inhibition experiments showed that the 
potency of the α1-adrenoceptor agonists was proportional to their ability to induce Ca
2+
 
sensitisation. A61603, a specific α1A- adrenoceptor agonist, produced a long-lasting 
contractile tone, whilst tone was not maintained following stimulation with noradrenaline.  
Incubation of tissues with A61603 and phenylephrine caused desensitisation of subsequent 
responses to noradrenaline. Rho kinase and protein kinase C activity, as well as cytoplasmic 
Ca
2+
,
 
contributed to the A61603-induced desensitisation, whilst only Rho kinase contributed 
to phenylephrine-induced desensitisation. These results suggest Rho kinase involvement in a 
feedback mechanism to prevent chronic overstimulation of the α1-adrenoceptor in the urethra. 
Prior activation of muscarinic receptors before activation of α1-adrenoceptors had no 
significant effect on α1-adrenoceptor-mediated responses in the presence of the 
urothelium/lamina propria. However, in the absence of the urothelium/lamina propria, prior 
activation of muscarinic receptors significantly reduced the α1-adrenoceptor-mediated 
responses, suggesting the modulation of receptor interactions by the urothelium/lamina 
propria. This interaction was independent of neuronally released factors or prostaglandins.  
Finally, this study showed co-transmission in the internal anal sphincter, with neurogenic 
contraction mediated by noradrenaline and ATP, whilst neurogenic relaxation of the porcine 
internal anal sphincter was mediated by the simultaneous release of the gasotransmitters nitric 
oxide, carbon monoxide and hydrogen sulphide, with relative contributions of nitric oxide > 
carbon monoxide > hydrogen sulphide. Neurotransmission in the pig internal anal sphincter 
does not appear to involve acetylcholine. All of these transmitters represent possible targets 
for drug development, where enhancing sphincter tone may aid the treatment of faecal 
incontinence or reductions in internal anal sphincter tone may aid healing of anal fissures. 
Based on these observations Ca
2+
 sensitization is a significant pathway involved in the 
mediation of urethral contractile responses and basal tone, as well as modulation of α1A-
iii 
 
 
adrenoceptor desensitisation. Thus, the Ca
2+
 sensitization pathway stands out as a prospective 
drug target for the development of new treatments for lower urinary tract symptoms such as 
stress urinary incontinence.  
Further research is necessary to determine the relative contribution of the Ca
2+
 sensitization 
pathways in incontinence, as there is the possibility of a switch towards a reduced Ca
2+
 
sensitization mechanism, which could underlie stress urinary incontinence and faecal 
incontinence, whilst greater Ca
2+
 sensitization may underlie hypertonia of the internal anal 
sphincter resulting in an inhibition of healing of anal fissures. 
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1 GENERAL INTRODUCTION 
Approximately 1.9 billion individuals worldwide experience lower urinary tract symptoms, 
and this prevalence is predicted to increase by 18.4% to 2.3 billion by 2018 (Irwin et al., 
2011). Worldwide,  across Europe, the USA and Asia, the prevalence of urinary incontinence 
ranges from 21%-65.0% (Ge et al., 2015; Hunskaar et al., 2004; Liu et al., 2014; Markland et 
al., 2011; Shin et al., 2009). In Australia in 2005 over 2 million people were urinary 
incontinent, while over 1 million were faecally incontinent (Chiarelli et al., 2005). There is a 
greater prevalence in women than men, although beyond age 60, the percentage of 
incontinent males increases almost to that of incontinent females, due to incontinence 
associated with prostate surgery (Buckley et al., 2010).  
Incontinence severely affects quality of life. It is responsible for social isolation, depression, 
loss of productivity, unemployment, anxiety and also poses an enormous economic burden 
(Bogner et al., 2002; Chong et al., 2011; Melville et al., 2005; Xu et al., 2012; Yip et al., 
2013). The cost of treatment and care of patients with incontinence is significant, with the 
institutionalisation of patients compounding the cost (Wilson  et al., 2001). The annual cost 
of care for patients with urinary incontinence in the USA was estimated to be approximately 
$16.3 billion in the community and nursing homes (Wilson  et al., 2001). Moreover, Australia 
spent $710.44 million in 1998 on healthcare for urinary incontinence; approximately $387 
per person, with total personal expenditure around $371.97 million (Doran et al., 2001).  
1.1 THE LOWER URINARY TRACT 
1.1.1 Structure 
In males, the lower urinary tract is made up of the urinary bladder, urethra and prostate 
(Figure ‎1.1A), while in females the prostate is absent (Figure ‎1.1B).  The bladder is a 
pyramid shape structure, which lies entirely within the pelvis when empty. Upon filling, the 
bladder rises into the abdominal cavity (Shah et al., 2014). 
 There are two parts to the bladder: the body, lying above the ureteral orifices, and the base, 
consisting of the trigone and bladder neck (De Groat & Yoshimura, 2015). 
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The bladder dome is the greater part of the bladder body. The entry of the ureters marks the 
triangular area trigone within the base of the bladder (Shah et al., 2014).  The distance 
between the ureteral orifices is usually around 2.5 cm extending up to 5 cm when the bladder 
is full.  The trigone is histologically and embryologically different from the rest of the 
bladder and contains a rich plexus of neuronal tissue. It is also the least movable part of the 
bladder and is adherent to the underlying muscle (Mangera et al., 2013).  
The bladder wall is composed of the mucosal layer, the muscularis propria and the adventitia 
(Aydin et al., 2002). The bladder mucosa consists of the urothelium, a basement membrane, 
and the lamina propria, which contains the vascular system and sensory nerves (Figure 1.2) 
(Aydin et al., 2002; Wiseman et al., 2002). Bladder wall thickness ranges between 2.0 and 3.4 
mm in humans and is greater in men than women (Hakenberg et al., 2000; Kanyilmaz et al., 
2013). Moreover, the thickness of the bladder wall depends on the degree of distension by the 
contained urine (Kanyilmaz et al., 2013). 
The bladder neck is the anatomical area of the bladder outlet and the entrance to the urethra. 
It is formed by several structures, including the detrusor smooth muscle, the vesical sphincter, 
and adjacent proximal prostatic tissue in males (Li et al., 2015). 
The urethra is a smooth muscle tube, attached proximally to the bladder, and surrounded 
distally by a skeletal muscle ring (the rhabdosphincter), and through which urine is expelled 
out of the body (Figure 1.1). The urethra begins at the internal meatus of the bladder and 
extends to the external meatus, and is composed of an inner longitudinal and middle circular 
smooth muscle layer (Figure 1.2) (Pradidarcheep et al., 2011).  
In the male, four segments of the urethra are readily identified. The first is the pre-prostatic 
portion, or the bladder neck, which consists of a complete circular collar of smooth-muscle 
cells that extends distally to surround the proximal part of the urethra (De Groat & 
Yoshimura, 2015; Li et al., 2015). The prostatic urethra (second segment) extends throughout 
the length of the prostate gland, terminating at its apex. The membranous urethra (third 
segment) extends from the prostatic apex through the pelvic floor musculature forming the 
bulbous and penile urethra (fourth segment) at the base of the penis (Yucel & Baskin, 2004).  
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The male striated muscle extends from the base of the bladder and the anterior aspect of the 
prostate to the full length of the membranous urethra (Figure 1.1A). The prostate is a male 
accessory sex gland found only in mammals that functions to produce a major fraction of 
seminal fluid. The human prostate sits at the base of the bladder and encircles the urethra. In 
some species e.g. mouse the prostate is multi-lobed (Hayashi et al., 1991). However, men 
have a prostate without exterior lobation that contains distinct glandular regions, including a 
peripheral zone, a central zone, a transition zone, and a non-glandular anterior fibromuscular 
stroma region. The prostate is composed of multiple glands in each of these “zones” with 
ductal conduits to the urethra. The prostate epithelial cell compartment is comprised of two 
cell layers, consisting of basal and terminally differentiated luminal cells. The luminal cells 
secrete prostatic secretions into the luminal space (Lilja & Abrahamsson, 1988). 
The female urethra differs from that of the male in that the female urethra lacks a prostate, 
and is shorter (approx. 4cm) compared to the male (approx.20cm) (Fry & Young, 2010; 
Kohler et al., 2008). In the female urethra, the smooth muscle sphincter at the bladder neck is 
not evident, and the majority of muscle bundles in this region extend slanting or 
longitudinally into the urethra (Yucel & Baskin, 2004). The female has a weakly striated 
sphincter mechanism divided into a proximal and distal striated sphincter.  The proximal 
sphincter consists of the circular muscle that forms the outermost layer of the muscle wall, 
while the distal comprises of two arch-shaped straps of muscle, the compressor urethrae, and 
urethrovaginal sphincter. The compressor urethrae arise laterally near the ischiopubic rami 
while the urethrovaginal sphincter closely follows the vaginal wall (Yucel & Baskin, 2004). 
1.1.1.1 Smooth muscle of the lower urinary tract 
The smooth muscle of the lower urinary tract is responsible for contraction of the urinary 
bladder and urethra and is primarily under the control of the autonomic nervous system. It is 
associated with maintenance of resting tone, organ dimensions due to tonic contraction, as 
well as relaxation of the lower urinary tract (Andersson, 2001).   
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In many species, detrusor smooth muscle cells are oriented longitudinally in the outer and 
inner layers and circularly in the middle layer (Andersson & Arner, 2004). The human 
detrusor is a meshwork of muscle cells of varying size surrounded by connective tissue rich 
in collagen (Lepor et al., 1992).  The detrusor muscle meshwork is of various sizes, often a 
few millimetres in diameter, and composed of several smaller sub-bundles (Brading, 1987). 
The orientation and interaction between the smooth muscle cells in the bladder determines 
how the bladder wall behaves and its shape and intravesical pressure (Andersson & Arner, 
2004). The detrusor smooth muscle of the bladder extends to form the longitudinal and the 
circular smooth muscle of the urethra, as shown in Figure 1.2 (Li et al., 2015).  The 
longitudinal smooth muscle of the urethra is continuous with the inner longitudinal layer of 
the bladder detrusor while the thicker urethral circular smooth muscle is continuous with the 
external detrusor muscle of the bladder (Patel & Chapple, 2008).  
Sphincters of the lower urinary tract  
Traditionally, the urethra has been reported to have two sphincters, the internal urethral 
sphincter and the external urethral sphincter, also known as the rhabdosphincter. The ‘internal 
urethral sphincter’ is however controversial. Some report that the smooth muscles lining the 
bladder neck and the urethra form the internal sphincter (Yucel & Baskin, 2004), whilst 
others report that neither the internal urethral sphincter nor external urethral sphincter is 
visible (Lim et al., 2013). Whilst still debatable, the internal urethral sphincter is thought to 
be located at the inferior end of the bladder, at the level of the bladder neck. The internal 
urethral sphincter surrounds the proximal urethra and is seen as a continuation of the detrusor 
smooth muscle. In the mid-urethra, layers of striated muscle, arranged in a circular 
configuration, thought to be derived from levator ani, surround the smooth muscle layer of 
the internal urethral sphincter (Yucel & Baskin, 2004).  
Striated muscle, which is present in the distal wall of the male and female urethra, forms the 
external urethral sphincter. The external urethral sphincter covers the inferior side of the 
prostate and is located at the level of the membranous urethra in males (Karam et al., 2005a). 
However, the external urethral sphincter is located at the distal inferior end of the bladder in 
females (Hudson et al., 2002). Unlike the internal urethral sphincter, the external urethral 
sphincter is composed of skeletal muscle; therefore, it is voluntarily controlled. The urethral 
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striated muscles are anatomically and functionally quite distinct from the striated skeletal 
muscle of the pelvic floor. They are attached to the pelvic floor muscles and each other by 
connective tissue but do not attach directly to pelvic floor bone. 
The striated muscles of the urethra are both slow-twitch and fast-twitch. These slow twitch 
fibres are slower to fatigue and are responsible for maintenance of tone and the resting 
urethral pressure profile (Stafford et al., 2012).  The fast twitch fibres come into play during 
transient events which increase the abdominal pressure abruptly e.g. a cough. Any activities 
that cause abdominal compressions, such as coughing or exercise, produce dramatic increases 
in the number of units firing in fast twitch fibres (Stafford et al., 2012). In the male, the 
rhabdosphincter consists of 35% fast-twitch and 65% slow twitch fibres (Ho et al., 1998).  
However, the female rhabdosphincter consists of 13% fast-twitch fibres and 87% slow twitch 
fibres (Padykula & Gauthier, 1970).   
1.1.1.2 Urothelium of the lower urinary tract 
A transitional epithelium (urothelium) lines the entire lower urinary tract (Achtstatter et al., 
1985), including the renal pelvis, ureters, bladder, upper urethra and glandular ducts of the 
prostate (Khandelwal et al., 2009). It forms the interface between the urinary space and the 
underlying vasculature, connective, nervous, and muscular tissues (Khandelwal et al., 2009).  
The urothelium differs from one part of the lower urinary tract to another. A distinct 
difference in morphology of ureteral and bladder urothelial cells exist. However, there seems 
to be no apparent difference between the urothelium of the trigone compared with the 
detrusor (Jost et al., 1989; Liang et al., 2005). Therefore, the urothelium has been classified 
into three lineages; (I) ureter/renal pelvis (II) bladder neck/proximal urethra and (III) 
bladder/trigone urothelium (Liang et al., 2005).  
The outer layer of the bladder urothelium is made up of hexagonal umbrella cells lined with 
glycosaminoglycan/mucin, uroplakins, and cytokeratins (Buckley et al., 1996; 2000). The 
intermediate layer is made up of pear-shaped cells, while the cells of the basal layer are 
mononucleated (Figure  1.3). The umbrella cells of the bladder aid in increasing surface area. 
This process occurs during filling, in a process achieved by exocytosis and endocytosis (Kreft 
et al., 2009; Truschel et al., 2002).  Likewise, the tight junctions between these cells form a 
 9 
 
 
barrier which prevents ions and solutes from moving through the urothelium. Moreover, 
uroplakin protein in the bladder umbrella cells of the apical layer reduces infiltration of small 
molecules such as water, urea, and protons through the urothelium, while the mucin layer of 
the umbrella cells protects the lower urinary tract from microbial adherence and infection 
(Mulvey et al., 1998). 
The urothelium of the proximal urethra transitions to a stratified or columnar epithelium 
accompanied by a lack of urothelial-specific differentiation markers. The epithelial lining of 
the anterior urethra of males consists of stratified columnar epithelium except at the fossa 
navicularis where it becomes stratified squamous epithelium. The epithelial lining of the 
female urethra is transitional in the proximal one-third and non-keratinized stratified 
squamous in the distal two-thirds. The uroplakins are absent from the urethral urothelium 
(Romih et al., 2005), although there are microvilli on the apical surface of the urethral 
urothelium. The microvilli may play a role in increasing the surface area of the cell, 
participation in both sensory and transducer functions, and in fluid transport.  
The lamina propria also referred to as the sub-urothelium lies between the basement 
membrane of the urothelium and the detrusor muscularis (Figure  1.3). It is composed of an 
extracellular matrix containing several types of cells, including fibroblasts, adipocytes, 
interstitial cells (IC), and afferent and efferent nerve endings (Gevaert et al., 2011; Gosling & 
Dixon, 1974; Wiseman et al., 2003). The lamina propria also contains a rich vascular network, 
lymphatic vessels, elastic fibres, and smooth muscle fascicles (muscularis mucosae) (Dixon 
& Gosling, 1983; Paner et al., 2007; 2009). 
The role of the urothelium as a transducer of signals is also apparent in its expression of 
sensory receptors including purinergic, adrenergic, nicotinic, muscarinic and oestrogen 
receptors (Figure ‎1.4) (Beckel et al., 2006; Bschleipfer et ., 2007; Moro et al., 2013; Shabir et 
al., 2013; Teng et al., 2008). These receptors enable the urothelium to respond to sensory 
inputs (physical and chemical) from a variety of sources. The urothelium can respond to a 
wide range of mechanical stresses during bladder filling and emptying including bladder 
pressure, tension in the urothelium or bladder wall, torsion, geometrical tension, movement of 
visceral organs and even urine tonicity. Afferent and autonomic efferent nerves are located 
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near the urothelium, and can be activated by a variety of transmitters and mediators released 
in part by the urothelium (Birder et al., 2002a; Gabella & Davis, 1998; Grol et al., 2008).  
 
 
Figure  1.3 The diagrammatic representation of the urothelium layers and components, smooth muscle 
and serosa. ICC= interstitial cells of Cajal. Green structure= neurone. Modified from Merrill et al., 2016. 
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1.1.1.3 Interstitial cells 
In recent years, cells resembling the interstitial cells of Cajal (ICC) of the gastrointestinal 
tract have been discovered in the lower urinary tract (Smet et al., 1996). In the 
gastrointestinal tract, these cells act as pacemakers and drive peristaltic activity (Nakagama et 
al., 2005). Interstitial cells of Cajal can be identified with antibodies raised against the Kit 
receptor (cluster of differentiation [CD117] of the receptor tyrosine kinase) (Gevaert et al., 
2012). Moreover, ICC has been identified with antibodies to vimentin, and more recently, 
platelet-derived growth factor receptor-α (Koh et al., 2012; Monaghan et al., 2012).  Kit 
(CD117) is a member of the family of CD cell surface molecules, which perform some 
important roles in the development of the immune system and physiology of various cells, 
including gastrointestinal ICCs. Kit (CD117) is also a proto-oncogene, and its mutation or 
overexpression can lead to the development of cancers in some organs including the ovaries, 
testes, skin, gastrointestinal tract, blood and the kidney (Ahmed & Youssif, 2009; Heinrich et 
al., 2003).  
Kit-positive interstitial cells were found within the smooth muscle layers of the rabbit urethra, 
in association with nerves, on the edge of smooth muscle bundles and in the inner bundle 
spaces. The contact with neuronal nitric oxide synthase (NOS)-containing neurones implies 
participation in the nitrergic inhibitory neurotransmission of the urethra (Lyons et al., 2007). 
Much evidence suggests that the urothelium together with suburothelial ICC (myofibroblasts) 
may serve as a mechanosensor in the bladder (Sui et al., 2008).  
Interstitial cells of Cajal-like cells (ICC-LCs) may play a major role in the nerve-mediated 
modulation of detrusor smooth muscle excitability (Davidson & McCloskey, 2005; Smet et 
al., 1996). Interstitial cells of Cajal-like cells may also be involved in neuromuscular 
transmission, and thus changes in ICC-LC numbers may account for increased excitability of 
detrusor smooth muscle in overactive bladders. Generation of spontaneous transient 
depolarizations occurs in urethral ICC-LCs, while isolated single smooth muscle cells are 
electrically quiescent, indicating that ICC-LCs in the urethra may have a genuine pacemaker 
role (Sergeant et al., 2000). Urethra ICC-LCs may randomly increase excitability of urethral 
smooth muscle cells to maintain the tone of urethral smooth muscles (Hashitani & Suzuki, 
2007). The precise role of these cells however remains unclear. 
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1.1.2 Innervation and function of the lower urinary tract 
The lower urinary tract receives an efferent innervation from the thoracic and lumbosacral 
segments of the spinal cord. Efferent axons are carried in three sets of peripheral nerves: 
sacral parasympathetic (pelvic nerves), thoracolumbar sympathetic (hypogastric nerves), and 
sacral somatic nerves (pudendal nerves) (Kluck, 1980; Thor et al., 1989). Preganglionic 
axons carrying information from the spinal cord to the bladder and urethra synapse with 
autonomic ganglion cells. Acetylcholine acting on nicotinic acetylcholine receptors mediates 
synaptic transmission in all ganglia (Park et al., 2006). Sympathetic preganglionic pathways 
that arise from the T11–L2 spinal segments pass to the sympathetic chain ganglia and then to 
prevertebral ganglia in the superior hypogastric and pelvic plexus and also to short adrenergic 
neurones in the bladder and urethra. Sympathetic postganglionic nerves that release 
noradrenaline provide an excitatory input to smooth muscle of the urethra and bladder base, 
and inhibitory input to smooth muscle in the body of the bladder (Figure ‎1.5).  
Sacral parasympathetic efferent nerves from the S2-S4 level of the sacral spinal cord 
(Figure ‎1.5) provide an excitatory cholinergic input to the bladder smooth muscle and a nitric 
oxide (NO)-mediated inhibitory input to the urethral smooth muscle. Also, somatic 
cholinergic nerves, which originate from the Onuf nucleus in the sacral spinal cord (S2-S4 
level) (Figure ‎1.5) excite the skeletal smooth muscle at the distal urethra (Thor et al., 1989).  
1.1.2.1 Sympathetic innervation 
The catecholamine noradrenaline is synthesised from tyrosine, stored in synaptic vesicles and 
released by sympathetic adrenergic nerves, activating the adrenoceptors. The synaptic 
reuptake and degradation of noradrenaline terminate its action. Noradrenaline mediates 
contraction of the bladder neck/ proximal urethra via adrenoceptors (Kedia et al., 2013).   
Adrenoceptors in the lower urinary tract 
Adrenoceptors (ARs) belong to the large family of G-protein-coupled receptors (GPCRs), 
also known as seven-transmembrane receptors (7-TMRs), which transduce extracellular 
stimuli into cellular responses. Adrenoceptors were initially subdivided into two main types, 
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α- and β-, based on the rank orders of the potency of noradrenaline, adrenaline and 
isoprenaline, as well as the physiological outcome of the response (contraction vs. relaxation) 
(Ahlquist, 1948). 
 
Figure  1.5  Innervation of the female lower urinary tract. The hypogastric sympathetic nerves (blue), 
pelvic parasympathetic nerves (green) and somatic pudendal nerves (orange) innervate the female lower 
urinary tract.  The sympathetic innervation originates from T11-L2 of the thoracolumbar region of the spinal 
cord while the pelvic parasympathetic nerves originate from the S2-S4 of the sacral spinal cord. Moreover, 
the somatic pudendal nerves also originate from the S2-S4 region of the sacral spinal cord. Adapted from 
(Fowler et al., 2008).  
With the discovery of new synthetic and more selective ligands, new receptor subtypes were 
identified within each of the two groups. Beta-ARs include the β1, β2, and β3- subtypes 
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(Emorine et al., 1989; Lands et al., 1967 ), and the introduction of molecular cloning 
confirmed the existence of these genetically and pharmacologically distinct subtypes of β-AR. 
The technique also allowed a final classification of the α1- subgroup into α1A-, α1B- and α1D-
ARs (Ford et al., 1994) and α2- into α2A-, α2B- and α2C-ARs (Bylund, 1992; Bylund et al., 
1992). The three subtypes of the α1-AR have been identified corresponding to the ADRA1A 
(α1a), ADRA1B (α1b), and ADRA1D (α1d) genes. Pharmacological profiles of these α1-AR 
subtypes, all typified by a high affinity (subnanomolar KD) for prazosin (a prototypic, 
selective α1-AR antagonist) have been verified for the recombinantly expressed receptors, 
which reflect the same phenotype observed for these subtypes in intact tissues (Cotecchia et 
al., 1988; Lomasney et al., 1991; Perez et al., 1991; Schwinn et al., 1990; 1995).  
The major AR isoforms present in the human bladder are α1-ARs and β3-ARs (Figure  1.6). 
However, the expression of α-ARs, as determined at the mRNA and protein levels, is very 
low compared with β-ARs (Nomiya & Yamaguchi, 2003).  The direct effects of α1-AR 
stimulation on detrusor contraction are rather weak, amounting for approximately 10%–40% 
of the contractile force that results from muscarinic acetylcholine receptor (mAChR) 
stimulation. Alpha1-AR-mediated function is prominent near the bladder outlet and maintains 
outlet resistance (Michel & Barendrecht, 2008). Therefore, α1-ARs appear to play only a 
minor functional role in the detrusor. 
The α1-Adrenoceptors: The presence of α1-ARs in the urethra has been assessed at the 
mRNA level, protein level (Yono et al., 2004) and pharmacologically characterised in pigs 
(Bagot & Chess-Williams, 2006), rat (Fukata & Yamazaki, 2016) and human (Yoshiki et al., 
2013). Contractions mediated through α1-ARs have been reported in the urethral tissue of 
animals and man (Al-Noah et al., 2014; Kedia et al., 2013; Yoshiki et al., 2013). The entire 
length of isolated female human urethral strips contracts to noradrenaline, but not clonidine 
(α2-adrenoceptor agonist) with a peak in the mid- to proximal urethra, confirming that α1-ARs 
mediate urethral contraction (Taki et al., 1999). Furthermore, studies in animals and human 
urethral tissues have detected a rank order of abundance of α1A-ARs > α1B-ARs ≥ α1D-ARs 
(Yono et al., 2004).  
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Figure  1.6  Adrenoceptor and muscarinic receptor expression in the lower urinary tract. The human 
bladder expresses α1 and β-adrenoceptors as well as muscarinic receptors (M). Noradrenaline stimulates 
contraction of urethral and bladder neck smooth muscle via activation of the α1A-adrenoceptors and causes 
relaxation of detrusor via activation of the β2-adrenoceptors and β3-adrenoceptors. The detrusor expresses 
both M3 and M2. However, the M3 receptors mediate the detrusor contraction to acetylcholine (Yamanishi 
et al., 2000). α1L-ARs are a functional phenotype of the α1A-ARs. ACh= acetylcholine & NA= 
noradrenaline. Modified from (Nishimune et al., 2012). 
The α1-ARs are coupled to pertussis toxin insensitive G proteins (Gq/11), and their effector is 
tissue and species specific (Wu et al., 1992). Activation of Gq activates phospholipase C 
which releases inositol 1, 4, 5-tris-phosphate and diacylglycerol from phosphatidyl inositol-4, 
5-bisphosphate hydrolysis. Moreover, activation of the α1-ARs has been associated with 
activation of other effector proteins such as phospholipase A2, phospholipase D and Ca
2+
 
channels (Ruan et al.,1998; Xing & Insel et al., 1996). 
The α1A-ARs of isolated tissues from prostate gland (Hiraoka et al., 1995), urethra (Bagot & 
Chess-Williams, 2006; Yoshiki et al., 2013), bladder (Yoshiki et al., 2013) and iris 
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(Muramatsu et al., 2009) exhibit a low affinity for prazosin. This receptor is referred to as the 
α1L-AR, reflecting its unique low affinity for prazosin (Muramatsu et al., 2009). The α1L-ARs 
relatively low affinity in functional and binding assays for prazosin (pKi < 9), might represent 
different receptor states between α1A-AR and α1L-AR (Alexander et al., 2011). This receptor 
also shows low affinity for 5-methylurapidil and RS-17053 (α1A-antagonists), and BMY 7378 
(α1D -antagonist). It has high-affinity for silodosin (α1A-AR antagonist) and tamsulosin (an 
α1A-AR antagonist) (Ford et al., 1996; Muramatsu et al., 1998; Murata et al., 1999; 
Morishima et al., 2007; Testa et al., 1997).  
The two distinct α1-AR phenotypes (α1A-ARs and α1L-ARs) are known to originate from a 
single ADRA1A (α1a) gene by an unknown mechanism. It was demonstrated with the use of a 
genetically modified AR knockout mouse that α1L-ARs are indeed a functional phenotype of 
the α1A-AR (Gray et al., 2008; Muramatsu et al., 2008). Gray et al., (2008) showed that α1L-
AR-mediated responses in mouse prostate are abolished in α1A-AR knockout mouse, 
demonstrating that the α1A-AR gene is essential to the manifestation of the prostatic α1L-AR 
phenotype.  
Early attempts to explain how the α1L-AR phenotype could arise from the α1A-AR gene 
concentrated on genetic polymorphisms and gene splicing. However, α1A-ARs generated by 
known polymorphisms and splice variants in cell culture models all showed similar 
pharmacological characteristics to that of the α1A-AR (Ramsay et al., 2004; Shibata et al., 
1996; Suzuki et al., 2000). 
In functional studies in intact tissues only α1L-ARs were detected. However, after 
homogenization to produce membrane homogenate for radioligand binding studies, the 
pharmacological profile of the α1L-ARs was lost (Morishima et al., 2007; 2008; Muramatsu et 
al., 2008; Su et al., 2008a; Suzuki et al., 2000) and an ‘interacting protein’ theory to explain 
the generation of α1L-ARs from α1A-ARs was postulated. Nishimune et al., (2010a) suggested 
that this discrepancy was caused by the homogenization process disrupting the cell membrane 
and thus separating α1A-ARs from the putative ‘interacting protein’.  
In support of the ‘interacting protein’ theory, Nishimune et al., (2010b) identified cysteine-
rich epidermal growth factor-like domain 1α (CRELD1α) as a novel down-regulating protein 
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and therefore a protein that interacts with the α1A-ARs. Nishimune et al., (2010b) 
hypothesised that the CRELD1α protein interaction with α1A-AR could generate the α1L-AR 
phenotype. Transfection of α1A-AR cDNA alone yielded Chinese hamster ovary (CHO) cells 
expressing α1A-ARs having a predominant high-affinity site for prazosin, with a low 
proportion (<10%) of prazosin-low affinity sites (α1L-ARs). However, over-expression of 
CRELD1α reduced α1A-ARs expression, yielding α1L-ARs -dominant cells expressing a high 
proportion (50%) of the α1L-ARs phenotype.  
The α2-Adrenoceptors: Radioligand binding experiments have detected α2-ARs in the 
detrusor of rabbits (Latifpour et al., 1990) and human (Goepel et al., 1997). The function of 
α2-ARs in the bladder depends on the α2-ARs stimulated (the central or peripheral α2-ARs) 
(Michel & Vrydag, 2006). Moreover, in vivo, the effect of α2-AR agonists depends on the use 
of anaesthetized or conscious animals. Clonidine, oxymetazoline and tizanidine (α2-AR 
agonists) caused bladder hyperactivity in the conscious male rat, which was prevented by the 
selective α2-AR antagonist, idazoxan (Kontani et al., 2000). Likewise, Jeong & Lee, (2000) 
reported in a cystometry experiment in anaesthetised rats that clonidine markedly increased 
bladder basal pressure and frequency, whereas micturition volume and bladder capacity was 
not affected. However, intravenous dexmedetomidine (α2-AR agonist) significantly decreased 
the maximum bladder pressure and urinary flow rate, and the amplitude of rhabdosphincter 
electromyography in the anaesthetized rat (Streng et al., 2010). Dexmedetomidine also 
abolished the intraluminal pressure high-frequency oscillations, usually observed during rat 
voiding. 
Urethral α2-ARs have also been identified in radioligand-binding studies in rabbits (Latifpour 
et al., 1990). Larsson et al., (1986) found that the density of α2-ARs increased from the 
proximal to the distal urethra, which appeared to belong largely, if not exclusively, to the α2A-
subtype (Latifpour et al., 1990). The α2-AR can elicit urethral contraction in rabbits 
(Andersson et al., 1984) and horses (Garcia-Sacristan et al., 1984). Moreover, clonidine 
increased intra-urethral pressure via α2-ARs in the dog (Shapiro et al., 1987).  
The β-adrenoceptors: Expression of all three β-AR subtypes has been found both at the 
mRNA and at the protein level in the human bladder (Nomiya & Yamaguchi, 2003). Cellular, 
in vitro and subsequent in vivo studies, have shown the predominant β-AR in human bladder 
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tissue to be β3-AR (Igawa et al., 2001).  The β3-AR isoform in the human bladder accounts 
for >95% of β-ARs. However, both β3 and β2-ARs contribute to relaxation responses of the 
rat bladder (Oshita et al., 1997). Pig detrusor smooth muscle also has a similar population of 
β-AR subtypes, with β3-ARs predominating and a minor population of β2 -ARs (Yamanishi et 
al., 2002b).  
The β3-ARs largely mediate isoprenaline-induced bladder relaxation in humans, whilst in rats 
both β2 and β3-ARs are involved (Igawa et al., 1999; Michel et al., 2011; Takeda et al., 1999). 
Isoprenaline induced relaxation via β2-ARs and β3-ARs in the pig urethra, in spite of β3-ARs 
predominating (Yamanishi et al., 2002c: 2003b). Takeda et al., (2003) also showed that the 
relaxations in canine and rat urethra were predominantly mediated by β2-ARs and β3-ARs, 
with a greater role for β2-ARs.  
The canonical β-AR signalling pathway involves Gs-protein-mediated adenylyl cyclase 
activation, cyclic AMP elevation and subsequent protein kinase A activation (Frazier et al., 
2008).  Moreover, there is evidence of cyclic AMP-dependent, as well as independent effects 
of β-AR stimulation (Frazier et al., 2008).  Compelling evidence suggested that β-AR can 
also stimulate large-conductance Ca
2+
-activated K
+
 channels, for example in the guinea pig 
(Petkov and Nelson, 2005), rat (Hristov et al., 2008; Uchida et al., 2005), mouse (Brown et al., 
2008) and human bladder (Afeli et al., 2013). Combined administration of inhibitors of the 
cyclic AMP/protein kinase A and the large-conductance Ca
2+
-activated K
+
 channels pathway 
inhibited β-AR-mediated bladder relaxation by less than half (Frazier et al., 2005), suggesting 
that other pathways might also be involved in β-AR-mediated response. Recently, Cernecka 
et al., (2015) showed in the rat and human bladder that the extent of large-conductance Ca
2+
-
activated K
+
 channels and Rho kinase involvement in relaxation induced by β-AR depends on 
pre-contractile stimulus and species. 
1.1.2.2 Parasympathetic innervation 
The main contractile transmitter in the human bladder is acetylcholine (Creed et al., 1994). It 
is released from postganglionic efferent cholinergic (parasympathetic) nerves, acts on 
mAChRs, and produces the contraction that empties the bladder (Zagorodnyuk et al., 2009; 
Wang et al., 1995). Acetylcholinesterase-positive nerves are also present in the urethral tissue 
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of the pig (Crowe & Burnstock, 1989) and human (Kluck, 1980), and acetylcholine induces 
contraction in the proximal urethra (Taki et al., 1999).  However, Kedia et al., (2013) 
reported a minor contractile effect of acetylcholine in the human male urethra. Acetylcholine 
is also associated with contraction of the urethral rhabdosphincter, by activation of the 
nicotinic acetylcholine receptor (Blaivas, 1982; Thor et al., 1989). 
Muscarinic receptors 
The bladder, bladder base and urethra express mAChR subtypes (M1–M5) (Figure ‎1.6) 
(Sigala et al., 2002; Tyagi et al., 2006). In the human detrusor, 70 percent of the total mAChR 
population are the M2 subtype, 20 percent are M3 subtype while 10 percent are M1 subtype 
(Mansfield et al., 2005). In rats, pigs and humans, the ratio between M2 and M3 receptors in 
binding studies was estimated as 9:1, 3:1 and 3:1, respectively (Wang et al., 1995; Mansfield 
et al., 2005; Yamanishi et al., 2002a). Although there was a predominance of M2 receptors in 
the detrusor, the contraction was mediated mainly by the M3 receptors in rat (Hegde et al., 
1997), pig (Sellers et al., 2000; Yamanishi et al., 2002a) and human (Fetscher et al., 2002). In 
the human detrusor, muscarinic agonist-induced contraction largely depends on Ca
2+
 entry 
through nifedipine-sensitive channels and activation of the Rho kinase pathway (Schneider et 
al., 2004b).  
In the human urethra, mAChR activation contracts the proximal urethra and bladder neck 
(Taki et al., 1999). Similar, in the pig mAChRs (M2 and M3) seem to mediate contraction of 
the bladder base and urethra (Yamanishi et al., 2002a), although, M3 receptors are mainly 
responsible for contraction. In rabbits (Nagahama et al., 1998), rat (Kakizaki et al., 1997) and 
hamster (Pinna et al., 1996) muscarinic stimulation caused urethral relaxation. However, the 
cholinergic response in the rabbit urethra is site dependent; mAChR-mediated contraction of 
rabbit proximal urethra and relaxed the distal urethra through the release and actions of NO 
(Nagahama et al., 1998).  
Co-transmission in the lower urinary tract 
Atropine-resistant contractile responses of the urinary bladder following stimulation of 
parasympathetic nerves have been shown to be due to non-cholinergic, non-adrenergic 
transmission in animals and human detrusor (Bicer et al., 2012). In the normal human bladder 
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this component amounts to only a few percent, whereas in for example rodent bladder, the 
atropine-resistant component can exceed 50% (Brading & Williams, 1990; Igawa et al., 
1993). The atropine-resistant component in the bladder is purinergic and ATP is co-released 
with acetylcholine in the bladder (Tsai et al., 2012). Purinergic receptors respond to 
nucleosides and nucleotides including adenosine, ADP, ATP, UTP, and UDP.  The P1 and P2 
receptors are the two classes of purinergic receptors. The P1 receptors respond to adenosine 
while P2 receptors respond to nucleotides.  P2 receptors are classified as ligand-gated ion 
channels (P2X) or GPCR (P2Y) (Fredholm et al., 1994). There are currently seven P2X 
subunits (P2X1–7) that may arrange as heteromeric or homomeric ligand-gated ion channels 
and eight metabotropic P2Y subunits (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and 
P2Y14) that may couple to Gs, Gi, or Gq (Abbracchio et al., 2006). The P2 receptors are 
expressed throughout the urinary bladder detrusor (Vial & Evans, 2000). The primary 
purinergic receptor present on the detrusor is P2X, as confirmed by organ bath experiments, 
immunostaining (Lee et al., 2000) and P2X1 knockout mouse (Vial & Evans, 2000). P2X1–6 
receptors have been demonstrated in rodent urinary bladder smooth muscle cells (Dutton et 
al., 1999). Moreover, work by Yu et al., (2013) confirmed the functional evidence for a P2Y 
(P2Y6) in the mouse detrusor. In some species ATP produces a dual effect (contraction and 
relaxation) on detrusor smooth muscle via activation of P2X and P2Y receptors respectively 
(Bolego et al., 1995; McMurray et al., 1998). 
ATP released from inhibitory nerves induces relaxation of the urethra of the hamster (Pinna 
et al., 1998) and pig (Werkstrom & Andersson, 2005). ATP causes only relaxation of the 
urethra via P2Y receptors, in several species including pig (Hernandez et al., 2009) and 
hamster (Pinna et al., 1998). 
Afferent and efferent nerves also express NOS (Vizzard et al., 1994; 1995a; 1996). Nitric 
oxide synthase-containing nerve fibres normally occur in the bladder, and NO thus seems to 
have a physiological impact on efferent and afferent neurotransmission in the normal bladder 
(Ehren et al., 1994). The absence of NO causes bladder overactivity, possibly via modulation 
of the threshold for afferent nerve firing (Ozawa et al., 1999; Pandita et al., 2000). The 
expression of NOS-containing nerves is greatest in the outlet region of the bladder (Persson et 
al., 1993; Dixon & Jen, 1995). The urethra also contains a dense network of NO expressing 
nerves, and the presence of NOS has been confirmed by constitutive NOS 
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immunohistochemistry, NADPH diaphorase immunohistochemistry and inhibition of NOS in 
a functional organ bath experiment (Garcia-Pascual et al., 1996). The urethra, bladder 
neck/trigone smooth muscle was positive for NADPH-diaphorase/NOS in the rat 
(Radziszewski et al., 1996),  sheep (Garcia-Pascual et al., 1996), pig (Persson et al., 1993) 
and human (Leone et al., 1994).  Likewise, neuronal nitric oxide synthase (nNOS) has been 
reported in the rhabdosphincter of the human (Ho et al., 2003) and sheep (GonzÁLez-Soriano 
et al., 2003). Thus NO modulates the lower urinary tract responses. 
In the clinical setting, the NO pathway has been targeted via the use of phosphodiesterase 
inhibitors, such as sildenafil, which result in elevated levels of intracellular cyclic GMP and 
enhanced relaxation of the bladder neck and urethra (Uckert et al., 2008). In one study, a 
group of healthy male volunteers, given a NO donor sublingually and studied urodynamically, 
exhibited lowered bladder outlet resistance characterised by reduced detrusor pressure during 
voiding and a lower maximal flow rate (Muntener et al., 2006). Thus NO relaxes the bladder 
neck and urethra. 
1.1.2.3 Sensory innervation of the lower urinary tract 
Afferent axons in the pelvic, hypogastric, pudendal, and levator ani nerves transmit 
information from the lower urinary tract and pelvic floor to second-order neurones in the 
lumbosacral spinal cord (De Groat, 1986; Janig & Morrison, 1986). The small myelinated 
(Aδ) and unmyelinated C-fibres are the two populations of pelvic nerve afferents that 
innervate the bladder and urethra. Aδ fibres, located primarily in the detrusor smooth muscle 
layer, respond to detrusor stretching during bladder filling and convey fullness sensations 
(Zagorodnyuk et al., 2006; 2007). Aδ mechanoreceptor afferents identified in the pelvic nerve 
have conduction velocities ranging between 2.5 and 15 m/s (Habler et al., 1993). They are 
silent when the bladder is empty but during slow filling of the bladder display a graded 
increase in discharge frequency at intravesical pressures below 25 mmHg (Bruns et al., 2011). 
Electrophysiologic studies in cats revealed that the normal micturition reflex is triggered by 
myelinated Aδ -fibre afferents (Habler et al., 1990). 
Unmyelinated sensory C-fibres are more widespread and reside in the detrusor muscle, close 
to the urothelium in the lamina propria and directly adjacent to urothelial cells (Wakabayashi 
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et al., 1993). C-fibres carry information on bladder volume changes (Morrison, 1999). 
Volume receptor afferents are mainly C fibres that discharge during normal bladder 
distention but with higher thresholds than Aδ in-series tension receptors (Habler et al., 1990). 
Various neurotransmitters and chemical mediators released by the detrusor and the 
urothelium activate the C-fibres.  Bladder C-afferents in cats are mechano-insensitive (“silent 
C-fibres”) (Habler et al., 1990). Many of these afferents are nociceptive and respond to cold 
stimuli or chemical/ noxious stimuli such as high potassium, low pH, high osmolality, and 
irritants such as capsaicin and turpentine oil (Habler et al., 1990). The C-fibre afferents 
express various receptors including transient receptor potential vanilloid-1 and the capsaicin 
receptor (Avelino et al., 2002). These fibres also express the transient receptor potential 
ankyrin 1 receptor (Streng et al., 2008), mAChR, endothelin receptor, and purinergic 
receptors (P2X2, P2X3, P2Y) that can be activated by ATP (Cockayne et al., 2005; Munoz et 
al., 2012). 
Immunohistochemical studies have revealed that the bladder afferent neurones contain 
various neuropeptides, such as substance P, calcitonin gene-related peptide, pituitary 
adenylate cyclase-activating polypeptide and vasoactive intestinal peptide. The neurones also 
contain the putative excitatory amino acid transmitters, glutamic and aspartic acid (Keast & 
Stephensen, 2000; Vizzard, 2000 ). Peptide-containing axons are distributed throughout all 
layers of the bladder but are especially dense in the lamina propria just beneath the 
urothelium. Primary sensory fibres are extremely abundant in the rat (Avelino et al., 2002), 
mouse (Yu et al., 2011) and human (Yiangou et al., 2001) urinary tract. Findings have 
differentiated two afferent pathways, one involving the bladder urothelium, basement 
membrane and lamina propria, and the second involving the detrusor muscle (myogenic 
pathway) (Wakabayashi et al., 1993; Yoshimura et al., 2003).   
Urethral afferent-mediated neural pathways also exist (Gustafson et al., 2003). The plexus of 
afferent nerves is most dense in the bladder neck and proximal urethra (Gabella & Davis, 
1998).  Urethral afferents can evoke reflexes that augment (Gustafson et al., 2003; Jung et al., 
1999) or inhibit (Chang et al., 2006; Thor & Muhlhauser, 1999) reflex bladder contractions. 
Urethral flows consistently evoked detrusor contractions in awake ewes (Robain et al., 2001).  
Robain, et al., (2001) also showed that the reflex was selectively suppressed by local 
anaesthesia of the urethral urothelium, indicating that the effect originated from within the 
 24 
 
 
urethra. Urethral anesthetisation to block activity in urethral afferents, led to incomplete 
emptying and the need to strain in healthy volunteers (Shafik et al., 2003). Electrical 
stimulation of urethral afferents also evokes reflex bladder contractions in the cat and rat, and 
improves bladder emptying (Chen et al., 2012; McGee & Grill, 2014).  Electrical stimulation 
of the pudendal nerve afferents in the cat allows both inhibition and activation of the bladder, 
depending on the urethral location of stimulation and the frequency (Woock et al., 2009). 
Thus, the afferent innervation of the urethra appears tightly associated with bladder control. 
Whilst Aδ fibres are present in the proximal urethra, C-fibres increase in density towards the 
outflow region of the urethra, have a high mechanical threshold and respond to chemical 
irritation of the mucosa, as well as to changes in temperature (Gabella & Davis, 1998). The 
positive staining for calcitonin gene-related peptide or substance P in the lamina propria and 
the muscular layers in all portions of the urethra signify the presence of C-fibres (Hokfelt et 
al., 1978; Warburton & Santer, 1994).  
Afferent signalling can be modulated by stimulation of mAChRs (Daly et al., 2010) and β-
ARs (Aizawa et al., 2010). Bladder afferent nerves were found to express (by RT-PCR) the 
mAChR subtypes M2, M3, and M4 but not M1 and M5 (Nandigama et al., 2010). In a rat model, 
intravesical oxybutynin (mAChR antagonist) depressed the afferent activity recorded in the 
pelvic nerve (De Wachter & Wyndaele, 2003), whilst systemic administration decreased 
afferent activity in C-fibres after 90 minutes. In the A𝛿 fibres, a decrease in afferent spike 
rate was significant after 30 minutes administration of oxybutynin (De Laet et al., 2006). 
Similar effects were obtained with darifenacin (Iijima et al., 2007). The inhibitory pre-
junctional mAChRs have been classified as M4 in the human bladder (D'Agostino et al., 
2000). 
Likewise, systemic administration of β3-AR agonist inhibits the mechanosensitive Aδ 
afferent fibre activity and prostaglandin E2-induced C-fibre hyperactivity (Aizawa et al., 
2010). Moreover, in vivo, cystometric parameters such as voiding frequency and amplitude 
of voiding contractions, are improved not only by the systemic administration but also by 
intravesical instillation of β3-AR agonists (Kullmann et al., 2011).  Data by Kullmann et al., 
(2011) indicated that β3-AR activation may alter reflex voiding via the release of factors from 
 25 
 
 
the urothelium that act on afferent nerves to influence bladder contractility. To our 
knowledge, modulation of afferent fibre activity in the urethra is not known. 
1.1.2.4 Smooth muscle contraction in the lower urinary tract 
Phosphorylation and dephosphorylation of the 20-kDa regulatory myosin light chain 
regulates contraction and relaxation of smooth muscle (Chacko et al., 1977; Deng et al., 
2011). Both Ca
2+
 and Rho kinase signalling pathways modulate myosin light chain 
phosphorylation (Mizuno et al., 2008; Poley et al., 2008), and these pathways constitute the 
classical Ca
2+ 
pathway and the Ca
2+ 
sensitization pathways respectively.  
Calcium-dependent smooth muscle contractions and relaxations 
Increased intracellular Ca
2+ 
([Ca
2+
]i) is a key event in the activation of smooth muscle 
contraction in response to extracellular signals (Ozaki et al., 1991; Taguchi et al., 1998).  
Agonists elevate cytoplasmic Ca
2+
 concentration by inducing Ca
2+
 influx from the 
extracellular area via L-type Ca
2+
 channels and non-selective cation currents, along with 
stimulating Ca
2+
 release from intracellular stores (Narayanan et al., 2012). The classical 
pathway for phenylephrine and noradrenaline activation of α1A-ARs is elevation of 
intracellular Ca
2+
 (Kitazawa et al., 2009; Taguchi et al., 1998).  Receptor occupation activates 
phospholipase C, which mediates hydrolysis of phosphatidylinositol 4, 5-bisphosphate into 
inositol 1, 4, 5-tris-phosphate and diacylglycerol (Dupuis et al., 2008) (Figure ‎1.7). Inositol 1, 
4, 5-tris-phosphate binds its receptors on the sarcoplasmic reticulum to trigger Ca
2+
 release. 
The increase in cytosolic Ca
2+  
triggers phosphorylation of myosin light chain at Ser19, in a 
pathway mediated by Ca
2+
-calmodulin (Ca
2+
-CaM)-activated myosin light chain kinase (He 
et al., 2008a; Isotani et al., 2004).  
Relaxation of smooth muscle is induced by dephosphorylation of myosin light chain by a 
specific type 1 phosphatase, myosin light chain phosphatase (Shirazi et al., 1994). 
Termination of the contractile stimulus leads to a decrease in [Ca
2+
]i, thereby decreasing 
myosin light chain kinase activity. The degree of myosin light chain phosphorylation and 
smooth muscle tone is determined by the relative activities of myosin light chain phosphatase 
and myosin light chain kinase (Kitazawa & Somlyo, 1990; Kitazawa et al., 1991). 
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Non-adrenergic, non-cholinergic transmitters such as NO (Kitazawa et al., 2009), carbon 
monoxide (Zhang et al., 2015) and hydrogen sulphide (Nalli et al., 2015) induce relaxation by 
reducing myosin light chain phosphorylation. For example, NO induces protein kinase G 
activation, which results in a decrease in [Ca
2+
]i via inhibition of phospholipase C and 
inositol 1,4,5-tris-phosphate formation (Hirata et al., 1990). These transmitters also induce 
relaxation by activation of potassium channels (K
+
 channels). For example, hydrogen 
sulphide activates protein kinase G, producing relaxation via activation of ATP-dependent K
+
 
channels in the pig bladder neck (Fernandes et al., 2013). 
Sources of Ca
2+
for contractile responses: Ca
2+
 influx and efflux modulate intracellular Ca
2+
 
ion concentrations via plasma membrane channels and transporters. Ca
2+
 can also enter the 
cytosol from the largest intracellular Ca
2+
 store, the sarcoplasmic reticulum. These channels 
mobilise Ca
2+
 across a Ca
2+
 concentration gradient (Harraz & Altier, 2014). In mammalian 
smooth muscle, Ca
2+
 entry is through voltage-gated Ca
2+
 channels, as a key process to elevate 
intracellular Ca
2+
 levels (Harraz & Altier, 2014). Elevated intracellular Ca
2+
 levels were 
proven to be consistent with action potential spike events observed in smooth muscle cells 
(Kyle et al., 2013).  Two types of voltage-gated Ca
2+
 channels, long-lasting and transient (L-
type and T-type voltage-gated Ca
2+
 channels) have been identified in the human myocyte 
(Sui et al., 2003).     
Greater depolarisation voltages activate L-type Ca
2+
-channels, and their activity generates the 
upstroke phase of the detrusor myocyte action potential allowing for a net influx of Ca
2+
 to 
initiate muscle contractility (Sui et al., 2003). On the other hand, T-type Ca
2+
 channels have a 
lower threshold of activation and are therefore active at the resting membrane potential of 
approximately -40 mV and could regulate smooth muscle excitability (Sui et al., 2003).  
Because more negative potentials activate the T-type Ca
2+
 channels, they also facilitate L-
type Ca
2+ 
channels opening (Sui et al., 2003).  
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Previous reports have indicated that L-type Ca
2+
 channels are mainly involved in smooth 
muscle contraction while the T-type Ca
2+
 channels are critical for cell proliferation (Cribbs, 
2006). Recently Lu et al., (2015) showed that L-Type Ca
2+
 channels modulate the protein 
expression of myosin light chain, and ablation of these channels resulted in a decrease in the 
protein expression of myosin light chain in the mouse. L-type Ca
2+ 
and T-type Ca
2+
currents 
are dependent on extracellular Ca
2+
concentration. 
Ca
2+
 ions are also stored in intracellular Ca
2+
 stores that include the sarcoplasmic reticulum 
and endoplasmic reticulum. Store-operated Ca
2+ 
channels are Ca
2+
-permeable cation channels 
and are activated when the intracellular Ca
2+
 stores are depleted (Putney, 1986).  The inositol 
1, 4, 5-tris-phosphate pathway is the principal mechanism of store-operated Ca
2+ 
channels 
activation (Putney & McKay, 1999). These stores are replenished through a feedback 
mechanism employing L-type Ca
2+
 channels (Wu et al., 2002). Ca
2+
 released from the 
sarcoplasmic reticulum induces further Ca
2+
 influx (Weigl et al., 2003).  
Calcium sensitization and desensitisation in smooth muscle 
In general, contractile agonists acting via receptors produce more tension for a given 
elevation of [Ca
2+
]i than membrane depolarization alone in smooth muscle (Gerthoffer et al., 
1991). This suggested that factors in addition to myosin light chain phosphorylation or 
changes in [Ca
2+
]i regulate cross-bridge cycling rates in smooth muscle contraction. Since at a 
given [Ca
2+
]i, more force is generated, this phenomenon was termed “Ca
2+
 sensitization of the 
contractile apparatus”, which signifies an increase in Ca2+ sensitivity of the contractile 
response (Kitazawa et al., 1991). 
Ras homolog gene family, member A (RhoA) activation of Rho kinase mediates Ca
2+
 
sensitization. Replacement of RhoA-bound GDP with GTP results in activation of Rho kinase 
leading to inhibition of myosin light chain phosphatase via phosphorylation of the myosin 
targeting subunit of the phosphatase (MYPT1) at Thr697 and Thr855 (rat)/ Thr696 and 
Thr853 (human) (Figure ‎1.7; Muranyi et al., 2005). However, Khasnis et al., (2014) showed 
that thio-phosphorylation at Thr696, but not at Thr853, inhibited the activity of recombinant 
myosin light chain phosphatase purified from the mammalian cell lysates. Both Thr696 and 
Thr853 sites underwent autodephosphorylation. The phosphorylation of Thr696 was more 
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stable compared with that of Thr853, and it facilitated Thr853 phosphorylation. Also, 
Khasnis et al., (2014) showed that the Thr696(s) of endogenous MYPT1 are spontaneously 
phosphorylated in quiescent human leiomyosarcoma cells. They suggested that the 
spontaneous phosphorylation at Thr696 might mediate the basal activity of myosin light 
chain phosphatase and the temporal phosphorylation at Thr853. The spontaneous 
phosphorylation at Thr696 synchronised with myosin targeting. So, phosphorylation at 
Thr696 seems to be more important and initiate Ca
2+
 sensitization. Moreover, protein kinase 
C (PKC)-mediated phosphorylation of  CPI-17 (PKC-potentiated inhibitory protein for 
protein phosphatase-1 of 17 kDa) at Thr38 also ensures myosin light chain phosphatase 
inhibition (Kitazawa et al., 2003). 
Apart from PKC and RhoA/Rho kinase, receptor-mediated tyrosine kinase activation has also 
been implicated in Ca
2+
 sensitization via activation of the RhoA/Rho kinase pathway in rat 
aortic rings (Seok et al., 2008). Using human prostate tissues, Kunit et al., (2014) showed that 
two different focal adhesion kinase inhibitors, PF-573228 and Y-11, inhibited α1-AR-
mediated smooth muscle contraction. Their data suggested that focal adhesion kinase was 
activated by α1-ARs and was involved in smooth muscle contraction in the hyperplastic 
human prostate. Pharmacological inhibition of focal adhesion kinase impaired contraction in 
isolated human bladder smooth muscle cells and prostate, suggesting similar functions of 
focal adhesion kinase in the two tissues (Kunit et al., 2014; Luo et al., 2013).  
In contrast, increased myosin light chain phosphatase activity by reduced Thr855 
phosphorylation of MYPT1 or reduced Thr38 CPI-17 phosphorylation shifts the [Ca
2+
]i: 
force ratio, effectively reducing Ca
2+
 sensitivity (Da Silva-Santos et al., 2009). Smooth 
muscle relaxation results from a reduction in Ca
2+
-sensitization of myosin light chain 
phosphorylation and force development. For example, NO triggers vascular smooth muscle 
relaxation by stimulating the cyclic GMP formation and activating protein kinase G. Protein 
kinase G activation results in a desensitisation of myosin light chain phosphorylation to Ca
2+
 
by phosphorylating MYPT1, resulting in myosin light chain phosphatase activation (Surks et 
al., 1999). Protein kinase G also mediates RhoA phosphorylation, that inhibits activation and 
membrane translocation (Kato et al., 2012); hence, mediating RhoA-mediated Rho kinase 
inhibition (Sauzeau et al., 2000). 
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1.1.2.5 Desensitisation of smooth muscle responses 
G-protein-coupled receptors are under tight regulation which protects against the potentially 
harmful effects of acute or chronic overstimulation. As part of this regulation, α1-ARs 
undergo regular turnover which involves internalisation and recycling back to the membrane 
(Morris et al., 2004; Stanasila et al., 2008). The constitutive internalisation of α1A-AR 
involves clathrin-mediated endocytosis and the receptors are not degraded in lysosomes 
(Morris et al., 2004). Thus, the surface receptor density is maintained by recycling during 
constitutive internalisation (Morris et al., 2004). 
The waning of GPCR signalling and loss of drug responsiveness in the continued presence of 
an agonist involves a co-ordinated series of events. These events include receptor uncoupling, 
sequestration, and down-regulation.  Like many other GPCRs, α-ARs undergo agonist-
promoted desensitisation, initiated by phosphorylation of the receptor in its third intracellular 
loop (Diviani et al., 1997).  The well-characterized family of serine/threonine kinases termed 
GPCR kinases (GRKs) (Price et al., 2002), and second messenger-dependent kinases (Diviani 
et al., 1997) mediate phosphorylation of GPCR. For example, Diviani et al., (1997) showed 
that PKC mediates phosphorylation of Ser394 and Ser400, whereas GRK targets Ser404, 
Ser408, and Ser410 of the α1B-AR.  
GRK phosphorylation alone has little effect on G-protein coupling in the absence of arrestin. 
The role of GRK phosphorylation is to increase the affinity of the receptor for arrestin (Lohse 
et al., 1992). Binding of arrestin to the GPCR inhibits further receptor coupling to G-proteins. 
Furthermore, arrestin-bound GPCRs interact with clathrin and a β2-adaptin subunit of the 
clathrin adaptor AP-2 (adaptor protein complex-2) to target the receptor to clathrin-coated 
pits and the endocytic machinery, leading to receptor internalisation (sequestration) (Naga 
Prasad et al., 2002) (Figure ‎1.8). Using fluorescence microscopy Laporte et al., (2000) 
reported that arrestin/ AP-2 interactions are essential for compartmentalisation and targeting 
of β2-AR to clathrin for trafficking. 
The AP-2 complex directly links the clathrin coat with transmembrane cargo proteins that 
sort into coated pits and vesicles. The AP-2 adaptor can initiate endocytosis of membrane 
receptors by either associating directly with the receptor cytoplasmic tail or by interacting 
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with additional molecules, such as arrestins, as described for the β2-AR in COS-1 cells (Kim 
et al., 2002). Also, Conner et al., (1997) observed that arrestin knockout mice developed 
normally, but the normal adrenergic responses required arrestin. Depending on the GPCR 
subtype, arrestin either dissociates from the receptor at the plasma membrane or after co-
internalization with the receptor. 
 
Figure  1.8  The mechanism of desensitisation, sequestration, re-sensitisation and downregulation of the 
G-protein-coupled receptor (GPCR).  Desensitisation involves phosphorylation by a kinase, e.g., GPCR 
kinase (GRK), uncoupling of the G-proteins from the GPCR by the arrestin, transfer to the clathrin-coated 
pits and possibly endocytosis. From the early sorting endosomes, receptors separated from other adapters 
e.g. adaptor protein complex (AP-2) are moved to the recycling endosomes for membrane reinsertion and 
re-sensitisation (short-term desensitisation). On the other hand, long-term desensitisation and 
downregulation may involve lysosomal degradation of the receptors, gene transcription, and reinsertion of 
the receptor into the membrane. Modified from (Ramachandran et al., 2012). ER= endoplasmic reticulum. 
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Two other potent regulators of GRK activity are phosphatidylinositol 4, 5-bisphosphate and 
Gβγ, which are also critical for the membrane targeting of these kinases (Pitcher et al., 1995; 
DebBurman et al., 1996). Other important GPCR trafficking pathways include caveolae and 
lipid rafts (Xiang et al., 2002; Escriche et al., 2003).   
In addition to kinases such as GRK, the regulation of GPCR is also modulated by molecules 
such as the mitogen-activated protein kinase (MAPK) (Keffel et al., 2000). These kinases 
phosphorylate many transcription factors and other kinases that are important regulators of 
gene expression (Heckler et al., 2014). The MAPK subgroups include the extracellular 
signal-regulated kinase, c-Jun N-terminal kinase, and p38 MAPK. The GRKs and arrestins 
activated during α1-AR signalling activate the GPCR-mediated MAPK signalling cascade, 
e.g., for β-AR (Daaka et al., 1998; Copik et al., 2015) and α1A-AR (Perez-Aso et al., 2013). 
Thus the MAPK signalling pathway also regulates the GPCR activities. 
Internalisation of GPCRs, also termed receptor sequestration or endocytosis, occurs more 
slowly than desensitisation, happening over a period of several minutes after agonist 
exposure (Figure ‎1.8). The process of GPCR sequestration is important not only in 
attenuating GPCR signalling in the continued presence of agonist but also for receptor re-
sensitisation and downregulation  (Sibley et al., 1986). The re-sensitisation of a GPCR 
requires the dephosphorylation and dissociation of the receptor from its ligands.  
Receptor down-regulation, defined as the loss of receptors from the cell membrane, is another 
critical component of receptor regulation. Downregulation of GPCRs is the persistent loss of 
cell surface receptors that occurs over a period of hours to days. When stimulation is 
chronically persistent for hours and days, internalised receptors may be degraded in the 
lysosomes (Figure  1.8) (Moore et al., 1999).  
Short term and long term desensitisation 
Receptor internalisation and degradation and/or recycling may influence the rate of recovery 
of responses to the ligand in question. For most GPCRs, internalisation following relatively 
short-term agonist treatment (within seconds to minutes) leads to dephosphorylation and 
recycling of the GPCR. The dissociated receptor may be inserted into the plasma membrane 
(re-sensitisation) (short-term desensitisation). Goral et al., (2011) observed that in A431 cells 
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expressing β2-ARs, the shorter the initial stimulation, the greater the re-sensitization of the β2-
AR.  
On the other hand, long-term desensitisation includes downregulation of surface receptor 
number, which involves internalisation, and degradation of receptors (Carter & Hill, 2005). In 
addition to the role of GRK in regulation of short-term desensitisation, GRK-mediated 
phosphorylation is an important mechanism underlying long-term desensitisation of the β2-
ARs in COS-7 cells (McGraw et al., 1998).  Long-term desensitisation is associated with loss 
of surface receptors as shown for human lung mast cell β-AR (Chong et al., 2003; Scola et al., 
2004). For example, prolonged exposure to isoprenaline decreased the net number of 
expressed β2-AR (Nantel et al., 1995) and reduced the extent to which isoprenaline inhibited 
histamine release (Bastan et al., 2014).  Also, studies in a human epithelial cell line indicated 
that long-term treatment with β-AR agonists led to reductions in receptor density, and the 
degree of internalisation is proportional to the agonist concentration (Williams et al., 2000). 
Long-term desensitisation could also lead to receptor downregulation, for example, Yin et al., 
(2016) showed that isoprenaline induced downregulation of β-ARs in the rat heart by an 
increase of mRNA degradation and not inhibition of transcription. Moreover, the human 
Antigen-R, the RNA binding protein, which promotes RNA degradation, was responsible for 
downregulation of β-ARs (Yin et al., 2016). Human Antigen-R recognises reiterated 
AUUUA sequences and was implicated in the regulation of RNA stability of β1-AR and β2-
AR through binding to their untranslated regions (Bai et al., 2006; Kandasamy et al., 2005). 
Inhibition of DNA transcription has also been proposed to be responsible for β-AR 
downregulation. However, the expression and activation of cyclic AMP-response element 
binding protein (CREB) is not changed during downregulation and thus, excluded CREB 
from receptor downregulation. CREB is a 43-kD basic leucine zipper transcription factor 
which regulates the transcription of many genes by binding to the CRE, an 8-bp palindromic 
consensus element (TGACGTCA), in their promoters (Maureira et al., 2016). CREB 
regulates the transcription of both α1-AR (Thonberg et al., 2002), and β-AR (Lee et al., 2013; 
Sato et al., 2011). 
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Homologous desensitisation  
With homologous desensitisation, only responsiveness to the receptor that is activated is lost. 
GRK-mediated phosphorylation of GPCR initiates homologous desensitisation, resulting in 
increased affinity of the phosphorylated receptor for arrestin (Diviani et al., 1996). GRK-
mediated phosphorylation of serine or threonine residues in the third intracellular loop or 
COOH-terminus of the GPCR contribute to the arrestin binding (Seibold et al., 2000). GRK2 
and GRK3 were shown to be involved in phosphorylation of agonist-occupied α1B-ARs 
during homologous desensitisation (Diviani et al., 1997). GRK-mediated GPCR 
phosphorylation and binding of arrestin to the receptor facilitates agonist-promoted 
endocytosis of many GPCRs, including the β2-ARs and  M2-M5 mAChRs (Lee et al., 1998; 
Nobles et al., 2011). 
Heterologous desensitisation  
Phosphorylation of serine and threonine residues within the cytoplasmic loops and C-terminal 
tail domains of many GPCRs by protein kinases, including protein kinase A and PKC, 
induces heterologous desensitisation. Heterologous desensitisation does not require agonist 
occupancy of the target GPCR. Thus, activation of second-messenger-dependent protein 
kinases mediates desensitisation of the receptors that have not bound agonist, including 
receptors for other ligands (Molina-Muñoz et al., 2008; Rodríguez-Pérez et al., 2009). For 
example, α1-ARs activation desensitises thromboxane prostanoid (TP) receptors through 
activation of PKC in the aorta of adult spontaneously hypertensive rats (Zhao et al., 2015).  
Also, activation of lysophosphatidic acid receptor, sphingosine 1-phosphate receptor and 
oestrogen receptor induces α1B-AR phosphorylation (Casas-González et al., 2000; 2003; 
Castillo-Badillo et al., 2012; Garcia-Sainz et al., 2000; González-Arenas et al., 2006). The 
phosphorylation, desensitisation and internalisation were via a signalling process involving 
phosphoinositide-3-kinase (PI3K) and PKC (Castillo-Badillo et al., 2012). Moreover, 
activation of receptors coupled to Gq/11, such as endothelin ETA (Vázquez-Prado et al., 1997) 
or bradykinin BK2 (Medina et al., 1998) receptors , or receptors with intrinsic tyrosine kinase 
activity (such as epidermal growth factor), or platelet-derived growth factor receptors (Del 
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Carmen Medina et al., 2000) can induce α1B-AR phosphorylation/desensitization. Thus PKC 
mediates heterologous desensitisation of GPCR. 
 Protein Kinase C (PKC) and desensitisation 
Agents which activate PKC, such as GPCR agonists and phorbol esters, attenuate responses 
to AR agonists (Grandordy et al., 1994).  Protein kinase C activation enhances homologous 
desensitisation of β2-ARs (Boterman et al., 2006). Likewise, PKC-mediated desensitisation of 
α2A-ARs function is primarily due to phosphorylation of serine 360 (Liang et al., 2002). 
Nishizaki & Sumikawa, (1998) demonstrated that PKC or protein kinase A phosphorylation 
of nicotinic acetylcholine receptors accelerated the rate of desensitisation.  
There is a marked cross-talk between protein kinases, for example, Winstel et al., (1996) 
showed that the  PKC phosphorylates, and membrane targets GRKs in CHO cells. Protein 
kinase C can mediate changes in the cellular expression and activity of GRKs (De Blasi et al., 
1995); can mediate phosphorylation of GRKs (Chuang et al., 1995) and can target GRKs to 
the plasma membrane (Winstel et al., 1996).  PKC phosphorylates GRK, and this 
phosphorylation relieves the inhibitory effect exerted by calmodulin on GRK. However, PKC 
phosphorylation can also be inhibitory on GRK (Pronin et al., 1998). Thus, PKC can 
modulate desensitisation or serve as a feedback loop for GRK homologous desensitisation 
mechanisms.  
Rho kinase and desensitisation 
RhoA-GTP, which activates Rho kinase, is a binding partner of GRK (Robinson & Pitcher, 
2013). Also, arrestin expression and interactions were upregulated in mesenteric arteries in 
patients and rats with cirrhosis, resulting in GPCR desensitisation, G-protein dysfunction and 
Rho kinase inhibition (Chen et al., 2013). This suggests a relationship between arrestin and 
Rho kinase. Arrestins have also been shown to mediate β2-AR signalling to the RhoA (Ma et 
al., 2012) and MAPK pathways (Gao et al., 2004). Arrestin forms a complex with Rho 
guanine nucleotide exchange factor in the cytosol in resting RCC7 or HEK-293 cells (Ma et 
al., 2012). Upon β2-AR activation, both arrestin and Rho guanine nucleotide exchange factor 
translocate to the plasma membrane, with concomitant activation of RhoA. This suggested 
that arrestin may serve as a convergence point for non-G12/13 and non-Gq protein-coupled 
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receptors to activate RhoA.  All these observations suggest that Rho kinase can modulate 
desensitisation.  
Calcium and desensitisation 
Cellular Ca
2+ 
 levels appear to modulate GRK activity, Ca
2+
-sensing proteins interacting with 
different GRKs (Sallese et al., 2000). Calmodulin, a universal mediator of Ca
2+
 signals, 
inhibited GRK binding to the plasma membrane (Sallese et al., 2000), suggesting that 
calmodulin may serve a general role in mediating Ca
2+
-dependent regulation of GRK activity 
(Pronin et al., 1997). In HEK-293 cells expressing the P2Y11 receptor, Haas et al., (2014) 
detected a significant reduction in the intracellular Ca
2+
 level in the course of 30-minutes 
ATP treatment. After a 60-minutes recovery period, the cells showed only a slightly 
recovered Ca
2+ 
response probably because of the internalisation of the P2Y11 receptors. This 
long-term desensitisation reflects a decrease in [Ca
2+
]i during desensitisation. 
Beta-ARs desensitisation 
Most studies on desensitisation of AR have been performed on β-AR. An intense stimulation 
of the β2-AR by β-AR agonists often leads to rapid desensitisation due to uncoupling of the 
receptor from Gs protein and adenylate cyclase. Prolonged activation leads to internalisation 
of the receptor into an intracellular endosome, thereby effectively removing the receptor from 
the cell surface. Desensitisation may lead to degradation and permanent receptor 
downregulation defined by an overall decrease in receptor number and the corresponding 
intracellular cyclic AMP accumulation (Oehme et al., 2015). 
Regulation of β-AR includes two modes of desensitisation, one mediated by protein kinase A 
and another by GRK as shown in HEK-293 cells (Tran et al., 2004). Protein kinase A 
phosphorylation of β-ARs can lead to a “switch” in β-AR coupling from the Gs to Gi subtype 
of GTP-binding proteins (Zamah et al., 2002). Activated Gi proteins can then release 
GiαGTP and Giβγ subunits that can directly inhibit the catalytic activity of adenylate cyclase, 
thus reducing cyclic AMP production. 
Incubation of human airway smooth muscle cells with salmeterol short-term (10 minutes) or 
long-term (2 and 14 hours) depresses isoprenaline stimulation (Gimenez et al., 2015). 
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Isoprenaline and salbutamol induces a significant concentration- and time-dependent 
decrease in β2-ARs density (Oehme et al., 2015). Moreover, both isoprenaline and salbutamol 
reduce cyclic AMP generation in a concentration-dependent manner. Upon repeat exposure, 
all β2-AR agonists produce functional desensitisation of β2-ARs to the same degree and rate 
(Rosethorne et al., 2015). Moreover, the β2-AR agonists are capable of causing robust 
receptor internalisation and arrestin recruitment, the rate of which is influenced by agonist 
efficacy. Pre-treatment with isoprenaline decreases isoprenaline-induced cyclic AMP 
generation compared with isoprenaline for 10 minutes alone, paralleled by increases in β2-AR 
and GRK2 phosphorylation (Albano et al., 2015). 
Isoprenaline (1µM) stimulation of β2-ARs leads to rapid desensitisation and trafficking of the 
receptors to lysosomes (Macia et al., 2012: Samoshkin et al., 2015). Moreover, previous 
reports showed that Rab5 protein orchestrates internalisation and endocytotic trafficking of β-
ARs in the endothelial cells (Yang et al., 2015) and human airway smooth muscle cells (Jiang 
et al., 2012). 
Also, Rumzhum et al., (2016) recently showed that β2-ARs can undergo heterologous 
desensitisation induced by bioactive sphingolipid acting on the sphingosine 1-phosphate 
receptor. The treatment of the airway smooth muscle cells with sphingosine 1-phosphate 
(1μM) for up to 24 hours induced heterologous β2-ARs desensitisation. Thus desensitisation 
of β-AR is mediated by either protein kinase A or GRK as shown in airway smooth muscle. 
1.1.2.6 Heterologous G-protein coupled receptor sensitisation 
Heterologous-induced GPCR-mediated sensitization is a known phenomenon, at least in 
neuronal and other cell cultures of the airways smooth muscles. For example, Magalhaes et al. 
(2010) have demonstrated that the activation of the corticotropin-releasing factor receptor-1 
resulted in the ‘heterologous sensitization’ of 5-HT2R signalling in both heterologous cell 
cultures and primary prefrontal cortical neurones. Specifically, pre-stimulation of the 
corticotropin-releasing factor receptor-1 led to a significant potentiation of 5-HT2R signal 
transduction and enhanced 5-HT2R receptor-mediated inositol phosphate formation. Also, in 
the HEK-293 cells, Kurian et al., (2009) showed that Gαq/11-coupled M3 -mAChR facilitated 
Ca
2+
 signalling by Gαs-coupled β2-AR. The crosstalk required Gαs and was dependent upon 
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intracellular Ca
2+
 release channels, particularly inositol 1, 4, 5-tris-phosphate receptors 
(Kurian et al., 2009).  Therefore, receptor sensitization seems to be associated with Ca
2+
 
mobilisation. 
1.1.2.7 Urothelium function in the lower urinary tract 
The urothelium serves as a transducer; communicating physical and mechanical stimuli to the 
underlying cells via secretion of chemical mediators and activities of expressed receptors. 
Little is known about the receptors of the urethral urothelium but that of the bladder is well 
studied and the literature is summarised below. 
Muscarinic receptors (mAChRs) of the urothelium 
Messenger RNA for all five mAChR subtypes have been shown in the rat (Kim et al., 2008) 
and human (Mansfield et al., 2005; Tyagi et al., 2006) bladder urothelium, and the expression 
of all five mAChR (M1 - M5) subtypes have been shown in the bladder urothelium of mouse 
(Zarghooni et al., 2007) and human (Bschleipfer et al., 2007).  The urothelial cells express a 
high density of mAChRs, even greater than the bladder smooth muscle cells, as shown in the 
porcine urinary bladder (Hawthorn et al., 2000). Data from cultured rat urothelial cells, has 
suggested that activation of M1-3 mAChR subtypes stimulates the release of ATP through an 
increase of intracellular Ca
2+
 (Kullmann et al., 2008b; Sui et al., 2014), which might 
modulate bladder responses. 
Nicotinic receptors of the urothelium 
Beckel et al., (2006) identified mRNA for the α3, α5, α7, β3, and β4 nicotinic subunits in rat 
urothelial cells using real time-PCR, and the expression of nicotinic acetylcholine receptors 
in the urothelium was shown in the rat (Beckel et al., 2006; Beckel & Birder, 2012) and 
mouse bladder (Zarghooni et al., 2007).  Stimulation of nicotinic acetylcholine receptors via 
the intravesical administration of nicotine increased the inter-contraction interval of rat 
bladder (Beckel et al., 2006). The specific activation of α7 homomeric receptors inhibited 
bladder reflexes while α3 heteromeric receptors had an excitatory effect on bladder reflexes 
(Beckel et al., 2006). Stimulation of the α7 receptors and the α3 heteromeric receptors with 
low concentrations of acetylcholine inhibited the release of urothelial ATP (Beckel & Birder, 
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2012). However, stimulation with high concentrations of acetylcholine caused the α3 
heteromeric receptors to stimulate the ATP release. Thus, the nicotinic acetylcholine receptor 
appears to mediate bladder activity and reflexes by modulating urothelial release. 
Alpha-adrenoceptors (α-ARs) of the urothelium 
High levels of α1A-AR mRNA were detected in the urothelium of the human bladder dome 
and bladder base (Walden et al., 1997).  The α1A-AR subtype is also expressed in the bladder 
urothelium of pig (Moro et al., 2013), rat (Yanase et al., 2008; Walden et al., 1997) and 
monkey (Walden et al., 1997).  However, the α1A-ARs were undetectable at the protein level 
in the human bladder (Walden et al., 1997). Thus, the α1A-AR mRNA appeared to be 
transcribed, but not translated in the human urothelium.  However, in the pig, α1/L-ARs 
mediate an increase in the urothelium contractile rate and tension to phenylephrine (Moro et 
al., 2013).  
Similarly, the expression of α1D-ARs was detected in rat urothelial tissue via western blot and 
immunohistochemistry (Ishihama et al., 2006), and endogenous catecholamines act on α1D-
ARs in the urothelium to facilitate mechanosensitive bladder afferent nerve activity and 
reflex voiding (Ishihama et al., 2006). Moreover, Kurizaki et al., (2011) found an increased 
α1D-ARs mRNA expression in the bladder urothelium of men with lower urinary tract 
symptoms/benign prostatic obstruction. Men with a first desire to void (FDV) ≤ 200 ml and 
strong desire to void (SDV) ≤ 300 ml expressed more α1D-AR mRNA compared with patients 
having FDV ≥ 201 ml and SDV ≥ 301 ml (Kurizaki et al., 2011). This suggests a role for 
urothelial α1D-ARs in bladder sensation. 
Beta-adrenoceptors (β-ARs) of the urothelium 
The human (Otsuka et al., 2008; Tyagi et al., 2009) and pig (Moro et al., 2013) bladder 
urothelium express mRNA for β1-, β2- and β3-ARs. Moreover, studies have shown the 
expression of β-ARs in the bladder urothelium of rat (Kullmann et al. 2009, 2011) and pig 
(Moro et al., 2013) and human (Limberg et al., 2010). Immunostaining for β1, β2, and β3 was 
prominent in the female bladder urothelium (Limberg et al., 2010). Using radioligand 
techniques, Rojanathammanee et al., (2009) reported an overwhelming presence of β2-ARs in 
UROtsa cells, and their activation protected the cells against programmed cell death. 
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Beta-AR stimulation activates the adenylate cyclase pathway (Limberg et al., 2010) in 
bladder urothelial cells and initiates an increase in intracellular Ca
2+
 that triggers NO 
production and release (Birder et al., 2002b). Moreover, Moro et al., (2013) showed the β2-
AR subtype induced inhibition of porcine urothelium spontaneous contractile activity. The β1-
ARs and β2-ARs were possibly involved in the relaxation of the tension responses (Moro et 
al., 2013).  
Purinergic receptors of the urothelium 
There is substantial evidence that many of the purinergic receptor subunits are expressed 
throughout the urinary bladder urothelium of animals (Birder et al., 2004; Chopra et al., 2008; 
Kim et al., 2008) and human (Shabir et al., 2013). In the human bladder urothelium, 
glycosylated P2X2 and P2X3 transcripts and protein expression were detected (Tempest et al., 
2004). Furthermore, in the human urothelial cell line, UROtsa, P2Y1, P2Y2, and P2Y11 
transcript expression were detected (Save & Persson, 2010).  Wang et al., (2005) showed that 
upon binding of urothelially released ATP to P2Y and P2X receptors on the umbrella cell, 
downstream Ca
2+ 
and protein kinase A may act to stimulate membrane insertion at the apical 
pole of umbrella cells. 
Prostanoid receptors of the urothelium 
There are nine prostanoid receptors classified as DP1, DP2 (CRTH2), EP1, EP2, EP3, EP4, FP, 
IP and TP, which are preferentially activated by the major prostanoids PGD2, PGE2, PGF2α 
PGI2 and TxA2. Immunohistochemical analyses revealed that EP1 and EP2 receptors are 
expressed in the guinea-pig bladder urothelium (Rahnama’i et al., 2010). Moreover, the 
expression of the prostaglandin E receptors, EP1, EP2, EP3, and EP4, and mRNA for EP2, EP3, 
and EP4 were reported in dog urethral urothelium (Ponglowhapan et al., 2010). Thus, locally 
released prostanoid by the smooth muscle or the urothelium may act in an autocrine or 
paracrine manner to modulate the activity of the bladder and urethra via the urothelium. 
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1.1.2.8 Urothelium released factors and function of the lower urinary tract 
The urothelium secretes factors including ATP, acetylcholine, NO (Apodaca et al. 2007) and 
nerve growth factor (NGF) (Birder et al., 2007) through the apical and/or serosal surfaces in 
response to mechanical, chemical, and thermal stimuli (Birder & Andersson, 2013). These 
factors diffuse to underlying submucosal sensory nerve fibres and ICCs and appear to be 
involved in normal bladder function (Birder et al., 2002a).    
Urothelial released ATP 
The urothelium is capable of releasing ATP into both the mucosal and serosal compartments 
of the bladder wall (Ferguson et al., 1997; Lewis & Lewis et al., 2006) and ATP act as an 
important autocrine (Wang et al., 2005) and paracrine mediator (Cockayne et al., 2000), 
respectively. The paracrine action of ATP released from urothelial cells induces detrusor 
smooth muscle contraction in the guinea-pig and human (Sui et al., 2014). Urothelial ATP 
was released mainly via vesicular transport or exocytosis in rabbit bladder (Wang et al., 2005) 
or pannexin-1 hemichannels conductive efflux in mice (Negoro et al., 2013) and rat bladder 
(Beckel et al., 2015; Timóteo et al., 2014).  Timoteo et al., (2014) reported co-localisation of 
pannexin-1 hemichannels and P2Y6 receptors in the rat urothelium. Other mechanisms 
implicated in ATP release by the urothelial cells include (i) uridine triphosphate- (UTP-) 
mediated Ca
2+
-dependent ATP release and (ii) agonist-mediated Ca
2+
-independent ATP 
release (Sui et al., 2014).   
ATP released from both the apical and basolateral urothelial surfaces acts via P2X and 
possibly P2Y receptors on the umbrella cells to stimulate stretch-induced exocytosis, as well 
as endocytosis in the rabbit (Wang et al., 2005). Moreover, ATP released from the basolateral 
surface of the bladder urothelium of mice during bladder filling stimulates P2X3 receptors on 
suburothelial sensory nerve fibres, thus relaying information about the degree of bladder 
filling to the central nervous system (Cockayne et al., 2000; 2005).  
Increased ATP released from the urothelium may, in part, underlie the development of lower 
urinary tract symptoms in bladder dysfunction (Munoz et al., 2011). The dysfunction is 
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thought to be due to increased firing rate of bladder afferent nerves inducing bladder 
overactivity (Pandita & Andersson, 2002; Yu & de Groat, 2008).  
Urothelial released acetylcholine 
Parasympathetic nerves are not the only source of acetylcholine, as it can also be formed and 
released non-neuronally by the urothelium (Hanna-Mitchell et al., 2007; Lips et al., 2007; 
McLatchie et al., 2015; Yoshida et al., 2006). The urothelium contains the essential 
components of the machinery needed to synthesise acetylcholine including carnitine 
acetyltransferase, but the presence of choline acetyltransferase remains controversial (Hanna-
Mitchell et al., 2007; Lips et al., 2007). Hanna-Mitchell et al., (2007) reported that rat bladder 
urothelial cells expressed choline acetyltransferase. However, RT-PCR data from human and 
mouse urothelial cells by Lips et al., (2007) does not support the expression of choline 
acetyltransferase. The variation in result may be associated with species differences. The 
urothelium lacks the vesicular acetylcholine transporter, which is characteristic for 
cholinergic neurones, but rather expresses the polyspecific organic cation transporters OCT1 
and OCT3 (Lips et al., 2007).  In the urothelium, acetylcholine may act on nicotinic 
acetylcholine receptors as well as on mAChRs (Beckel & Birder, 2012; Zarghooni et al., 
2007). 
Unlike neuronal acetylcholine released from parasympathetic nerves, which occurs largely 
during the voiding phase, urothelial acetylcholine release is promoted during bladder filling, 
that is, by stretch (Yoshida et al., 2006; 2008). Therefore, urothelial acetylcholine release is 
likely to occur during the storage phase.  
Urothelial released nitric oxide (NO) 
Formation of NO can occur in urothelial cells via inducible nitric oxide synthase (iNOS) 
(Chuang et al., 2013) or endothelial nitric oxide synthase (eNOS) (Birder et al., 2002b). Some 
reports also implicate nNOS in urothelial release of NO (Gillespie et al., 2005). Nitric oxide 
can be released from urothelial cells upon mechanical force or stretch, mimicking bladder 
distension (Birder et al., 2002a).  Moreover, NO is released from the urothelium upon 
activation of mAChRs (Andersson et al., 2012; Kullmann et al., 2008a), vanilloid receptors 
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(Birder et al., 2001) and ARs (Birder et al., 2002b). The urethral urothelium releases NO in 
response to electrical field stimulation in the hamster (Pinna et al., 1999). 
Urothelial released prostanoids 
Prostanoids are produced locally within the bladder urothelium in the human and other 
species (Kang et al., 2015a; Jeremy et al., 1987). The umbrella cells of guinea-pig bladders 
do not express cyclooxygenase I, however, cyclooxygenase I was present in basal urothelial 
cells, making them a possible site of prostaglandin synthesis (Rahnama'i et al., 2010). Guan 
et al., (2014b) showed that prostaglandin E2 and prostaglandin D2 were released mainly from 
urothelium of guinea-pig urinary bladders. Moreover, reports have shown that prostaglandin 
E2 is synthesised in the rabbit (Klausner et al., 2011) and rat (Masunaga et al., 2006) bladder 
urothelium. Stretch of the rabbit bladder also mediates urothelial prostanoid production 
(Downie & Karmazyn, 1984).  
Prostaglandin E2 contributed to the detrusor spontaneous rhythmic activity in the mouse 
(Klausner et al., 2011; Kobayter et al., 2012). Moreover, prostaglandin D2 inhibited the 
motility of guinea pig urinary bladder induced by nerve stimulation, and post-junctional 
action of acetylcholine or ATP (Guan et al., 2014b). Prostaglandin E2 release from the guinea 
pig bladder urothelium was modulated by the complex interaction between ATP, NO (Nile et 
al., 2010), acetylcholine and M2 mAChRs (Nile & Gillespie, 2012). Nile & Gillespie, (2012) 
showed that activation of M2 receptors induced production of prostaglandin E2, while in the 
presence of NO donor, prostaglandin E2 production was inhibited. 
1.1.2.9 Interstitial cells and spontaneous contractile activity in the lower 
urinary tract 
The lower urinary tract and urogenital tract develops spontaneous contractile activity. Such 
spontaneous contractile activity was initially considered to originate from the smooth muscle 
cells themselves, and thus often referred to as ‘myogenic activity.' However, with the 
establishment of the ICC as the primary pacemakers, driving slow wave generation in the 
gastrointestinal tract, many regions of the urogenital tract have been examined for the 
presence of similar cells. Interstitial cells of Cajal-like cells have been identified in many 
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regions of the lower urinary tract by immunohistochemical studies and electron microscopy 
(Davidson & McCloskey, 2005; Johnston et al., 2010; Kubota et al., 2008).   
In the bladder, myofibroblasts in the lamina propria have a morphology similar to ICC-LCs 
and can also generate spontaneous electrical and Ca
2+
 activity (Wu et al., 2004). Interstitial 
cells of Cajal-like cells in the bladder are preferentially located along the boundary of smooth 
muscle cell bundles where many spontaneous smooth muscle cell Ca
2+
 transients originate 
(Hashitani et al., 2001; McCloskey & Gurney, 2002).  
Sergeant et al., (2000) have shown that the rabbit urethra possesses ICCs, with structural and 
morphological properties similar to those found in the gastrointestinal ICC. Urethral ICC-LCs 
in situ and after enzymatic isolation generated spontaneous Ca
2+
 transients relying on Ca
2+
 
release from the endoplasmic reticulum and Ca
2+ 
influx through non-L-type Ca
2+ 
channel 
pathways (Hashitani & Suzuki, 2007). Urethral ICC-LCs Ca
2+
 transients are consistently 
recorded at lower frequencies and have a longer duration than the Ca
2+
 transients recorded in 
neighbouring smooth muscle bundles of guinea pig bladder (Hashitani et al., 2004a) and 
mouse’ renal pelvis (Lang et al., 2007a;b). Interstitial cells of Cajal isolated from the urethra 
generated slow waves through a combination of Ca
2+
 release from the internal stores and the 
opening of Ca
2+
-activated Cl
−
 channels (Hollywood et al., 2003b). Spontaneous Ca
2+
 
transients observed in ICC-LCs of the rabbit urethra in-situ occurred at a frequency of 1–
10/min. The Ca
2+
 transients also have a much longer duration (5–30 sec.) than the Ca2+ 
transients in the urethral smooth muscle cells (1–3 sec. duration) measured in same 
preparation (Hashitani & Suzuki, 2007). Thus the lower urinary tract expresses ICC-LC with 
pacemaker activity. 
1.1.2.10 Urine storage and micturition 
Normal coordination of storage and voiding functions requires integration via the pontine 
micturition centre and the pontine storage centre and has supraspinal input (Blaivas, 1982; 
Thor et al., 1990). The switch of lower urinary tract function between storage and voiding is 
mediated by a long-loop spino-bulbospinal voiding reflex which has its rostral terminus in the 
brainstem (De Groat et al., 2015; Noto et al., 1991). The pontine micturition centre 
coordinates brain centres including the periaqueductal gray. The periaqueductal gray is a key 
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organising centre for several higher brain regions involved in micturition, including the 
prefrontal cortex with which it has strong connections (Sugaya et al., 1997; Vizzard et al., 
1995b).  
Urine storage  
During filling, there is low-level activity from bladder afferent fibres that signal via the pelvic 
nerve and this, in turn, stimulates sympathetic outflow to the bladder neck and wall through 
the hypogastric nerve. These fibres regulate relaxation of the detrusor via β3-ARs and 
constriction of the urethra via α1-ARs in the internal urethral sphincter. There is also 
pudendal outflow, which keeps the external urethral sphincter closed. Acetylcholine acts on 
nicotinic acetylcholine receptor in the striated muscle, inducing muscle contraction to 
maintain closure of the external urethral sphincter (Thor et al., 1989; Blaivas, 1982). Motor 
neurones innervating the striated muscles of the external urethral sphincter exhibit a tonic 
discharge that increases during bladder filling (Thor and de Groat, 2010). During 
accommodation, neurones within the pontine storage centre in the brain are quiescent 
(Michels et al., 2015; Tai et al., 2009). 
The urethral outlet remains closed, and the external urethral sphincter contracts with greater 
and greater frequency while the bladder is filling. This progressive increase in activity of the 
external urethral sphincter during bladder expansion is known as the guarding reflex. As the 
bladder fills, bladder sacral afferent signals increase in strength until they exceed a certain 
threshold in the brainstem, specifically the periaqueductal gray.  
Micturition 
The switch from the storage to the micturition phase is elicited by slowly adapting 
mechanoreceptors in the urinary bladder wall (Gonzalez et al., 2014). The spinobulbospinal 
pathway consisting of an ascending sensory limb that passes from the sacral spinal cord to 
circuitry in the rostral brainstem mediates the micturition reflex. The micturition reflex leads 
to activation of neurones in the pontine micturition centre that send excitatory signals back to 
the sacral spinal cord to complete the reflex circuit (Noto et al., 1991; Tai et al., 2009). A 
complex integration of afferent signals along with conscious perceptions of how full one’s 
bladder is and an appreciation of the social environment of the moment, mediates voiding. 
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When the urinary bladder fills to approximately 200-300 ml, there is an increase in afferent 
firing from tension receptors in the bladder which produces firing in the sacral 
parasympathetic pathways and inhibition of sympathetic and somatic pathways (Sugaya et al., 
2003; Tanaka et al., 2003). At a critical level of bladder distention, the afferent activity 
arising from mechanoreceptors in the bladder wall switches the pontine micturition centre 
“on” and enhances its activity. At this point, the accommodation centre shuts “off” and 
ascending afferent input passes through the periaqueductal gray relay centre before reaching 
the pontine micturition centre and elicits efferent outflow (De Groat & Yoshimura, 2009). 
The signal stimulates the spinal cord, which responds with parasympathetic activity that 
relaxes the smooth muscle of the internal urethral sphincter and contracts the detrusor muscle. 
Postganglionic axons that terminate in the detrusor layer release acetylcholine onto the 
smooth muscle fibres, with consequent contractions of the bladder in processes mediated by 
mAChRs in detrusor cells. ATP is co-released with acetylcholine from the parasympathetic 
nerves. The acetylcholine and ATP released activate the mAChRs and purinergic receptors 
respectively (Tsai et al., 2012). Moreover, urine does not flow until a voluntary nerve impulse 
from the pudendal nerve relaxes the striated muscle of the external urethral sphincter. 
1.1.3 Disorders of the lower urinary tract  
Lower urinary tract symptoms can be divided into three groups, namely, storage symptoms 
(e.g. urgency, frequency, urinary incontinence, overactive bladder), voiding symptoms (e.g. 
hesitancy, straining, low flow rate, increased residual volume) and post-micturition 
symptoms (a feeling of incomplete emptying following urination) (Alexandre et al., 2016).  
1.1.3.1 Overactive bladder (OAB)  
Detrusor overactivity is the urodynamic observation characterised by involuntary detrusor 
contractions during the filling phase that may be spontaneous or provoked (Haylen et al., 
2010). In men, detrusor overactivity may cause overactive bladder.  Overactive bladder 
syndrome is characterised by urinary urgency, usually accompanied by frequency and 
nocturia, with or without urgency urinary incontinence, in the absence of urinary tract 
infection or other obvious pathology (Alexandre et al., 2016; Haylen et al., 2010). Overactive 
bladder has been shown to affect up to 36% of adult women in Europe and the U.S.A. (Coyne 
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et al., 2009). Neurogenic overactive bladder results from neurological disorders such as 
multiple sclerosis, spinal cord injury, stroke, or neurodegenerative diseases, while if the 
aetiology is unclear it is regarded as idiopathic or non-neurogenic overactive bladder. 
Detrusor smooth muscle taken from idiopathic overactive bladder have been shown to exhibit 
aberrant spontaneous activity, suggesting that the increased excitability of detrusor smooth 
muscles during this pathological condition may be attributed to the altered properties of the 
smooth muscle cells themselves (Sui et al., 2009).  Research has also implicated alterations at 
the level of the ICC (Johnston et al., 2008). In support, imatinib, an inhibitor of Kit receptor 
tyrosine kinase, was potent at inhibiting evoked and spontaneous contractions in overactive 
bladder than in normal bladder (Biers et al., 2006).  
The medical management of overactive bladder has focused on antimuscarinic agents such as 
oxybutynin, tolterodine, fesoterodine, trospium, darifenacin and solifenacin (Table ‎1.1). 
Oxybutynin is selective for M1 and M3 (Nilvebrant et al., 1997), tolterodine is selective for M2 
and M3, darifenacin and solifenacin are selective M3 mAChR antagonist (Steers, 2006). Also, 
fesoterodine and trospium are the non-selective mAChR antagonist. These drugs bind 
competitively to mAChRs to dampen the amplitude of bladder contractions, improving 
bladder capacity and reducing involuntary detrusor contractions, urgency, and frequency of 
micturition. Antimuscarinics may also decrease bladder afferent activity by blocking 
urothelial mAChRs; thereby further improving overactive bladder symptoms (De Laet et al., 
2006).  
The drawbacks of antimuscarinic treatment include limited tolerability due to the adverse 
effects such as dry mouth, constipation, blurred vision and cognitive impairment, especially 
in the elderly (Wagg et al., 2014). Despite more selective newer antimuscarinics, the drugs 
have limited long-term benefit (Jayarajan & Radomski, 2013; Veenboer & Bosch, 2014). 
Further concerns regarding antimuscarinics have been brought to light as recent cohort 
studies have correlated an increased likelihood of Alzheimer’s disease or dementia in those 
who are undergoing cumulative anticholinergic exposure (Gray et al., 2015). 
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Three β3-AR agonists, mirabegron, ritobegron, and solabegron, have been studied in detail 
regarding their efficacy in treating overactive bladder (Chapple et al., 2014a; Nitti et al 2013; 
2014; Ohlstein et al., 2012). 
Cystometric experiments in rats treated with mirabegron have demonstrated a reduction of 
resting intravesical pressure and contraction frequency without any effect on the amplitude of 
micturition contraction (Takasu et al., 2007).  Based on these findings, sponsored trials which 
recruited over 10,500 patients with overactive bladder were conducted (Chapple et al., 2013a, 
2013b, 2013c; Herschorn et al., 2013; Kuo et al., 2014; Yamaguchi et al., 2014). The 
evidence described suggested mirabegron not being a cure for overactive bladder, but as 
efficacious as most antimuscarinics including tolterodine.  
Ritobegron and solabegron are in differing phases of research while mirabegron is now 
available for the treatment of overactive bladder in many countries. The US Food and Drug 
Administration (FDA) approved mirabegron in June 2012 and the National Institute for 
Health and Care Excellence (NICE) in the UK in June 2013. Mirabegron is also licensed for 
overactive bladder treatment in Japan, Europe and Canada. 
Recently botulinum toxin A was suggested for treatment of overactive bladder (Hsieh et al., 
2016). The mechanism of botulinum toxin A includes inhibition of vesicular release of 
neurotransmitters and the axonal expression of capsaicin and purinergic receptors in the 
lamina propria, as well as attenuation of central sensitization (Hsieh et al., 2016).  Hsieh et al., 
(2016) reported that in a multiple randomised, placebo-controlled trials, botulinum toxin A 
was an effective treatment for patients with refractory idiopathic or neurogenic detrusor 
overactivity. The urinary incontinence episodes, maximum cystometric capacity, and 
maximum detrusor pressure were improved greater by botulinum toxin A compared to 
placebo. Moreover, the adverse effects of botulinum toxin A, such as urinary retention and 
urinary tract infection, were primarily localised to the lower urinary tract.  
Urgency urinary incontinence is the complaint of involuntary leakage accompanied by, or 
immediately preceded by urgency. Urgency urinary incontinence is associated with a sudden 
and strong desire to void as a result of detrusor overactivity or increased sensation in the 
overactive bladder (Abrams et al., 2002). In men with benign prostatic hyperplasia, urgency 
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urinary incontinence co-exists with overactive bladder syndrome or occurs after benign 
prostatic hyperplasia surgery (Han et al., 2007).  Urgency urinary incontinence commonly 
occurred in elderly patients with stroke, Parkinson disease, multiple sclerosis, and various 
spinal cord disorders and Alzheimer disease (Lee et al., 2014; Na et al., 2015).  
1.1.3.2 Bladder outlet obstruction (BOO) 
In ageing men, lower urinary tract symptoms have been attributed to bladder outlet 
obstruction as a result of benign prostatic enlargement resulting from the condition of benign 
prostatic hyperplasia (Abrams et al., 2013). Bladder outlet obstruction is also common in men 
as a result of carcinoma, or calculi which increase back pressure during micturition. 
During the early stages of urethral restriction due to benign prostatic hyperplasia, the bladder 
undergoes compensatory hypertrophy to produce the greater contractile force required to 
force urine past the restriction and keep residual urine volumes low. The primary effects of 
urethral obstruction are found in the bladder and can manifest as hydronephrosis which can 
threaten kidney function (Harrison et al., 1983). If bladder outlet obstruction is left untreated, 
the bladder wall ultimately decompensates and becomes hyperactive with the loss of 
functional capacity. 
Apart from the overactive bladder and bladder outlet obstruction, interstitial cystitis is also a 
disorder of the lower urinary tract.  Interstitial cystitis is a chronic inflammatory bladder 
disease characterised by urinary frequency, urgency, and bladder/pelvic pain. Afferent 
pathways are sensitised in interstitial cystitis (Parsons et al., 1998; Theoharides et al., 1995). 
Moreover, the release of ATP and NO are increased with interstitial cystitis (Logadottir et al., 
2004; Sun & Chai, 2006). Antibiotics and pentosan polysulfate have been suggested to 
relieve the bladder pain or discomfort associated with interstitial cystitis (Table ‎1.1). 
Antibiotics and pentosan polysulfate are only effective in relieving bladder pain in about 
30%-60% of patients. Moreover, they mediate unfavourable side effects, including nausea, 
diarrhoea, gastric distress, and hair loss (Fiehn & Kim, 2014).  
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1.1.3.3 Stress urinary incontinence (SUI)  
Stress urinary incontinence (SUI), characterised by involuntary loss of urine during exertion, 
sneezing and coughing is most common in women, although, it does occur in men following 
prostatectomy (Khandelwal & Kistler, 2013). Stress urinary incontinence is a common 
condition affecting nearly half of all women suffering from urinary incontinence (Medina et 
al., 2016). The estimated worldwide number of women aged ≥20 years projected to have SUI 
or mixed urinary incontinence in 2018 is 153.5 and 52.5 million, respectively (Irwin et al., 
2011).  A recent study by Mckenzie et al., (2016) showed that prevalence of SUI in women 
was 49.3% in Western Australia (mean age of 39 years).  
Stress urinary incontinence is characterised by impaired closure mechanisms of the urethra as 
a result of a weak pelvic floor or poorly supported urethral sphincter (urethral hypermobility) 
and/or a damaged urethral sphincter system (intrinsic sphincter deficiency). The two 
conditions result in impaired urethral closure and involuntary loss of urine (Khandelwal & 
Kistler, 2013; Yoshimura & Miyazato, 2012).  In SUI animal models, both urethral striated 
and smooth muscles are significantly reduced (Badra et al., 2013). However, SUI is linked to 
intrinsic sphincter deficiency more than urethral hypermobility. Several studies have shown 
incontinence could emanate from damage to the urethral sphincter (Chaliha et al., 1999).  
Furthermore, pelvic floor musculature and hormonal changes coupled with the shorter urethra 
in the female contribute to the prevalence of SUI in female (Kristiansson et al., 2001; Tunn et 
al., 2006).  Menopause, pregnancy, obesity, constipation, diabetes mellitus, pelvic organ 
prolapse and vaginal parity further predispose women to SUI (Brown et al., 2006; Zhu et al., 
2009).   
Present treatments for SUI have been limited largely to continence surgery and various types 
of behavioural interventions (conservative method); including pelvic floor muscle training 
(e.g. Kegel exercises) (Table 1.2). Hormonal, minimal invasive surgeries and 
pharmacotherapy are also treatments for SUI (Ishiko et al., 2001; Zyczynski et al., 2015). 
Although pelvic floor muscle training can be effective, it requires motivation on the part of 
the patient for up to 20 weeks; moreover, the dropout rate is high (Ashworth & Hagan, 1993). 
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Likewise, the efficacy of pelvic floor muscle training is limited in women with severe 
incontinence. Conservative methods have been shown to be time consuming and of variable 
efficacy (Berghmans et al., 1998).  
Oestrogen replacement therapy with oestrogen or progestogens, which acts on the supporting 
tissue of the pelvic floor as well as increasing α-ARs density, vascularity/thickness, 
sensitivity, neuronal sensitivity and metabolism poses the question of safety (Csizmadi et al., 
2004). Oestrogen replacement therapy is associated with breast cancer, ovarian cancer, and 
stroke. The FDA thereby mandated that all labels of oestrogen replacement medication must 
carry a warning stating the increased risks for heart disease, heart attacks, strokes and breast 
cancer. Moreover, continual use of oral oestrogen substitution has been stated to increase the 
risk of developing SUI  (Goldstein et al., 2005; Sood et al., 2014 ). Thus, due to the lack of 
evidence of its effectiveness and increased awareness of the harms of hormone therapy (Sood 
et al., 2014), oral oestrogen is less prescribed as a treatment of SUI.  
Pharmacological treatment of stress urinary incontinence 
In women who are not candidates for conservative therapies or surgical interventions, 
pharmacological agents are often used off-label to alleviate the symptoms.  Pharmacotherapy 
focuses on increasing maximal urethral closure pressure, that is, enhancing the resistance of 
the proximal urethra and the bladder neck. Alpha-AR agonists, such as pseudoephedrine and 
phenylephrine, are used off-label for SUI treatment based on the urethral smooth muscle 
response to stimulation and improvements in intrinsic sphincter deficiency.  
Imipramine: The tricyclic antidepressant, imipramine, used off-label for the treatment of 
SUI, facilitates urine storage by several mechanisms. It decreases bladder contractility 
through an antispasmodic effect on the detrusor muscle, increasing outlet resistance through 
an α-adrenergic effect on the bladder neck (Cameron et al., 2013). It also antagonises 
mAChR, inhibits noradrenaline uptake into nerve terminals and smooth muscle. Moreover, 
imipramine mediated Ca
2+
antagonism and histamine H1 receptor blockade (Dave et al., 2002). 
Older animal studies and low-quality human trials have suggested a benefit in SUI and 
urgency urinary incontinence, but high-quality evidence is lacking. Currently, the use of 
imipramine for the management of SUI and urgency urinary incontinence lacks strong 
 54 
 
 
clinical evidence and cannot be recommended. Dave et al., (2002) reported serious 
cardiovascular toxicity in the form of ventricular dysrhythmias and orthostatic hypotension 
for imipramine usage. Recently, Caldwell et al., (2016) reported from randomised and quasi-
randomised trials that imipramine reduced the number of wet nights during treatment, but it 
does not have a sustained effect.  
Fesoterodine (Antimuscarinic): Fesoterodine 8 mg improved severe urgency and symptom 
in urgency urinary incontinence patients (Dubeau et al., 2014; Ginsberg et al., 2013). In a 12-
week, randomised, double-blind, placebo-controlled, multinational trial of men and women 
aged ≥18 years with overactive bladder symptoms including urgency urinary incontinence, 
fesoterodine 8 mg showed significantly superior efficacy vs. placebo as measured by 
reductions in urgency urinary incontinence episodes (Chapple et al., 2014b). However, in a 
randomised, double-blind, placebo-controlled, crossover study, using urethral pressure 
reflectometry, fesoterodine did not affect urethral pressure (Klarskov et al., 2014). Moreover, 
it did not significantly decrease the number of incontinence episodes in women with SUI. 
Thus, the study of Klarskov et al., (2014) does not support the use of antimuscarinics for SUI. 
Thus the effectiveness of fesoterodine in the management of SUI is still unclear. 
Duloxetine: Duloxetine, a dual noradrenaline and serotonin reuptake inhibitor has been 
reported to improve SUI symptoms (Dmochowski et al., 2003). Duloxetine reduced 
incontinence episodes and increased micturition control (Redaelli et al., 2015). Data also 
support duloxetine's efficacy in women with severe SUI (Cardozo et al., 2004; Dmochowski 
et al., 2003; Millard et al., 2004).  A study by Fink et al., (2008) on the effect of off-label 
duloxetine on men with SUI after prostate surgery, showed that 40 mg duloxetine twice daily 
was effective. When taking Duloxetine, the average use of incontinence pads decreased per 
day. Moreover, Cardozo et al., (2004) showed a significant improvement with duloxetine 
compared with placebo in incontinence episode frequency. At the conclusion of the 8-week 
study, 20% of duloxetine-treated women were no longer interested in surgery. Ayeleke et al., 
(2015) reported the combined therapy of duloxetine and pelvic floor muscle exercise. 
However, there were no statistically significant differences between women (with SUI, 
urgency urinary incontinence or mixed urinary incontinence) who received pelvic floor 
muscle therapy added to duloxetine and those who received duloxetine alone. 
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Discontinuations due to side effects were significantly more widespread with duloxetine 
(Cardozo et al., 2004; Dmochowski et al., 2003; Millard et al., 2004). Side effects leading to 
discontinuation of duloxetine included dry mouth, fatigue, nausea, constipation, and 
hyperhidrosis (Bump et al., 2008; Lin et al., 2008; Schagen Van Leeuwen et al., 2008; Vella 
et al., 2008). The FDA currently approves duloxetine for the treatment of depression. It failed 
FDA approval for the treatment of SUI due to poor efficacy and increased suicidal ideation 
and suicide in depressed patients (Cameron et al., 2013). 
Alpha1-AR agonists: The α1-ARs are a promising drug target for increasing the urethral 
luminal pressure in stress urinary incontinent patients (Segev et al., 2015). However, only 
preliminary data on the use of the α1-ARs agonist for treating the SUI is available.  
a) Phenylpropanolamine (PPA) 
Collste & Lindskog, (1987) showed in a double-blind placebo-controlled study in 24 patients 
that phenylpropanolamine, 50 mg twice daily increased maximum urethral closure pressure. 
However, only 8-29% improvement in maximum urethral closure pressure was recorded. 
Complete continence was not achieved in this study. This effect was quite low compared to 
the expected maximum urethral closure pressure improvement targeted in patients. Ek et al., 
(1978) showed up to 55% maximum urethral closure pressure improvement using 100mg 
(norephedrine) instead, which increased the severity of side effects. Moreover, only 2 of 22 
patient conditions improved. In a cross-over, blinded study in dogs, Segev et al., (2015) 
showed a significant increase in systolic, diastolic, and mean blood pressure following 
administration of phenylpropanolamine at 2 mg/kg body weight. Based on the cardiovascular 
side effect in human, phenylpropanolamine was withdrawn for use in humans in 2003 by the 
US FDA. 
No increase in maximum urethral closure pressure with phenylpropanolamine was found in 
human (Obrink & Bunne, 1978) or beagle dogs (Noel et al., 2013); only one of 10 women 
reported improvement.  The result reported by Obrink & Bunne, (1978) might be 
significantly affected by the loss of tissue response on long-term exposure (up to three weeks). 
White & Pomeroy, (1989) reported this response in female dogs with a decrease in a urethral 
response associated with recurrence of incontinence after a prolonged administration (three 
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months) of phenylpropanolamine.  Furthermore, another pharmacokinetic and urodynamic 
study for continent female beagle dogs showed that urethral resistance increased after single 
daily phenylpropanolamine administration, but not when phenylpropanolamine was 
administered every 6 hours during the day (Noel et al., 2010). Desensitisation of the α-ARs 
has been proposed by several authors to explain this observation (Akinaga et al., 2013).  
b) Other α1-AR agonists  
A61603, an α1A-AR agonist, shows high specificity for α1A- and α1L-AR phenotypes and is 
essentially inactive at the α1B- and α1D-ARs (Yoshiki et al., 2013). A61603 was more potent 
than noradrenaline at the α1A-AR phenotype and showed full agonist activity at both α1A and 
α1L phenotypes (Yoshiki et al., 2013). Systemic administration of A61603 in dog and 
conscious rat models elevated the intraurethral pressure (Knepper et al., 1995). To our 
knowledge, no report has used A61603 to increase the urethral luminal pressure in the human. 
Methoxamine an α1- AR agonist evoked non-significant increases in maximum urethral 
pressure but also caused a significant rise in blood pressure and significant fall in heart rate at 
maximum dosage in women (Radley et al., 2001). This study also reported systemic side 
effects including headaches, piloerection, and cold extremities in subjects.   
The potential therapeutic benefits of the selective α1A/L-AR partial agonist Ro 115-1240 have 
also been investigated in women with mild-to-moderate SUI (Musselman et al., 2004). 
Clinical studies suggested that selective α1A/L-AR partial agonists have the potential to 
improve the symptoms of SUI with little or no cardiovascular effect (Blue et al., 2004; 
Musselman et al., 2004). In an in vivo model of urethral function, PF-3774076, a partial 
agonist at the human α1A-AR resulted in a dose-dependent increase in urethral pressure in 
both the proximal and distal regions of the urethra (Conlon et al., 2009).  However, further 
clinical applications of these drugs are lacking in the literature. 
The present challenge in the use of α-AR agonists for SUI pharmacotherapy is the lack of 
exclusive selectivity for the urethral α-ARs, as severe cardiovascular adverse side effects 
such as headaches, elevated blood pressure, anxiety, tremor, weakness, respiratory difficulty 
are common (Ek et al., 1978; Segev et al., 2015). A better understanding of the 
pharmacology/physiology of urethral tissue is crucial to aid better drug development for SUI. 
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1.2 THE ANORECTUM 
1.2.1  Structure  
The rectum is a muscular channel (12-15cm) that stores stools and terminates with a 2-4cm 
long muscular tube called the anus (Figure ‎1.9). The internal anal sphincter (IAS), external 
anal sphincter, anal mucosa folds, as well as the vascular cushion surround the anal opening 
(Figure ‎1.9) (Stoker, 2009).  The mucosa of the upper anal canal is lined by columnar 
epithelium while squamous epithelium lines the mucosa below the dentate line (Tanaka et al., 
2012). Furthermore, the transition between columnar, transitional or squamous epithelium is 
present above the dentate line.  The anal crypt is of importance in anorectal disorders because 
foreign materials may lodge there, thereby obstructing faecal passage and leading to sepsis. 
The mucosa folds and the vascular cushion mediate the tight sealing of the anus, thereby, 
helping to reinforce tone during voluntary squeeze (Gibbons et al., 1986a;b ).   
1.2.1.1 Internal Anal Sphincter (IAS) 
The IAS is a 0.3-0.5cm thick extension of the circular smooth muscle of the rectum. It is 
tonically contracted and accounts for 80% to 85% of the anal canal resting pressure 
(Frenckner & Euler, 1975). Internal anal sphincter basal tone is inherently myogenic, 
although angiotensin II and prostaglandin F2α have been shown to modulate the tone (De 
Godoy et al., 2004; De Godoy et al., 2009). This tone is dependent on extracellular Ca
2+
 entry 
via the L-type Ca
2+
 channels (Cook et al., 1999b). Moreover, IAS spontaneous basal tone 
contributes to the pathophysiology of numerous gastrointestinal disorders, such as anal 
fissures, constipation, haemorrhoids, and Hirschsprung's disease. 
The IAS contracts in response to noradrenaline released by sympathetic innervation 
(Carlstedt et al., 1988).  Internal anal sphincter relaxation is neurogenic and is mediated via 
non-adrenergic, non-cholinergic neurotransmitters such as NO and vasoactive intestinal 
peptide. Beta-ARs and peptidergic receptors also contribute but via mechanisms that are not 
entirely understood. Moreover, contraction and relaxation of the IAS are regulated by the 
actions of other cell types, including ICC and fibroblast-like cells (De Lorijn et al., 2005). 
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Figure  1.9 The anorectum. The anorectum is a channel that serves as the temporary store and passage for 
stools. The anorectum is made up of the internal anal sphincter, external anal sphincter; extension of the 
levator ani, puborectalis, and the anal cushion that helps to maintain faecal continence. Adapted from 
(Gordon & Nivatvongs, 2007). 
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1.2.1.2 External Anal Sphincter (EAS) 
The external anal sphincter, a 0.6-1cm thick striated muscle contributes to the tonic 
contraction as well as the voluntary control of the anorectum. It is an extension of the levator 
ani muscle and morphologically separated from the IAS. A spinal reflex causes the external 
anal sphincter to contract during sudden intra-abdominal pressure increases, such as coughing, 
thereby, external anal sphincter helps to maintain continence (Kumar et al., 1990; Sun et al., 
1990). 
1.2.1.3 Puborectalis muscle 
The puborectalis muscle is also a striated muscle which wraps around the rectum. It creates 
the anorectal angle (normally 60° to 105°) which slows the progress of stool to the anal canal. 
This muscle also prevents movement of faeces from the rectum to the anal canal between 
defecations. The puborectalis muscle functions with voluntary control and produces a tonic 
contraction (Fernandez-Fraga et al., 2002). 
1.2.2 Innervation and function 
The anorectum is innervated by the autonomic (sympathetic and parasympathetic nerves) and 
enteric nervous systems while the outer funnel-shaped tube of the anorectum has somatic 
innervation. The main innervation of the gastrointestinal tract is intrinsic, from neurones of 
the enteric nervous system.  These innervations modulate peristalsis and are involved in the 
defecation reflex. The autonomic inputs to the IAS are tyrosine hydroxylase staining fibres 
(sympathetic) and NO staining fibres (parasympathetic) (Ishiyama et al., 2014; Kinugasa et 
al., 2014).  
The proximal gastrointestinal tract (proximal-mid colon) receives extrinsic parasympathetic 
efferent innervation via the vagus nerve (Ranson & Saffrey, 2015). Extrinsic parasympathetic 
efferents to the distal bowel arise from spinal segments S2–S4 in humans and innervate the 
distal colon, anorectum, and IAS. The sympathetic innervation of the distal bowel originates 
in spinal segments T5–L2 and these thoracolumbar innervations inhibit bowel movement and 
maintain continence by contracting the IAS (Ranson & Saffrey, 2015). The sympathetic 
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hypogastric nerves of the IAS control involuntary activities of the IAS (Barleben & Mills, 
2010). Moreover, the epithelium of the proximal region to the anorectal dentate line is 
innervated by the autonomic nervous system, while the somatic nervous system innervates 
the epithelium of the distal part of the anal canal (Wang et al., 2013). The epithelial fibres 
either have a sensory function, for example, those positive for calcitonin gene-related peptide 
and substance P or secretory function, for example, the vasoactive intestinal peptide (Wang et 
al., 2013). 
The sacral spinal cord accommodates the motoneurons that regulate the voluntary response of 
the pelvic floor muscles and external anal sphincter during defecation (Ranson &Saffrey, 
2015). The external anal sphincter has somatic innervation from the pudendal nerve (S2–S4). 
Moreover, the puborectalis muscle has somatic innervation from the pelvic branches of the S3 
and S4 pudendal nerves.  The pudendal nerve modulates sensation in the perianal and genital 
skin, the tone of the external anal sphincter and rectoanal contractile reflexes (Frenckner & 
Euler, 1975).    
1.2.2.1 Sympathetic innervation of the internal anal sphincter 
IAS contraction occurs through sympathetic nerve stimulation (Moszkowicz et al., 2012). 
Autoradiographic studies with [
3
H] prazosin showed a positive association of α1-AR with 
immunohistochemically identified smooth muscle fibres of sheep and human IAS (Rayment 
et al., 2010).  The sheep IAS also showed a positive result to adrenergic nerves staining using 
a tyrosine hydroxylase antibody (Rayment et al., 2010).  
Oral administration or intravenous infusion of α-AR antagonist caused a reduction in anal 
sphincter pressure (Gutierrez & Shah, 1975; Pitt et al., 2001) suggesting a role for α-ARs in 
the tonic control of sphincter pressure. Likewise, adrenergic stimulation via intravenous 
infusion of α-and β-AR agonists in cats (Penninckx et al., 1973) and humans (Gutierrez & 
Shah, 1975) has demonstrated that the effects of α-AR stimulation are excitatory to the IAS 
and that β-AR effects are inhibitory. The selective α1-AR antagonist prazosin reduced 
hypogastric nerve induced elevation of resting pressure of the sphincter in anaesthetised 
opossum (Yamato & Rattan, 1990). Moreover, exogenous addition of phenylephrine 
increases IAS resting pressure in opossum, an effect blocked by prazosin. Tetrodotoxin did 
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not modify this effect and was consistent with a post-junctional location for α1-ARs on 
smooth muscle cells (Yamato & Rattan, 1990). The importance of α-ARs in IAS tone is 
underlined by the use of L-erythro-methoxamine (α-AR agonist) to elevate mean anal resting 
pressure of patients with faecal incontinence (Nisar et al., 2005). Moreover, radioligand 
binding studies and immunohistochemistry have revealed the presence of α1A-ARs and α2D-
ARs binding sites in the sheep IAS (Rayment et al., 2010). Activation of the α1-AR subtype 
mediates contraction of IAS smooth muscle of pig (Mills et al., 2008), sheep (Rayment et al., 
2010) and human (Owaki et al., 2015). The α1A-AR subtype predominantly contributes to 
human IAS contraction (Owaki et al., 2015) and specifically the α1L-AR subtype in the 
porcine IAS (Mills et al., 2008).  
Alpha2-ARs are known to be present in the duodenum and proximal colon (Zhang et al., 1992; 
Valet et al., 1993) and α2-AR agonists induce colonic and rectal relaxation (Viramontes et al., 
2001; Camilleri et al., 2003). Radioligand binding studies have revealed the presence of α2-
AR binding sites in the sheep anal sphincter membranes, but the density was only half of that 
detected for α1-AR binding sites (Rayment et al., 2010). Activation of α2-AR inhibits non-
adrenergic, non-cholinergic -mediated recto-anal inhibitory reflex-induced IAS relaxation of 
opossum IAS (Yamato & Rattan, 1990). The α2-AR agonists induced contraction in the sheep 
IAS (Rayment et al., 2014). Rayment et al., (2014) also provided evidence for a dual role for 
α2-ARs on the sheep isolated IAS: direct constrictor effect and modulation of noradrenergic 
transmission. Also, α2-ARs played a role in noradrenaline-mediated constriction of the pig 
isolated IAS, but only at high concentrations (Mills et al., 2008).   
The inhibitory effect of sympathetic nerve stimulation in the human gastrointestinal tract is 
mediated by the activation of post-junctional β-ARs (Manara et al., 2000). The classical β1-
ARs, β2-ARs, and β3-ARs mediate these responses. Beta2-ARs activate both Gsα and Gi/o α-
protein subunits and induce relaxation in the rat IAS via both cyclic AMP/cyclic GMP 
pathways. In contrast, β1-ARs / β3-ARs activation caused smooth muscle relaxation via the 
Gi/oα- guanylate cyclase/cyclic GMP/protein kinase G pathway (Li et al., 2004). The β3-AR-
mediated effect was mediated via the cyclic GMP pathway similar to NO (Banwait & Rattan, 
2003). Agonists acting at all three β-ARs relaxed the opossum IAS (Rathi et al., 2003). 
Ballester et al., (2010) reported a β3-mediated relaxation of sphincter tone of human IAS. 
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Direct β3-relaxation appears smaller than that obtained for nonselective agonists, however, 
β3-AR activation does mediate IAS relaxation. 
1.2.2.2 Parasympathetic innervation of the internal anal sphincter 
Cholinergic neurones mediate the contraction of gastrointestinal smooth muscle (Inoue & 
Isenberg, 1990). Acetylcholine binding to mAChRs (M2, M3) on canine colonic circular 
smooth muscle mediates increases in cytosolic Ca
2+
 and contraction (Zhang et al., 1991). 
Likewise, bethanechol induced contraction of the human IAS acting through M3 mAChRs 
(Singh et al., 2009). However, in some studies, acetylcholine and carbachol have been shown 
to exert inhibitory effects on IAS smooth muscle (Burleigh et al., 1979; Ramalingam et al., 
2010). According to Ramalingam et al., (2010), the carbachol caused relaxation of IAS strips 
via two mechanisms, which includes the release of noradrenaline which might activate β-AR 
because guanethidine (10μM) blocked the carbachol responses. Secondly, the report suggests 
that mAChR were present on NO-releasing nerves such that the activation of mAChR 
mediated the release of NO, because inhibitors of NOS attenuated the response to carbachol 
(O'Kelly et al., 1993b; Ramalingam et al., 2010).  
1.2.2.3 Sensory innervation of the internal anal sphincter 
The sensory nervous system analyses the exact contents of the rectum and produces the sense 
of urge. Anal sensations are necessary for a person to contract the external anal sphincter if 
defecation is to be postponed. Both unmyelinated and myelinated afferent nerve fibres are 
present in the anorectum (Bharucha, 2006) and mediate the stretch or distension-induced 
sensory responses. They also induced the viscero-visceral, the recto-anal inhibitory and the 
recto-anal contractile reflexes (Remes-Troche et al., 2010). Sensory fibres transmit the 
sensation of rectal distention in the S2-S4 pudendal nerves (Rogers, 1992).  Pudendal nerve 
block creates a loss of rectoanal contractile reflexes and sensation in the perianal and genital 
skin.  
The function of sensory nerves of the anal canal is to allow anal sampling. The anal sampling 
reflex, including short-lasting rectal contraction and relaxation of the upper part of the anal 
canal, allows the subject to sense the content of the rectum. Rectal sensation arises from the 
 63 
 
 
stimulation of nerve endings and mechanoreceptors, both in the rectal wall and the adjacent 
pelvic structures (Rogers, 1992). This is supported by the finding of existence of 
intraganglionic laminar nerve endings in the myenteric plexus of the rat rectal wall that are 
sensitive to mechanical distension (Zagorodnyuk et al., 2005). 
1.2.2.4 Enteric Nervous System (ENS) 
The enteric nervous system ‘the second brain’ works in concert with neural control centres in 
the lower brain stem, spinal cord and sympathetic ganglia (Furness, 2015). The enteric 
nervous system consists of the network of ganglia (myenteric plexus) and the smaller ganglia 
(the submucous plexus) (Furness, 2015). The myenteric plexus lies between the rectal wall 
smooth muscle layers, the longitudinal and circular muscle layers which make up the 
muscularis externa. However, the smaller ganglia, the submucosal plexus, are present in the 
connective tissue that lies between the muscularis externa and the mucosa.  
The mechanosensitive neurones have been described in the myenteric plexus using 
extracellular electrodes and within the gut, the enteric nervous system can sense mechanical 
stimuli and trigger gut reflex behaviour (Mazzuoli & Schemann, 2012). Mazzuoli & 
Schemann, (2009) presented evidence for multifunctionality of rapidly adapting 
mechanosensitive enteric neurones which may fulfil sensory, integrative and motor functions. 
The roles of the enteric nervous system include control or regulation of movements of the 
digestive tract and release of gastrointestinal hormones. The enteric nervous system controls 
the complex functions of the gastrointestinal tract such as peristalsis, blood flow, independent 
regulation of motility and secretion (Benarroch, 2007; Brehmer, 2006; Lake & Heuckeroth, 
2013; Wood, 2010; Zhang & Hu, 2013).  Moreover, the distension induced motor behaviour 
of the isolated intestine is regulated by the enteric nervous system (Mazzuoli & Schemann, 
2012).  
1.2.2.5 Stool Storage/Expulsion 
When an individual is not defecating the rectum is compliant. During faecal storage, the 
rectum receives increasing amounts of stool volume while maintaining a constant 
intraluminal pressure. The rectum can accommodate up to 300 ml of faecal material before 
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intraluminal pressure increases and a feeling of urgency develops. The IAS relaxes 
temporarily in response to rectal distension and this relaxation reflex, mediated by enteric 
nerves, is not under voluntary control. When a stool accumulates in the rectum, the rectum 
distends (compliance), and the IAS relaxes while the external anal sphincter contracts. The 
external anal sphincter contraction helps to perceive and differentiate between a hard stool, 
soft stool and gas (anal sampling) (Miller et al., 1988a), which is frequently abnormal in 
incontinent patients (Miller et al., 1988b).  If the environment is not conducive for defecation, 
faecal materials can be returned to the colon for more water reabsorption. If a patient chooses 
not to defecate, they increase contraction of the external anal sphincter to maintain continence. 
Some stool also moves slightly more to the proximal colon, thereby reducing the pressure in 
the rectum as well as the urge to defecate. 
When the environment is conducive for passing out the stool, defecation is initiated.  
Initiation of defecation is associated with activation of the stretch receptors in the rectum, as 
well as initiation of the recto-anal inhibitory reflex (Scharli & Kiesewetter, 1970). Neurally-
mediated relaxation of the IAS muscle is mediated by distension sensed by mechanoreceptors 
of the rectal wall. To defecate, a suitable posture is assumed, the rectal angle straightens, the 
sphincters relax, the pelvic floor descends, the rectum contracts and abdominal pressure rises 
due to straining. The pelvic floor then descends and the rectum contracts, the external anal 
sphincter relaxes while the tonic activity of the external anal sphincter is inhibited. Together, 
these events lead to the evacuation of the rectal contents (Bartolo et al., 1985). Any activity 
or damage that affects the processes described could cause or increase the risk of faecal 
incontinence. 
1.2.3 Faecal incontinence (FI) and anal fissures 
Faecal incontinence is defined as a complaint of involuntary loss of flatus and/or liquid or 
solid stool via the anus. The prevalence of faecal incontinence varies between 5% and 15% of 
the general population (Damon et al., 2006; Macmillan et al., 2004). The prevalence increases 
with age from approximately 3% in people in the second decade to 16% in people aged 70 
years or over (Ditah et al., 2014). US community-based prevalence data suggest that faecal 
incontinence affects approximately 20 million adults (Whitehead et al., 2009). A cross-
sectional survey conducted in a primary care setting in Sydney, Australia, reported a 
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prevalence of 12.1% for faecal incontinence (Ng et al., 2015). However, these figures are 
most probably underestimated, since less than 25% of patients with faecal incontinence report 
it to their physician.  
The incidence of faecal incontinence increases in the frail, immobile, elderly and patients 
with severe behavioural, neurological and obstetric disorder/injury (Ditah et al., 2014; Shah 
et al., 2012). Chronic inflammatory bowel diseases and side effects of radiotherapy can also 
lead to faecal incontinence (Table 1.3).  In addition, high body mass index, smoking, 
diarrhoea and constipation are all associated with faecal incontinence (Ditah et al., 2014; 
Townsend et al., 2013).  Faecal incontinence is a cause of significant cost due to diagnostics, 
treatment, care and reduced ability to work (Xu et al., 2012). The average annual total cost 
for faecal incontinence management was $4110 per person annually in the United States in 
2010 (Xu et al., 2012). 
Faecal incontinence can be classified as urge, passive, overflow or post-defecatory. Urge 
faecal incontinence is the need to pass faecal material, but the stool being released before 
getting to the convenience, due to lack of voluntary control. It is associated with dysfunction 
of the external anal sphincter (Engel et al., 1995).  On the other hand, passive faecal 
incontinence is a situation where the individual is aware of faecal leakage only after the 
faecal material has been released. Moreover, overflow faecal incontinence is related to 
leakage of stools when the rectum is blocked by a hard stool, incomplete evacuation, and 
impaired rectal sensation is responsible (Engel et al., 1995; Rao et al., 2004). Post defecatory 
faecal incontinence is characterised by faecal leakage following passing out faecal material. 
Post defecatory faecal incontinence is usually associated with an inability to clear the rectum 
as well as a loss of proper function of the IAS  (Engel et al., 1995; Vaizey et al., 1997). 
Faecal incontinence is prevalent due to thinning of the external anal sphincter, degeneration 
of the IAS, weakening of the muscular contraction and increased latency of the pudendal 
nerve firing (Lubowski et al., 1988; Santoro et al., 2012; Tetzschner et al., 1995). Useful 
examinations for faecal incontinence include anal endosonography to detect any damage to 
the anal sphincters and anorectal manometry to measure compliance and rectal sensation as 
well as pelvic floor muscle strength (Mahony et al., 2004). 
 66 
 
 
T
a
b
le
  1
.3
 C
o
m
m
o
n
 C
a
u
se
s 
o
f 
fa
ec
a
l 
in
co
n
ti
n
en
ce
 a
n
d
 p
re
d
is
p
o
si
n
g
 f
a
ct
o
rs
 
R
ef
er
en
ce
s 
A
ls
ad
iu
s 
et
 a
l.
, 
2
0
1
2
. 
 
B
y
tz
er
 e
t 
al
.,
 2
0
0
1
; 
 
C
h
ia
 e
t 
al
.,
 1
9
9
5
; 
L
u
n
n
is
s 
et
 a
l.
, 
2
0
0
4
. 
B
h
ar
u
ch
a 
et
 a
l.
, 
2
0
1
5
. 
 B
h
ar
u
ch
a 
et
 a
l.
, 
2
0
1
5
. 
 
F
y
n
n
e 
et
 a
l.
, 
2
0
1
1
. 
P
re
d
is
p
o
si
n
g
 f
a
ct
o
rs
 
C
o
n
g
en
it
al
, 
an
o
re
ct
al
 m
al
fo
rm
at
io
n
s,
 r
ad
ia
ti
o
n
 t
h
er
ap
y
, 
o
b
st
et
ri
c 
an
al
 s
p
h
in
ct
er
 i
n
ju
ry
, 
an
al
 s
u
rg
er
y
, 
p
er
ia
n
al
 
fi
st
u
la
s,
 s
ex
u
al
 a
b
u
se
. 
S
p
in
al
 c
o
rd
 l
es
io
n
s,
 s
tr
o
k
e,
 m
u
lt
ip
le
 s
cl
er
o
si
s,
 d
ia
b
et
ic
 
n
eu
ro
p
at
h
y
, 
o
b
st
et
ri
c 
n
er
v
e 
d
am
ag
e.
 
In
fl
am
m
at
o
ry
 b
o
w
el
 d
is
ea
se
, 
ra
d
ia
ti
o
n
 t
h
er
ap
y
, 
re
ct
al
 
p
ro
la
p
se
, 
fa
ec
al
 i
m
p
ac
ti
o
n
. 
D
em
en
ti
a.
 
S
y
st
em
ic
 s
cl
er
o
d
er
m
a.
 
C
o
m
m
o
n
 C
a
u
se
s 
o
f 
fa
e
ca
l 
in
co
n
ti
n
en
ce
 
A
n
al
 s
p
h
in
ct
er
 d
y
sf
u
n
ct
io
n
 
N
eu
ro
lo
g
ic
al
 d
is
o
rd
er
s 
R
ec
ta
l 
d
is
o
rd
er
s 
P
sy
ch
o
lo
g
ic
al
 
M
y
o
p
at
h
y
 
 67 
 
 
1.2.3.1 Treatments for faecal incontinence 
Conservative therapy is the first-line treatment for patients with faecal incontinence. Personal 
hygiene and diet control, the use of antidiarrheal drugs (loperamide, codeine) and pelvic floor 
therapy characterise conservative treatment (Palmer et al., 1980). Constipating agents 
decrease intestinal motility and stool frequency.  Stool-bulking agents, such as mucilage, are 
also useful in the management of faecal incontinence with loose stool because they improve 
stool consistency by increasing water absorption by stools (Table 1.4). Even though the 
efficacy of synthetic fibres has not been rigorously proved scientifically, mucilages are still 
recommended in clinical practice (Vitton et al., 2014), particularly combined with other 
conservative treatments (Sjodahl et al., 2015). However, this therapy is useful only in the 
patient with low volume loose-stool associated faecal incontinence (Meyer & Richter, 2016). 
In regards to antidiarrheal drugs, Markland et al., (2015) reported that the usage of 
loperamide induces chronic constipation in patients in a randomised double-blind placebo-
controlled crossover trial. Thus, antidiarrheal drugs are not the best option for treating faecal 
incontinence. 
Surgery, pelvic floor muscle exercise, and electrical stimulation are the next level of 
treatment (Leung et al., 2006; Pager et al., 2002). The data on pre- and post-treatment 
comparisons of pelvic floor muscle exercises for faecal incontinence are less well established 
compared with urinary incontinence. Anorectal surgery is associated with complications such 
as bleeding and infection (Kunitake & Poylin, 2016). The most feared long-term 
complications of surgery include faecal incontinence, anal stenosis, and chronic pelvic pain 
(Kunitake & Poylin, 2016). 
A double-blind randomised trial applying topical oestrogens in postmenopausal women with 
faecal incontinence showed improvement of continence (Pinedo et al., 2009). Pinedo et al., 
(2012) also reported in a randomised double-blind trial that novel zinc-aluminium ointment 
decreases faecal incontinence significantly compared with placebo. Aluminium ions induce 
cytoplasmic Ca
2+
 oscillation, most probably by acting on the plasma membrane and 
mediating Ca
2+
influx into smooth muscle cells via the L-type Ca
2+
channels (Himpens et al., 
1991). 
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Aluminium ions increase the amplitude of K
+
-induced contraction and mediate changes in the 
physical properties of the plasma membrane and the sarcoplasmic reticulum. They can also 
influence actomyosin ATPase and produce structural changes to the muscle-actomyosin 
complex (Davidovskaya & Bogutska, 2003; Himpens et al., 1991). Although Pinedo et al., 
(2012) showed that zinc-aluminium ointment decreases faecal incontinence, the issue of risk 
of cancer and other complications needs consideration. 
Topical administration of an α1A-AR agonist, L-erythro-methoxamine 3% (w/w) gel (higher 
α1A-AR activity than phenylephrine) applied to the anal canal or rectum of healthy volunteers 
increased maximum anal resting pressure for 5 hours. L-erythro-methoxamine 3% (w/w) gel 
also elevated systemic blood pressure in some healthy volunteers (Nisar et al., 2005). 
Moreover, when lower concentrations of L-erythro-methoxamine (0.3% or 1% (w/w) were 
used the same result (3%) was reported (Nisar et al., 2007). Recently, Simpson et al., (2014) 
reported in a randomised controlled trial, an increase in anal sphincter tone with the use of 
NRL001 (one of four possible stereoisomers of methoxamine). There was a dose-dependent 
increase in anal sphincter tone when comparing the 5 and 10 mg doses of NRL001. However, 
the 15 mg dose did not have a significantly greater effect than the 10 mg dose. The inability 
of methoxamine to maintain the resting pressure for longer hours may suggest desensitisation 
of α1-ARs to this agonist. 
Siproudhis et al., (2014) used NRL001 in phase II double-blind randomised trial and 
evaluated the efficacy, safety, and tolerability of locally applied NRL001 in the patients with 
faecal incontinence. However, the results are yet to be published.  Bell et al., (2014a) further 
reported in another double-blind, placebo-controlled, randomised trial that NRL001 was 
generally well tolerated over 14 days with a daily dosing. Likewise, plasma NRL001 did not 
accumulate over recorded time. Treatments caused changes in vital sign, most notably 
decreased heart rate and other adverse events commonly reported with NRL001 treatment 
were events indicative of a systemic α-adrenergic effect. Moreover, Bell et al., (2014b) did 
report in another randomised, controlled, crossover study that administration of NRL001 
suppositories led to decreases in heart rate when compared with placebo data. NRL001 was 
found to have a dose-dependent effect on heart rate; however clinically relevant bradycardia 
was not reported (Gruss et al., 2014). 
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Thus, topical agents such as phenylephrine (Badvie & Andreyev, 2005; Carapeti et al., 2000a; 
Park et al., 2015) have shown some efficacy for faecal incontinence. However, given the 
limited number of studies and the potential adverse effects such as headaches and dermatitis, 
these treatments are not recommended in clinical practice.  
1.2.3.2 Anal Fissures 
A typical anal fissure is a tear/ulcer in the anoderm distal to the dentate line, which usually 
causes pain during and after defecation (Hananel & Gordon, 1997 ; Madalinski, 2011). In 
contrast, an atypical anal fissure is characterised by multiple ulcers located in locations other 
than the anoderm and could be associated with Crohn's disease, ulcerative colitis, anal cancer, 
tuberculosis, HIV, syphilis, herpes, and leukaemia (Herzig & Lu, 2010; Nelson et al., 2012).  
When a tear in the anoderm heals within six weeks, it is considered as an acute anal fissure, 
while if extended beyond six weeks, it is regarded as a chronic anal fissure (Madalinski, 
2011).  Features of a chronic fissure are exposed fibres of IAS at the base, hypertrophied anal 
papilla proximally, and a skin tag or sentinel pile distally (Brown et al., 1989). The exact 
cause of an anal fissure is not entirely clear, but it is thought to result from trauma to the anal 
canal. The trauma includes those to the anoderm during the passage of hard or large bowel 
movements, local irritation from diarrhoea, anorectal surgery, and anoreceptive intercourse 
(Beaty & Shashidharan, 2016; Markland et al., 2016). Males and females have an equal 
frequency of anal fissures. Fissures are commonly seen in middle-aged and younger patients, 
with a mean age of onset 39.9 years (Hananel & Gordon, 1997).  
Increased pressure within the anal canal is a common characteristic of fissures. Studies have 
shown that the resting pressure of the IAS is higher in patients with fissures compared with 
normal controls (Garg, 2010; Nzimbala & Bruyninx, 2007). Hypertonicity of the anal 
sphincter is also responsible for some of the pain and spasm experienced with defecation, and 
it also has a deleterious effect on wound healing by reducing blood flow to the traumatised 
anoderm (Klosterhalfen et al., 1989). 
Symptoms associated with acute fissures include anal pain, spasm, and/or bleeding with 
defecation (Hananel & Gordon, 1997). The pain is sharp or tearing and associated with 
defecation. The pain may also be present only during the defecation or last for several 
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minutes to hours after defecation. Bleeding is also a common symptom of anal fissure 
(Hananel & Gordon, 1997). 
Present treatments for chronic anal fissure include surgery and conservative methods 
(consumption of fibre and warm water bath). The majority of acute anal fissures resolve 
without surgical intervention. Non-operative management of anal fissures includes alleviation 
of constipation and straining and relaxation of the IAS to improve blood flow and allow 
healing. Prescription of sitz baths, psyllium fibre supplementation and the use of stool 
softeners is a non-operative management.   
However, when chronic fissures develop, healing is harder to achieve, thereby surgery is 
prescribed. Surgical methods,  used to cause a therapeutic tear in the anorectum to correct 
chronic anal fissure, include anal stretch, open or close lateral sphincterotomy and dermal 
flap coverage of the fissure (Nelson et al., 2012). Although the gold standard for treating 
chronic anal fissure is surgical methods, they predispose the patient to the development of 
faecal incontinence (Poh et al., 2010). Hence, pharmacotherapy will be more appealing to 
many patients.   
Present pharmacological approaches to chronic anal fissure include the use of topical nitrates 
(glyceryl trinitrate) (Scholefield et al., 2003), which release NO to relax the IAS (Berndt et 
al., 2004).  Furthermore, Ca
2+
 channel blockers such as nifedipine (Cook et al., 1999a), 
blockers of acetylcholine release and botulinum toxin, which block nerve activity in the IAS, 
have been used for treating chronic anal fissure (Antropoli et al., 1999; Chrysos et al., 1996; 
Jost, 1997). Recently, Gandomkar et al. (2015) reported a recent randomised trial of 99 
patients where lateral internal sphincterotomy was combined with botulinum toxin A 
injection and topical diltiazem in the treatment of chronic fissures.  Overall healing rates were 
65% in the botulinum toxin A-diltiazem group and 94% in the lateral internal sphincterotomy 
group. However, there was no statistical difference between these groups.  
Nelson and colleagues reported the use of agents for anal fissure treatments in randomised 
controlled trials of nonsurgical therapies (Nelson, 2006; Nelson et al., 2012). These agents 
include nitroglycerin ointment (NO donor), isosorbide dinitrate, botulinum toxin, diltiazem, 
nifedipine, hydrocortisone, lignocaine, bran, minoxidil, indoramin, and placebo. 
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Nitroglycerin was found to be marginally but significantly better than placebo in healing anal 
fissure (Nelson, 2006; Nelson et al., 2012). However, late recurrence of the fissure was 
common. The dose of nitroglycerin has been studied extensively by Bailey et al., (2002) & 
Carapeti et al., (1999b). Carapeti et al., (1999b) reported healing in 67% patients treated with 
nitroglycerin compared with 32% with placebo in a randomised controlled trial with 0.2% 
nitroglycerin three times daily, or nitroglycerin starting at 0.2% with weekly 0.1% increments 
to a maximum of 0.6%. Headaches were reported by 72% of patients on nitroglycerin 
compared with 27% on placebo. However, of the fissures healed 25% to 33% of those healed 
with nitroglycerin recurred. Significant recurrence of symptomatic fissures and a high 
incidence of headaches are limitations of the treatment. Moreover, a report from Bailey et al., 
(2002) randomised, double-blind study and  Scholefield et al., (2003) double-blind 
randomised controlled trial of intra-anally applied nitroglycerin ointment showed no 
difference in fissure healing among treated and placebo group. Thereby, they concluded that 
nitroglycerin ointment did not alter healing but significantly and rapidly reduced the pain 
associated with chronic anal fissures. 
Although present pharmacological drugs seem to alleviate the pain of anal fissure, they are 
less effective than surgery, with diminished healing rates and severe adverse effects such as 
headaches and light-headedness, which discourages users and suggests a need for targeted 
specific drugs for the treatment of this condition.   
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Aim and objectives 
Faecal incontinence and stress urinary incontinence are common conditions severely 
affecting the quality of life (QOL) of over 3 million Australians and which need better 
treatment options. The number of patients suffering from these conditions will increase as the 
ageing population increases and as a result of an increase in life expectancy due to the 
availability of better treatment for chronic diseases. 
Presently, there are no effective treatments for incontinence and anal fissure. Current 
pharmacotherapy is non-specific to the urethra and the anorectum, and has limited success, a 
number of systemic side effects, low efficacy and morbidity (Bell et al., 2014a; Carapeti et al., 
1999b; Nelson, 2006; Nelson et al., 2012). Although there is some understanding of the 
factors that help to maintain continence in the urethra and the anorectum, a greater 
understanding of the receptors, neurotransmitters involved and the intracellular signalling 
within the urethra and anorectum smooth muscle is needed.  To develop more effective 
treatments, a better understanding of the physiology and pathophysiology of the urethra and 
anorectum is required; in particular the smooth muscle component, which is densely 
populated by α1A-ARs and is responsible for maintaining continence in the bladder 
neck/urethra and also in the anorectum. Ultimately, the findings of the study may help 
identify novel drug targets and in the long-term the development of more effective 
pharmacotherapies for these critical conditions.  
Aim: To elucidate the pharmacology of the urethral circular smooth muscle and IAS using 
the large White-Landrace pigs. 
Objectives: 
 To investigate the effect of age and the influence of the urothelium on receptor-
mediated responses in the urethra.  
 To compare the receptor-mediated responses in different regions of the urethra. 
 To investigate potential desensitisation of receptor-mediated responses in urethral 
tissues.  
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 To investigate the postsynaptic interaction between the adrenergic and muscarinic 
system in the urethra. 
 To investigate the neurotransmitters involved in modulating internal anal sphincter 
basal tone and contractility. 
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CHAPTER 2 
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2 MATERIALS AND METHODS  
2.1 TISSUE SOURCE 
For this project, porcine tissues were used as a model for human. Porcine tissues from the 
lower urinary tract and anorectum have been shown to be a good model for human, since pigs 
have similar physiology, autonomic pharmacology and functional properties to humans 
(Crowe & Burnstock, 1989; Brading et al., 2001; Burdzinska et al., 2012; Lentle et al., 2015; 
Mills et al., 2008; Sellers et al., 2000). In particular,  the female pig urethra possesses many 
characteristics similar to that of the human female urethra  (Greenland et al., 1996). Pig is 
often used as a suitable anorectal model of humans, being of a similar size. The porcine IAS 
is both qualitatively and quantitatively similar to human IAS tissue.   
2.2 ETHICS  
This project did not require ethical approval. All porcine tissues were collected from a local 
abattoir as remnants from animals being slaughtered for human consumption.  
2.3 ANIMALS 
Tissues from young (average age 6 months) female non-parous bacon pigs and aged parous 
female sows (average age 36 months) were used. The mean body weight of young non-
parous bacon pigs was 80kg, while the mean body weight of aged parous sows was ≥180kg. 
The samples were from large White-Landrace pigs. 
2.4 FUNCTIONAL TISSUE BATH TECHNIQUE 
Fresh pig tissues collected from a local abattoir were immersed in fresh cold Krebs-
bicarbonate buffer while being transported to the laboratory. In the laboratory, these fresh 
tissues were placed on a dissecting board in ice-cold Krebs bicarbonate (NaCl 118.4 mM, 
NaHCO3 24.9 mM, CaCl2 1.9 mM, MgSO4 2.41 mM, KCl 4.6 mM, KH2PO4 1.18 mM and d-
glucose 11.7 mM), and with a sharp razor and dissecting scissors the urethra and the 
anorectum were dissected, so as to isolate the urethral circular smooth muscle (Figure ‎2.1A-C) 
 
 77 
 
 
and the IAS of the anorectum (Figure ‎2.2A-D). The urethra was divided into proximal (2-3cm 
from the bladder neck), mid (3-5cm from the bladder neck) and distal, which is the remaining 
part up to the external orifice (Figure ‎2.1). The urethral regions were cut open, and strips of 
(2cm x 0.5cm) the circular smooth muscle were dissected out. When the urothelium/lamina 
propria was removed, this was achieved using fine dissection scissors.  
For the anorectum, the tissue was cut open as shown in Figure ‎2.2A-B with scissors. The 
epithelium was carefully removed, and circular smooth muscle IAS strips (1.5cm x 0.3cm) 
were removed (Figure ‎2.2C-D) with a fine dissecting scissors. Tissues were set up in EZ-Bath 
tissue baths (Global-Town Microtechnology, Sarasota, FL, USA) containing Krebs-
bicarbonate solution at 37°C and gassed with 5% CO2 in oxygen and attached with a surgical 
thread to force transducers (MCT050/D, ADInstruments, Castle Hill, Australia) (Figure ‎2.3). 
The tensions developed by tissues were recorded using a PowerLab system using LabChart 
software (version 7) (ADInstruments).  
Both urethral and IAS tissues were mounted under 100-250 milliNewton (mN) resting 
tension and allowed to equilibrate for 30-60 minutes, during which they were washed with 
the fresh Krebs-bicarbonate solution every 15 minutes, before the commencement of the 
experimental protocol.  
2.5 PHARMACOLOGICAL PROTOCOLS  
For pharmacological studies, adjacent pieces of tissues were dissected, set up in triplicate 
under identical conditions, and allowed to equilibrate. After equilibration, one tissue was 
incubated with the inhibitor for 30 minutes, the other served as a control in the absence of any 
inhibitor, while the third served as a vehicle control. Tissues were contracted to cumulative 
concentrations of agonist and responses compared with control tissues. 
To investigate the effect of the urothelium/ lamina propria on receptor-mediated responses, 
the urothelium/lamina propria was carefully dissected off and separated from the smooth 
muscle. The tissues, with and without urothelium/lamina propria, were set up in pairs and 
cumulative concentration-response curves to agonists were constructed. Where the effects of 
inhibitors were investigated, these were incubated for 30 minutes after equilibration. 
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Figure ‎2.2 Dissection of the internal anal sphincter from the porcine anorectum. The anorectum was 
dissected open (B), the mucosa removed (C) and the IAS strips removed (D). 
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For noradrenaline responses, two concentration-curves were constructed to compare the 
noradrenaline response in the presence or absence of inhibitors. The initial cumulative 
concentration-response curves were constructed to noradrenaline followed by a 30-minutes 
washout.  Following the washout, a second cumulative concentration-response curve to 
noradrenaline was obtained in all the tissues.  In experiments where the effects of signalling 
pathways were analysed, the tissues were incubated with inhibitor of the specific pathway 
throughout the experiment. All experiments involving the noradrenaline curves were 
performed in the presence of desipramine (1M), to block neuronal uptake-1, corticosterone 
(1M), to block uptake-2 into non-neuronal tissues and propranolol (1M) to prevent any β-
AR-mediated effects. 
2.6 ELECTRICAL FIELD STIMULATION (EFS) 
Electrical field stimulation (EFS) is a functional in-vitro technique in which an electric 
current is used to stimulate the intrinsic nerves to release endogenous neurotransmitters. 
Internal anal sphincter tissues were placed between two platinum electrodes to study 
responsiveness to transmural nerve stimulation. Single square-wave pulses at supra-
maximum voltage were delivered by a Grass S48 stimulator (Grass Instruments Co, MA, and 
U.S.A.). Internal anal sphincter tissues were set up and equilibrated in tissue baths as 
described and stimulated with 40volts for 1millisec duration at frequencies of 5 or 10Hz, 
which are the optimised parameters for stimulating neurotransmitter release in the IAS 
without direct stimulation of the smooth muscle (Folasire et al., 2016). Moreover, responses 
were abolished when tissues were stimulated in the presence of tetrodotoxin, TTX (1μM), a 
potent neurotoxin and selective inhibitor of neuronal sodium channel conductance.  
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2.7 DATA ANALYSIS AND STATISTICS 
All changes in developed tension were measured and analysed using GraphPad Prism and 
Instat software (GraphPad, San Diego, CA). GraphPad Prism software was used for analysis 
of concentration-response curves via nonlinear regression to determine agonist potency 
(pEC50, the negative logarithm of the molar concentration that gives a half-maximal effect) 
and maximal responses.  The agonist potencies were expressed as mean pEC50±SEM and 
maximum responses of data were expressed as mean ± SEM. Also, in some cases EC50 and 
EC75 were calculated. Tissues responses normalised for weight were similar to un-normalised 
responses, as shown in Table ‎2.1 and Table ‎2.2. Moreover, normalisation did not have any 
significant effect on the agonist potency and percentage difference in maximum responses, 
thus un-normalised data and responses were used throughout this thesis. 
For EFS experiments, changes in developed tension were represented as the percentage of the 
tone of the tissue at the time of stimulation.  The responses seen in the presence of antagonist/ 
inhibitor were compared to the initial response in the absence of antagonist from the same 
tissue strips. 
Instat software was used for statistical analysis. Where two samples were compared, unpaired 
or paired Student’s t-test was used for analysis. Comparisons between more than two data 
groups were evaluated statistically with one-way ANOVA and Tukey or Bonferroni post hoc 
tests as appropriate. Data were considered significant only when p<0.05. Except otherwise 
indicated, all data are expressed as mean ± SEM. 
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2.8 DRUGS  
Drugs used in this project obtained from Sigma-Aldrich (Castle Hill NSW, Australia) are 
listed below; 
  α,β-Methylene ATP (lithium salt)  
  AOAA (aminooxyacetic acid)  
  Atropine (sulphate salt monohydrate)  
  Carbachol (carbamoylcholine chloride)  
  Corticosterone (11β,21-dihydroxyprogesterone) 
  EDTA(N,N'-1,2-ethanediylbis[N-(carboxymethyl)]glycine)  
  Guanethidine (1-[2-uanidinoethyl] octahydroazocine monosulfate)  
  Indomethacin (1-[p-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic acid) 
  ± Isoproterenol (1-(3′,4′-dihydroxyphenyl)-2-isopropylaminoethanol hydrochloride)  
  L- NNA (Nω-nitro-L-arginine)  
  Methylene blue hydrate 
  Noradrenaline (±arterenol norepinephrine [+] hydrogen tartrate )  
  PAG (propargylglycine)  
 PheLeu-VIP ([D-p-Cl-Phe
6
,Leu
17
] -vasoactive intestinal peptide) 
  (R)-(−)-Phenylephrine hydrochloride 
  Propranolol (S)-1-isopropylamino-3-(1-naphthyloxy)-2-propanol hydrochloride)  
  ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one)  
  Tetrodotoxin  
The following drugs listed below were obtained from Tocris Bioscience, (Ellisville, Missouri, 
USA). 
 A61603 (N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-
tetrahydronaphthalen-1-yl]methanesulfonamide hydrobromide)  
 Calphostin C  
 Cyclopiazonic acid  
 Desipramine (10-11-dihydro-N-methyl-5H-dibenz(Z) [b,f] azepine-5-propanamine 
hydrochloride)  
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 Fasudil hydrochloride  
 Nifedipine (1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid 
dimethyl ester)  
 Y27632 (trans-4-[(1R)-1-aminoethyl]-N-4-pyridinylcyclohexanecarboxamide 
dihydrochloride)  
 ZnPPIX (zinc protoporphyrin IX)  
A comprehensive list of drugs, sources and concentrations used in this project can be found in 
the appendix. 
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3 REGIONAL & AGE-RELATED DIFFERENCES IN 
THE PHARMACOLOGY OF THE URETHRA 
3.1 REGIONAL DIFFERENCES IN THE LOWER URINARY 
TRACT 
Studies of pharmacology of the urethra have yielded contradictory results that may partly be 
due to the use of different models, strains, and age plus the techniques used.  
Regional difference within urethral structure  
The structure of the urethra differs along its length, with respect to striated muscle (Karam et 
al., 2005b; Pel et al., 2006; Zhang et al., 2016a). In the rat, reports indicate an increase in 
striated muscle fibres starting from the end of the proximal urethra and peaking in the mid-
urethra (Kim et al., 2007; Zhang et al., 2016a). Zhang et al., (2016a) found most of the 
striated muscle fibres in the middle part of the rat urethra, with the smooth muscle partly 
interlaced with the striated muscles. Lim et al., (2013), however, observed the striated muscle 
of the external urethral sphincter primarily in the proximal urethra of the rat. The circular 
smooth muscle is more prominent proximally in the bladder neck/proximal urethra, becoming 
thinner in the middle section and again increases distally in the female rat (Zhang et al., 
2016a). On the other hand, longitudinal smooth muscle fibres remain thin but more consistent 
throughout the length of the rat urethra (Zhang et al., 2016a). 
As in human (Karam et al., 2005b), the male pig urethra is composed of an outer layer of 
striated muscle and an inner layer of smooth muscle (Ragionieri et al., 2016). In the female 
pig urethra, the smooth muscle consists of an inner and outer longitudinal layer with a middle 
circular layer (Dass et al., 2001). Pel et al., (2006) reported striated muscle at the level of the 
pig bladder neck, which contrasted with the report by Dass et al., (2001), who stated that 
circular striated muscles are confined to the distal third of the pig urethra.   
Regional differences also exist in the epithelial lining of the urethra. For example, the pig 
bladder neck and proximal urethra are lined with transitional urothelium (Dass et al., 2001). 
Several layers of epithelial cells are present at the level of the bladder neck, while fewer cell 
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layers have been observed in the porcine proximal urethra (Dass et al., 2001). Distally the pig 
urethra is lined by non-keratinising stratified squamous urothelium, and the region between 
consists of the pseudostratified urothelium (Dass et al., 2001). In the middle section of the rat 
urethra, the urothelium is surrounded by a submucosal layer containing venous plexus and 
smooth muscle (Zhang et al., 2016a).  The vascular plexus of the pig urethra consists of 
predominantly longitudinally orientated blood vessels and this is most developed in the 
proximal urethra (Dass et al., 2001). Dass et al., (2001) suggested that the more highly 
developed lamina propria in the proximal urethra may reflect a larger vascular bed, and may 
contribute to luminal closure in this region.  
In human volunteers, the maximum urethral pressure was shown to be highest in the proximal 
urethra during rest, cough and strain (Kirby et al., 2015). However, in the rat, the highest 
urethral pressure was recorded in the mid-urethra (Xu et al., 2015). Kamo et al., (2006) 
reported that a decreased active closure mechanism in the mid urethra mediated sneeze-
induced stress urinary incontinence in a rat model of birth trauma.  The mid-urethral closure 
mechanism was mediated by somatic nerves in rats (Kamo et al., 2006) and these nerves are 
important for preventing urine leakage during sneezing in rats (Kamo et al., 2003). Also, in 
the pig, cystometry and urethral pressure profilometry revealed a fall in mid-urethral pressure 
before micturition (Bridgewater et al., 1993). In the cat, during sneezing the neurally driven 
reflex contractions of the external urethral sphincter at the distal urethra contributed to active 
urethral closure mechanisms and ensured urinary continence (Bernabe et al., 2008; Julia-
Guilloteau et al., 2007). In summary, the variation in the region contributing most to urethral 
luminal pressure seems to be species related.  
Difference in the urethral regions; innervation and function 
Given the differences in the structure over the length of the urethra, functional differences are 
expected. Whilst the sympathetic and parasympathetic nervous system innervates both the 
proximal urethra and bladder neck, the medial and distal urethra are to a greater extent under 
the control of the sympathetic innervation at least in the rabbit (Deplanne et al., 1998).  In the 
rat, the inner longitudinal muscle layer of the proximal urethra receives an equal distribution 
of adrenergic and cholinergic fibres (Zhang et al., 2016a). However, in the circular layer, as 
well as in the outer longitudinal layer, most of the nerve endings are adrenergic. The 
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cholinergic fibres are located in the longitudinal and circular smooth muscle layer in the rat 
mid urethra (Zhang et al., 2016a). Moreover, tyrosine hydroxylase staining for adrenergic 
nerves was expressed more in the smooth muscle layers in the middle part of the urethra, and, 
the nerve distribution, identified by phalloidin and nNOS/tyrosine hydroxylase/choline 
acetyltransferase double staining, showed that nNOS expressing fibres were also expressed in 
greater quantities in the mid urethra (Zhang et al., 2016a). In the pig, the greatest density of 
catecholamine-, acetylcholinesterase- and peptide- positive nerves fibres was found in the 
smooth muscle of the distal urethra, followed by the bladder neck, middle urethra, and 
proximal urethra (Crowe & Burnstock, 1989). 
Closure of the bladder neck and urethra depends on the adrenergic system, and the α1-AR  
subtype is the predominant postjunctional α-AR in human (Brading et al., 1999) and pig 
(Bagot & Chess-Williams, 2006) urethral smooth muscle. The pig (Bridgewater et al., 1995) 
and rabbit (Larsson et al., 1986) urethra have been reported to have no regional variation in 
the distribution of α-ARs, with binding studies performed on membranes prepared from the 
rabbit bladder base, and proximal and distal regions of the urethra, revealing that the density 
of α1-ARs does not significantly differ between the three areas in rabbits (Larsson et al., 
1986). Similar α1-AR densities and phenylephrine-induced contractions were recorded across 
all regions of the human prostatic urethra (Lepor et al., 1993). Moreover, Taki et al., (1999) 
also reported that noradrenaline (non-selective α-AR agonist), not clonidine (α2-AR agonist) 
produced concentration-dependent contractions in all urethral regions in women, but 
contractions were most intense in mid to proximal urethra.  
On the other hand, the density of α2-AR is increased distally in the rabbit urethra (Larsson et 
al., 1986) and α2-AR are able to mediate contractile responses in the pig distal urethral region 
(Bagot & Chess-Williams, 2006). Larsson et al., (1986) showed that clonidine, but not 
phenylephrine was more potent in the distal than the proximal region of the rabbit urethra. 
Thus the α2-AR-mediated responses seem to be restricted only to the distal urethra.   
The mAChR subtypes are distributed in a similar fashion throughout the length of the male 
rabbit urethra (Nagahama et al., 1998). Carbachol-induced contractile responses in rabbit 
urethra are mediated through the M1 and/or M3 and possibly M2 subtypes (Mutoh et al., 1997). 
Carbachol produced a dose-dependent contraction of the rabbit proximal urethral region 
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(Mutoh et al., 1997; Nagahama et al., 1998), although, no cholinergic-mediated effect was 
recorded in the distal urethral region (Nagahama et al., 1998).  Whilst the pig has been shown 
as a suitable model for understanding the lower urinary tract, α-AR agonist efficacy and 
potency has not been studied in detail in different regions of the urethra. 
3.2 AGE-RELATED DIFFERENCES IN THE LOWER 
URINARY TRACT 
In elderly patients, especially parous women, stress urinary incontinence is a common 
problem which suggests that ageing may be related to the change in contractile function in 
the urethra.  The studies of age-related differences in the lower urinary tract have yielded 
contradictory results that may be partly due to a species and gender differences. Moreover, 
the techniques used and the ages of the models is likely to have contributed to these 
variations. The muscularis and lamina propria layers in the bladders of aged female rats 
showed significantly decreased collagen density (Lluel et al., 2000). However, Zhao et al., 
(2010) reported an increase in collagen content in aged male rats. Older rabbits showed 
significantly greater thickening of the serosa than young rabbits while young rabbits showed 
a significant expansion of the lamina propria (Agartan et al., 2005). Morphometric analysis 
has shown a significant increase in the mean thickness of the detrusor layer with age in 
female rats (Lluel et al., 2000). However, Zhao et al., (2010) reported a reduction in both 
muscle mass and urothelial thickness in aged male rats.  
Age-related differences in the urethra 
Carlile et al., (1988) observed an increase in the relative volume of connective tissue in aged 
human urethra; but no change in the smooth muscle component. The urethral length and 
maximum closure pressure decreased in ageing women (Trowbridge et al., 2007). Likewise, 
the urethral urothelium became atrophic because of a decline in oestrogen in women 
(Trowbridge et al., 2007). Carlile et al., (1988) also observed that ageing decreased the 
relative volume of striated muscle and blood vessels in the human urethra, whilst, a decline in 
the number and density of striated urethral sphincter nerve and muscle fibres was observed in 
ageing women (Pandit et al., 2000; Perucchini et al., 2002a; 2002b). Perucchini et al., (2002a) 
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estimated the approximate striated urethral sphincter muscle fibres lost every year to be 2% 
an average of 364 fibres.  
Urodynamic studies consistently report a decrease in urethral closure pressures for continent 
women with advancing age (Rud, 1980). In a sample of nulliparous women, maximal urethral 
closure pressure in the senescent urethra was 40% of that in the younger urethra (Trowbridge 
et al., 2007). Moreover, electromyography studies showed a decrease in sphincter activity 
after menopause (Kenton et al., 2005). The current perception threshold was significantly 
higher in the distal urethra of older women, and older women experienced a loss of urethral 
sensation associated with loss of urethral afferent nerve function (Kenton et al., 2007a; 
2007b). 
There is limited literature on age-related differences in the urethra with respect to innervation, 
and receptor expression but, it has been shown that the intramuscular nerve density declines 
with age in female urethra (Pandit et al., 2000). Older women also showed a decreased motor 
unit action potential (striated muscle) recruitment, corroborating that ageing reduced urethral 
innervation (Kenton et al., 2011).  Age-related changes in the function of the proximal 
urethra, distribution of α1-AR binding sites and smooth muscle densities was not observed in 
dog urethral tissues (Ahmed et al., 2000). Similarly, Suzuki et al., (1999) also reported that  
α1A-ARs distribution in the canine urethral smooth muscle were not affected by age and/or 
parity. Electrical field stimulation produced approximately the same response in the bladder 
base of old and younger rats (Longhurst et al., 1992).  
3.3 DESENSITISATION OF RESPONSES OF THE SMOOTH 
MUSCLE 
Desensitisation is the loss or reduction in response to subsequent exposure to the agonist. 
Agonist-induced desensitisation of cellular responses to stimulation of GPCR is a widespread 
biological phenomenon. For example, with β-ARs, desensitisation can occur upon enhanced 
stimulation by endogenous neurotransmitters or hormones such as in chronic heart failure 
(Merlet et al., 1992). The cellular and molecular mechanisms underlying agonist-induced 
desensitisation have largely been explored using the β2-AR as a model (Scola et al., 2004; 
Tran et al., 2007).   
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Desensitisation of ARs can occur at the receptor level, as well as the second messenger 
pathway. For example, β3-ARs desensitisation does not primarily occur at the receptor level 
but largely at the level of adenylyl cyclase (Vrydag et al., 2009) and perhaps, at the level of 
the Gs, Gi-proteins (Michel-Reher & Michel, 2013). Also, studies using β1-ARs and/or β2-
ARs have demonstrated receptor down-regulation at mRNA level (Engelhardt et al., 1997) 
and G-proteins level (Adie & Milligan, 1994).  
Interestingly, the susceptibility to agonist-induced down-regulation of AR appears to differ 
between β-ARs subtypes with β1-ARs typically being less affected than β2-ARs, e.g., in the 
heart (Nanoff et al., 1990) and HEK-293 cells (January et al., 1998). Also, the β3-AR was 
thought to be insensitive to agonist-induced desensitisation because it lacks the 
phosphorylation sites considered to be involved in desensitisation (Nantel et al., 1993). 
However, Bengtsson et al., (1996) showed that exposure of β3-ARs to noradrenaline in mouse 
induced a marked transient down-regulation of adipocyte β3-ARs mRNA. Michel-Reher & 
Michel, (2013) also revealed that β3-ARs are susceptible to desensitisation in transfected 
HEK cells. Therefore, β3-ARs resistant to agonist-induced desensitisation seems to be cell or 
tissue type dependent. 
Previously, the efficacy of the agonist was shown to determine desensitisation, high-efficacy 
β2-AR agonists (e.g. formoterol) causing more phosphorylation and internalisation of the 
receptor than low efficacy agonists in HEK-293 cells (e.g. salmeterol, partial agonist) 
(January et al., 1997; Moore et al., 2007). However, other studies disagree, with Rosethorne 
et al., (2015) recently showing that different β2-AR agonists of different efficacy produced 
the same degree and rate of functional desensitisation in primary human bronchial smooth 
muscle cells. Thus, desensitisation may be cell type specific at least for β2-ARs. 
Desensitisation of receptor-mediated responses in smooth muscle 
Desensitisation of AR, especially the β-ARs, is well studied in the smooth muscle respiratory 
tract, with regard to repeated use of β-AR agonist, although much less well studied in the 
lower urinary tract (Sears et al., 1990). Repeated exposure of guinea pig (Fogli et al., 2011), 
rat (Finney et al., 2001) and human (Cooper et al., 2011) tracheal smooth muscle to β-AR 
agonists resulted in the gradual attenuation of relaxation responses. Similarly, repeated 
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inhalation of β-ARs agonist caused a reduction in bronchodilation in guinea-pigs in vivo 
(Fogli et al., 2011).  Subcutaneous administration with osmotic mini-pumps delivering the 
long-acting β2-ARs agonist salmeterol was demonstrated to reduce the pulmonary β2-ARs 
number in rats by 70%, without affecting the levels of β2-ARs mRNA transcripts (Finney et 
al., 2001). Finney et al., (2001) reported a significant reduction in the lungs membrane β1-
ARs and β2-ARs density from animals treated with salmeterol. The decrease in receptor 
density mediated an impaired salmeterol-induced signalling.  
With respect to the lower urinary tract, and particularly the urethra, studies investigating 
desensitisation are few, and most focus on the bladder. Desensitisation occurs in the bladder 
of the rat (Michel, 2014). Chronic stimulation of membrane-bound M3 mAChR has been 
shown to result in receptor desensitisation in mouse bladder smooth muscle strips (Cha et al., 
2006). Cha et al., (2006) reported that repeated pilocarpine (non-selective mAChR agonist) 
injections of mouse for six days induced M3 mAChR desensitisation. Moreover, Oh et al., 
(2000) have shown that a repetitive carbachol application in the neonatal and adult bladder 
induces an attenuation of the contractile response. However, the neonatal bladder was more 
resistant to desensitisation, suggesting that ageing increases desensitisation of mAChR-
mediated responses.  
Ruggieri & Braverman, (2006) also reported a functional desensitisation of rat bladder strips 
to increasing concentrations of carbachol. Moreover, Ruggieri & Braverman, (2006) 
indicated that the repeated exposure to cumulative carbachol altered the mechanism of 
contraction, possibly by suppression of M3 mAChR-mediated signalling. 
Lastly, Michel, (2014) reported that agonist-induced desensitisation was prominent for the β2-
ARs involved in rat bladder relaxation but much weaker or even absent for the β3-ARs. 
Moreover, β2-ARs agonist pre-treatment reduced contractile responses to the muscarinic 
agonist carbachol and the receptor-independent stimulus KCl (Michel, 2014).  Clinically, one 
year of treatment of overactive bladder with mirabegron (β3-ARs agonist) did not provide any 
evidence for attenuation of the clinical response over time (Chapple et al., 2013c), thus 
confirming that response to the β3-ARs agonist may also be resistant to desensitisation in the 
human bladder. Failure of α-AR agonists for stress urinary incontinence may be due to 
desensitisation of receptor. 
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Aim and objective 
The aim of this chapter was to investigate α1-AR-mediated responses of the porcine urethra 
and compare the effect of age and urethral region. In addition, desensitisation of responses of 
urethral tissues to subsequent addition of α1-AR agonists was explored.  
This chapter answers the following questions: 
 Do α1-AR-mediated responses differ between regions of the porcine urethra? 
 Does age affect α1-AR-mediated responses of the porcine urethra? 
 Can desensitisation of receptor-mediated responses be demonstrated in the pig urethra? 
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3.4 MATERIALS AND METHODS 
Animals and tissues 
Isolated strips of porcine urethral tissues were prepared as described in chapter 2. 
Experimental protocol 
 Following set up and equilibration for 1 hour, cumulative concentration-response curves to 
phenylephrine (1nM-1mM), noradrenaline (1nM-1mM) or A61603 (0.1nM-100μM) were 
constructed in tissues from various urethral regions and from young (average age 6 months) 
and older (average age 36 months) pigs. Where a second concentration-response curve was 
performed, tissues were washed for 30 minutes before the second addition of agonist. 
Data analysis 
Data were analysed and expressed as described in chapter 2. 
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3.5 RESULTS 
Alpha1-adrenoceptor-mediated responses in urethral regions 
Maximum contractile responses of strips of porcine proximal urethra to cumulative 
concentrations of noradrenaline, phenylephrine and A61603, were greater than those of the 
mid and the distal urethral regions though only significant for phenylephrine and A61603 
(Table ‎3.1, Figure  3.1, n=6-9). The pEC50 values for noradrenaline, phenylephrine and 
A61603 were similar for the three regions (Table ‎3.1: Figure ‎3.1), although A61603 was 
significantly more potent than noradrenaline and phenylephrine.  
Effect of age on α1-adrenoceptor-mediated urethral responses  
Age did not affect α1-AR-mediated responses of the urethra. Maximum contractile responses 
of the urethral tissues (old pigs) to cumulative concentrations of noradrenaline, phenylephrine 
and A61603, were similar to the maximum contractile responses of the tissues from younger 
pigs (Table ‎3.2 and Figure ‎3.2). Moreover, similar pEC50 values for noradrenaline, 
phenylephrine and A61603 were recorded for the young and old pig tissues. 
Repeatability of receptor-mediated responses in the urethra 
Maximum responses of porcine proximal urethral tissues to noradrenaline were similar for 
both first and second concentration-response curves (Figure  3.3). However, with 
phenylephrine, A61603 and carbachol, maximum responses were significantly lower in the 
second curves than those of the first curves (Table ‎3.3 and Figure ‎3.3; n=5-9). The percentage 
desensitisation of responses to phenylephrine, A61603 and carbachol were 49.9±6.9% 
(p<0.001), 55.6±7.3% (p<0.01) and 52.5±12.5% (p<0.01) respectively. Moreover, the pEC50 
values for noradrenaline, phenylephrine, A61603 and carbachol were similar for both the first 
and second curves. 
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Effect of age on repeatability of concentration-response curves to 
phenylephrine   
Repeatability of responses to cumulative concentrations of phenylephrine was not achievable 
in the young and old pig urethral tissues. Desensitisation of the α1-AR-mediated responses to 
phenylephrine in the urethra was greater in tissues from the older pigs compared to the 
younger pig tissues (Table ‎3.4 and Figure ‎3.4; n=9). pEC50 values for phenylephrine were 
similar between the young and older pigs for the first and second concentration-response 
curves. 
 Young Old 
 1
st
 Curve 2
nd
 Curve 1
st
 Curve 2
nd
 Curve 
Max response (mN) 124.8±15.3 91.7±19.6 163.7±13.5 54.6±8.2*** 
pEC50 5.4±0.3 5.4±0.5 5.7±0.2 5.7±0.4 
Percentage reduction in Max 
response (%) 
29.6±19.4 67.2±5.8 
N 9 9 
Table ‎3.4 Mean (± SEM) maximum contractile responses and pEC50 values for phenylephrine in young 
and old porcine urethral tissues (Data for first and the second curve is shown).  ***p<0.001 vs 1
st
 curve 
maximum (Paired Student’s t-test).  
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Figure  3.1  Mean concentration-response curves to agonists on various regions of the pig urethra from 36 
months old animals; n=6-9. *p<0.05, **p<0.01, ***p<0.001 vs. maximum responses of proximal urethra 
(One-way ANOVA with Tukey post-hoc test). 
 
Noradrenaline 
Phenylephrine 
A61603 
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Figure  3.2 Comparison of the mean concentration-response curves to agonists in proximal urethral 
tissues from old and younger pigs; n=9-15.        
    
Noradrenaline 
Phenylephrine 
A61603 
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Noradrenaline  Phenylephrine 
 
 
 
A61603  Carbachol 
 
 
 
 
Figure  3.3 Comparison of the 1st and 2nd mean concentration-response curves of proximal urethral tissues 
to agonists (36 months old pigs); n=5-9. **p<0.01 and ***p<0.001 vs 1
st
 curve responses (Paired Student’s 
t-test). 
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Figure  3.4  Concentration-response curves to phenylephrine in proximal urethral tissues. Results were 
expressed as mean ± SEM; n=9. ***p<0.001 vs. first curve response (Paired Student’s t-test).  
Young 
Old 
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3.6 DISCUSSION 
Do α1-adrenoceptor-mediated responses differ between regions of the 
porcine urethra? 
For urinary continence, the resting luminal pressure of the urethra must be maintained to 
prevent urine leakage.  However, the urethral region with the greatest contribution to resting 
pressure is still a matter for debate.  Responses of urethral tissues to phenylephrine and other 
α1-AR agonists, in-vivo, in human and in animal models have shown region and species-
dependent variations along the length of the urethra (Conlon et al., 2009; Walters et al., 2006; 
Zhang et al., 2016a). For example, in the rat the greatest responses to phenylephrine were 
found in the proximal urethra, whilst in the guinea-pig, the opposite result has been shown, 
with the greatest amplitude of contraction seen at the distal end of the urethra (Walters et al., 
2006). Clinically, urodynamic studies suggest a significant contribution of the proximal 
urethra in maintaining continence (Bagi, 2002; Bagi et al., 2002). Moreover, Kirby et al., 
(2015) reported highest maximum urethral closure pressures in the proximal urethra during 
different manoeuvres, including rest, cough and strain with high-resolution manometry 
catheter. Using urethral pressure reflectometry, Aagaard et al., (2014) also reported an 
increase in the urethral opening and closing pressure and hysteresis from the bladder neck to 
the sphincter region (proximal urethra) in men. Together, these studies suggested that the 
functional responses along the urethra may vary between species.   
In this project, we aimed to establish any regional differences in α1-AR-mediated contractile 
response in the pig and determine the similarity to human urethra. Maximum contractile 
responses to noradrenaline, phenylephrine and A61603 were greatest in the proximal region 
of the porcine urethra, followed by the mid and then distal urethral regions. Cystometry 
reports from studies using the porcine model have also described the proximal urethra as the 
high-pressure zone with high contractile tone (Greenland et al., 1996). The high-pressure 
zone, approximately 3cm below the bladder neck (Werkstrom et al., 1995), correlates with 
the proximal region used in this thesis as the region with greatest agonist-induced contractile 
responses. This finding supports earlier urethral pressure profilometry and cytometry 
observations in human (Aagaard et al., 2014; Kirby et al., 2015; Taki et al., 1999).  
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The novelty in the present experiment was in the elucidation of α1-AR-mediated responses in 
the porcine urethral regions using agonists of different efficacy and potency. A61603 and 
phenylephrine were used in addition to noradrenaline, and the responses to the three agonists 
were consistently greater in the proximal urethral region though only significant for 
phenylephrine and A61603.  A close look at Greenland et al., (1996) report showed that they 
used younger pigs (60 to 100kg) in their experiments. In this study, we used much older pigs 
(≥180kg). Therefore, we have shown that the proximal urethral region is associated with 
greatest agonist-induced contractile responses in the older pig which is similar to the data 
from young pig reported by Greenland et al., (1996). 
A61603 caused a greater contractile response than the other three agonists, and was the most 
potent of all the agonists in urethral tissues. These results are consistent with a large body of 
evidence stretching back decades showing that A61603 is highly potent and specific for α1A-
ARs, in the urethra (Bagot & Chess-Williams, 2006) and other tissues including rat prostate 
(Thiyagarajan et al., 2002), dog prostate, rat vas deferens  (Knepper et al., 1995), rabbit 
arteries (Smith et al., 1997), rat spleen (Zhou & Vargas, 1996) and dog arteries (Argyle & 
McGrath, 2000). Phenylephrine and noradrenaline had similar potency in this experiment, 
which is also reflected in the literature (Bagot & Chess-Williams, 2006; Minneman et al., 
1994).  
Does age affect α1-adrenoceptor-mediated responses in the porcine urethra? 
Age may change the morphology (Agartan et al., 2005; Zhao et al., 2010) and functional 
responses (Daly et al., 2014; Tykocki et al., 2013) of the lower urinary tract. The research on 
the effect of ageing on lower urinary tract morphology and functional characteristics has 
provided contradictory results. Detrusor contractility, bladder sensation, and urethral pressure 
decline with ageing in women (Pfisterer et al., 2006). However, other reports have shown that 
ageing does not affect these factors (Ameda et al., 1999; Gosling, 1997).  These variations 
can be related to animal species or strain used, sex or experimental procedure.  
There is convincing evidence showing that the urethra expresses α1-ARs (Nasu et al., 1998; 
Yono et al., 2004). Specifically, the α1A -AR subtype is the main α1-AR present in the urethra 
of different animal species, including man (Nasu et al., 1998; Testa et al., 1993; Walden et al., 
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1997). There is also evidence that urethral tissue contraction occurs predominantly if not 
exclusively, via α1-ARs (Bagot & Chess-Williams, 2006; Chess-Williams et al., 1994; Kedia 
et al., 2013). Therefore, changes in α1-AR-mediated responses could have a negative effect 
on continence, although, it is not yet clear how α1-AR-mediated responses are affected by 
ageing. In this study, we sought to examine how ageing affects α1-AR-mediated responses of 
the urethral tissues. 
Contractions of urethral tissues to cumulative concentrations of noradrenaline, phenylephrine 
and A61603 were found to be similar in the young and older porcine urethral tissues. 
Moreover, potencies of the agonists were similar between the young and older porcine 
urethral tissues. These results suggest that ageing does not affect α1-AR-mediated contractile 
responses in the pig. The results presented here were consistent with those reported in the 
literature, although in different species. There was no significant age-dependent difference in 
the total α1-AR density and mRNA expression of all three α1-AR subtypes or the maximum 
contractile responses to phenylephrine in the bladder base of rat (Yono et al., 2006). 
Furthermore, receptor-mediated responses were similar in young and older dog urethral 
tissues (Suzuki et al., 1999), and no correlation could be established between age and urethral 
pressure in healthy males (Bagi et al., 2002).  In the aged human prostate, the contractile 
response to exogenously administered α1-AR agonists also remains unchanged with ageing 
(Tsujii et al., 1992). Moreover, the amplitude of urethral responses during sneezing was 
unchanged in middle-aged rats compared to younger rats (Kitta et al., 2016). Similar α1-AR-
mediated responses were recorded in young and older urethral tissues in the present study, 
could be associated with the findings of unchanged receptor expression in the urethra, as 
shown in the dogs and rats (Ahmed et al., 2000; Suzuki et al., 1999; Yono et al., 2006).  
The age of young pigs used in this study correlate to adolescence in human, whilst the older 
pigs correlate to 60 years and above. Thus from this study, ageing does not appear to affect 
the α1-AR-response. 
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Can desensitisation of receptor-mediated responses be demonstrated in pig 
urethra?  
Alpha1-AR agonists have been reported to increase urethral luminal pressure and improve 
stress urinary incontinence in animal models (Blue et al., 2004; Segev et al., 2015) and 
human (Collste & Lindskog, 1987; Musselman et al., 2004; Radley et al., 2001). Alpha1-AR 
agonists have also shown efficacy in reducing stress urinary incontinence symptoms in 
clinical studies (Radley et al., 2001; Segev et al., 2015). However, they are associated with 
severe cardiovascular effects (Dave et al., 2002; O’Neill et al., 2001; Radley et al., 2001). 
Also, the effect on maximum urethral closure pressure improvement was fairly minimal in 
beagle dogs (Noel et al., 2010; 2013). Desensitisation of the α-ARs has been proposed by 
several authors to explain this observation (Akinaga et al., 2013).  Indeed desensitisation of 
ARs has been reported for β-ARs in asthma treatment (Lin et al., 2012) and α1-ARs in HEK-
293 cells (Castillo-Badillo et al., 2015). Thus, the efficacy of treatment with agonists at α1-
AR subtypes over time may be limited by agonist-induced (homologous) desensitisation 
and/or by unrelated stimuli (heterologous) desensitisation (Castillo-Badillo et al., 2015). 
Functional desensitisation of α1-ARs occurs in a tissue- and cell type-dependent manner and 
as far as we are aware, this work is the first to investigate desensitisation of α1-AR-mediated 
responses in the porcine urethra, with agonists of different efficacy and potency.  
This study showed desensitisation of subsequent contractile responses of urethral tissues to 
phenylephrine and A61603. The desensitisation produced was greatest for A61603 (55.6%), 
followed by phenylephrine (49.9%). However, noradrenaline responses did not desensitise 
upon repeated application. All tissues were washed for the same amount of time, to return 
tissues to baseline tension, thus differential washing cannot explain the desensitisation of 
phenylephrine and A61603-induced responses. A61603 is a full agonist with a maximum 
response and potency significantly greater than that of noradrenaline, whilst phenylephrine 
and noradrenaline have similar efficacy and potency (Bagot & Chess-Williams, 2006).  Thus, 
noradrenaline the endogenous agonist for these receptors, was actually a partial agonist 
compared to A61603. This is surprising but not unexpected since other studies have also 
reported the greater maximum responses to A61603 (Knepper et al., 1995). Thus, the agonist 
with the greatest efficacy, potency and affinity for α1A-ARs induced greatest desensitisation. 
 109 
 
 
In addition, the desensitisation may be due to fall in receptor number, however, ascertaining 
this hypothesis is beyond the scope of this project. 
Most studies on desensitisation of AR have been carried out on the β-AR subtype, and in cell 
studies. Drawing parallels from these studies, a similar effect to the present study has been 
shown for the β-ARs in mast cells, with desensitisation of subsequent responses following 
exposure to β-AR agonists (Chong et al., 2003; Scola et al., 2004). Similarly, the efficacies of 
different agonists were correlated to the degree of desensitisation of the β2-ARs expressed in 
HEK-293 cell lines (January et al., 1997; Pittman et al., 1984) and μ-opioid receptors 
expressed in AtT20 cells (Borgland et al., 2003) or  HEK-293 cell lines (McPherson et al., 
2010). Benovic et al., (1988) established an excellent correlation between the ability of β-AR 
agonists to stimulate adenylate cyclase activity and receptor phosphorylation by GRKs. Also, 
McPherson et al., (2010) established an excellent correlation between efficacy for G-protein 
activation and arrestin recruitment for μ-opioid receptors. The intensity of the peptide maps 
of receptor phosphorylated by GRK in the presence of partial agonists was lower compared to 
full agonists (Benovic et al., 1988). High-efficacy β2-AR agonists (e.g. formoterol) caused 
more phosphorylation and internalisation of the receptor than low efficacy agonists (e.g. 
salmeterol) in HEK-293 cell lines (January et al., 1998). Also, salmeterol binding to β-ARs 
induced an active receptor state that was unable to recruit arrestin or undergoes significant 
endocytosis or degradation despite stimulating considerable GRK-site phosphorylation 
(Moore et al., 2007). These reports suggest that high-efficacy agonists mediate greater 
desensitisation because they induce a greater intracellular signalling, receptor 
phosphorylation and internalisation (Benovic et al., 1988; McPherson et al., 2010; Scola et al., 
2004). Greater efficacy would also result in a greater number of activated receptors than for 
partial agonists (Benovic et al., 1988; McPherson et al., 2010).  
In contrast, earlier studies using equi-efficient concentration of β-AR agonists in human 
airway cells showed that desensitisation induced by agonists were independent of the agonist 
efficacies (Duringer et al., 2009). Duringer et al., (2009) used formoterol which is a full 
agonist and salmeterol which is a partial agonist at β-ARs (Condemi, 2001; Palmqvist et al., 
1999). Using equi-efficient concentrations of formoterol and salmeterol, formoterol induced 
the least reduction of responsiveness (cyclic AMP response) after the 1 hour prior exposure in 
human airway cells (Duringer et al., 2009). Their study showed that under conditions of 
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continuous agonist stimulation, reductions in receptor responsiveness were relative to the 
initial functional effect and similar for all agonists studied. Duringer et al., (2009) used equi-
efficient concentrations of agonist rather than agonist occupancy in their experiments. Using 
equi-effective concentrations, full agonist would occupy fewer receptors to give the response 
reported by Duringer et al., (2009). Thus, the less desensitisation induced by formoterol may 
be related to the number of receptors occupied i.e. fewer thus, a small desensitisation. 
In the present study, A61603 was more potent than noradrenaline and phenylephrine at the 
α1A-AR subtype of the pig urethra confirming full agonist activity at α1A-ARs (Yoshiki et al., 
2013). Potency of each agonist examined was also proportional to the desensitisation 
produced (noradrenaline exempted). The ability of phenylephrine and A61603 to induce 
desensitisation could be mediated by GRK or PKC associated phosphorylation and 
modulation of desensitisation (Xiang et al., 2001). Desensitisation mediated by PKC has been 
shown to be induced by A61603 in HEK-293 cells (Xiang et al., 2001) and rat 
cardiomyocytes (Rohde et al., 2000), and by phenylephrine in the rat aorta (Zhao et al., 2015). 
However, noradrenaline may be a weak activator of PKC in the urethra or mediates down-
regulation of PKC, as shown in the rat cardiomyocytes (Rohde et al., 2000), which may 
explain the lack of desensitisation observed with noradrenaline. Moreover, total repeatability 
of noradrenaline-mediated responses in the present study after the washing period also 
suggested a complete recovery of surface receptors from intracellular pools, as shown in the 
Rat-1 fibroblasts (Morris et al., 2004). A61603, which has a higher affinity for α1A-ARs, 
compared to phenylephrine and noradrenaline (Knepper et al., 1995; Thiyagarajan et al., 2002) 
and a higher affinity for α-ARs has been associated with greater phosphoinositide hydrolysis 
(Knepper et al., 1995). Moreover, diacylglycerol a product of phosphoinositide hydrolysis, 
induces Ca
2+
 influx and PKC activation, which can also mediate desensitisation (Xiang et al., 
2001). Therefore, the greater desensitisation seen with A61603 may also be proportional to 
its greater ability to induce phosphoinositide hydrolysis and inositol 1, 4, 5-tris-
phosphate/diacylglycerol production, resulting in PKC-mediated desensitisation. Intracellular 
pathway involved in desensitisation is further investigated in chapter 6. 
Muscarinic acetylcholine receptor activation is also known to contract the proximal 
urethra/bladder neck (Nagahama et al., 1998; Taki et al., 1999; Yamanishi et al., 2002a). 
Therefore, we investigated desensitisation of carbachol-mediated responses in the urethra. 
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The potency of carbachol was lower than that of A61603, phenylephrine and noradrenaline, 
confirming that the α1-ARs mediate the predominant contractile responses of the urethra 
(Bagot & Chess-Williams, 2006). Desensitisation of muscarinic responses by prior 
application of carbachol (52.5%) was similar to the desensitisation of α1-AR responses 
produced by A61603 and phenylephrine. We believe this report is the first to show 
desensitisation of mAChR-mediated responses to carbachol in porcine urethral tissues. 
Desensitisation of the mAChRs has been reported in the mouse bladder (Cha et al., 2006). 
Desensitisation of all mAChRs (except M1) has been shown to be mediated by the GRK2 
(Tsuga et al., 1998), whilst, M1 mAChR internalisation is dependent on arrestin, G protein 
and the third intracellular loop of these receptors, as shown in CHO cells (Tsuga et al., 1998; 
Yeatman et al., 2014). Budd et al., (1999) also showed that M3-mAChR mediated 
heterologous phosphorylation of β2-ARs in a GRK-independent fashion, but via PKC. 
Therefore, there is a possibility of the desensitisation of subsequent responses to carbachol 
being induced by GRK/ PKC (Borroto-Escuela et al., 2011; Hosey et al., 1995), arrestin and 
G-protein recruitment (Tsuga et al., 1998; Yeatman et al., 2014).  
The extent and rate of internalisation of M1-M5 mAChR expressed in COS-7 and BHK-21 
cells has been shown to differ from one receptor subtype to another (Tsuga et al., 1998). 
Specifically, M2 mAChRs were not re-sensitised in most cases and did not recycle back to the 
plasma membrane in HEK-293 cells compared to M1 mAChR (Vogler et al., 1998). Also, the 
dominant negative arrestin mutant only displayed a significant effect on M1, M3 and M4 
mAChR sequestration, which indicated that the receptor subtypes may differ in their 
requirement for arrestin (Vogler et al., 1999). Coincidentally, the M2 and M3 mAChR 
subtypes which were susceptible to desensitisation (Vogler et al., 1998; 1999) are the 
receptors that mediate carbachol-induced contraction of the porcine urethral smooth muscle 
(Yamanishi et al., 2002a; 2002d). Therefore, these results suggest that the desensitisation of 
responses to carbachol involving M2 and M3 receptors in the porcine urethra. However, a 
thorough study researching the receptor protein density and intracellular signalling is needed 
to confirm the contribution of these receptors to desensitisation, and precise intracellular 
mechanisms.  
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Does age affect desensitisation of α1-adrenoceptor-mediated responses? 
Alpha1-ARs are prospective drug targets for stress urinary incontinence, however, as shown 
above, the efficacy of treatment with α1A-AR agonists may be limited by desensitisation. The 
effect of desensitisation may increase or decrease with ageing; a phenomenon is already 
shown in the vascular system (Dinenno et al., 1999; 2001; Smith et al., 2007). Therefore, we 
investigated the effect of age on desensitisation of contractile responses of the urethral tissues 
to phenylephrine. We found that α1-AR-mediated responses are not altered with age in 
porcine urethral tissues in this chapter and when considering the downstream effect of ageing, 
no differences in PKCα activity were reported between young and older mice, although in the 
trachea and lungs (Bailey et al., 2014). Other researchers have also shown no change in PKC 
isoforms in the ageing brain (Battaini & Pascale, 2005), the ageing myocardium (Korzick et 
al., 2001), and in lymphocytes (Whisler & Grants, 1993), and no change in GRK activity in 
the ageing human heart (Leineweber et al., 2003).  Thus, we hypothesised that desensitisation 
of contractile response of the urethral tissues to phenylephrine would be age-independent. 
However, this was not the case and desensitisation of responses to phenylephrine was in fact 
greater in the old compared to the younger urethral tissues. Jiang et al., (1993) showed that 
age-related desensitisation was related to decrements in β-AR-mediated cyclic AMP 
accumulation, phosphorylation of phospholamban and troponin I.  Moreover, an age-related 
increase in GRK (Iaccarino et al., 2005; Ping et al., 1997; Rengo 2014), and increase in Gi 
(Fu et al., 1992) were reported in human heart, and an age-related increase in β-arrestin, 
GRK2 and GRK5 expression have been reported in the rat (Lymperopoulos et al., 2007; 
Rengo 2012a; 2012b; 2012c; Vinge et al., 2001).  The increased desensitisation of subsequent 
contractile response to phenylephrine in the older porcine urethra may therefore involve 
several possible intracellular mechanisms including increases in Gαq, GRK, PKC and β-
arrestin expression. Greater desensitisation in the older pig tissue may also be associated with 
an increase in Ca
2+
 influx and increase in Ca
2+
 release from the sarcoplasmic reticulum, as 
found by Lopes et al., (2006) in intestinal smooth muscle.  The specific signalling pathways 
contributing to desensitisation of subsequent contractile responses in the urethral tissues is 
investigated further in chapter 6. 
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Conclusion  
Greatest α1-AR-mediated responses were recorded in the proximal porcine urethral region. 
Phenylephrine, A61603 and carbachol responses showed desensitisation upon repeated 
application. However, responses to noradrenaline did not desensitise.  Moreover, age had no 
significant effect on α1-AR-mediated responses, but responses to phenylephrine desensitised 
to a greater extent in the older urethral tissues. 
Based on the results from this chapter, the proximal urethra was used for the rest of the 
studies in this thesis, except where stated. Moreover, repetition of concentration-response 
curves to phenylephrine, A61603 and carbachol were avoided for the rest of the experimental 
work, to prevent desensitisation interfering with results. Since the α-AR-mediated responses 
were similar for the young and old urethral tissues, porcine urethral tissues from older 
animals were used for the rest of the studies in this thesis except, were specified. 
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CHAPTER 4 
 
Modified from Merrill et al., 2016. 
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4 THE EFFECT OF THE UROTHELIUM ON 
URETHRAL RESPONSES  
4.1 UROTHELIUM DERIVED INHIBITORY FACTOR 
In the 80’s, Furchgott & Zawadzki, (1980) observed that in a rabbit aorta ring with 
endothelium preparation acetylcholine produced marked relaxation. They showed that 
relaxation of isolated preparations of rabbit aorta and other blood vessels by acetylcholine 
requires the presence of endothelial cells, and that acetylcholine, acting on mAChR of these 
cells, stimulates the release of a substance(s) that causes relaxation of the vascular smooth 
muscle. They proposed that this inhibitory effect may be one of the principal mechanisms for 
acetylcholine-induced vasodilation in vivo (Furchgott & Zawadzki, 1980). 
Maggi et al., (1987) was one of the first to report that contractile responses to the sensory 
nerve mediator substance P in the guinea-pig urinary bladder were smaller when the 
urothelium was intact. This suggested the release of an inhibitory factor from the guinea-pig 
urothelium. Also, removal of the mucosa enhanced responses to transmural nerve stimulation 
at low voltages and pulse durations in guinea-pig bladder (Krasnopolsky et al., 1995).  
Levin and colleagues (1995) found that the urothelium had a significant inhibitory effect on 
the contractile response of the cat bladder to stimulation with several agonists. Later, 
Hawthorn et al. (2000) reported an enhanced response to carbachol in tissues without 
urothelium in the pig urinary bladder. When a second urothelium-intact tissue was co-
incubated, the responses returned to a lower amplitude which was due to the effect of the 
urothelium suggesting the release of a diffusable inhibitory agent (Hawthorn et al., 2000). 
Furthermore, the presence of a second bladder strip without urothelium, failed to inhibit 
contractions in the first strip, suggesting the inhibitory factor is released by the urothelium 
and not the detrusor smooth muscle. Hawthorn et al. (2000) conclusion was supported further 
by the finding that responses to carbachol were potentiated following removal of the 
urothelium from previously intact bladder strips. Similar to the work of Fovaeus et al., (1999) 
in the rat bladder, Hawthorn et al. (2000) showed that NO does not appear to mediate the 
effect of the pig bladder urothelium, since L-NOARG (NOS inhibitor) had no effect on the 
inhibition. Moreover, inhibition of guanylate cyclase, and incubation with indomethacin, 
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suramin, propranolol, and potassium channel blocker TEA  had no effect on the urothelium 
induced inhibition, excluding cyclooxygenase products, P2Y receptors, β-ARs,  gamma-
aminobutyric acid and voltage-activated or ATP-dependent K
+
 channels respectively from 
potential factors mediating the effect. Templeman et al., (2002) shared a similar inhibitory 
effect of the urothelium in the pig trigone. Contractile responses to carbachol and histamine 
but not to phenylephrine were depressed in the presence of the urothelium. However, 
activation of mAChRs and histamine receptors resulted in the responses of intact urothelium 
strips to phenylephrine being significantly depressed. Thus, Templeman et al., (2002) showed 
that the urothelium derived factor appears to mediate cross-talk between the mAChR, 
histamine receptor and the α-AR in the pig trigone. 
Beta-AR agonists, possibly via urothelial β3-ARs (Masunaga et al. 2010) also seem to 
stimulate the release of this unidentified factor which inhibits detrusor contractility directly or 
indirectly (Murakami et al. 2007).  Urothelium-derived inhibitory factor appears to be 
released in the human bladder, as responses to EFS or carbachol were also enhanced in the 
absence of urothelium (Chaiyaprasithi et al., 2003).  However, contractions elicited by KCl 
and by neurokinin A were not modified by the urothelium.  In the human bladder, the 
urothelium derived inhibitory factor was not NO, cyclooxygenase product and not mediated 
by guanylate cyclase and β-ARs (Chaiyaprasithi et al., 2003). 
Although studies have indicated that the urothelium-derived inhibitory factor is diffusible 
within an organ bath (Fovaeus et al., 1998; 1999; Hawthorn et al. 2000; Templeman et al., 
2002; Chaiyaprasithi et al., 2003) and over a longer distance (from one bath to another) 
(Guan et al., 2014a), the chemical nature of this ‘urothelium-derived relaxing factor’ has not 
been resolved.  Also, most studies on the urothelium are based in the bladder and less is 
known about the physiology and pharmacology of the urethral urothelium. Particularly it is 
not yet known whether the urethral urothelium affects the underlying smooth muscle 
response. Since the maintenance of luminal pressure of the urethra is paramount to 
maintaining continence, it is important to know whether the urothelium is involved in 
modulating the porcine urethral responses, tone and luminal pressure. In addition, 
dysfunction of any urothelial mechanism may be involved in the pathology of disorders such 
as stress urinary incontinence, and provide a new potential target for therapeutic intervention.  
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Study aim 
The aim of this chapter was to investigate the role of the urothelium in the porcine urethra. 
Specifically, this study focussed on: 
 Does the urothelium affect α1-AR, β-AR and mAChR-mediated responses of the 
urethra? 
 Does the effect of the urothelium depend on age or urethral region?  
 What factors contribute to any effect?  
 Does the urothelium affect desensitisation of α1-AR-mediated responses? 
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4.2 MATERIALS AND METHODS 
Methods 
To determine the effect of the urothelium/lamina propria (LP) on receptor-mediated 
responses, the urothelium/LP was carefully dissected off and separated from the smooth 
muscle of the urethra. The tissues with and without urothelium/LP were set up in pairs, in 
8ml organ baths, as described in chapter 2. Following set up and equilibration for 1 hour, 
cumulative concentration-response curves to agonists (noradrenaline, phenylephrine, A61603, 
carbachol and isoprenaline) were constructed.  
To investigate what factors may be contributing to the effect of urothelium/LP, urethral tissue 
strips with or without urothelium/LP were set up in pairs and incubated with inhibitors for 30 
minutes after equilibration. The tissues were then contracted to cumulative concentrations of 
agonists and responses compared with control tissues (absence of inhibitors). Indomethacin 
(10μM) and LNNA (100μM) were used to block prostaglandins and NO production 
respectively. Concentration-response data were plotted and analysed as described in chapter 2.  
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4.3 RESULTS 
Investigation of α1-adrenoceptor-mediated responses in urethral tissues 
As shown in an earlier chapter, A61603 produced significantly greater contractions than the 
endogenous agonist noradrenaline, or phenylephrine (Table ‎4.1; Figure ‎4.1). Also, the pEC50 
values for A61603 were significantly greater than for the other agonists, showing greater 
potency (Table ‎4.1).  
 Noradrenaline Phenylephrine A61603 
Maximum response 
(mN) 
148.3±8.9 121.4±11.1 339.3±23.2** 
pEC50 5.0±0.1 5.5±0.2 7.7±0.3*** 
n 4 6 10 
Table ‎4.1 Mean (±SEM) maximum contractile response and pEC50 values for agonists for contractile 
responses of porcine urethral tissues to noradrenaline, phenylephrine and A61603. **p<0.01, ***p<0.001 
vs. response to noradrenaline (one way ANOVA, with Tukey post hoc test). 
 
Figure  4.1 Concentration-response curves to phenylephrine, noradrenaline and A61603 in urethral 
tissues of the pig.  **p<0.01 vs. response to noradrenaline (one way ANOVA, with Tukey post hoc test); 
n=4-10. 
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The effect of urothelium/lamina propria on receptor-mediated responses 
Removal of the urothelium/LP resulted in increased maximum contractions to A61603, 
phenylephrine and noradrenaline (Table  4.2, Figure  4.2; p<0.05). The percentage inhibition 
of contractile responses by the urothelium/LP was similar for all agonists (Figure  4.2). 
Comparison of the role of the urothelium/lamina propria in regions of the urethra  
The urothelium/LP significantly depressed responses by a similar amount to phenylephrine in 
both the proximal (p<0.05) and mid (p<0.001) urethra (Table ‎4.3). However, the effect was 
not observed in the distal region of the urethra. The urothelium/LP had no significant effect 
on pEC50 values for phenylephrine in the mid and distal urethral tissue. However, in the 
presence of urothelium/LP, the pEC50 values for phenylephrine in the proximal urethra were 
increased, showing increased potency (Figure  4.3; p<0.001).  
Effect of age on the role of the urothelium/lamina propria in the proximal urethra 
Removal of the urothelium/LP from urethral tissues from young and older pigs resulted in 
significantly greater maximum contractile responses of urethral tissues to phenylephrine, 
(Table  4.4, Figure ‎4.4; n=6-7). The amount of inhibition caused by the presence of the 
urothelium/LP was similar in the tissues from the young and older pigs. Moreover, the pEC50 
values for phenylephrine in tissues with urothelium/LP were akin to those in tissues without 
urothelium/LP in both young and older pigs. 
Influence of urothelium/lamina propria on desensitisation of concentration-response 
curves to phenylephrine 
The urothelium/LP had no significant effect on the desensitisation or repeatability of 
responses to phenylephrine. Responses to subsequent additions of phenylephrine were 
significantly desensitised both in the presence or absence of urothelium/LP, and 
desensitisation of responses was similar in the young and the older pig tissues (Table  4.5; 
Figure  4.5; n=6). Furthermore, the pEC50 values for phenylephrine were not affected by the 
removal of the urothelium/LP and by the subsequent addition of phenylephrine in the young 
or old tissues. 
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Figure  4.2  Concentration-response curves of proximal urethral tissues (36 months, +/- urothelium/LP) to 
noradrenaline, phenylephrine and A61603.  *p<0.05 vs. smooth muscle with urothelium/LP response 
(Student’s t-test); n=4-10. LP=lamina propria. 
Noradrenaline 
Phenylephrine 
A61603 
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Figure  4.3  Concentration-response curves to phenylephrine for urethral tissues (36 months, +/- 
urothelium/LP) from various regions of the urethra. n=8-13. *p<0.05, ***p<0.001 vs. smooth muscle with 
urothelium/LP response (Student’s t-test). LP=lamina propria. 
Proximal 
Mid 
Distal 
 126 
 
 
 
 
 
 
 
Figure  4.4  Concentration-response curves of proximal urethral tissues (+/- urothelium/LP) from young 
and older pigs to phenylephrine. n=6-7. *p<0.05, ***p<0.001 vs. smooth muscle with urothelium/LP 
response (Student’s t-test). LP=lamina propria. 
  
Young 
Old 
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  Smooth muscle only  Smooth muscle + urothelium/LP 
                                    
     
 
  
  Smooth muscle only  Smooth muscle + urothelium/LP 
          
        
 
Figure  4.5  Mean concentration-response curves for urethral tissues (proximal) from young and older 
urethral tissues (+/- urothelium/LP) to phenylephrine; n=6.*p<0.05, **p<0.01, ***p<0.001 vs 1
st
 response 
curve (Paired Student’s t-test). LP=lamina propria. 
  
Young 
Old 
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Influence of urothelium/lamina propria on muscarinic receptor-mediated responses of the 
porcine urethra  
Maximum contractile responses of urethral tissues without urothelium/LP to cumulative 
concentrations of carbachol were significantly greater than those with urothelium/LP 
(Table ‎4.6; Figure ‎4.6; n=5, p<0.01). The pEC50 values for carbachol for tissues with 
urothelium/LP were similar to those of tissues without urothelium/LP. 
 Carbachol 
 Smooth muscle + urothelium/LP Smooth muscle only 
Max response (mN) 49.8±7.6 141.0±25.1** 
pEC50 5.8±0.2 5.2±0.2    
Percentage decrease 
in max (%) 
64.7±22.6 
n 5 
Table  4.6 Mean (±SEM) maximum contractile responses and pEC50 values for carbachol for proximal 
urethral tissues from 36 months old pig (+/- urothelium/LP). ** P<0.01 vs. smooth muscle with 
urothelium/LP (Student’s t-test). LP=lamina propria.  
 
Figure  4.6 Concentration-response curves of proximal urethral tissues (36 months, +/- urothelium/LP) to 
carbachol; n=5. ** P<0.01 vs. smooth muscle with urothelium/LP (Student’s t-test). LP=lamina propria. 
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Influence of the urothelium/lamina propria on β-AR-mediated responses of the porcine 
urethra 
Cumulative concentrations of isoprenaline caused concentration-dependent relaxations of the 
porcine urethral from baseline (Table ‎4.7, Figure ‎4.7).  Tissues without urothelium/LP-
relaxed to a significantly greater extent to isoprenaline than tissues with an intact 
urothelium/LP (p<0.05). Moreover, the pEC50 values for isoprenaline were similar for tissues 
with and without urothelium/LP.  
 Isoprenaline 
 Smooth muscle + urothelium/ LP Smooth muscle only 
Max relaxation response 
(mN) 
89.3±6.1 131.3±13.8* 
pEC50 7.2±0.2 7.0±0.2 
Percentage inhibition of 
relaxation (%) 
32.0±12.8% 
n 10 
Table  4.7 Mean (±SEM) maximum relaxation responses and pEC50 values for isoprenaline in proximal 
urethral tissues (36 months, +/- urothelium/LP). *p<0.05 vs. smooth muscle with urothelium/LP (Student’s 
t-test); n=10. LP=lamina propria. 
 
Figure  4.7 Concentration-response curves to isoprenaline for proximal urethral tissues (36 months, +/- 
urothelium/LP). *p<0.05 vs. smooth muscle with urothelium/LP (Student’s t-test); n=10. LP=lamina 
propria. 
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Role of prostaglandins and nitric oxide in urothelium/lamina propria inhibition in the 
urethra 
Incubation with LNNA (100μM) had no effect on proximal urethral responses to 
noradrenaline (Table 4.8; Figure  4.8), phenylephrine (Table 4.8; Figure  4.9) and A61603 
(Table 4.8; Figure  4.10) irrespective of whether with urothelium/LP was present or not. The 
presence of indomethacin (10μM) also had no effect on responses, except for urethral tissues 
without urothelium/LP, where contractions to phenylephrine (Table 4.8; Figure  4.9; p<0.05), 
but not other agonists, were reduced by indomethacin.  
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           Smooth muscle only  Smooth muscle + urothelium/LP 
 
  
  Smooth muscle only  Smooth muscle + urothelium/LP 
 
  
Figure  4.8 Concentration-response curves of porcine urethral tissues (+/-urothelium/LP) to noradrenaline 
in the presence or absence of cyclooxygenase inhibitor (indomethacin (10μM)) or nitric oxide synthase 
inhibitor (LNNA (100μM)); n=5. LP=lamina propria. 
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         Smooth muscle only  Smooth muscle + urothelium/LP 
 
          
  Smooth muscle only  Smooth muscle + urothelium/LP 
 
 
Figure  4.9 Concentration-response curves of porcine urethral tissues (+/-urothelium/LP) to 
phenylephrine in the presence or absence of indomethacin (10μM) or LNNA (100μM). *p<0.05; n=5. 
LP=lamina propria. 
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  Smooth muscle only  Smooth muscle + urothelium/LP 
 
 
   Smooth muscle only  Smooth muscle + urothelium/LP 
 
 
Figure  4.10 Concentration-response curves of porcine urethral tissues (+/-urothelium/LP) to A61603 in 
the presence or absence of cyclooxygenase inhibitor (indomethacin (10μM)) or nitric oxide synthase 
inhibitor (LNNA (100μM)); n=5. LP=lamina propria. 
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4.4 DISCUSSION 
The experiments conducted in this chapter were performed to investigate the influence of the 
urothelium/LP on AR and mAChR-mediated responses of porcine urethral tissues. 
Contractions of the normal porcine urethra to carbachol are mediated by M2 and M3 mAChRs 
in circular muscle but by M3 mAChRs in the longitudinal muscle (Yamanishi et al., 2002d). 
Similarly, urethral tissue from human and animals expresses β-ARs (Morita et al., 2000; 
Yamanishi et al., 2002c; 2003a), which mediate relaxation (Takeda et al., 2003; Yamanishi et 
al., 2003a). However, the effects of exogenous β-AR agonists on urethral tissues are small 
relative to those of the bladder (Takeda et al., 2003).  So far, the physiological role of the 
mAChRs and β-ARs in the urethra is still a matter for debate given the major role of the α1-
AR.  
In this study, activation of β-ARs with isoprenaline relaxed the urethral tissues, while 
carbachol contracted the urethral tissues. This supports previous work (Alexandre et al., 2016 
and Giglio & Tobin, 2009; Kedia et al., 2013). Moreover, mAChR-mediated responses were 
significantly less than α1-AR-mediated responses. Ek and colleagues, (1977) reported that 
acetylcholine produced only a weak contraction in the isolated human urethra, and this effect 
was blocked by atropine, suggesting that mAChRs mediated the responses. Kedia et al., 
(2013) showed that acetylcholine and carbachol had only minor contractile effects on the 
human male urethral smooth muscle. Therefore, this finding is in accordance with earlier 
reports and suggests only a minor role for mAChR in contraction of the urethra. 
Does the urothelium/lamina propria affect the receptor-mediated responses 
of the urethra? 
The inhibitory effects of the urothelium/LP on smooth muscle contractions have been shown 
to involve a receptor-mediated mechanism in the bladder (Templeman et al., 2002; 
Chaiyaprasithi et al., 2003). Therefore, it was hypothesised that stimulation of α-ARs and 
mAChRs would trigger a similar inhibitory effect via the urothelium/LP, and depress urethral 
smooth muscle responses. It was observed that the urethral urothelium/LP indeed did have an 
inhibitory effect on receptor-mediated responses. The receptor-mediated responses were 
significantly greater in tissues without urothelium/LP compared to those with their 
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urothelium/LP intact for all agonist (AR and mAChR agonist).  The inhibitory effect seems to 
be similar in size to that reported in the porcine bladder in response to carbachol (Hawthorn 
et al. 2000). Previous reports have shown that the urothelium/LP depressed receptor-mediated 
response in the rat (Fovaeus et al., 1999), guinea-pig (Guan et al., 2014a), cat (Levin et al., 
1995), pig (Hawthorn et al. 2000; Templeman et al., 2002) and human (Chaiyaprasithi et al., 
2003) detrusor smooth muscle only. The smaller responses in urethral strips with 
urothelium/LP could be argued to be due to poor agonist penetration through urothelium/LP. 
However, the muscle is exposed to the agonist on all sides of the strips. However, 
Templeman et al., (2002) showed that in the presence of an intact urothelium, contractile 
responses to phenylephrine were not depressed in the pig bladder trigone. The inability of 
phenylephrine to induce the inhibitory effect of the urothelium/LP may be associated with the 
lower contribution of α1-ARs to bladder contraction (Nomiya & Yamaguchi, 2003). In the 
present study, the inhibitory effect in urethra was observed with stimulation by mAChR and 
α1-AR agonists. Thus this report shows for the first time that the urothelium/LP has an 
inhibitory effect on receptor-mediated responses in the porcine urethra. 
In addition, previous reports showing inhibitory effects of the urothelium/LP have not 
compared inhibitory effect of the urothelium/LP in relation to α1-AR agonist efficacy, affinity 
and potency, thereby making this report the first to do so. The effects of the urothelium/LP on 
receptor-mediated responses were similar for the α1-ARs agonist irrespective of their affinity, 
efficacy and potency. Moreover, the effects of urothelium/LP on receptor-mediated responses 
were similar for the α1-AR- and mAChR-mediated responses, thus suggesting that the 
inhibitory effect may not be receptor-type dependent in the porcine urethra.  
Effect of the urothelium/lamina propria on β-adrenoceptor-mediated 
relaxation responses 
In the present study, isoprenaline-induced relaxations were significantly depressed in tissues 
with urothelium/LP. Since there are no reports showing the effect of urothelium/LP on β-AR-
mediated responses in the urethra, the comparison could only be made with responses in the 
bladder. Murakami et al., (2007) showed that maximum relaxation to isoprenaline and 
potency was similar in the absence and presence of the urothelium/LP in the pig bladder. 
Although this report was based on the relaxation of carbachol pre-contracted bladder strips, 
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whereas relaxation of basal tension was shown in the present study, this suggests a difference 
in the role of urothelium/LP between the bladder and urethra in response to β-ARs activation. 
The attenuated relaxation to isoprenaline in the presence of the urothelium/LP could indicate 
the release of a contractile agent from the urothelium/LP.  Such an agent may include ATP 
(Young et al., 2012), which is known to be released from urothelium, and which acts on P2Y 
or P2X receptor, or acetylcholine (Hanna-Mitchell et al., 2007; Yoshida et al., 2006) which 
acts on the mAChR. Moreover, activation of the P2Y receptor may mediate further ATP 
release from the urothelium (Hanna-Mitchell et al., 2007).   
The possibility of the urothelium releasing a ‘contracting factor’ in addition to the ‘inhibitory 
factor’ has been suggested previously albeit in the bladder (Propping et al., 2013; 2015a, b). 
Such a phenomenon may exist in the urethra, and a possibility is a contractile prostaglandin 
(Downie & Karmazyn, 1984) which may act on receptors on the smooth muscle or 
urothelium/LP to mediate the depression of isoprenaline-mediated relaxation. Prostaglandin 
E2 has been shown to contract animal and human bladder smooth muscle strips (Root et al., 
2015) and the expression of the prostaglandin E receptors, EP1, EP2, EP3, and EP4, and 
mRNA for EP2, EP3, and EP4 have been reported in dog urethral urothelium (Ponglowhapan 
et al., 2010). Reductions in bladder capacity have been attributed to one or more of the 
contractile prostanoid receptor subtypes EP1, EP2 and EP3 in cells, animal models and human 
(Schroder et al., 2004; Wang et al., 2008; Su et al., 2008b; Palea et al., 1998). Furthermore, 
inhibition of the EP1 prostanoid receptor has been shown to increase the capacity of 
rat bladder in vivo (Lee et al., 2007). Thus, activation of prostaglandin E receptors via a 
contractile prostaglandin released by the urothelium may also be responsible for depression 
of isoprenaline-mediated relaxation reported in this study. 
Influence of urothelium/lamina propria in different urethral regions and 
effect of age 
Templeman et al., (2002) reported the inhibitory effect of the urothelium/LP on receptor-
mediated responses in the pig trigone but did not investigate the urethra or the regions. We 
found that the urothelium/LP of the proximal and the mid-urethra had a greater inhibitory 
effect on phenylephrine-induced contractile responses compared to that in the distal urethra. 
This difference in the inhibitory effect between the proximal, mid and distal urethral tissues 
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may reflect differences in innervation (Yoshimura et al., 2003). The proximal urethra/bladder 
neck is densely innervated (Sienkiewicz et al., 2004) and the bladder neck/proximal urethra 
helps to maintain continence. Therefore, this result suggests the proximal urethra acts as a 
possible centralised region for neural control and modulation of the luminal pressure of the 
urethra as suggested by Pidsudko, (2004).  
Investigation of factors mediating the urothelium/lamina propria 
inhibitory effects 
Previous attempts to elucidate the nature of urothelium derived inhibitory factor in the 
bladder have been unsuccessful (Chaiyaprasithi et al., 2003; Guan et al., 2014a; Hawthorn et 
al., 2000). Agents that may inhibit smooth muscle contraction and which are released from 
the urothelium include prostanoids (Guan et al., 2014b) and NO (Andersson et al., 2012; 
Birder et al., 1998; 2001; Kullmann et al., 2008a). NO is released from urothelium in 
response to β-AR activation via NOS (Birder et al., 2002b). NO is released from the 
urothelium upon activation of mAChRs, and this NO can directly or indirectly attenuate 
detrusor smooth muscle contractility (Andersson et al., 2012; Kullmann et al., 2008a). 
Prostanoids are also produced locally within the bladder urothelium in human and other 
species (Kang et al., 2013; 2015a; 2015b; McDermott et al., 2012; 2013; Nile & Gillespie, 
2012; Wheeler et al., 2002) and are produced in response to physical stretch (Downie & 
Karmazyn, 1984; Kang et al., 2013; 2015a; 2015b; McDermott et al., 2013). Nile & Gillespie, 
(2012) showed that activation of M2 -mAChR induced production of prostaglandins. Whilst 
urothelium-derived inhibitory factor in the bladder has been shown not to be nitric oxide or 
prostaglandins, the possibility of either nitric oxide or prostaglandins or both mediating the 
urothelium/LP inhibitory effect was a possibility in the urethra.  
Inhibition of NOS and cyclooxygenase with LNNA and indomethacin respectively did not 
affect the inhibitory effect of the urothelium/LP.  Thus our result is similar to that reported in 
the bladder of guinea-pig (Guan et al., 2014a), pig (Hawthorn et al., 2000) and human 
(Chaiyaprasithi et al., 2003).  
Other possible agents that could mediate the inhibitory effect include ATP, hydrogen 
sulphide (H2S) and carbon monoxide. Gai et al., (2013) reported the expression of all the 
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three synthases of endogenous H2S, (cystathionine-β-synthethase, cystathionine-γ-lyase and 
3-mercaptosulfutransferase) in the urothelium of human and rat urethra. ATP could also 
mediate the urothelium inhibitory effect via the A2A, P1 receptors after breakdown to 
adenosine or via P2Y1 receptors after breakdown to ADP (Hernandez et al., 2009). Moreover, 
relaxation may be associated with K
+
 channels opening and activation of guanylate cyclase 
since these relaxing transmitters (carbon monoxide, ATP and H2S), mediate relaxation by 
opening of the K
+
 channels (Li et al., 2008; Naik & Walker et al., 2003) and activation of 
guanylate cyclase (Zakhary et al., 1997). Although it is not possible to comment on the 
likelihood of the candidates mediating the inhibitory effect in the urethra in the present study, 
in the bladder, the inhibitory agents appears to be neither NO, a cyclooxygenase product, a 
catecholamine, adenosine, cyclic GMP, γ-aminobutyric acid nor an endothelium-derived 
hyperpolarizing factor sensitive to apamin (inhibitor of the small-conductance Ca
2+
-activated 
K
+
-channels ) because urothelium-induced inhibition of contractions was not prevented in the 
presence of L-NOARG, methylene blue, indomethacin, propranolol, ODQ, suramin, TEA or 
apamin (Chaiyaprasithi et al., 2003; Hawthorn et al., 2000). These drugs inhibit NOS, 
guanylate cyclase, cyclooxygenase, β-adrenoceptors, guanylate cyclase, P2 receptors, K
+
 
channel and small conductant Ca
2+
-activated K
+
 channel respectively. Thus whether further 
study in the urethra elucidates the candidate is not known. 
An additional finding in the present study was that cyclooxygenase inhibition with 
indomethacin significantly reduced urethral smooth muscle contractility to phenylephrine. 
This result suggests that phenylephrine induces α1-AR-mediated prostaglandin release from 
the urethral smooth muscle and that the prostaglandin release had a contractile effect on the 
urethral smooth muscle.  
Prostaglandin was not released from the urothelium, but the urethral smooth muscle because 
indomethacin had no effect on responses of tissues with urothelium. Earlier we have shown 
that the urothelium had an inhibitory effect on the contractile responses of the urethral 
smooth muscle in response to α1-ARs activation with noradrenaline, phenylephrine and 
A61603. Moreover, the urothelium has an inhibitory effect on smooth muscle in the bladder 
and the inhibitory effect is mediated by the release of factors which are diffusible within a 
short and longer distance (Chaiyaprasithi et al., 2003; Guan et al., 2014a; Hawthorn et al. 
2000; Templeman et al., 2002). The absence of the effect of the indomethacin in urethral 
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tissues with urothelium suggests that the urothelium inhibitory effect masked the 
prostaglandin contractile effect. Moreover, the effect of indomethacin was seen only in 
phenylephrine-contracted tissues which suggested that the release of a contractile 
prostaglandin may depend on activation of receptor-coupled pathways, which differ between 
agonists (discussed in chapter 5).  
Prostaglandins can be released upon α1-AR activation, as shown in the rabbit (Yousufzai & 
Abdel-Latif, 1983; 1984) and bovine iris (Yousufzai & Abdel-Latif, 1983).  Analysis of 
tissue prostaglandin E2 revealed that rabbit and bovine iris prostaglandin E2 content was 
increased following 15 minutes incubation with an α1-AR agonist (Yousufzai & Abdel-Latif, 
1983). The release of prostaglandin E2 was time-dependent and the agonist-induced release of 
prostaglandin E2 was abolished by low concentrations of indomethacin, thus confirming the 
release of prostaglandin E2 via activation of cyclooxygenase.  
Phenylephrine stimulation of prostaglandin release in the porcine urethra is probably 
mediated through α1-ARs and maximal adrenoceptor stimulation may require the presence of 
Ca
2+
 as shown for rabbit and bovine iris (Yousufzai & Abdel-Latif, 1983).  Moreover, 
phenylephrine may induce the responses via the increase of the breakdown of 
phosphatidylinositol which may be accompanied by a significant increase in the release of 
arachidonic acid and consequently prostaglandin as shown in the rabbit iris (Yousufzai & 
Abdel-Latif, 1984). 
α1-AR agonists are prescribed off-label for the therapeutic increase of urethral tone, and 
agonist-induced increase in prostaglandin synthesis may play a significant role in mediating 
the pharmacological effects of these therapeutic agents. 
Does the urothelium/lamina propria have an effect on desensitisation of α1-
adrenoceptor-mediated responses? 
In the previous chapter, it was shown that responses to agonists that have a high affinity for 
α1-ARs (phenylephrine and A61603) are desensitised to a greater extent than responses to 
noradrenaline. In this chapter, we investigated whether the presence of the urothelium affects 
desensitisation of α1-AR responses.  
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The urothelium/LP had no significant effect on desensitisation of the subsequent contractile 
responses of the urethral tissues to phenylephrine. Moreover, these observations were similar 
between the young and older urethral tissues. Ferguson et al., (2015) showed that the 
urothelium could increase desensitisation of receptors, albeit for purinergic receptors. They 
showed urothelial P2X3 mediated desensitisation of detrusor responses in the rat, and 
explained this observation by a P2X3 receptor driven paracrine amplification of ATP release 
from umbrella cells, to increase afferent transmission in the suburothelial sensory plexus and 
desensitisation of P2X1-mediated purinergic detrusor contractions (Ferguson et al., 2015). 
The finding that the urothelium/LP does not influence α1-AR desensitisation, suggests that 
desensitisation of α1-AR is responsible for failure of α1-AR agonist in the treatment of stress 
urinary incontinence clinically, the mechanism does not appear to involve the urothelium and 
must lie at the level of receptor-mediated signalling pathways. 
Presently, the importance of these results for normal urethral function is not entirely known. 
However, the urothelium/LP may play a significant role in the normal physiology of the 
urethra and the aetiology and pathophysiology of stress urinary incontinence. 
Conclusion 
 The urothelium/LP has an inhibitory effect on receptor-mediated responses of the 
porcine urethra. 
 The inhibitory effect of the urothelium/LP is seen in all urethral regions except the 
distal portion.  
 The influence of the urothelium/LP on phenylephrine-mediated responses is not 
affected by age.  
 The inhibitory effect of the urothelium/LP on the urethral smooth muscle  is not 
mediated by prostaglandins or NO.  
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CHAPTER 5 
 
Modified from Puetz et al., 2009. 
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5 THE INTRACELLULAR PATHWAYS 
CONTRIBUTING TO URETHRAL CONTRACTILITY 
5.1 BASAL SMOOTH MUSCLE TONE IN THE LOWER 
URINARY TRACT 
Urethral closure pressure develops principally by contraction of the smooth and striated 
muscle (Shafik, 1999). However, an isolated rat urethral preparation was “continent” in the 
absence of external neural input,  and flow ensued when the smooth muscle was relaxed 
(McHale et al., 2006). Furthermore, stimulation of the skeletal muscle made little difference 
to the ability of the contracted urethra to retain fluid and paralysing the striated muscle 
encircling the urethra of anaesthetized rats with D-tubocurarine did not result in urine leakage 
(Conte et al., 1991). Thus, it appears, that skeletal muscle is more important for resisting 
rapid pressure rises caused by coughing or laughing, than for maintaining a constant urethral 
tone, while the smooth muscle contributes greatly to the maintenance of basal tone 
(Bridgewater et al., 1993), maintaining urethral luminal pressure. 
It is the circular smooth muscle of the urethra which exhibits intrinsic basal tone 
(Bridgewater et al., 1993), and this basal tone is resistant to neural blockade and mAChR 
antagonists, but sensitive to blockers of voltage-gated Ca
2+
 channels, and hence is myogenic 
(Brading et al., 1999; Bridgewater et al., 1993; Malmqvist et al., 2004; McKeag et al., 2001). 
The urethral basal tone can be enhanced by adrenergic and cholinergic input, or inhibited by 
non-adrenergic, non-cholinergic innervation, partially mediated by the transmitter NO 
(Bridgewater et al., 1993). Also, exogenously applied prostaglandin evoked a sustained 
increase in the rabbit urethral basal tone, suggesting a role of locally generated 
cyclooxygenase products (Ito & Kimoto, 1985). Moreover, Rho guanosine triphosphatases 
are involved in the generation of basal urethral tone (Malmqvist et al., 2004). To our 
knowledge, the pathways contributing to the urethra basal tone in the pig are not known and 
thus were the aim of the present study.  
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5.2 CALCIUM MOBILISATION IN THE LOWER URINARY 
TRACT 
In the bladder, extracellular Ca
2+
 influx is mainly mediated by the opening of voltage-
dependent L-type Ca
2+
 channels, which mediate detrusor contraction (Jiang et al., 2014) and 
spontaneous activity (Hashitani et al., 2001; 2004a, b). L-type Ca
2+
 channels have the greatest 
influence on [Ca
2+
]i and their activity largely determine detrusor contractile state in human 
and animals (Brading, 2006; Kajioka et al., 2002; Hashitani et al., 2004b; Kirschstein et al., 
2014). For example, entry of Ca
2+
 through L-type Ca
2+
 channels plays important roles in both 
human and rat bladder contraction (Fleichman et al. 2004; Schneider et al. 2004a, b).   
In the human detrusor, carbachol-induced contraction has been associated with 
phosphoinositide hydrolysis (Harriss et al., 1995). However, the phospholipase C inhibitor 
U73122 did not significantly affect carbachol-stimulated bladder contraction, despite 
blocking inositol 1, 4, 5-tris-phosphate generation in humans and rats (Schneider et al., 2004a, 
b; Frazier et al., 2007). Schneider et al., (2004a) concluded that carbachol-induced 
contraction of the human urinary bladder via M3 mAChR largely depends on Ca
2+
 entry 
through nifedipine-sensitive channels.  
T-type Ca
2+
 channels activity has also been recorded in human, guinea-pig and rat detrusor 
myocytes (Igawa et al., 2014; Li et al., 2007; Sui et al., 2001; 2003) as well as interstitial cells 
of the bladder (Deng et al., 2012). T-type Ca
2+
 channels have roles in generating spontaneous 
excitation in the guinea-pig detrusor (Yanai et al., 2006). Ca
2+
 influx via T-type Ca
2+
-
channels mediates depolarizations that lead to action potentials and are coupled functionally 
to small-conductance Ca
2+
-activated K
+
 channels, contributing to the stability of the resting 
membrane potential in detrusor smooth muscle (Yanai et al., 2006).  Yanai et al., (2006) 
thereby suggested that the pharmacological manipulation of T-type Ca
2+
 channels in detrusor 
smooth muscles could be of potential value for treating the overactive bladder. Ca
2+
release 
from the sarcoplasmic reticulum seems to contribute to some contractile responses, for 
example, spontaneous vasoconstriction of suburothelial venules in the rat bladder appears to 
result from Ca
2+
release from the sarcoplasmic reticulum upon activation of inositol 1, 4, 5-
tris-phosphate receptors (Hashitani et al., 2011). 
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Less research has been done in the urethra compared to the bladder. In the urethra, both L-
type and T-type Ca
2+
-currents (Bradley et al., 2004) have been recorded in isolated urethral 
myocytes (Hollywood et al., 2003a) and rat urethral tissues (Shafei et al., 2003). L-type Ca
2+
 
channels have the greatest influence on [Ca
2+
]i and their activity largely determine the 
urethral tissue contractile state in human and animals (Brading, 2006; Bradley et al., 2004; 
Kajioka et al., 2002). Bradley et al., (2004) showed that the frequency of Ca
2+ 
bursts in rabbit 
urethral smooth muscle was attenuated by blockade of T-type Ca
2+
 channels current. Thus, 
the L-type Ca
2+
 channels modulate urethra tonic contraction while the T-type Ca
2+
 channels 
modulate spontaneous activity. 
5.3 CALCIUM SENSITIZATION IN THE LOWER URINARY 
TRACT 
Rho kinase is expressed in the human detrusor (Kirschstein et al., 2015) with Rho kinase II 
showing a significantly greater expression than Rho kinase I. Ca
2+
 sensitization contributes to 
receptor-mediated contractile responses in the guinea-pig (Shahab et al., 2012b), pig 
(Tatsumiya et al., 2009), mouse (Chen et al., 2015; Isotani et al., 2004) and human 
(Kirschstein et al., 2014) detrusor smooth muscle. Fasudil (an inhibitor of Rho kinase) 
provokes relaxation of the pig bladder detrusor via both urothelium-dependent and 
independent pathways (Tatsumiya et al., 2009). Nakanishi et al., (2009) showed that the 
concentration of RhoA mRNA and activated RhoA were greater in urothelium than in pig 
bladder detrusor. Also, Y-27632 (an inhibitor of Rho kinase) showed a greater inhibitory 
effect in detrusor with intact urothelium than in that without urothelium (Nakanishi et al., 
2009). 
Chen et al., (2015) investigated the contribution of Thr694 and Thr852 phosphorylation sites 
in bladder smooth muscles from MYPT1 mutant mouse, by establishing two single point 
mutation mouse lines, T694A and T852A. MYPT1 was constitutively phosphorylated at 
T694 by unidentified kinases in vivo, whereas the Rho kinase phosphorylated the T852 site. 
They showed that phosphorylation of MYPT1 Thr694, but not Thr852, was the primary 
mechanism contributing to inhibition of myosin light chain phosphatase activity and 
enhancement of myosin light chain phosphorylation in vivo. Moreover, the constitutive 
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phosphorylation of MYPT1 Thr694 provided a mechanism for regulating force maintenance 
of the detrusor smooth muscle (Chen et al., 2015).  
In detrusor smooth muscle, Ca
2+
 sensitization is modulated by Ca
2+
 mobilisation and vice 
versa. For example, Durlu-Kandilci & Brading, (2006) demonstrated that inhibitors of 
sarcoplasmic reticulum-released Ca
2+ 
reduced carbachol-induced Ca
2+
 sensitization in the rat 
bladder.  Moreover, Kirschstein et al., (2014) showed that human detrusor smooth muscle 
cells have two major intracellular mechanisms underlying mAChR-mediated contractions; 
activation of myosin light chain kinase predominantly following Ca2+-influx via L-type 
Ca2+ channels, and activation of Rho kinase that is independent of a rise in intracellular Ca2+, 
but occurred as a consequence of L-type Ca2+channels activation (Kirschstein et al., 2014). 
On the other hand, constitutive Rho kinase activity was shown to be required for a quick 
stretch to activate Ca
2+
 entry and cause a myogenic contraction of the detrusor (Poley et al., 
2008).  
Recently, Tsai et al., (2014) showed that MYPT1 knockout did not cause significant 
derangement of bladder or ileal smooth muscle contractility in mice (Gao et al., 2016). Thus, 
the results suggest that in these tissues, Ca
2+
 sensitization is dependent on myosin light chain 
kinase and myosin light chain phosphatase activities without changes in constitutive MYPT1 
phosphorylation. Also, PKC contributes to receptor-mediated Ca
2+ 
sensitization in the rat and 
guinea-pig bladder (Durlu-Kandilci & Brading, 2006). However, animal studies suggested 
that PKC plays a minimal role in bladder contractility (Durlu-Kandilci & Brading, 2006; 
Fleichman et al., 2004; Schneider et al., 2004a).  
Again less research has been carried out on the urethra compared to the bladder. RhoA is 
expressed in the rat urethra (Teixeira et al., 2007). Moreover, the urethra expresses other Ca
2+
 
sensitization elements; Rho kinase I and Rho kinase II.  However, Rho kinase I and Rho 
kinase II protein levels were significantly lower in the rat urethral tissues compared to the 
trigone and the detrusor (Teixeira et al., 2007).  Incubation with a Rho kinase inhibitor 
inhibited contractions elicited by phenylephrine in the rabbit urethra (Walsh et al., 2011). 
Also, a role for RhoA and Rho kinase in urethral tone was indicated by the demonstration 
that inhibition of RhoA with Clostridium difficile toxin B, or inhibition of Rho kinase with 
Y27632, abolished porcine urethral tone without affecting intracellular Ca
2+
 (Malmqvist et al., 
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2004). These results suggest that Rho kinase plays a major role in urethral smooth muscle 
contraction (Walsh et al., 2011).  
5.4 CALCIUM CHANNELS AND CALCIUM SENSITISATION 
RELATED PATHOPHYSIOLOGY IN THE LOWER 
URINARY TRACT 
L-type and T-type Ca
2+ 
channels can be affected by pathological conditions. The density of 
T-type channels Ca
2+
 current is increased, and that of L-type Ca
2+
 decreased, in human 
detrusor myocytes from idiopathic detrusor overactivity patients compared to normal 
bladders (Sui et al., 2007). However, total Ca
2+
 current density was similar. A greater T-type 
Ca
2+
-channels density was also recorded in isolated myocytes from bladder outlet obstruction 
and overactive bladder rat models (Li et al., 2007). Also, reports have shown that enhanced 
extracellular Ca
2+ 
influx through L-type Ca
2+
 channels mediate overactive detrusor in diabetic 
mouse (Leiria et al., 2011). Thus, an increase in the density of L-type Ca
2+ 
channels which 
may enhance extracellular Ca
2+ 
influx seems to contribute to conditions such as the 
overactive bladder. 
Ca
2+
 sensitization is thought to contribute to pathological conditions underlying benign 
prostatic hyperplasia, erectile dysfunction, kidney failure, bladder outlet obstruction 
(Boopathi et al., 2014; Shahab et al., 2012a), ejaculation disorders, prostate cancer, bladder 
cancer initiation and metastasis (Gur et al., 2011). Takahashi et al., (2009) showed 
enhancement of the mAChR-coupled RhoA/Rho kinase pathway in the detrusor of rats with 
bladder outlet obstruction. Rho kinase enhanced signalling may mediate a compensatory 
mechanism for expelling urine against the obstruction (Shahab et al., 2012a; Takahashi et al., 
2009). The association of Ca
2+ 
sensitization with physiology and pathophysiology of smooth 
muscle contraction suggests that a greater understanding of the Ca
2+
-sensitization pathway 
might provide a novel drug target for stress urinary incontinence. 
The overall aim of this study, therefore, was to gain further insights into the intracellular 
signalling pathways involved in the regulation of porcine urethral smooth muscle contraction. 
This study investigated the classical Ca
2+ 
pathway, as well as Ca
2+ 
sensitization for both basal 
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urethral tone and α1-AR-mediated contractions. The following specific questions were 
addressed:  
 Which signalling pathways mediate maintenance of urethral intrinsic basal tone? 
 What are the intracellular pathways associated with α1-AR-mediated responses? 
 Does agonist concentration determine which intracellular pathways contribute to 
contraction?   
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5.5 MATERIALS AND METHODS 
Methods 
Strips of old female pig urethra from the proximal region (with urothelium/LP) were set up in 
8ml organ baths in pairs as described in chapter 2 (as control and test tissues). Following set 
up and equilibration for 1 hour, the effects of inhibitors of intracellular signalling molecules 
were investigated. These included fasudil (10μM), Y27632 (10μM), nifedipine (100nM), 
cyclopiazonic acid (CPA) (10μM), indomethacin (10μM) and calphostin C (1μM). These 
drugs inhibited Rho kinase, Ca
2+ 
influx via L-type Ca
2+
 channels, Ca
2+ 
release via 
sarcoplasmic reticulum, cyclooxygenase and PKC respectively (Figure  5.1). Incubating 
tissues in Krebs solution without Ca
2+ 
and with EDTA (3mM) was also used to block 
extracellular Ca
2+ 
influx. The tissue pairs were incubated with/without the inhibitor for 30 
minutes after equilibration to investigate the contribution of intracellular pathways to basal 
tone and α1-AR-mediated responses. 
Changes in basal tone were measured after 30 minutes incubation with an inhibitor to 
investigate the contribution of intracellular signalling molecules to the basal tone, and basal 
tone was compared between tissues incubated with and without inhibitors. Following this 
cumulative concentration-response curves to noradrenaline, phenylephrine and A61603 were 
constructed and maximum responses or sensitivity pEC50 values calculated as described in 
chapter 2. The contribution of intracellular signalling molecules to equivalent, half maximal, 
three-quarter maximal and maximal responses to agonists was also investigated using single 
agonist concentrations shown in Table ‎5.1. These concentrations were extrapolated from the 
cumulative concentration curves for agonists as illustrated in Figure ‎5.2. 
In all experiments, only one drug was tested on each tissue. The α1-AR-mediated responses 
were analysed and data expressed as described in chapter 2. 
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Figure  5.1 Intracellular signalling pathways inhibited to allow analysis of pathways activated by α1-
adrenoceptor activation. Fasudil blocks Rho kinase (ROCK), nifedipine blocks Ca
2+
 influx via the L-type 
Ca
2+
 channels, calphostin C blocks protein kinase C whilst cyclopiazonic acid blocks sarcoplasmic 
reticulum release of Ca
2+
. 
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 Concentrations inducing 
equivalent response  
Concentrations inducing 
half maximal response 
Concentrations inducing 
three-quarter maximal 
response 
Concentrations 
inducing maximal 
response 
Noradrenaline 10μM 4μM 10μM 1mM 
Phenylephrine 10μM 5μM 10μM 1mM 
A61603 30nM 37nM 300nM 100μM 
Table ‎5.1 The concentrations of agonists producing equivalent, half maximal, three-quarter maximal and 
maximal responses, chosen to compare the contribution and role of intracellular signalling pathways in 
urethral smooth muscle. 
  
Figure  5.2 Concentration-response curves to phenylephrine, noradrenaline and A61603 in porcine 
proximal urethral tissues, showing choice of concentrations of agonists inducing equivalent, half maximal, 
three-quarter of maximal and maximal responses. Point A and B corresponded to where contractile 
responses to noradrenaline, phenylephrine and A61603 were equivalent and the concentration that induced 
these responses were 10μM, 10μM, and 30nM of noradrenaline, phenylephrine and A61603 respectively. 
Point B also coincidentally was the three-quarter of maximal responses of noradrenaline and phenylephrine; 
therefore point B(s) were also compared to point C, which was the three-quarter of maximal responses of 
A61603. Furthermore, half maximal and maximal responses induced by agonists were also compared. n=7-
8; *** P<0. 001 vs. maximum contractile response to noradrenaline (One-way ANOVA with Tukey post-
hoc test).    
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5.6 RESULTS 
The intracellular pathways contributing to urethral basal tone  
The basal tone of the urethral tissues consistently increased slowly over time during the 
equilibration period (Figure ‎5.3) and plateaued after 40-60 minutes. 
 
Figure ‎5.3 Example of spontaneous development of porcine urethral basal tone during the 
equilibration period (1g= 100mN).  
Incubation with Y27632, fasudil, nifedipine, indomethacin or Ca
2+ 
exclusion/EDTA 
significantly reduced the basal tone of the urethral strips (Table ‎5.2; Figure ‎5.4). Nifedipine 
reduced basal tone by 155.1±17.7% (p<0.001), whilst Ca
2+ 
exclusion/EDTA reduced basal 
tone by 169.2±19.6% (p<0.0001). Fasudil and Y27632 significantly reduced the basal tone of 
the urethra by 357.2±31.2% (p<0.0001) and 688.7±45.8% (p<0.0001) respectively. Moreover, 
indomethacin (10µM) reduced urethra tissue basal tone by 219.3±37.6% (p<0.001). However, 
no change in the urethral basal tone was observed following incubation with CPA or 
calphostin C. 
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 Control (mN) Test (mN) Percentage reduction (%) n 
+ Nifedipine (100nM) 26.5±8.3 -14.6±4.7*** 155.1±17.7 10 
Ca
2+
 exclusion/EDTA 
(3mM) 
29.3±5.7 -20.3±5.7**** 169.2±19.6 11 
+ CPA (10μM) 27.5±5.9 16.5±11.5 40.0±41.7 10 
Indomethacin (10μM) 28.7±6.1 -34.3±10.8*** 219.3±37.6 7 
Fasudil (10μM) 29.0±5.9 -74.5±9.0**** 357.231.2+++ 17 
Y27632 (10μM) 26.2±7.8 -154.1±12.0**** 688.745.8+++ 7 
+ Cal C (1μM) 25.2±7.0 31.0±8.0 +23.2±31.9++ 10 
Table  5.2 Mean (±SEM) basal urethral tone (proximal tissues with urothelium/lamina propria), with or 
without inhibitor.  ***P<0.001 and ****P<0.0001 compared to the control responses (Student’s t-test), 
(++p<0.01, +++p<0.001 vs. percentage reduction in maximum for Ca
2+
 exclusion/EDTA (3mM) (One-way 
ANOVA with Tukey post-hoc test). Negative values= tone went below initial basal tone; positive value= 
tone of test tissue was greater than control tissue. 
Intracellular signalling contributing to α1-adrenoceptor-mediated urethral 
contractile responses of urethra 
Noradrenaline: Incubation with the various inhibitors caused a significant decrease in the 
contractile responses to cumulative concentrations of noradrenaline (Table  5.3; Figure ‎5.5).  
 Control Max 
(mN) 
Test Max 
(mN) 
Percentage reduction 
in max response (%) 
Control 
pEC50 
Test     
pEC50 
n 
Nifedipine 198.2±31.7 92.9±14.4** 53.1±7.3 5.4±0.2 5.2±0.2 8 
Ca
2+ 
free/EDTA(3mM) 
211.9±33.0 24.8±5.6**** 88.3±2.6++++ 5.5±0.2 4.8±0.3 7 
CPA 240.8±15.3 162.9±23.1* 32.4±9.6 5.3±0.1 5.4±0.2 7 
Fasudil 285.1±29.5 140.5±12.5*** 50.7±4.4 5.2±0.1 4.9±0.1 8 
Calphostin  C 243.6±18.3 167.7±14.1** 31.2±5.8 5.3±0.1 5.2±0.1 6 
Table  5.3 Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline in the 
presence or absence of inhibitors (proximal tissues with urothelium/lamina propria). *p<0.05, **p<0.01, 
*** P<0.001, **** P<0.0001 vs. respective control responses (Student’s t-test). (++++P<0.0001 (one-way 
ANOVA with Bonferroni post-hoc test)). 
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The reduction in maximum contractile responses was greatest in tissues incubated in Ca
2+ 
free/EDTA solution (p<0.0001). The pEC50 values for noradrenaline for urethral tissues 
incubated with or without inhibitors were similar and unchanged by any of the inhibitors. 
Similar to responses observed with noradrenaline, contractile responses to phenylephrine 
were significantly decreased after incubation with nifedipine, Ca
2+ 
free solution /EDTA, CPA 
and fasudil (Table  5.4, Figure  5.6). Reductions in maximum contractile responses were 
greatest in tissues incubated with CPA (10µM). However, a non-significant potentiation of 
the responses to phenylephrine was observed in tissues incubated with calphostin C (1μM) as 
shown in Figure ‎5.6E. Furthermore, pEC50 values for phenylephrine for tissues incubated 
with or without inhibitors were unchanged by any of the inhibitors. 
 
 Control 
response (mN) 
Test response 
(mN) 
Percentage 
reduction in 
Max (%) 
Control 
pEC50 
Test     
pEC50 
n 
Nifedipine 150.5±6.2 67.8±6.3**** 54.9±4.2 5.3±0.1 5.1±0.1 8 
Ca
2+ 
free/EDTA(3mM) 
150.5±5.6 73.2±7.0**** 51.4±4.6 5.4±0.1 5.1±0.1 8 
CPA 180.2±22.0 74.8±15.6** 58.5±8.7 5.4±0.2 5.4±0.2 8 
Fasudil 154.7±6.5 103.3±16.2* 33.2±10.5 5.3±0.1 5.0±0.1 6 
Calphostin C 155.1±6.5 209.8±28.0 +35.2±18.1 5.3±0.1 5.4±0.2 6 
Table  5.4  Mean (±SEM) maximum contractile responses and pEC50 values for phenylephrine with or 
without signalling inhibitors (proximal tissues with urothelium/lamina propria). *p<0.05, **p<0.01, and 
**** P<0.0001 vs. respective control responses (Student’s t-test). Positive value= maximum response of 
test tissue was greater than control tissue. 
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Figure  5.4 Mean (±SEM) urethral basal tone with or without inhibitors of signalling pathways (proximal 
tissues with urothelium/lamina propria). n=7-17; ***P<0.001 and ****P<0.0001 compared to the control 
tissues (Student’s t-test).  
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                           A                                                            B 
     
 
                               C                                                         D 
 
             
 
                                                              E 
                                                        
 
Figure  5.5  Mean (±SEM) concentration-response curves to noradrenaline with or without inhibitors of 
extracellular Ca
2+ 
influx (A-B), intracellular Ca
2+
 release (C), Rho kinase (D) and protein kinase C (E) 
(proximal tissues with urothelium/lamina propria). n=6-8; *p<0.05, **p<0.01, *** P<0.001, **** 
P<0.0001 vs. control responses (Student’s t-test).  
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                                       A                                                  B 
             
 
                                  C                                                   D 
 
         
 
                                                                 E 
 
                                                                       
 
Figure  5.6 Mean (±SEM) concentration-response curves to phenylephrine in the presence or absence of 
inhibitor of extracellular Ca
2+ 
influx (A-B), intracellular Ca
2+
 release (C), Rho kinase (D) and protein 
kinase C (E) (proximal tissues with urothelium/lamina propria). n=6-8. *p<0.05, ** P<0. 01, **** 
P<0.0001 vs. control responses (Student’s t- test)   
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Responses to A61603 were also significantly decreased after prior incubation with inhibitors 
(Table  5.5, Figure ‎5.7), with the greatest inhibition in tissues incubated with calphostin C 
(p<0.001). The pEC50 values for A61603 for tissues incubated with or without Ca
2+
 free 
solution /EDTA, CPA, fasudil and calphostin C were similar. In contrast, pEC50 values for 
A61603 for tissues incubated with nifedipine were significantly lower compared to those 
without nifedipine (p<0.05). The concentration-response curves of tissues incubated with 
nifedipine were shifted to the right significantly, compared to those without nifedipine. 
 Control 
response (mN) 
Test response 
(mN) 
Percentage 
reduction in 
Max (%) 
Control 
pEC50 
Test     
pEC50 
n 
Nifedipine 576.4±75.3 302.2±61.0* 47.6±10.6 7.5±0.2 6.8±0.2* 6 
Ca
2+ 
free/EDTA(3mM) 
531.2±90.6 204.2±24.6** 61.5±4.6 7.5±0.3 7.1±0.1 6 
CPA 505.3±66.6 204.0±24.6*** 59.6±4.9 7.6±0.2 7.4±0.2 8 
Fasudil 533.7±76.6 290.3±28.1* 45.6±5.3 7.4±0.2 7.2±0.1 7 
Calphostin C 566.9±81.7 83.9±22.9*** 85.2±4.0++ 7.4±0.2 6.3±0.6 6 
Table  5.5   Mean (±SEM) urethral maximum contractile responses, pEC50 values and percentage 
reduction in maximum response for A61603 in the presence of inhibitors (proximal tissues with 
urothelium/lamina propria). *p<0.05, ** P<0.01, *** P<0.001 vs. respective control responses (Student’s 
t-test). (++p<0.01 (One-way ANOVA with Bonferroni post hoc-test)). 
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                                   A                                                               B 
           
                                C                                                             D 
         
 
E 
 
 
Figure  5.7 Mean (±SEM) concentration-response curves to A61603 for urethral tissues with or without 
an inhibitor of extracellular Ca
2+ 
influx (A-B), intracellular Ca
2+
 release (C), Rho kinase (D) and protein 
kinase C (E) (proximal tissues with urothelium/lamina propria). n=6-8; *p<0.05, ** P<0. 01, *** P<0.001 
vs. maximum contractile responses of the control tissues (Student’s t-test).   
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Intracellular signalling involved in producing an equivalent, half maximal, 
three-quarter maximal and maximal response in urethra 
For comparison of the contributions of the intracellular signalling pathways involved in 
producing an equivalent, half maximal, three-quarter maximal and maximal response, three 
points were chosen from concentration curves for control tissues (as shown in Figure ‎5.2).  
Signalling pathways involved in producing maximal responses 
Maximal contractile responses to noradrenaline were reduced significantly by all inhibitors 
(Table 5.6A; Figure 5.8, Figure 5.9).  Ca
2+
 exclusion /EDTA had the greatest inhibitory effect 
on noradrenaline-induced maximal contraction while calphostin C (1µM) had the lowest 
inhibitory effect.  
All inhibitors reduced the maximal response to phenylephrine (1mM) except for calphostin C 
(1µM) (Table 5.6B; Figure 5.8. Figure 5.9), which produced a non-significant potentiation. 
Lastly, maximum responses to A61603 were reduced by all inhibitors (Table 5.6C; Figure 5.8. 
Figure 5.9).  The inhibitory effect was greatest with calphostin C (1µM) (p<0.001). 
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Signalling pathways involved in producing equivalent responses 
Effect of inhibitors on equivalent responses induced by noradrenaline, phenylephrine or 
A61603 was also analysed.  
Noradrenaline: Incubation with inhibitors reduced responses of noradrenaline (Table  5.7A; 
Figure 5.10, Figure 5.11). Exclusion of Ca
2+ 
from the bathing solution had the greatest 
inhibitory effect on noradrenaline-induced contractions (p<0.0001). Incubation with 
nifedipine, fasudil and calphostin C also had an inhibitory effect on the responses to 
noradrenaline but not CPA. 
Phenylephrine: In addition, contractile responses to phenylephrine were significantly reduced 
by nifedipine, Ca
2+
 free/EDTA, CPA and fasudil (Table  5.7B; Figure 5.10, Figure 5.11). 
However, incubation with calphostin C had no significant effect on tissue responses.  
A61603: Also, contractile responses to A61603 were significantly reduced by all inhibitors 
(Table  5.7C; Figure 5.10, Figure 5.11). Incubation with calphostin C had the greatest 
inhibitory effect on responses (p<0.01), followed by Ca
2+
free/EDTA (p<0.05), nifedipine 
(p<0.05), fasudil (p<0.05) and CPA (p<0.05).  
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Signalling pathways involved in producing half maximal responses 
Incubation with inhibitors reduced half maximal responses to noradrenaline (Table ‎5.8A; 
Figure 5.12, Figure 5.13). Exclusion of Ca
2+ 
from the bathing solution had the greatest effect 
on noradrenaline-induced contractions (p<0.0001). Incubation with nifedipine, CPA, fasudil 
and calphostin C also had inhibitory effects on the half maximal responses to noradrenaline, 
while calphostin C exerted no statistically significant effect.  
Also, half maximal contractile responses to phenylephrine were significantly reduced by 
nifedipine, Ca
2+
 free/EDTA, CPA and fasudil (Table ‎5.8B; Figure 5.12, Figure 5.13). 
However, incubation with calphostin C (1μM) did not have any significant effect on half 
maximal responses to phenylephrine. 
Lastly, half maximal contractile responses to A61603 were significantly reduced by all 
inhibitors (Table ‎5.8C; Figure 5.12, Figure 5.13). Similar to the effect on equivalent 
responses, incubation with calphostin C had the greatest inhibitory effect (p<0.01) on 
A61603. 
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Signalling pathways involved in producing three-quarter of maximal responses 
Three-quarter maximal response of the tissues to noradrenaline and phenylephrine in the 
presence or absence of inhibitors was similar to that for equivalent responses (Table ‎5.9A-B; 
Figure 5.14, Figure 5.15). Also, all inhibitors reduced the three-quarter maximal contractile 
responses to A61603 (Table ‎5.9C; Figure 5.14, Figure 5.15). The inhibitory effect on A61603 
induced contraction was greatest with calphostin C (p<0.01).  
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5.7 DISCUSSION 
Davies et al., (2000) showed that the potency of fasudil and Y27632 are similar, and they 
have similar ability to inhibit Rho kinase, which implies that these inhibitors can be used 
interchangeably and either will produce a similar and reproducible result. In this report, the 
two Rho kinase inhibitors induced similar and reproducible inhibition of Rho kinase. Thus, 
fasudil (10μM) was used (except where stated otherwise) for Rho kinase inhibition in these 
studies because its inhibitory effect on Rho kinase is well reported in the literature. 
Which signalling pathway mediates maintenance of urethral intrinsic basal 
tone? 
The maintenance of urethral luminal pressure depends on basal urethral smooth muscle tone  
(Malmqvist et al., 2004; Werkstrom et al., 1995). It is known that urethral muscle generates a 
high myogenic tone in the pig (Bridgewater et al., 1993; Malmqvist et al., 2004), sheep 
(Thornbury et al., 1992), rat (McKeag et al., 2001) and human (Brading et al., 1999). 
However, to our knowledge the underlying signalling pathway is not known for the porcine 
model of the urethra. Voltage-dependent Ca
2+
 currents have been demonstrated in urethral 
myocytes of human and animals (Bradley et al., 2004; Hollywood et al., 2003a). Also, 
urethral/trigone tissues express RhoA/Rho kinase signalling components (Teixeira et al., 
2007) and PKC (Roosen et al., 2008). Thus, we hypothesised that basal urethral tone might 
arise from a sustained elevation in intracellular Ca
2+
 and Ca
2+
 sensitization. 
The data presented in this study revealed the development of basal tone in all tissue strips 
during the equilibration period. Exclusion of extracellular Ca
2+ 
and incubation with EDTA 
(3mM) significantly decreased the basal urethral tone, confirming a previous report by 
Malmqvist et al., (2004). Blockade of L-type Ca
2+
 channels with nifedipine reduced the basal 
tone significantly and confirmed their essential role in generating a spontaneous basal tone. 
Several reports have shown that the urethral myogenic tone is critically dependent on the 
influx of Ca
2+
 across the cell membrane. The removal of external Ca
2+
 or inhibition of L-type 
Ca
2+
 channels reduces tone significantly in rat and human urethra in vitro (Brading, 1999; 
Shafei et al., 2003). In contrast, Mawby et al., (1991) showed that L-type Ca
2+
-channels do 
not contribute to urethral luminal pressure in the cat suggesting possible species differences. 
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The inhibition of sarcoplasmic reticulum Ca
2+
-ATPase (exhaustion of sarcoplasmic reticulum 
Ca
2+
 store) with CPA did not have any significant effect on basal urethral tone suggesting 
that basal tone is dependent only on extracellular Ca
2+
 influx and not intracellular 
sarcoplasmic reticulum Ca
2+
 release in the pig urethra.  
Rho kinase is essential in the maintenance of basal tone of hollow organs in rat (Patel & 
Rattan, 2006; Rattan et al., 2006) and human (Rattan & Singh, 2012). In the current study 
Y27632 and fasudil, which are selective inhibitors of Rho kinase (Uehata et al., 1997; He et 
al., 2008b), abolished the basal urethral tone and induced relaxation below basal tension. 
Both fasudil and Y27632 produced a similar result, which confirm the contribution of Rho 
kinase to basal urethral tone (Malmqvist et al., 2004). This study supports an earlier report 
showing that Toxin B, which specifically glucosylates Rho and disrupts its effector 
interaction, completely abolished pig urethral tone, strongly arguing that monomeric Rho 
guanosine triphosphatases in the Rho family have an essential role in the generation of 
urethral tone (Malmqvist et al., 2004).  
Data from previous studies in smooth muscle such as the urethra (Teixeira et al., 2007), and 
vascular smooth muscle (Alvarez et al., 2010; Clelland et al., 2011: Ratz and Miner 2009; 
Ratz et al., 2009), have suggested constitutive Rho kinase activity which regulate basal 
phosphorylation of MYPT1. Thus, constitutively active Rho kinase may maintain myosin 
light chain phosphatase activity at a low level, resulting in a basal level of phosphorylated 
myosin light chain (as seen in the rabbit artery by Alvarez et al., (2010)), and contributing to 
the basal tone. 
The possibility of PKC contributing to basal urethral tone was also addressed in the current 
study. Both Rho kinase and PKC signalling are both associated with Ca
2+
 sensitisation 
(Kitazawa et al., 2000; Kitazawa et al., 1999). Attenuation of PKC-induced contraction of 
smooth muscle by an inhibitor of Rho kinase II (though in the IAS) suggests that the PKC 
pathway involves Rho kinase activation (Patel & Rattan, 2007). In agreement with this, Baek 
et al., (2009) showed that PKC-mediated contractions of vascular smooth muscle contractions 
are mediated primarily via Rho kinase activation (Baek et al., 2009; Kandabashi et al., 2003). 
Thus, it was hypothesised that PKC may contribute to basal urethral tone. Surprisingly, 
inhibition of PKC with calphostin C (1μM) had no significant effect on the basal urethral 
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tone.  This supports studies in the bladder, where animal studies suggested that PKC plays a 
minimal role in contractility (Schneider et al., 2004a).  In addition, earlier studies testing the 
effects of selective inhibition of PKC in tissues of the gastrointestinal tract with basal tone, 
such as the lower oesophagal sphincter and IAS, suggested that PKC contributes little or 
nothing to the basal tone (Chakder et al., 2001; Kim et al., 2004). Thus, PKC may play a 
minor role in mediating basal tone in the hollow organs such as the urethra. 
The urethra expresses cyclooxygenase enzyme, as shown in the dog (Ponglowhapan et al., 
2009). Moreover, the dog urethra expresses prostaglandin receptors (Ponglowhapan et al., 
2010), and prostaglandin-mediated relaxations and contractions have been shown in the rat 
(Kurihara et al., 2016) and human (Kedia et al., 2013) urethra. The human proximal urethral 
smooth muscle contracts to prostaglandin F2α, and relaxes to prostaglandin E1 and 
prostaglandin E2 (Andersson, et al. 1977). Thus, we tested the effect of inhibiting 
prostaglandins synthesis on basal urethral tone. Inhibition of cyclooxygenase reduced the 
basal urethral tone significantly, suggesting the contribution of prostaglandins in the 
maintenance of tone.  Prostaglandins may mediate the basal tone via Ca
2+ 
influx through the 
L-Type Ca
2+
 channels and activation of Ca
2+
 sensitization, since Rho kinase has been shown 
to mediate prostaglandin F2α -induced contraction of the rabbit aorta (Ito et al., 2003). Thus, 
localised release of prostaglandins from urethral tissues may contribute to basal tone via L-
type Ca
2+
 influx and Rho kinase. The PKC or intracellular Ca
2+
 released from the 
sarcoplasmic reticulum is not obligatory for generating a basal urethral tone in the pig.  
What are the intracellular pathways associated with α1-adrenoceptor-
mediated responses?  
The α-AR subtypes mediate an increase in cytosolic Ca2+, and Keffel et al., (2000) showed in 
CHO cells that the maximum elevation of intracellular Ca
2+
 by α1-AR subtypes occurred with 
the rank order α1A > α1D > α1B. Furthermore, trigone myocytes respond to phenylephrine by 
increasing force and intracellular Ca
2+
 (Roosen et al., 2008). However, the specific Ca
2+
-
channel and other intracellular pathways contributing to α1-AR-mediated responses in the 
urethra remain to be elucidated.   
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In the previous chapter, we showed that A61603 induced the greatest contractile responses in 
the urethra and had the greatest potency compared to noradrenaline and phenylephrine. 
Moreover, the literature has shown that A61603 has greater specificity for α1A-AR (Knepper 
et al., 1995). Thus, we intended to ascertain whether the receptor-coupled intracellular 
signalling pathways might explain the difference in potency.  
L-type Ca
2+
 channels contributed only 60.1% (Figure 5.5) of the total extracellular Ca
2+ 
to 
responses to noradrenaline, suggesting other means of Ca
2+
 increase are involved. T-type 
Ca
2+
 currents have been recorded in rabbit and human urethral myocytes, but these mediate 
spontaneous contractions (Bradley et al., 2004; Hollywood et al., 2003a). Although T-type 
Ca
2+
 channels activate at more negative potentials than L-type Ca
2+
 channels, they facilitate 
L-type Ca
2+ 
channels opening (Sui et al., 2003). Thus, if this is the case in these experiments, 
then noradrenaline may have activated T-type Ca
2+ 
channels, which may trigger further 
opening of the L-type Ca
2+ 
channels. The reverse-mode Na
+
-Ca
2+
 exchanger is another 
possible channel allowing Ca
2+ 
influx from the extracellular environment (Bradley et al., 
2006; Drumm et al., 2015). The function of this exchanger as a mediator of Ca
2+
 waves has 
been shown in ICC isolated from the rabbit urethra (Drumm et al., 2015); though whether this 
channel is important in the pig urethra is not clear.  
In contrast, for A61603 and phenylephrine-induced contractions, the L-type Ca
2+ 
channels 
mediate Ca
2+ 
influx from the extracellular space. This is similar to the trigone where the 
influx of Ca
2+ 
is via the L-type Ca
2+ 
channels in response to α1A-AR stimulation (Roosen et 
al., 2009).  
The Rho kinase pathway has been shown to contribute to rat (Teixeira et al., 2007) and rabbit 
(Walsh et al., 2011) urethral contraction. From our experiments, we observed that the Rho 
kinase also contributes to agonist-mediated responses in the pig urethra and this was similar 
for all agonists. PKC significantly contributed to responses mediated by A61603 but not to 
phenylephrine-induced contraction. Walsh et al., (2011) also showed that PKC inhibition had 
no effect on phenylephrine-induced, KCl-induced or electrical field stimulation-induced 
contraction although in the rabbit. These findings together suggest that PKC contributes little 
to phenylephrine-induced contraction in the urethra. In the bladder, the role of the PKC on 
contractility appears to be species dependent with a role in guinea-pig tissues (Durlu-Kandilci 
& Brading, 2006) but not other species (An et al., 2002; Schneider et al., 2004b).  
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Thus responses to A61603 appear to involve both Rho kinase and PKC in the 
Ca
2+
sensitization pathway.  Earlier data, although not from urethral tissues, suggests that Rho 
kinase and PKC pathways lie in series, PKC being upstream of RhoA/Rho kinase (Sims et al., 
2008; Wang et al., 2012). Activation of PKC will induce Ca
2+ 
sensitization via CPI-17 and 
Rho kinase (a synergistic effect) (Wang et al., 2012). Thus may explain the greater potency 
and efficacy of A61603 compared to noradrenaline and phenylephrine and agonists 
depending solely on Rho kinase (e.g. phenylephrine) may induce smaller contractile 
responses.   
Signalling pathways contributing to α1-adrenoeptor-mediated responses in 
the urethral tissues; comparing equivalent, half maximal, three-quarter 
maximal and maximal responses 
In the previous section, we showed that the contributions of the intracellular signalling 
pathway to contractile responses differ between α1-AR agonists. However, this conclusion 
was based on comparison of the maximum contractile responses induced by the agonists. 
Given the differences in potency, there is the possibility the signalling pathways triggered by 
the agonists may differ depending on the magnitude of the response.  
For maximal responses to noradrenaline, extracellular Ca
2+
 was the most significant 
contributor whilst intracellular sarcoplasmic reticulum released Ca
2+
 contributed less. 
Specifically, the L-type Ca
2+
 channels contributed (60.1%) to extracellular Ca
2+
 influx for 
this response.  However, in contrast sarcoplasmic reticulum released Ca
2+
 and PKC 
contributed most to phenylephrine- and A61603-induced contractile responses respectively. 
Similarly, at half maximal responses induced by agonists, extracellular Ca
2+
 was the most 
significant contributor, while sarcoplasmic reticulum released Ca
2+
 contributed less to 
noradrenaline-mediated responses. Specifically, the L-type Ca
2+
 channels contributed (64.1%) 
to the extracellular Ca
2+
 influx.  L-type Ca
2+
 and PKC contributed most to phenylephrine- and 
A61603-induced contractile responses respectively. At three-quarter maximal responses, 
extracellular Ca
2+
 was still the most significant contributor to noradrenaline-mediated 
responses. While L-type Ca
2+
 and PKC contributed most to phenylephrine- and A61603-
induced responses respectively.  
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When looking at equivalent responses induced by the agonists, extracellular Ca
2+
, L-type 
Ca
2+
 and PKC were still the most significant contributor to noradrenaline-, phenylephrine- 
and A61603-mediated responses respectively. Specifically, the L-type Ca
2+
 channels 
contributed (64.1%; Figure 5.10) to the extracellular Ca
2+
 influx for noradrenaline-mediated 
responses. Thus, for all responses at all concentrations, extracellular Ca
2+
 plays a significant 
contribution to agonist-mediated responses. Sarcoplasmic reticulum released Ca
2+
 seems to 
be more important for the smooth muscle spontaneous contractions as shown in the rabbit 
urethral circular smooth muscle (Hashitani et al., 2006).  
This finding is similar to that seen for mAChR activation in the bladder, where the L-type 
Ca
2+
 channels and calcium sensitization (Durlu-Kandilci and Brading, 2006) were most 
important for receptor-mediated responses (Frazier et al., 2008; Schneider et al., 2004b). 
Ablation of L-type Ca
2+
 channels in the mouse resulted in a decrease in the protein expression 
of myosin light chain (Lu et al., 2015), and Martinsen et al., (2014) showed myosin light 
chain kinase controlled mRNA expression of L-type Ca
2+
 channels in vascular smooth 
muscle cells, which suggest a relationship between muscle contraction and L-type Ca
2+
 
channels. 
For noradrenaline at all responses, extracellular Ca
2+
 was the most significant contributor to 
contraction while the contribution of Rho kinase and PKC varies between different responses.  
Extracellular Ca
2+ 
influx and Ca
2+ 
sensitization mediate the noradrenaline-induced contraction 
at half maximal and maximal responses. This result supports an earlier report stating that 
agonist-induced contraction of rat ventricular cells and trigone of the guinea-pigs largely 
depends on Ca
2+
 entry from the extracellular area (Liu et al., 1994) and  Ca
2+ 
sensitization 
(Roosen et al., 2008) respectively. The contributing intracellular pathways to phenylephrine-
induced contractile response also vary with the concentration.  Extracellular Ca
2+
 was more 
important at half maximal response and three-quarter maximal and equivalent responses. 
However, for maximal responses to phenylephrine, sarcoplasmic reticulum Ca
2+
 release was 
the most important factor.  The change from extracellular Ca
2+
 influx to sarcoplasmic 
reticulum Ca
2+
 release suggests Ca
2+
-induced Ca
2+
 release from the sarcoplasmic reticulum 
(Collier et al., 2000). Ca
2+
-induced Ca
2+
 release is a function of the net flux of Ca
2+
 ions into 
the cytosol (Collier et al., 2000).  
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PKC did not contribute to phenylephrine-mediated responses. Additionally, PKC may have 
an inhibitory effect on phenylephrine-induced contractions; an inference made based on the 
potentiation of responses in the presence of PKC inhibitor, although this effect was not 
statistically significant. In contrast, A61603-induced contractions were significantly 
dependent on PKC at all concentrations analysed. Hypolite et al., (2015) showed in the 
bladder that low levels of PKC stimulation could inhibit spontaneous contractions and lower 
basal resting tone, while high levels of PKC activity contributed to increasing and 
maintenance of total force. In the present study phenylephrine may induce low PKC 
activation which could mediate inhibition of contractile responses or have no significant 
effect at equivalent, half maximal, three-quarter maximal and maximal responses, whereas 
A61603 and noradrenaline may induce high PKC activation which mediates contractions. 
A61603 may also induce greater activity of PKC than noradrenaline, which may explain PKC 
being the greatest contributor to A61603-mediated responses compared to noradrenaline. 
However, it is still unknown whether different PKC isoforms mediate the effect of the 
different agonists at various responses.  
Thus, responses of the urethral to agonists acting via the α1-AR are determined by the relative 
intracellular signalling pathway activated. The intracellular signalling pathway contributing 
most to responses was different for phenylephrine at maximal responses, but did not differ for 
A61603 and noradrenaline at any response or concentration. PKC contributed most to 
A61603-mediated responses, while Ca
2+ 
contributed most to noradrenaline and 
phenylephrine-mediated responses respectively.  
Conclusion 
 The basal tone of porcine urethral tissues is dependent on L-type Ca2+ channel influx, 
prostaglandins and Rho kinase activity.  However, intracellular Ca
2+ 
release from the 
sarcoplasmic reticulum and PKC does not contribute to basal tone.  
 For noradrenaline, all contractile responses depend mainly on extracellular Ca
2+
 
influx. For maximal responses to phenylephrine, intracellular Ca
2+
 stores contribute 
most to contractions. 
 In contrast, contractile responses to A61603 depended mainly on Ca2+ -sensitization; 
PKC.  
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6 DESENSITISATION AND MAINTENANCE OF 
TONE IN THE URETHRA 
Alpha1A-ARs are a potential drug target for increasing urethral luminal pressure in stress 
urinary incontinent patients (Noel et al., 2010; Segev et al., 2015). Fortunately, the α1A-ARs 
appear to be less desensitised, internalised and downregulated than α1B-ARs and α1D-ARs 
(Cabrera-Wrooman et al., 2010; Stanasila et al., 2008). Several drugs selective for the α1-ARs 
have been developed. However, most drugs investigated have never made it to clinical 
applications. Particularly, drugs with selectivity for the α1A-subtype have been developed 
preclinically, including NS-49 (Obika et al., 1995), A-61603 (Knepper et al., 1995) and Ro 
115–1240 (Blue et al., 2004). The latter compound was successfully tested in a proof-of-
concept clinical study in stress incontinence patients (Musselman et al., 2004), but its clinical 
development was discontinued due to undisclosed reasons. One of the explanations for this 
set back may be desensitisation of the α1A-ARs.  
Since any future treatment to increase the urethral luminal pressure using α1-AR agonists 
would involve the long-term usage of an agonist, this may mediate chronic activation and 
desensitisation of these receptors and thus, could worsen the symptoms of stress urinary 
incontinence.  
6.1 ALPHA1-ADRENOCEPTORS DESENSITISATION 
The α1-ARs are known to be subject to phosphorylation and internalisation on exposure to 
noradrenaline, or phenylephrine in Rat-1 fibroblasts cells (Vazquez-Prado et al., 2000).  The 
α1A-AR subtype has been observed in lipid rafts under basal conditions (Lei et al., 2009; 
Morris et al., 2008) and it undergoes constitutive and phenylephrine-mediated internalisation 
via clathrin-coated vesicles (Morris et al., 2004; Pediani et al., 2005; Price et al., 2002).  The 
α1A-AR exits from these rafts after stimulation with phenylephrine, therefore allowing 
endocytosis (Morris et al., 2008). The α1A-AR stimulation causes the exit of the receptors 
from lipid rafts within 3-10 minutes in Rat-1 fibroblasts cells. However, G proteins remain in 
this raft suggesting that receptor signalling and desensitisation of α1A-ARs occurs in the raft 
(Morris et al., 2008). 
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Human α1A-AR-mediated inositol phosphate signalling is acutely desensitised in response to 
both agonist and phorbol 12-myristate 13-acetate (PKC activator) exposure in Rat-1 
fibroblasts cells (Price et al., 2002). Concurrent with desensitisation, in response to both 
noradrenaline and phorbol 12-myristate 13-acetate, kinases mediate phosphorylation of the 
α1A-ARs in the cells. Akinaga et al., (2013) observed using HEK-293 cells a GPCR-
dependent α1A-AR phosphorylation, desensitisation and internationalisation at least after 5 
minutes of stimulation. Phosphorylation of α1A-ARs exposed to noradrenaline depends on 
PKC activity and is not followed by desensitisation. Moreover, α1A-ARs exposed to 
noradrenaline undergo delayed internalisation (∼35% after 60 minutes of stimulation) 
(Akinaga et al., 2013). Oxymetazoline (α1-AR agonist) also desensitise the α1A-ARs in the rat 
tail artery and vas deferens, but this does not occur with noradrenaline or phenylephrine. This 
suggests that agonists with functional selectivity for α1A-ARs lead to significant receptor 
desensitisation and internalisation. 
Alpha1A-ARs are phosphorylated and desensitised to a lesser extent on exposure to 
noradrenaline, adrenaline, or phenylephrine compared to the α1B and α1D subtypes (Cabrera-
Wrooman et al., 2010; Vazquez-Prado et al., 2000). For example, α1B-ARs are 
phosphorylated to a greater extent in response to either noradrenaline or tetradecanoyl 
phorbol acetate (PKC activation) than α1A-ARs (Cabrera-Wrooman et al., 2010; Vazquez-
Prado et al., 2000).  Also, recombinant α1A-ARs expressed in the Rat-1 fibroblasts are much 
more resistant to desensitisation induced by noradrenaline than are α1B and α1D subtypes 
(Cabrera-Wrooman et al., 2010; Vazquez-Prado et al., 2000). 
Alpha1A-ARs are also internalised less on exposure to noradrenaline or phenylephrine than 
α1B and α1D subtypes (Cabrera-Wrooman et al., 2010; Chalothorn et al., 2002; Stanasila et al., 
2008; Wang et al., 2007). Phenylephrine stimulation promotes a more rapid internalisation of 
α1B-ARs than α1A-ARs in HEK-293 cells (Perez-Aso et al., 2013; Wang et al., 2007). 
Activation of α1A-AR elicits rapid PKC-dependent and independent phosphorylation and 
internalisation associated with arrestin. However, α1B-AR activation elicits PKC-dependent 
phosphorylation and internalisation. On the other hand, agonist activation of α1D-AR elicits 
rapid, transient PKC-independent phosphorylation. Thus Perez-Aso and colleagues, (2013) 
result suggested that the three α1-AR subtypes present different patterns of receptor 
phosphorylation and internalisation. Whole cell [
3
H]-prazosin binding assays showed that 
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α1A-AR functional receptors were detected both on the cell surface and in the cytoplasm; α1B-
ARs, however, were detected predominantly on the cell surface, while α1D-ARs were detected 
mainly in intracellular compartments (Wang et al., 2007).   
Thus, as far as receptor phosphorylation, desensitisation, internalisation and signalling are 
concerned, α1A-ARs are less affected than the α1B and α1D subtypes (Cabrera-Wrooman et al., 
2010; Chalothorn et al., 2002; Stanasila et al., 2008; Wang et al., 2007). Significant 
reductions in endocytosis recorded for α1A-AR in HEK-293 cells has been linked to its poor 
interaction with arrestins as well as with AP50 subunit of the AP2 clathrin adaptor complex 
(Stanasila et al., 2008). 
In addition, Segura et al., (2013) observed that constitutive as well as phenylephrine-induced 
trafficking of α1A-ARs and α1B-ARs maintain two different endosomal pools of receptors: one 
in proximity to the plasma membrane and the other farther into the cytosol of HEK-293 cells. 
The location of the receptors determines their signalling pathway. For example α1A-ARs 
signal via Ca
2+ 
pathways when located on the plasma membrane but, via arrestin when 
translocated to deeper endosomes. However, α1B-ARs signal through Ca
2+
 pathways only 
when located in the membrane and the signals disappear after endocytosis (Segura et al., 
2013).  
Many lines of evidence suggest that activation of α1-ARs also induces phosphorylation of 
MAPKs and extracellular signal-regulated kinase (Keffel et al., 2000; Wright et al., 2008). 
Moreover, trafficking, docking, and fusion with endosomes were made possible by the Rab 
(Rho guanosine triphosphatases), which characterises the endosome (Castillo-Badillo et al., 
2015). In experiments performed using transfected Rat-1 fibroblasts that express α1B-ARs in a 
stable fashion, selective epidermal growth factor-receptor kinase inhibition blocked the α1B-
AR phosphorylation induced by noradrenaline (Casas-González & García-Sáinz, 2006). This 
result suggested the epidermal growth factor receptors play a more general role in α1B-AR 
phosphorylation. 
In cultured neonatal rat cardiac myocytes and rats subjected to aortic banding, long-term 
activation of α1-ARs increased the α1A-AR, without desensitising α1-AR-mediated inositol 
phosphate turnover or growth, while also decreasing α1B-AR mRNA and protein levels 
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(Rokosh et al., 1996).  One of the explanations for the differences in desensitisation of α1-AR 
and β-ARs might reside in the expression and regulation of GRKs. For example, GRK3 has 
been found exclusively in myocytes, where it regulates α1-ARs, (Vinge et al., 2001, 2007; 
Aguero et al., 2012). However, GRK2 and GRK5 desensitised β-ARs but not α1-ARs (Vinge 
et al., 2001, 2007; Aguero et al., 2012). Thus, the difference in ARs trafficking evokes 
different signalling. 
Desensitisation of the responses of the lower urinary tract smooth muscle 
Desensitisation has been reported in bladder smooth muscle responses. For example, Cha et 
al., (2006) reported desensitisation of mAChRs of bladder smooth muscle strips isolated from 
mouse, where repeated pilocarpine injections revealed mAChR desensitisation to subsequent 
addition of drug. In contrast, stimulation of dog bladder strips with acetylcholine after prior 
incubation with bethanechol, induced no change in the responses, suggesting resistance of the 
mAChRs in the dog bladder to desensitisation (Buranakarl et al., 2001).  The variation in 
result may be associated with species of animal used or degree of receptor stimulation, as 
shown by Cha et al., (2006). Six hours pre-treatment with a β2-AR agonist significantly 
reduced subsequent relaxation to the agonist in the rat bladder (Michel, 2014). Moreover, 
agonist-induced desensitisation was prominent for the β2-AR component of rat bladder 
relaxation but much weaker or even absent for the β3-AR component (Michel, 2014). Thus, 
desensitisation of mAChR and β-AR-mediated responses occurs in the bladder.  
Reports showing desensitisation of the urethral response are limited. However, Chess-
Williams & Bagot, (2005) observed desensitisation of the α-AR-mediated responses in the 
porcine urethra. They compared the susceptibility of urethral and IAS smooth muscle and 
showed that the urethral responses to α1-AR- agonists are more susceptible to desensitisation 
compared to the IAS. After incubation with A61603 or methoxamine and washout of the drug, 
subsequent concentration-response curves to noradrenaline were similar to controls in IAS. In 
contrast, urethral tissues were readily desensitised. Incubation of the urethral smooth muscle 
strips with EC50 concentrations of methoxamine or A61603 caused a desensitisation of 
subsequent responses to noradrenaline with maximum responses being depressed by 42-56%. 
Moreover, the α1-AR-mediated desensitisation of the urethral tissues response is proportional 
to the concentration of agonist (unpublished result). Thus, we studied the effect of time of 
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incubation with α1-AR agonist on the desensitisation and elucidated the signalling pathways 
modulating this mechanism. 
Since little evidence of desensitisation is available for α1-ARs in the urethral tissues, this 
study aimed to broaden understanding of desensitisation of α1-AR-mediated responses in 
urethral tissues. 
Specific objectives: 
1. To investigate the maintenance of tone in the porcine urethra following agonist 
exposure.  
 Can urethral tone maintenance following a α1-AR agonist be demonstrated in 
the pig urethra? 
 Is tone maintenance dependent on α-AR agonist selectivity? 
 Is the urothelium/LP involved in the maintenance of urethral tone? 
 Are Rho kinase and prostaglandins involved in the maintenance of urethral tone? 
2. To investigate the desensitisation of urethral responses following exposure to an 
α-AR agonist.  
 Is desensitisation of α1-AR-mediated responses dependent on the α-AR 
agonist? 
 Does the degree of desensitisation depend upon the length of agonist exposure?  
3. To investigate the intracellular mechanism involved in desensitisation. 
 Do PKC, Rho kinase or Ca2+ contribute to desensitisation of α1-AR-
mediated responses, and to what extent? 
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6.2 MATERIALS AND METHODS 
Maintenance of urethral tone following α1-adrenoceptor stimulation: role 
of the urothelium/lamina propria/ Rho kinase and prostaglandins  
Strips of female pig proximal urethra were set up in 8ml organ baths as described in chapter 2. 
Following set up and equilibration for 1 hour, tissues were contracted to a single 
concentration of noradrenaline (10μM), phenylephrine (10μM) or A61603 (0.03μM) and the 
contraction was recorded for 120 minutes. These concentrations were equi-efficient 
concentrations of the agonists (as determined in chapter 5).  
To investigate the effect of the urothelium/ LP on desensitisation, tissues with or without 
urothelium/LP were set up in pairs and contracted to either phenylephrine (10μM) or A61603 
(0.03μM) for 120 minutes. The role of Rho kinase and prostaglandins in tone maintenance 
was determined in tissue pairs. Test tissues were incubated with fasudil (10μM) or 
indomethacin (10μM) for 30 minutes and then contracted to a single concentration of 
phenylephrine (10μM) or A61603 (0.03μM) for 120 minutes. 
Desensitisation of noradrenaline responses following α1-adrenoceptor 
stimulation 
Following set up and equilibration of tissue strips, initial cumulative concentration-response 
curves were constructed to noradrenaline. After the washout (1 hour, changing Krebs every 
20 minutes) the tissues were incubated with an EC50 concentration of one of the agonists 
(noradrenaline, phenylephrine, A61603) for either 15, 30 or 120 minutes.  The EC50 
concentrations for the various α1-AR agonists used were obtained from experiments carried 
out in chapter 4. At the end of the incubation period, the drugs were washed out until tensions 
returned to baseline (30 - 40 minutes). Tensions were recorded throughout the incubation 
period. Following washout, a second cumulative concentration-response curve to 
noradrenaline was produced (Figure ‎6.1).  Responses were plotted as a percentage of the 
maximum contraction to noradrenaline achieved in that tissue during the first concentration-
response curve. Control tissues without incubation with an α-AR agonist were used to allow 
correction for any time-dependent changes in maximum response or sensitivity (Figure  6.2).   
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In control experiments, there were similar maximum contractile responses to noradrenaline in 
first and second curves (Figure  6.2). However, the second response curves were significantly 
shifted to the right, thus, a correction factor was applied and used for normalising EC50 values 
to correct for time-dependent changes. Contribution of signalling pathways to urethral tone 
was determined in intact tissues. 
Role of intracellular pathways in desensitisation 
In separate experiments, urethral tissues were incubated throughout the experiments with an 
inhibitor of key molecules involved in intracellular pathways in the urethral smooth muscle 
(Figure ‎6.1). Fasudil (10μM), CPA (10μM), nifedipine (1μM), calphostin C (1μM) was used 
to block Rho kinase, intracellular release of Ca
2+
 from the sarcoplasmic reticulum, L-type 
Ca
2+
 channels Ca
2+
 influx or PKC respectively (Figure  6.3).  
Following equilibration, tissues were contracted to cumulative concentrations of 
noradrenaline (Figure ‎6.1). After washout (30 minutes, changing Krebs every 10 minutes) the 
tissues were incubated with an EC50 concentration of one of the α1-AR agonists 
(phenylephrine or A61603).  Since similar desensitisation of α1-AR-mediated responses was 
observed at 15 minutes, 30 minutes and 120 minutes (Figure  6.2), 15 minutes incubation was 
used in experiments reported in this section. At the end of the incubation period, the drugs 
were washed out four times and then every 10 minutes until tensions returned to baseline. 
Following the washout, a second cumulative concentration-response curve to noradrenaline 
was produced in all the tissues.  Control tissues without inhibitor were used to allow for time-
dependent changes. The α1-AR-mediated responses were analysed and data expressed as 
described in chapter 2. 
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Figure  6.2  Control experiments, first and second concentration-response curves of the urethral tissues to 
noradrenaline, with (A) 15 minutes, (B) 30 minutes and (C) 120 minutes incubation with Krebs solution 
only between contraction curves. n=6-8. 
A 
B 
C 
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Figure  6.3 Intracellular signalling pathways inhibited to allow analysis of desensitisation of α1-
adrenoceptor mediated responses. Fasudil blocks Rho kinase (ROCK), nifedipine blocks Ca
2+
 influx via 
the L-type Ca
2+
 channels, calphostin C blocks protein kinase C whilst cyclopiazonic acid blocks 
sarcoplasmic reticulum release of Ca
2+
. 
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6.3 RESULTS 
Maintenance of tone following α1-adrenoceptor stimulation  
Following addition of an equi-efficient concentration of agonist (noradrenaline, A61603 or 
phenylephrine), maximum contractile responses of urethral tissues were recorded within 5-10 
minutes (Figure ‎6.4). The maximal contractile responses were similar for all agonists 
(Table  6.1). After reaching the maximum contractile response, there was a gradual decline in 
tone over the duration of the experiment (120 minutes) as shown in Figure  6.4. Responses to 
noradrenaline rapidly declined during the first 60 minutes and completely by 120 minutes, for 
phenylephrine tone steadily declined over 120 minutes to 29.0±12.9% of the maximal. In 
contrast, tone to A61603 slowly declined, and 61.4±7.7% of the tone was maintained at 120 
minutes (Table  6.1). 
 Maximum Response (mN) Tone remaining (mN) at 
120 minutes 
Reduction in tone by 
120 minutes (%) 
Noradrenaline (10μM) 219.4±22.4 -12.8±16.5**** 105.8±14.6% 
Phenylephrine (10μM) 184.2±30.6 53.4±23.7** 71.0±14.6% 
A61603 (30nM) 192.0±18.5 118.0±14.8* 38.5±3.0%++ 
N 5 5 5 
Table  6.1 Maximum responses and tone remaining after 120 minutes following application of 
noradrenaline (10μM), phenylephrine (10μM) and A61603 (0.03µM) in porcine urethra.*p<0.05, **p<0.01 
and ****p<0.0001 vs. maximum responses (Student’s t-test).  ++ p<0.01 vs. reduction of noradrenaline 
tone at 120 minutes (one-way ANOVA, with Tukey post-hoc test); n=5. 
The role of the urothelium/lamina propria in the maintenance of urethral 
tone 
In separate experiments, using A61603 and phenylephrine, the role of the urothelium/LP in 
tone maintenance was investigated. Maximum contractions to A61603 and phenylephrine 
were greater in tissues without urothelium/LP compared to the tissues with urothelium/LP 
(Table  6.2; Figure  6.5). Contractile responses to phenylephrine decreased significantly over 
the 120 minutes period, and by a similar amount in tissues with or without urothelium/LP.  
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For A61603, the percentage of tone remaining at 120 minutes for urethral tissues with 
urothelium/LP was significantly greater than for those without the urothelium/LP.  
 Phenylephrine A61603 
 - urothelium/LP + urothelium/LP - urothelium/LP + urothelium/LP 
Max response (mN)  238.0±38.6 127.5±36.4 285.2±60.3 149.7±17.0 
Tone remaining at 120 
minutes (mN)  
38.7±22.9** 34.5±6.0* 61.7±20.3** 92.4±12.9* 
Reduction in tone at 120 
minutes (%) 
83.8±9.6% 72.9±4.7% 78.4±7.1% 38.3±8.6%## 
N 6 6 
Table  6.2 Mean (±SEM) contractile responses for phenylephrine and A61603 in urethral tissues with or 
without urothelium/LP.*p<0.05, **p<0.01 vs. maximum responses. ##p<0.01 vs. percentage reduction in 
tone to A61603 at 120 minutes for tissues without urothelium/LP (Student’s t-test).  LP= lamina propria. 
 
Figure  6.4  Maintenance of tone in urethral tissues with urothelium/lamina propria following exposure to 
a single concentration of noradrenaline, phenylephrine and A61603 over 120 minutes **p<0.01, 
***p<0.001 vs. responses to noradrenaline contraction (one-way ANOVA, with Tukey post-hoc test); n=5.  
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Figure  6.5  Maintenance of tone of urethral tissues with or without urothelium/lamina propria to 
phenylephrine and A61603 over 120 minutes. n=6.   PHE= phenylephrine.  
 
Phenylephrine 
A61603 
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The role of Rho kinase and prostaglandins in urethral tone maintenance  
Urethral tissues with urothelium/LP were incubated with fasudil (10μM) or indomethacin 
(10μM), for 30 minutes before contraction to A61603 (0.03μM) or phenylephrine (10μM), to 
inhibit Rho kinase and cyclooxygenase activity respectively. Rho kinase inhibition did not 
significantly reduce the maximum responses of the urethral tissues to phenylephrine 
compared to controls, as shown in Table  6.3. The tone at 60 minutes and 90 minutes was 
significantly less than in controls (Figure ‎6.6), however, the tone over the 120 minutes 
experimental period was similar to that of the control tissues.  
 Phenylephrine A61603 
 Control + Fasudil (10µM) Control + Fasudil (10µM) 
Max response (mN)  235.2±31.4 168.1±30.0 287.3±19.9 115.5±30.0** 
Tone remaining at 120 minutes 
(mN)  
58.3±7.3 46.4±5.0 243.0±32.1 94.5±30.2* 
Reduction in tone at 120 minutes 
(%) 
75.2±3.1 72.4±3.0 15.4±11.2 18.2±26.1 
n 7 4 
Table  6.3 Mean (±SEM) maximum contractile responses and percentage reduction in the responses of 
urethral tissues after 120 minutes exposure to A61603 (0.03μM) or phenylephrine (10μM) (+/-Rho kinase 
inhibitor (fasudil)). *p<0.05 and **p<0.01 vs. control responses (Student’s t-test). 
However, inhibition of Rho kinase did significantly reduce the maximum responses of the 
urethral tissues to A61603 (p<0.01, Table  6.3; Figure ‎6.6).  The percentage difference in 
maximum contractions between tissues treated with fasudil vs. control tissues was 
60.0±16.7%. For A61603 tone was maintained to a similar degree in the presence or absence 
of fasudil, with reduction in tone by 120 minutes being similar, although the final tone was 
significantly less in tissues treated with fasudil.   
  
 200 
 
 
 
 
 
 
 
 
 
 
Figure  6.6 Mean (±SEM) contractile responses of the urethral tissues over 120 minutes to phenylephrine 
and A61603 in the presence or absence of the Rho kinase inhibitor fasudil. n=4-7. *p<0.05, **p<0.01 vs. 
control responses (Student’s t-test). PHE= phenylephrine. 
 
Phenylephrine 
A61603 
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Effect of cyclooxygenase inhibition on urethral tone maintenance 
Incubation with indomethacin (10µM) reduced the maximum contractions to phenylephrine 
and A61603 (Table  6.4). However, neither reduction in maximum responses was statistically 
significant.  Incubation with indomethacin (10μM) had no significant effect on the 
maintenance of tone following exposure to phenylephrine. However, indomethacin did result 
in a greater reduction in tone to A61603 at 120 minutes, vs controls, and final tone was 
significantly less than in controls (Figure ‎6.7). 
 Phenylephrine A61603 
 Control + Indomethacin 
(10µM) 
Control + Indomethacin (10µM) 
Max response (mN)  225.7±35.4 167.2±41.8 287.3±19.9 202.8±66.1 
Tone remaining at 120 
minutes (mN) 
53.3±6.4 47.0±8.9 243.0±32.0 128.0±33.1* 
Reduction in tone at 120 
minutes (%) 
76.4±2.8 71.9±5.3 15.4±11.2 36.9±16.3 
n 6 4 
Table  6.4 Mean (±SEM) maximum contractile responses and percentage change in responses to 
phenylephrine and A61603 over 120 minutes in the absence or presence of indomethacin. *p<0.05 vs 
control responses (Student’s t-test). 
 
  
 202 
 
 
 
 
                                                           
 
 
 
Figure ‎6.7 Mean (± SEM) contractile responses of the urethral tissues to phenylephrine and A61603 over 
120 minutes in the presence or absence of indomethacin (10μM). n=4-6. *p<0.05 vs. control responses 
(Student’s t-test).  
Phenylephrine 
A61603 
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Desensitisation of α1-adrenoceptor-mediated responses 
Maximum contractile responses to noradrenaline after incubation with an EC50 concentration 
of noradrenaline (7μM) for 15 minutes (Table  6.5A; Figure  6.8), 30 minutes (Table  6.5B; 
Figure  6.9) or 120 minutes (Table  6.5C; Figure  6.10) were similar to the maximum responses 
before incubation. No desensitisation was observed. The pEC50 values for noradrenaline 
before and after incubation with noradrenaline were similar, except for tissues incubated for 
120 minutes (p<0.01), where the noradrenaline curves were shifted rightward significantly 
(Figure  6.10). 
In contrast, maximum contractile responses of urethral tissues to noradrenaline after 
incubation with an EC50 concentration of phenylephrine (4μM) or A61603 (0.03μM) were 
significantly desensitised (Table  6.5). Both phenylephrine and A61603 (15, 30 and 120 
minutes) triggered desensitisation of urethral responses (Figure  6.8; Figure  6.9; Figure  6.10). 
The pEC50 values for noradrenaline recorded before and after incubation with phenylephrine 
(4μM) and A61603 (0.03μM) were unchanged by 15 and 30 minutes incubation with 
phenylephrine. However, for 120 minutes incubation with phenylephrine, the pEC50 values 
for noradrenaline were significantly reduced (p<0.05) and the concentration-response curves 
shifted rightward (Figure ‎6.10). 
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A (15 minutes incubation) 
 Control + Noradrenaline 
(7μM) 
Control + Phenylephrine 
(4μM) 
Control + A61603 
(0.03μM) 
Max Response 
(mN) 
137.7±20.8 122.8±19.8 150.0±12.6 104.0±17.7** 187.9±24.8 103.6±15.8* 
pEC50 5.0± 0.1 5.0± 0.1 5.2±0.1 5.1±0.1 5.2±0.2 5.2± 0.1 
Reduction in max 
(%) 
10.8±6.0 30.7±11.8 58.4±17.8 
n 9 10 7 
B (30 minutes incubation) 
 Control +Noradrenaline 
(7μM) 
Control +Phenylephrine 
(4μM) 
Control + A61603 
(0.03μM) 
Max Response 
(mN) 
214.0±47.3 182.0±36.8 223.8±34.6 157.2±24.3* 349.0±63.8 176.1±17.5* 
pEC50 5.1±0.1 5.1±0.1 5.1±0.1 5.1±0.1 5.0±0.1 5.2± 0.1 
Reduction in max 
(%) 
15.0±17.2 29.8±10.8 49.5±5.0 
n 4 6 9 
C (120 minutes incubation) 
 Control + Noradrenaline 
(7μM) 
Control + Phenylephrine 
(4μM) 
Control + A61603 
(0.03μM) 
Max Response 
(mN) 
116.8±23.0 95.9±17.7 232.9±21.2 182.4±16.1* 185.6±19.7 102.8±19.5* 
pEC50 5.3±0.1 4.9±0.1** 5.2±0.1 5.0±0.1* 5.4±0.2 5.1±0.1 
Reduction in max 
(%) 
17.9±15.2 21.7±6.9 44.6±10.5 
n 9 7 5 
Table  6.5 Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline responses 
before and after incubation with noradrenaline (7μM), phenylephrine (4μM) or A61603 (0.03μM) for (A) 
15 minutes, (B) 30 minutes and (C) 120 minutes. *p<0.05, **p<0.01 vs. control responses (Paired 
Student’s t-test).  
 
 
 
 205 
 
 
 15 minutes incubation  
  
  
  
Figure  6.8 Mean (± SEM) concentration-response curves (CRC) to noradrenaline before and after 15 
minutes incubation with noradrenaline, phenylephrine and A61603. n=7-10, *p<0.05, **p<0.01 vs. control 
responses (Paired Student’s t-test).  
Noradrenaline 
Phenylephrine 
A61603 
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30 minutes incubation  
  
 
 
Figure  6.9 Mean (± SEM) concentration-response curves (CRC) to noradrenaline before and after 30 
minutes incubation with noradrenaline, phenylephrine and A61603. n=4-9; *p<0.05 vs. control responses 
(Paired Student’s t-test).   
Noradrenaline 
Phenylephrine 
A61603 
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120 minutes incubation  
 
 
 
Figure  6.10 Mean (± SEM) concentration-response curves (CRC) of the urethral tissues to noradrenaline 
before and after 120 minutes incubation with noradrenaline, phenylephrine and A61603. n=5-9. *p<0.05 vs. 
control responses (Paired Student’s t-test).  
Noradrenaline 
Phenylephrine 
A61603 
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The role of Ca
2+
, Rho kinase, and PKC in desensitisation of α1-
adrenoceptor responses 
Nifedipine (1μM) prevented the desensitisation of noradrenaline responses induced by 15 
minutes incubation with the EC50 concentration of A61603 (p<0.05), but not the 
desensitisation induced by phenylephrine (Table  6.6; Figure ‎6.11). The pEC50 values for 
noradrenaline were similar in all tissues. 
 Without Nifedipine With Nifedipine Without Nifedipine With Nifedipine 
 Control +  A61603 Control +  A61603 Control + PHE Control +  PHE 
Max response 
(mN) 
187.9±24.8 103.6±15.8* 81.4±13.5 69.5±20.2 150.0±12.6 104.0±17.7** 133.5±25.3 93.3±19.6** 
pEC50 5.2±0.2 5.2±0.1 5.5±0.1 5.1±0.2 5.2±0.1 5.1±0.1 5.1±0.1 5.0±0.0 
Percentage 
reduction in 
max (%) 
44.9±8.4 14.6±14.2 30.7±11.8 30.1±6.4 
n 7 5 10 10 
Table  6.6  Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline before and 
after 15 minutes incubation with phenylephrine or A61603, in the presence or absence of nifedipine (1μM). 
*p<0.05, **p<0.01 vs. control responses (Paired Student’s t-test). PHE= phenylephrine. 
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A 
Without Nifedipine  With Nifedipine 
         
 
B 
Without Nifedipine  With Nifedipine 
        
Figure  6.11 Mean (±SEM) concentration-response curves of urethral tissues to noradrenaline with or 
without prior incubation (15 minutes) with (A) A61603 (0.03μM) or (B) phenylephrine (4μM). The 
experiments were carried out in the presence or absent of nifedipine (1μM). n=5-10. *p<0.05, **p<0.01 vs. 
control responses (Paired Student’s t-test).  
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In the presence of CPA (10µM) to inhibit Ca
2+
 release from the sarcoplasmic reticulum 
maximum contractile responses to cumulative concentrations of noradrenaline after 
incubation with the EC50 concentration of A61603 or phenylephrine remained significantly 
desensitised (p<0.05; Table  6.7, Figure ‎6.12). The pEC50 values for noradrenaline were 
similar. 
Fasudil (10μM) prevented the desensitisation of the maximum responses to noradrenaline 
induced by A61603 and phenylephrine (Table  6.8; Figure ‎6.13). The pEC50 values for 
noradrenaline were not affected by fasudil (10μM).  
Moreover, calphostin C (1μM) prevented the desensitisation of the maximum responses to 
noradrenaline induced by A61603, but not the desensitisation induced by phenylephrine 
(Table  6.9; Figure ‎6.14). The pEC50 values for noradrenaline were not affected by calphostin 
C (1μM).  
 
 Without CPA With CPA Without CPA With CPA 
 Control +  A61603 Control +  A61603 Control + PHE Control +  PHE 
Max 
response 
(mN) 
187.9±24.8 103.6±15.8* 256.0±50.1 134.3±38.1* 150.0±12.6 104.0±17.7** 202.6±46.3 108.8±15.3* 
pEC50 5.2±0.2 5.2±0.1 5.2±0.2 5.2±0.2 5.2±0.1 5.1±0.1 5.2±0.1 5.1±0.1 
Reduction in 
max (%) 
44.9±8.4 47.6±13.9 30.7±11.8 46.3±15.6 
n 7 4 10 9 
Table  6.7  Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline with or 
without 15 minutes incubation with phenylephrine (4µM) or A61603 (0.03µM). The experiments were 
carried out in the presence or absence of cyclopiazonic acid (CPA) (10μM). *p<0.05, **p<0.01 vs. control 
responses (Paired Student’s t-test). PHE= phenylephrine. 
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 Without Fasudil With Fasudil Without Fasudil With Fasudil 
 Control +  A61603 Control +  A61603 Control + PHE Control +  PHE 
Max 
response 
(mN) 
187.9±24.8 103.6±15.8* 182.8±36.5 180.0±31.2 150.0±12.6 104.0±17.7** 204.9±43.2 202.3±46.3 
pEC50 5.2±0.2 5.2±0.1 4.9±0.0 5.0±0.0 5.2±0.1 5.1±0.1 4.9±0.0 4.9±0.0 
Reduction in 
max (%) 
44.9±8.4 1.5±9.6## 30.7±11.8 1.3±2.3# 
n 7 4 10 9 
Table  6.8  Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline with or 
without 15 minutes prior incubation with agonists in the presence or absence of fasudil (10μM). *p<0.05, 
**p<0.01 vs. control responses (Paired Student’s t-test); #p<0.05, ##p<0.01 vs. percentage reduction in 
maximum without fasudil (Student’s t-test).  PHE= phenylephrine. 
 
 Without calphostin C With calphostin C Without calphostin C With calphostin C 
 Control +  A61603 Control +  A61603 Control + PHE Control +  PHE 
Max 
response 
(mN) 
187.9±24.8 103.6±15.8* 254.3±62.2 262.9±71.3 150.0±12.6 104.0±17.7** 151.0±39.2 81.0±25.2* 
pEC50 5.2±0.2 5.2±0.1 5.1±0.1 5.1±0.1 5.2±0.1 5.1±0.1 5.2±0.2 5.0±0.0 
Reduction in 
max (%) 
44.9±8.4 3.4±4.7### 30.7±11.8 46.4±13.5 
n 7 8 10 5 
Table  6.9 Mean (±SEM) maximum contractile responses and pEC50 values for noradrenaline with or 
without 15 minutes prior incubation with agonists in the presence or absence of calphostin C (1μM). 
*p<0.05, **p<0.01 vs. control responses (Paired Student’s t-test); ###p<0.001 vs. percentage reduction in 
maximum for tissues without calphostin C (Student’s t-test). PHE= phenylephrine. 
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A 
Without CPA  With CPA 
         
 
B 
Without CPA  With CPA 
        
 
Figure  6.12 Mean (±SEM) concentration-response curves (CRC) of the urethral tissues to noradrenaline 
with or without prior 15 minutes incubation with agonist. The experiments were carried out in the presence 
or absence of cyclopiazonic acid (CPA) (10μM).  (A) A61603 (0.03μM) or (B) phenylephrine (4μM), n=4-
10; *p<0.05, **p<0.01 vs. control responses (Paired Student’s t-test).  
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A 
Without Fasudil  With Fasudil 
 
    
 
B 
Without Fasudil  With Fasudil 
 
Figure  6.13 Mean (±SEM) concentration-response curves (CRC) to noradrenaline before and after 15 
minutes incubation with agonists in the presence or absence of fasudil (10μM). (A) A61603 (0.03μM) or 
(B) phenylephrine (4μM); n=4-10. *p<0.05, **p<0.01 vs. control responses (Paired Student’s t-test). 
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A 
Without Calphostin C  With Calphostin C 
         
 
 
B 
Without Calphostin C  With Calphostin C 
        
Figure  6.14 Mean (±SEM) concentration-response curves (CRC) to noradrenaline before and after 15 
minutes incubation with agonists in the presence or absence of calphostin C (1μM). (A) A61603 (0.03μM) 
or (B) phenylephrine (4μM), n=5-10; *p<0.05, **p<0.01 vs. control responses (Paired Student’s t-test). 
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6.4 DISCUSSION 
The data in this study revealed that functionally there is agonist-mediated desensitisation of 
urethral tissue responses during 2 hours incubation with a single dose of an α1-agonist. We 
showed that noradrenaline-induced tone declined significantly during a 120-minute 
incubation, and tissues incubated with phenylephrine retained a small amount of tone, whilst 
A61603-induced responses reduced only slightly after 120 minutes incubation. Thus urethral 
tissues maintained tone to A61603 during these experiments. Furthermore, experiments 
confirmed that the maintenance of tone was not associated with Rho kinase or prostaglandins.  
Can maintenance of tone following stimulation with single α1-adrenoceptor 
agonist concentration be demonstrated in the urethral tissue? 
Exposure of α1-ARs to an agonist for an extended period will induce desensitisation (Akinaga 
et al., 2013). Such a phenomenon has been shown for the α1-ARs in HEK-293 cells, vascular 
smooth muscle and vas deferens of the rat (Akinaga et al., 2013). This report showed 
desensitisation to repeated addition of agonist. Reports showing tone maintenance and 
desensitisation during a prolonged exposure to a single dose of agonist are limited and 
particularly in the urethra.  Chess-Williams & Bagot, (2005) showed that during a 120-
minute incubation with methoxamine or A61603, porcine urethral tissues contracted initially 
but then tension declined by 25-60% during the incubation period. In this study, we further 
explored the maintenance of urethral tone to a single dose of noradrenaline and 
phenylephrine in addition to A61603. Practically, during treatment for stress urinary 
incontinence with α1-AR agonist, the drugs will be expected to be in contact with the ARs for 
an extended period. Thus, it is imperative to know if the long-term exposure to the α1-AR-
agonist is likely to continue to affect the urethral luminal pressure.  
During the 120 minutes incubation, tissues contracted initially but then tension declined 
during the incubation with the α1-AR agonists. Also, the maintenance of tone was 
proportional to agonist specificity, with noradrenaline (general AR agonist) tone desensitising 
the greatest, and A61603 (α1A-AR agonist) showing the least decline in tone for tissues with 
urothelium. When the urethral tissues attained the maximum contractions, a sustained 
response was developed in tissues contracted to A61603, while tissues contracted to 
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noradrenaline and phenylephrine diminished significantly. It was glaring that A61603-
induced responses were more resistant to loss of tone compared to the other agonists.   
A possible explanation for the difference in maintenance of tone observed between A61603 
and the other agonists is a difference in intracellular signalling pathways. For example, the 
contribution of Rho kinase and PKC to Ca
2+
 sensitization pathway may differ, as shown by 
Shahab et al., (2012a) in human detrusor and they may be regulated differently, as shown by 
Hayashi et al., (2016) in human detrusor. It is likely that the mechanism of tone maintenance 
differs for the agonists. In the previous chapter, we showed that A61603-mediated urethral 
contraction depends largely on Ca
2+ 
sensitization, compared to the contraction induced by 
noradrenaline and phenylephrine. Thus, A61603 may increase the Ca
2+
 sensitivity of the 
urethra. With the ability of A61603 to potently stimulate phosphoinositide hydrolysis 
(Knepper et al., 1995) and Ca
2+ 
sensitization, this may be responsible for the urethral tone to 
be significantly maintained compared to the other two agonists. 
As described earlier, decline in tone may be associated with receptor phosphorylation, 
desensitisation (Stanasila et al., 2008) and internalisation (Wang et al., 2007). GRK (Karoor 
& Malbon, 1996) or serine/threonine kinase, PKC may also play a vital role in mediating this 
decline in urethral tone (Akinaga et al., 2013; Molina-Muñoz et al., 2006).  
The resistance to desensitisation of tone with A61603 does not signify the absence of 
desensitisation. There is the possibility of desensitisation which may be characterised by a 
prompt recovery and re-sensitisation of α1A-AR as shown by Morris et al., (2004) in Rat-1 
fibroblasts cells. Also, an internal pool of α1A-ARs may be maintained and recycled to allow 
continuous agonist-induced signalling as shown by Morris et al., (2004) in Rat-1 fibroblasts 
cells. Protein kinase C may in part mediate desensitisation of the α1-ARs (Akinaga et al., 
2013), and phosphorylated GPCR may bypass the destruction in the lysosome. Thus, a 
reinsertion into the plasma membrane and readiness for another activation as shown for β-AR 
(Morrison et al., 1996; Pippig et al., 1995).  
A closer look at the profile of tone maintenance over 120 minutes revealed that the fall in 
tension in phenylephrine incubated tissues exhibited a biphasic profile with an initial phase 
from 5-10 minutes followed by a second phase from 30 to120 minutes, while that of 
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noradrenaline did not occur evenly over the 120 minutes. The major decline in noradrenaline-
induced response occurred within the first 60 minutes. This decline continued throughout the 
experimental period, and responses at the end of the incubation were below the initial basal 
level tone. Thus, there is the possibility of downregulation of α1-ARs in response to 
noradrenaline. This downregulation of α1-ARs is initiated by kinases, and may involve 
destruction or digestions in the lysosome which require gene transcription/translation before a 
new set of α1-ARs are expressed (McGraw et al., 1998). However, a comprehensive 
experiment determining receptor density and location during exposure would be needed to 
confirm this inference. 
Does the urothelium/lamina propria affect maintenance of tone? 
Previous studies have investigated the effect of the urothelium/LP on modulation of GPCR 
mediated responses (Hawthorn et al., 2000; Templeman et al., 2002), but have not examined 
the modulation of tone in response to prolonged α1-AR activation. In earlier chapters, we 
showed that the urothelium/LP inhibits smooth muscle contraction in the urethra. In this 
chapter, the possibility of the urothelium/LP inhibiting or mediating urethral tone 
maintenance was investigated. For this study, only phenylephrine and A61603 were used 
because A61603 is an α1A-AR specific agonist and urethral tone to this agonist was 
maintained, while phenylephrine is a known α1-AR agonist previously used in clinical trials 
for incontinence, and less tone was maintained during the 120 minutes incubation period.  
It seems removing the urothelium/LP affects the maximal contraction more but final tone at 
120 minutes is not different. Thus, the urothelium/LP does not contribute to maintenance of 
tone following exposure to α1-AR agonist. 
Are Rho kinase and prostaglandins involved in maintenance of urethral 
tone? 
Surprisingly, the addition of fasudil (10μM) had no significant effect on the maintenance of 
tone following exposure to α1-AR agonist. The A61603-induced maximum contraction was 
inhibited by fasudil (10μM)  indicating the Rho kinase pathway was involved in mediating 
contraction as shown by Teixeira et al., (2007) in the rat urethra. However, the maintenance 
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of tone during incubation with A61603 was not affected. In contrast, inhibition of Rho kinase 
did not have any significant effect on the maximum contractile response to phenylephrine, 
and did not affect the decline of tone during incubation with phenylephrine. This data 
supports the results in chapter 4, where we showed that Ca
2+
 sensitisation contributed more to 
A61603-mediated responses than phenylephrine-mediated responses. Thus, we concluded 
that Rho kinase does not contribute to maintenance of tone.  
Another possible agent that could be involved in tone maintenance are prostaglandins. If 
prostaglandins were involved, relaxing prostaglandins such as prostaglandin E2 may be 
released and its release may desensitise the EP receptors, thus, affecting maintenance of tone. 
Alternatively, a contractile prostaglandin e.g. prostaglandin F2α may be released which may 
counteract the agonist-induced desensitisation. Similar to the result from incubation of tissues 
with fasudil (10μM), the addition of indomethacin (10μM) had no significant effect on the 
effects of the urothelium on tone maintenance during α1-AR-mediated responses indicating 
prostaglandins did not contribute to tone maintenance. 
Thus tone maintenance in response to α1-AR activation is greater for A61603, followed by 
phenylephrine, whereas no tone was maintained to noradrenaline. Moreover, neither Rho 
kinase nor prostaglandins contributed to tone maintenance.  
Can α1-adrenoceptor stimulation desensitise subsequent responses to α1-
adrenoceptor agonist? 
Earlier we showed that urethral tissue responses desensitise on exposure to a single dose of 
α1-AR agonist. However, a further question was, what happens to the response to the 
endogenous agonist noradrenaline after prior exposure to synthetic α1-AR agonists? We 
thereby tested the effect of prior incubation with α1-AR agonists on the urethral tissue 
responses to subsequent noradrenaline addition. Based on the result of the earlier section and 
earlier reports (Price et al., 2002; Vazquez-Prado et al., 2000), we hypothesised that 
incubation of urethral tissues with noradrenaline, phenylephrine or A61603 would induce 
desensitisation of subsequent urethral responses to noradrenaline. 
In the present study, incubation of porcine urethra with an EC50 concentration of 
noradrenaline for up to 120 minutes failed to affect subsequent responses to noradrenaline. 
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This finding agrees with numerous reports showing that α1A-ARs are resistant to 
noradrenaline-mediated desensitisation (Vazquez-Prado et al., 2000; Cabrera-Wrooman et al., 
2010). It is well established that α1A-ARs are less phosphorylated and desensitised on 
exposure to noradrenaline (Vazquez-Prado et al., 2000; Cabrera-Wrooman et al., 2010) and 
are less internalised (Cabrera-Wrooman et al., 2010). Akinaga et al., (2013) observed, using 
HEK-293 cells, rat tail artery and vas deferens, that phosphorylation of α1A-ARs exposed to 
noradrenaline depends to a large extent on PKC activity and is not followed by 
desensitisation. Moreover, α1A-ARs undergo delayed internalisation after exposure to 
noradrenaline (Akinaga et al., 2013). Thus, the lack of significant desensitisation to 
noradrenaline after prior incubation with noradrenaline may be due to the characteristic of α1-
ARs being less phosphorylated, desensitised and internalise by noradrenaline. 
However, phenylephrine and A61603 did cause desensitisation of noradrenaline responses. 
After incubations for 15, 30 or 120 minutes with EC50 concentrations of drug the rank order 
of desensitisation for the time points was similar, with desensitisation to A61603 greater than 
for phenylephrine. A61603 desensitised α1-AR-mediated responses to a greater extent in the 
urethra at all three-time points. Thus, an agonist with greater specificity for α1A-ARs induced 
greatest desensitisation to noradrenaline. 
The literature regarding the effect of long-term exposure to these different agonists is 
currently limited. The most frequently used agonist in desensitisation studies of α1-ARs in 
addition to noradrenaline is phenylephrine (Wang et al., 2007; Zhao et al., 2015). However, 
these two agonists are not often used in parallel in the same cells/tissues, so it is arduous to 
judge whether the effects observed occurred separately of the stimulating agonist used. 
However, the literature does show that A61603 induced desensitisation of responses in cells, 
for example in astrocytes (Pankratov & Lalo, 2015). In astrocytes, application of A61603 
(100 nM) caused a marked reduction in the response amplitude and led to a period of non-
responsiveness (Pankratov & Lalo, 2015). 
The similarity of desensitisation responses at the three-time points suggests that 
desensitisation, phosphorylation and sequestration occurred at an early time point, while the 
effect was still manifested at 120 minutes. Wang et al., (2007) observed the internalisation of 
the α1A-ARs as early as 5 minutes after phenylephrine stimulation in HEK-293 cells.  An 
 220 
 
 
approximate 40% of surface α1A-ARs were internalised after 5 minutes of stimulation with 
α1A-AR agonist (oxymetazoline) in the HEK-293 cells (Akinaga et al., 2013). Likewise, 
Morris et al., (2008) reported receptor signalling and desensitisation of the α1A-ARs within 3-
10 minutes in the Rat-1 fibroblasts. Morris et al., (2008) confirmed the desensitisation 
because these receptors exited the lipid raft and non-raft plasma membrane within this 
timeline after stimulation with phenylephrine. Also, this result further suggests that the 
second messenger system and kinases such as PKC, GRKs associated with GPCR 
phosphorylation and signalling are activated within the first few minutes (Akinaga et al., 
2013). Akinaga et al., (2013) reported GRK2-dependent α1A-AR phosphorylation, as early as 
5 minutes with α1A-AR agonist. Also, Zhao et al., (2015) reported the activation of PKC, 40 
minutes after stimulation of the rat’s aorta with phenylephrine. 
Greater desensitisations induced by A61603 over phenylephrine at the three-time points may 
be associated with downstream signalling pathways activated by the respective agonist. For 
example, in the rat tail artery and vas deferens, Akinaga et al., (2013) showed that 
oxymetazoline (a partial α1A-ARs), but not phenylephrine or noradrenaline, desensitised 
responses. Oxymetazoline induced GRK2-mediated phosphorylation of α1A-ARs followed by 
rapid desensitisation and internalisation (∼40% internalisation after 5 minutes of stimulation) 
(Akinaga et al., 2013).  Thus, A61603 may induce greater desensitisation due to greater 
potential to activate GRK in the urethra.   
Moreover, greater desensitisation mediated by A61603 over phenylephrine could also be 
associated with agonist efficacy. A61603 has a greater efficacy than to phenylephrine (Bagot 
& Chess-Williams, 2006; Mills et al., 2008). Hence, an agonist with greater efficacy may be 
able to induce greater desensitisation. The relationship between agonist efficacy and 
amplitude of desensitisation is well established for the β-AR. For example, salmeterol (lower 
efficacy β-AR agonist) was associated with lower desensitisation compared with formoterol 
(Moore et al., 2007; January et al., 1997; 1998) and isoprenaline (higher efficacy β-AR 
agonist) in HEK-293 cells and human airway smooth muscle cells respectively. Salmeterol 
caused less β-AR phosphorylation and internalisation than the full agonist formoterol 
(January et al., 1997; 1998). Also, salmeterol showed weak efficacy for activation of adenylyl 
cyclase (Tran et al., 2004), recruitment of arrestin (Moore et al., 2007) and activation of GRK 
(Tran et al., 2004). Salmeterol did not induce significant β2-AR internalisation or degradation 
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in HEK-293 cells and was incapable of stimulating the translocation of arrestin (Moore et al., 
2007). Thus, A61603 may be able to induce greater GRK/PKC activity than phenylephrine 
and this may be responsible for the greater desensitisation by A61603. 
In contrast, some reports have shown that efficacy of agonist is not proportional to 
desensitisation. For example, for β-ARs, Cooper et al., (2011) observed that formoterol and 
salmeterol-induced similar desensitisation in human lungs. However, Cooper et al., (2011) 
experiments were based on 12 hours prior incubations with the β-AR agonists, which may 
reduce the tissue responses, thus, making it impossible to observe the effect of the two β-AR 
agonists. 
Thus, the result presented here is novel. We present results showing that phenylephrine, 
A61603, but not noradrenaline induced desensitisation to noradrenaline in urethral tissues. 
Also, desensitisation induced by A61603 was greater than that of phenylephrine. It appears 
from this study that the α1-ARs present in the porcine urethra are susceptible to 
desensitisation when subjected to prolonged stimulation. The data presented in this study also 
reveals that desensitisation of α1-AR-mediated responses may be related to agonist specificity 
and efficacy. 
Based on the result that A61603 and phenylephrine induced desensitisation of the subsequent 
urethral tissues responses to noradrenaline, we analysed the signalling pathways that may be 
involved. Specific inhibitors of extracellular Ca
2+ 
influx, sarcoplasmic reticulum Ca
2+
release, 
PKC and Rho kinase were used to reveal the role of Ca
2+
, PKC and Rho kinase in mediating 
agonist-induced desensitisation in these tissues. 
Do changes in Ca
2+
 mobilisation contribute to desensitisation of α1-
adrenoceptor-mediated responses? 
Key to α1A-AR agonist-mediated contraction is an increase in [Ca
2+
]i.  A reduction in 
receptor-mediated Ca
2+ 
mobilisation was consistent with α1-ARs desensitisation, as seen for 
α1B-ARs (Casas-González et al., 2000; González-Arenas et al., 2006; Molina-Muñoz et al., 
2006, 2008). Prior stimulation of α1B-ARs with lysophosphatidic acid reduced intracellular 
Ca
2+
 induced by noradrenaline in Rat-1 fibroblasts cells (Casas-González et al., 2000). Casas-
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González et al., (2000) found that reduction of [Ca
2+
]i results from depleted Ca
2+
 stores. 
However, other studies showed that desensitisation was dependent on [Ca
2+
]i of the F11 cells 
(Wu et al., 2013) and neurones (Yao et al., 2010), though, with the 5-HT1A receptor. The 
desensitisation was blocked by chelation of [Ca
2+
]i (Wu et al., 2013). Thus, desensitisation of 
the urethral responses may be dependent on [Ca
2+
]i. In this section, we examined Ca
2+
 as a 
modulator of desensitisation in the urethral tissues. Moreover, we elucidated the specific 
source of Ca
2+
 that may affect the desensitisation to noradrenaline. 
The inhibition of extracellular Ca
2+
 influx via the L-type Ca
2+
 channels with nifedipine (1μM) 
abolished desensitisation mediated by A61603 but not phenylephrine.  However, inhibition of 
intracellular Ca
2+
 release from the sarcoplasmic reticulum did not have any significant effect 
on the potency of noradrenaline or agonist-induced desensitisation. This suggests Ca
2+
 influx 
via the L-type Ca
2+
 channels as a contributor to A61603 but not phenylephrine-induced 
desensitisation. Furthermore, intracellular Ca
2+
 release from the sarcoplasmic reticulum does 
not contribute to A61603 or phenylephrine-induced desensitisation. In support of this result, 
although for β-AR, Ikenouchi and colleague, (2008) has reported Ca2+ influx via L-type Ca2+ 
channels involvement in desensitisation in airway smooth muscle. In their report, the 
presence of verapamil, an inhibitor of L-type Ca
2+
 channels, reversed the reduced 
responsiveness to isoprenaline and forskolin after a prior incubation with platelet-derived 
growth factor (Ikenouchi et al., 2008). In contrast,  Molina-Muñoz et al., (2006; 2008) 
reported a reduction in [Ca
2+
]i  for α1B-ARs phosphorylation and desensitisation. However, 
the Rat-1 fibroblast cells were pre-incubated with insulin-like growth factors. Also, their 
report was based on prior stimulation of α1B-ARs with noradrenaline. Desensitisation of  α1B-
ARs  was also associated with decreased intracellular inositol phosphates (Molina-Muñoz et 
al., 2006; 2008). Some reports have shown that [Ca
2+
]i reduces desensitisation because the 
Ca
2+ 
-calmodulin complex inhibits GRK activity (Chuang et al., 1996; Pronin & Benovic, 
1997).  
Our results thereby suggested that A61603-induced desensitisation may be mediated by an 
action on L-type Ca
2+
 channels during agonist exposure. Receptors such as the β2-AR are 
closely associated with L-type Ca
2+
 channels in ventricular myocytes (Balijepalli et al., 2006). 
Moreover, Patriarchi et al., (2016) observed that displacement of the β2-AR by S1928 
phosphorylation from L-type Ca
2+
 channels was a uniquely specific desensitisation 
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mechanism of the channels in mouse. Based on this report a clear interaction between AR and 
the L-type Ca
2+
 channels exists. Thus, we show for the first time that A61603-mediated 
desensitisation of subsequent response to noradrenaline is dependent on L-type Ca
2+
 channels.  
Do Rho kinase and PKC contribute to desensitisation of α1-adrenoceptor-
mediated responses?  
Evidence indicates that desensitisation of α1-ARs is mediated through phosphorylation of 
the carboxyl terminus of the receptor (Diviani et al., 1997; Lattion et al., 1994) by kinase e.g. 
GRK. However, Rho kinase is associated with myosin light chain phosphatase inhibition and 
Ca
2+ 
sensitization (Teixeira et al., 2007). Thus, we tested the effect of inhibition of Rho 
kinase on the desensitisation to noradrenaline, after incubation with A61603 or phenylephrine. 
Inhibition of Rho kinase with fasudil (10μM) eliminated desensitisation of α1-AR-mediated 
responses in tissues incubated with either A61603 or phenylephrine. The inference from this 
result is that Rho kinase contributed greatly to desensitisation of urethral tissues responses to 
noradrenaline after prior incubation with A61603 and phenylephrine. Fasudil, also known as 
HA1077, is a cyclic nucleotide-dependent protein kinase and Rho kinase inhibitor (IC50 = 
10.7μM). It shows good selectivity for Rho kinase over PKC and myosin light chain kinase 
(Sward et al., 2000; Uehata et al., 1997). However, at concentrations higher than 10μM, 
fasudil may cause an inhibition of cyclic AMP- and cyclic GMP-dependent protein kinases 
(Asano et al., 1989). Since in this study we used 10μM fasudil, the result suggests that 
sustained exposure of the urethra to A61603 or phenylephrine leads to α1-AR desensitisation 
and that Rho kinase contributes significantly to this phenomenon. 
The modulation of desensitisation by Rho kinase may act as a feedback mechanism for 
preventing chronic overstimulation of tissues. Thus, a process by which pathways associated 
with Ca
2+
 sensitization in smooth muscles can also result in receptor desensitisation, probably 
by phosphorylation when overstimulation of receptors ensues. Cario-Toumaniantz and 
colleague (2012) suggested a similar model in which Rho kinase had a negative-feedback on 
its signalling, by downregulating RhoA-guanine nucleotide exchange factor in arteries of rats. 
The inhibition of Rho kinase activity based on the level of MYPT1 phosphorylation 
inhibition, prevented agonist-induced down-regulation of the nine RhoA- guanine nucleotide 
exchange factor transcripts (Cario-Toumaniantz et al., 2012).  
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Protein kinase C is another kinase associated with α1A-ARs desensitisation (Akinaga et al., 
2013; Vázquez-Prado et al., 2000), and agents that activate PKC attenuate responses to 
agonists (Akinaga et al., 2013; Grandordy et al., 1994). For example Akinaga et al., (2013) 
showed that α1A-ARs activated by noradrenaline were phosphorylated to a large extent by 
PKC before being internalised.  Thus, we investigated the contribution of PKC to agonist-
induced desensitisation by A61603 and phenylephrine.  
Inhibition of PKC with calphostin C (1μM) confirmed that PKC contributed to A61603 but 
not phenylephrine-induced desensitisation. Moreover, inhibition of PKC did not have any 
significant effect on the agonist potency. Since PKC can also induce phosphorylation of un-
activated receptors (Casas-González et al., 2003), A61603 may be mediating a heterologous 
form of desensitisation. However, phenylephrine appears to induce desensitisation via a 
PKC-independent mechanism. A previous report by Johnson et al., (2006) reported a similar 
instance of which closely related agonist-mediated distinct mechanisms of desensitisation in 
the HEK- 293 cells. They showed that μ opioid receptor agonists morphine and [D-Ala2, N-
MePhe4, Gly-ol5] enkephalin induced desensitisation by different mechanisms, to a large 
extent by PKC or GRK-dependent respectively. In the pig urethra, A61603-induced 
desensitisation involved PKC.  The PKC activated by A61603 can also enhance homologous 
desensitisation (Boterman et al., 2006). Also, PKC can mediate changes in the cellular 
expression and activity of proteins associated with homologous desensitisation (Winstel et al., 
1996).  
Possible mechanisms to explain PKC-independent desensitisation by phenylephrine include 
receptor phosphorylation via GRK or mechanism may be phosphorylation independent. For 
example, activation of α1-ARs with phenylephrine resulted in the GRK2-mediated 
phosphorylation of the β2-ARs in the human prostate (Hennenberg et al., 2011). On the other 
hand, Bundey & Nahorski, (2001) reported that activation of α1B-ARs  in SH-SY5Y human 
neuroblastoma cells reduces mAChR-Gαq/11 protein coupling without an increase in 
mAChR phosphorylation.  
Thus desensitisation of urethral α1A-AR occurs and the mechanism involved is agonist-
dependent, but appears to include changes in the Ca
2+
-sensitisation pathway and PKC. 
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Conclusion 
 Tone and contractions of porcine urethra to A61603 are maintained to a greater extent 
than those to phenylephrine and noradrenaline for intact tissues. 
 The urothelium/LP does not contribute to the maintenance of urethral tone induced by 
A61603. 
 Tone maintenance in urethral tissues in response to A61603 does not depend on Rho 
kinase or prostaglandins. 
 A61603 and phenylephrine, but not noradrenaline, induce desensitisation of 
subsequent noradrenaline responses. 
 The mechanisms involved in the process of desensitisation depend on the agonist. 
  Rho kinase contributes to phenylephrine-induced desensitisations, while L-type Ca2+ 
channels, Rho kinase and PKC all contribute to A61603-mediated desensitisation 
(Table  6.10). 
 L-type Ca
2+
 
channels 
Ca
2+
 influx via 
sarcoplasmic 
reticulum  
Rho kinase PKC 
Phenylephrine no no yes no 
A61603 yes no yes yes 
Table  6.10 The pathways contributing to A61603 and phenylephrine-induced desensitisation of urethral 
tissues responses to noradrenaline.  
Clinical implication 
Several α1-AR agonists, particularly those with selectivity for the α1A-AR subtype, have been 
developed preclinically for stress urinary incontinence. However, none of these compounds is 
available for clinical usage. Desensitisation and severe side effect are the main limitations. 
This study analysed pathways associated with desensitisation of α1-ARs. Based on our result, 
agonists with higher potency and efficacy are recommended for maintaining higher urethral 
luminal pressure. However, these agonists can also induce greater desensitisation of 
physiological responses. Thus a balance between maximal urethral luminal pressure and 
desensitisation need to be considered for these agonists.   
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Modified from Dale et al., 2014. 
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7 THE POST-JUNCTIONAL INTERACTION 
BETWEEN ADRENERGIC AND MUSCARINIC 
PATHWAYS IN THE URETHRA  
7.1 RECEPTOR OLIGOMERIZATION 
Mutual interaction between GPCR families has been shown and results in distinct functional 
and pharmacological properties (Ecke et al. 2008; Uberti et al., 2005). Homo- and hetero-
oligomerization have been demonstrated for the α1A-AR, α1B-AR and α1D-AR subtypes in 
recombinant systems (Hague et al., 2004a; Stanasila et al., 2003; Uberti et al., 2005). Hague 
et al., (2004a) showed α1-AR heterodimerization in HEK-293 cells which was subtype-
specific, with α1B-ARs interacting with α1A- or α1D-ARs. Uberti et al., (2003; 2005) also 
showed in HEK-293 cells that α1-AR interactions are subtype-specific. Alpha1B-ARs 
interacted with α1A- or α1D-ARs, but with no detectable interactions occurred between α1A- 
and α1D-ARs. Moreover, heterodimerization of these receptors did not alter ligand-binding 
properties but, rather, resulted in increased receptor expression. In particular, α1B/α1D-AR 
hetero-dimerization increased surface expression of α1D-ARs. Also, confocal imaging 
confirmed that co-expression of α1D-AR with β2-AR resulted in translocation of α1D-AR from 
intracellular sites to the plasma membrane (Uberti et al., 2005). Co-expression of α1D-AR 
with β2-AR significantly enhanced the coupling of α1D-AR to noradrenaline-stimulated Ca
2+ 
mobilisation. Heterodimerization of AR also confers the ability to co-internalize with other 
different AR subtype upon agonist stimulation (Stanasila et al., 2003). Thus, 
heterodimerisation reveals a novel mechanism by which different AR subtypes may regulate 
each other's activity. Also, heterodimerisation suggests crosstalk between AR, and suggests 
that receptor interaction may mediate trafficking of the GPCR (Stanasila et al., 2003; Uberti 
et al., 2005). 
Copik et al., (2009) reported that interaction between α1A-ARs and β2-ARs led to increases in 
Ca
2+
 influx from the extracellular compartment which was greater than when each receptor 
was activated. Activation of α1A-ARs and β2-ARs with noradrenaline, or combined treatment 
with A61603 and isoprenaline, mediated greater Ca
2+
 influx in HEK-293 cells. However, 
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little or no increase in intracellular Ca
2+
 release was reported. Thus heterodimerisation also 
modulates intracellular signalling and Ca
2+
 mobilisation. 
Adrenoceptor interactions with other GPCRs has been shown to lead to trafficking of the 
non-AR (Hague et al., 2004b; Hudson et al., 2010). For example, interactions between β2-AR 
and the CB1 cannabinoid receptor (Hudson et al., 2010) or the M71 olfactory receptor 
(Hague et al., 2004b) lead to trafficking of these GPCRs to the cell surface. Hague et al., 
(2004b) showed that co-expression of olfactory receptors with β2-ARs increased olfactory 
receptors surface expression in HEK-293 cells. A persistent physical interaction between 
these receptors was demonstrated by co-immunoprecipitation and by co-internalization of the 
two receptors in response to their specific ligands. Co-expression of β2-AR and CB1 
cannabinoid receptor also altered the signalling properties of CB1 cannabinoid receptor 
(Hudson et al., 2010). Therefore, dimerization with other non-AR modulates signalling and 
trafficking of non-ARs. 
7.2 INTERACTION BETWEEN AUTONOMIC G-PROTEIN-
COUPLED RECEPTORS 
The sympathetic and parasympathetic systems are complex and mutually interacting (Dhein 
et al., 2013; Pera & Penn, 2014). Adrenoceptors and mAChRs exhibit cross regulation in 
many tissues including the heart (Borst et al., 1997; Dhein et al., 2013), airway smooth 
muscle (Pera & Penn, 2014) and bladder (Yamanishi et al, 2002a, d). Sympathetic 
denervation sensitised cardiac responses to catecholamines and concomitantly reduced 
mAChR expression in the dog heart (Vatner et al., 1985). Also, chronic β1-AR antagonist 
treatment desensitised mAChR function in human  (Motomura et al., 1990) and rat (Borst et 
al., 1997; Marquetant et al., 1992) heart. Thus, the AR and mAChR systems seem to interact. 
Pre-junctional interaction between G-protein-coupled receptors  
Prejunctional auto- and heteroreceptors can modulate transmitter release from 
parasympathetic and sympathetic nerve endings, with M2 (and perhaps M4) mAChR typically 
inhibiting transmitter release from both types of nerve terminals, and M1 mAChR and β2-AR 
facilitating it in the mouse (Trendelenburg et al., 2005). Studies in the bladder have focused 
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on mAChR autoreceptors regulating acetylcholine release and have demonstrated a role for 
facilitatory M1 mAChRs and inhibitory M2 and M4 mAChRs in rat (D’Agostino  et al., 1997; 
Lawrence et al., 2010; Somogyi et al., 1996), mouse (Ehlert et al., 2007), rabbit (Tobin & 
Sjogren, 1995) and human (D'Agostino et al., 2000) bladder. In the mouse bladder, carbachol 
reduced evoked noradrenaline release by 57-71% (Trendelenburg et al., 2005). Specifically, 
M2 and M4 mAChRs mediated this inhibition, because noradrenaline release was not 
recorded in bladders from M2 and M4 mAChR knockout animals (Trendelenburg et al., 2005).  
Thus pre-junctional mAChRs modulate acetylcholine and noradrenaline release. 
In other tissues, mAChR activation inhibited the release of endogenous noradrenaline from 
field stimulated rabbit trachea (Hey et al., 1994). Also, in the horse (Zhang et al., 1995; 1998) 
and guinea-pig (Belvisi et al., 1996) trachea, β2-ARs augmented acetylcholine release. Zhang 
et al., (1998) showed that the β2-AR agonists, albuterol and formoterol augmented 
acetylcholine release in a concentration-dependent manner in the horse trachea. In contrast, 
inhibition of acetylcholine release by β-AR agonists was observed in rat (Wessler et al., 1994) 
and bovine airways (Brichetto et al., 2003). Thus, the nature of prejunctional interaction of 
the β-AR on the mAChR system seems to be species related. 
In the urethra of human and rabbit Mattiasson and colleagues (1984) have shown a negative 
feedback regulation of the release of noradrenaline from adrenergic nerve endings. Pre-
junctionally located α2-ARs  mediated the feedback. Likewise, an interaction at the nerve 
terminal level between the adrenergic and cholinergic systems was reported (Mattiasson et al., 
1984). Carbachol inhibits release of noradrenaline from adrenergic nerve terminals and 
acetylcholine from cholinergic nerve terminals, by acting upon pre-junctional mAChRs, thus 
decreasing urethral tone and intra-urethral pressure (Mattiasson et al., 1984), providing 
evidence for prejunctional interaction between ARs and mAChRs in the urethra. 
Post-junctional interaction between G-protein-coupled receptors 
Past reports have demonstrated post-junctional interaction between ARs and non-ARs, which 
may modulate the signalling of the other (Budd et al., 1999; Miyoshi et al., 2007). For 
example, insulin-like growth factor-I receptors, sphingosine-1-phosphate receptors, mAChRs, 
μ-opiod receptors and epidermal growth factor receptors participate in signalling crosstalk 
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with ARs in cells such as CHO and fibroblasts (Budd et al., 1999; Castillo-Badillo et al., 
2012; Dang et al., 2012; Molina-Muñoz et al., 2006; 2008; Vázquez-Prado et al., 1997). The 
interaction between these receptors and AR modulates signalling of the AR and vice versa. 
Receptor interaction also modulates sorting and recycling of the ARs. For example, 
sphingosine-1-phosphate receptors stimulation in HEK-293 cells induced rapid and transient 
α1B-AR interactions with Rab monomeric G-proteins (a family of Rho guanosine 
triphosphatases located in endosomes (Seachrist et al., 2000)) thereby targeting and 
regulating the α1B-AR traffic from late endosomes to lysosomes and recycling to the trans-
Golgi (Castillo-Badillo et al., 2015). This indicates that an interaction between sphingosine-1-
phosphate receptors and α1B-AR induces heterologous desensitisation of α1B-ARs. Thus, the 
post-junctional interaction between AR and other non-ARs modulates desensitisation, 
trafficking, and sorting of the receptors. 
Crosstalk has also been observed between AR subtypes. Liang et al., (1998) observed a rapid 
crosstalk between the α2A-ARs and α1B-ARs co-expressed in CHO cells. Upon selective 
activation of α1B-ARs with phenylephrine, the function of α2A-ARs was desensitised (Liang et 
al., 1998).  
Post-junctional receptor interaction in the lower urinary tract 
Post-junctional interaction has been reported in the lower urinary tract. For example, 
interaction of mAChRs with β-ARs in the bladder occurs, as shown by studies using 
pharmacological inhibitors (Witte et al., 2011) and mAChR subtype knock-out mice (Ehlert 
et al., 2007; Matsui et al., 2003). Witte et al., (2011) showed that the concomitant presence of 
the mAChR agonist carbachol could attenuate relaxation responses by reducing potency 
and/or efficacy of β-AR agonists such as isoprenaline. Witte et al., (2011) observed that both 
M2 and M3 -mAChRs contributed to attenuation of β-AR-mediated relaxation of rat urinary 
bladder, and the M3-mAChR-mediated effect was via phospholipase C and not PKC. Michel, 
(2014) also observed that β-AR agonist pre-treatment reduced contractile responses to the 
mAChR agonist carbachol in rat urinary bladder smooth muscle. Thus, β-AR agonists 
mediate a functional antagonism of mAChR in the bladder. Roosen et al., (2008) showed a 
synergistic interaction between the mAChR and α1-AR system in the trigone of the guinea-
pig. Electrical field stimulation-evoked contractions of the guinea-pig trigone were enhanced 
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by a mAChR agonist and an AR agonist, and the activation of the α1-AR in the guinea-pig 
trigone augmented mAChR-mediated responses. In addition, Nagahama et al., (1998) have 
also shown a postjunctional interaction of the mAChRs with α-ARs in the proximal urethra of 
the rabbit. 
The prototypical primary signalling pathway of M2 -mAChRs is via inhibition of adenylyl 
cyclase; whilst M3 mAChRs and α1A-ARs stimulate phospholipase C, and β-AR signalling is 
via adenylyl cyclase leading to the formation of cyclic AMP, which can activate protein 
kinase A (Frazier et al., 2008) (Figure 7.1). Moreover, β-ARs can couple to activation of 
several potassium channels, mostly large conductance, Ca
2+
-activated channels as shown in 
urinary bladder smooth muscle of mouse (Brown et al., 2008; Sprossmann et al., 2009). 
M3 mAChR and α1A-AR stimulation leads to the formation of inositol phosphates and 
diacylglycerol, which in turn mobilise Ca
2+
 from intracellular stores and activate PKC, 
respectively. Additionally, they can be coupled to a phospholipase D as a downstream event 
(Wegener et al., 2014), mediate myosin light chain phosphorylation and activation of Rho 
kinase. Given the role of Ca
2+
 in initiating a smooth muscle contraction, phospholipase C 
activation is the molecular basis of mAChR and α1A-AR-mediated smooth muscle contraction. 
An overview of the signal transduction pathways of mAChR and AR in smooth muscle cells 
showing crosstalk between receptor-mediated signalling is shown in Figure 7.1. 
7.3 DESENSITISATION OF MUSCARINIC RECEPTOR 
Yoshida et al., (2014) showed that the third intracellular loops of mAChR M2 and M4 mediate 
agonist-dependent internalisation and recycling in HEK-293 tsA201 cells transiently 
expressing M2, M4, and M2-M4 chimera mAChRs. Treatment with carbachol (1 mM) for 1 
hour reduced numbers of cell surface M2 and M4 mAChRs by 40-50% (Ockenga & Tikkanen, 
2015). The M2 and M4 mAChRs, when chronically activated, mediated inhibition of adenylyl 
cyclase, intracellular Ca
2+
 concentration ([Ca2+]i) increase, and phospholipase C activation 
by 60-70% (Krudewig et al., 2000). Thus, mAChRs undergo desensitisation and 
internalisation usually, in a manner similar to previously described for ARs. 
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Using radioligand binding techniques, the rank orders for the rate of carbachol-induced 
internalisation of the mAChR subtypes were M2 > M4 = M5 > M3 = M1 (Thangaraju & 
Sawyer, 2011). These observations were based on post-exposure of CHO cells stably 
expressing mAChR subtypes to carbachol treatment (1 mM). Thangaraju & Sawyer, (2011) 
further reported that M1, M3, M4 and M5 mAChRs recycled back to the plasma membrane 
after 1-hour carbachol treatment. However, the M2 mAChR was not recycled back to the 
plasma membrane, suggesting a difference in mAChR desensitisation mechanisms. Moreover, 
the M2 and M4 mAChRs, which are analogous and share several signal transduction pathways 
show different endocytosis and post-endocytic trafficking routes. After agonist induction, the 
M2 mAChR was internalised via a clathrin-independent endocytosis pathway (Delaney et al., 
2002). These receptors are then targeted to lysosomes for degradation (Mosser et al., 2008). 
In contrast, the M4 mAChR was internalised through the clathrin-dependent endocytosis 
pathway (Wan et al., 2015) and then recycled back to the plasma membrane. This literature 
suggests a difference in mechanism of internalisation of mAChR subtypes. 
A 5-minute pre-exposure of CHO-M3 mAChR cells to carbachol resulted in attenuation of the 
initial peak inositol 1, 4, 5-tris-phosphate response to a subsequent application of the agonist 
(Tobin et al., 1992). Tsuga et al., (1994) also showed that phosphorylation of M2 mAChR by 
GRK2 facilitates sequestration in COS 7 or BHK-21 cells in an agonist-dependent manner. 
Cha et al., (2006) reported desensitisation of mAChRs of bladder smooth muscle strips 
isolated from mouse, with bladder smooth muscle strips with circulating anti-M3 mAChR 
autoantibodies exhibiting lower carbachol-evoked responses than smooth muscle strips 
without prior treatment. Moreover, repeated pilocarpine (mAChR agonist) injections of mice 
for six days caused mAChR desensitisation in the agonist-evoked contractile assay (Cha et 
al., 2006). Thus, it is clear that desensitisation of mAChR occurs, which may depend on GRK 
activity. To our knowledge, research into desensitisation of mAChR-mediated responses in 
the urethra has not been reported. 
Epithelial linings have been shown to influence desensitisation of smooth muscle. However, 
in the lower urinary tract little is known regarding the influence of urothelium on receptor 
interaction. In the rat bladder, Ferguson et al., (2015) observed that inhibition of urothelial 
P2X3Rs prevented desensitisation of P2X-mediated detrusor muscle contractions during EFS. 
Thus, suggesting that the urothelium expressed receptor may modulate receptor-mediated 
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responses by influencing desensitisation. Based on this data, they proposed a pathway 
involving P2X3R driven paracrine amplification of ATP released from umbrella cells to 
increase afferent transmission in the suburothelial sensory plexus and desensitisation of 
P2X1-mediated purinergic detrusor contractions.  
Little is known about the role of the urethral urothelium in receptor desensitisation/interaction. 
The urethral urothelium is likely to be part of a signalling system that involves projections of 
the neuroendocrine cells, interstitial cells, and sensory nerve endings (Deckmann et al., 2014; 
Hashimoto et al., 1999; McCloskey, 2010). Thus this study also looks into the effect of the 
urothelium on receptor interaction and desensitisation of urethral responses.  
Thus the aim of this chapter was to investigate post-junctional interaction between mAChRs 
and α1-ARs in modulating responses of the female pig urethra and the role of the urothelium. 
In particular, this study focused on the following questions: 
 Can desensitisation of mAChR- mediated responses be demonstrated in the pig 
urethra? 
 What is the role of urothelium in desensitisation of mAChR- mediated responses? 
 Does a post-junctional interaction between the AR and mAChR exist in the pig 
urethra? 
 Does activation of the α-AR or mAChR induce a homologous or heterologous type of 
desensitisation? 
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7.4 MATERIALS AND METHODS 
Strips of female pig urethra were set up in 8ml organ baths and allowed to equilibrate for 60 
minutes as described in chapter 2.  
Initial experiments were performed to examine the repeatability of concentration-response 
curves to carbachol. Second curves to carbachol were depressed, with maximum responses 
reduced from 102.4±23.0mN to 48.6±12.3mN  (n=9, p<0.01) without a change in pEC50 
(5.4±0.1 and 5.3±0.1 respectively).  For this reason, all experiments in this chapter were 
performed on pairs of identical tissues with only one concentration-response curve performed 
on each tissue. 
To investigate the effect of α1-AR stimulation on mAChR-mediated responses, control tissues 
were incubated with Krebs solution for 15 minutes before cumulative concentration-response 
curves were constructed to carbachol. Test tissues were incubated with EC50 concentrations 
of noradrenaline (7μM), phenylephrine (4μM) or A61603 (0.03μM) for 15 minutes followed 
by a 30-minute washout before cumulative concentration-response curves were constructed to 
carbachol.  
To investigate the effect of mAChR stimulation on α1-AR-mediated responses, control tissues 
were incubated with Krebs solution for 15 minutes before cumulative concentration-response 
curves were constructed to noradrenaline. Test tissues were incubated with carbachol (4μM; 
EC50 concentration) for 15 minutes followed by a 30-minute washout before cumulative 
concentration-response curves were constructed to noradrenaline.  
In addition, the experiments were repeated in tissues with or without urothelium. Where 
specified TTX (1μM) or indomethacin (10μM) was added to the tissues to determine any 
neuronally mediated effects or prostaglandin-mediated effects respectively, on the receptor-
mediated responses. 
Data analysis 
The receptor-mediated responses were analysed and data expressed as described in chapter 2.   
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7.5 RESULTS 
Effect of incubation with adrenoceptor agonists on urethral tissue 
responses to carbachol 
Maximum contractile responses to carbachol were significantly desensitised by a similar 
degree after 15 minutes incubation with noradrenaline (7μM), phenylephrine (4μM) or 
A61603 (0.03μM), as shown in Table ‎7.1 and Figure ‎7.2. Furthermore, incubation with 
noradrenaline, but not phenylephrine or A61603, reduced the pEC50 values for carbachol 
(p<0.01) (Table ‎7.1).  
Effect of incubation with carbachol on noradrenaline-induced responses 
Surprisingly, maximal contractile responses of urethral tissues to noradrenaline following 
incubation with carbachol (4μM) were greater than the response of control tissues without 
carbachol incubation (Figure ‎7.3), although the difference was not statistically significant 
(Table ‎7.2). Furthermore, the pEC50 values for noradrenaline were similar for tissues with or 
without prior incubation with carbachol (Table ‎7.2). 
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Figure ‎7.2 Mean (± SEM) concentration-response curves to carbachol in the pig urethral tissues, with or 
without prior 15 minutes incubation with α-adrenoceptor-agonists, n=5-9. *p<0.05, **p<0.01 vs control 
responses (Student’s t-test).  
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Figure ‎7.3  Mean (± SEM) concentration-response curves to noradrenaline in pig urethral tissues, with or 
without prior 15 minutes incubation with carbachol (4µM). n=8.  
 
The influence of the urothelium/lamina propria on adrenoceptor and 
muscarinic receptor interactions 
Maximum responses to carbachol were significantly desensitised to a similar degree, after 
prior incubation with noradrenaline (7μM) in tissues both with or without urothelium/LP 
(Table ‎7.3; Figure ‎7.4). Furthermore, in the presence of urothelium/LP, the curve for 
carbachol was shifted leftward significantly by the 15 minutes incubation with noradrenaline 
(Table ‎7.3), which was not observed in tissues without urothelium/LP. 
Desensitisation of noradrenaline responses after a prior incubation with carbachol was not 
observed in tissues with intact urothelium/LP, and no change in pEC50 values was observed 
(Figure ‎7.4). However, maximum responses to noradrenaline, in tissues without 
urothelium/LP, were desensitised after incubation with carbachol (4μM) for 15 minutes 
(Figure ‎7.4C).  The pEC50 values for noradrenaline following carbachol incubation were also 
altered, and concentration-response curves were shifted leftward (p<0.05) (Table ‎7.4).   
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– Urothelium/LP  + Urothelium/LP 
                            A                                                            B 
 
                              C                                                            D 
 
Figure ‎7.4 Cross desensitisation of muscarinic and α1-adrenoceptor-mediated responses. Mean 
(±SEM) concentration-response curves to carbachol (A-B) or noradrenaline (C-D) with or without prior 
incubation with noradrenaline (7µM) or carbachol (4µM) respectively, in urethral tissues with or without 
urothelium/LP. n=7-8; *p<0.05, **p<0.01 vs. control response (Student’s t-test).   LP= lamina propria.
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 Urethral tissues with urothelium/LP were also incubated with carbachol in the presence of 
TTX (1μM) to block the neuronal release of neurotransmitter, or indomethacin (10μM) to 
inhibit cyclooxygenase enzyme. TTX (1μM; Table ‎7.5) or indomethacin (10μM; Table ‎7.6) 
did not have any significant effect on responses to noradrenaline after prior incubation with 
carbachol (4μM) (Figure ‎7.5), and the pEC50 values for noradrenaline were similar for tissues 
with or without TTX (1μM) or indomethacin (10μM). 
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- TTX  + TTX 
                          A                                                              B 
   
 
- Indomethacin  + Indomethacin 
                          C                                                              D  
   
Figure ‎7.5 Mean ± (SEM) concentration-response curves to noradrenaline with or without prior 
incubation with carbachol. Experiments were carried out in the presence or absence of TTX (1µM) or 
indomethacin (10µM).  n=7-8.    
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7.6 DISCUSSION 
The interaction between GPCR may modulate tissue responses either by decreasing or 
potentiating responses (Budd et al., 1999; Bundey & Nahorski, 2001; Charles et al., 2003; 
Hague et al., 2004a; Stanasila et al., 2003). Interaction between ARs (Hague et al., 2004a; 
Stanasila et al., 2003; Uberti et al., 2005) and mAChRs  (Borst et al., 1997; Dhein et al., 2013; 
Motomura et al., 1990; Pera & Penn, 2014) is well documented in numerous cells and tissues, 
although not in the urethra. Thus, we investigated potential interaction of ARs and mAChRs 
in pig urethral tissues. 
Can desensitisation of muscarinic receptor-mediated responses be 
demonstrated in the pig urethra? 
It is also known that the mAChR desensitises, as shown in COS 7 and BHK-21 cells (Tsuga 
et al., 1994; 1998). Cha et al., (2006) also observed desensitisation of mAChRs in bladder 
smooth muscle strips isolated from mouse with circulating anti-M3 mAChR autoantibodies. 
However, to our knowledge, no work has been published in urethral tissues with regards to 
mAChR desensitisation. In this study, we observed desensitisation of mAChR-mediated 
responses in the porcine urethra following prior cumulative concentration-response curves to 
carbachol (page 236). In addition to carbachol reducing subsequent mAChR-mediated 
responses, agonist potency was also reduced significantly.  
Previous reports have shown that pre-stimulation of CHO cells expressing the human M1-
mAChR with agonist led to desensitisation of inositol 1, 4, 5-tris-phosphate accumulation 
with a 4-fold shift in the agonist dose-response curve (Waugh et al., 1999). Desensitisation 
has also been associated with a major reduction in the maximal agonist-induced responses 
and inositol monophosphate, which was associated with activation and translocation of PKC 
(Dillon-Carter & Chuang, 1989). Furthermore, desensitisation by carbachol has been shown 
in primary cultures of corticostriatal neurones and cultured cerebellar granule cells, and it was 
reported that incubation with carbachol attenuated phospholipase C responsiveness and 
decreased the number of cell surface mAChRs in these cells (Dillon-Carter & Chuang, 1989). 
Thus carbachol-induced desensitisation observation in this study may be associated with 
reduced inositol monophosphate level and PKC activity. The desensitisation may also include 
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uncoupling of receptors by kinases within seconds after the addition of carbachol, 
sequestration and or down-regulation of the mAChR as shown in CHO cells by Waugh et al., 
(1999). Down-regulation of receptors is a possibility, given that downregulation of mAChR 
has been reported at early time periods in murine fibroblast cell lines (Wei et al., 1994). Also, 
1-hour exposure of Fischer rat thyroid-epithelial cells to carbachol resulted in a 
desensitisation of mAChR-mediated intracellular Ca
2+
 mobilisation and induced the 
internalisation of constitutively expressed mAChR in this cell type (Montiel et al., 2004).  
Whether these diminished mAChR-mediated responses are a result of desensitisation or 
downregulation requires confirmation by further investigations.  
Does activation of urethral α1-adrenoceptors induce desensitisation of 
muscarinic receptor-mediated responses and vice versa? 
In the previous chapter we showed that A61603 and phenylephrine induced desensitisation of 
α1-AR-mediated responses. In this section, we investigated the possibility of α-AR agonists 
inducing desensitisation of mAChR-mediated responses and vice versa in the pig urethra, 
representing a postjunctional interaction between the AR and the mAChR systems. Post-
junctional interaction between the AR and the mAChR systems is well documented, although 
these studies examined β-AR and other tissues apart from the urethra. For example, Witte et 
al., (2011) showed that the concomitant presence of a mAChR agonist, can attenuate 
relaxation responses by reducing potency and/or efficacy of β-AR agonists such as 
isoprenaline in the rat bladder.  They observed that both M2 and M3 mAChRs contributed to 
attenuation of β-AR-mediated relaxation of rat urinary bladder, and the M3 mAChR-
mediated-effects was via phospholipase C but not via PKC. In addition, Budd et al., (1999) 
showed that activation of M3-mAChRs mediated heterologous phosphorylation of β2-ARs in 
a GRK-independent fashion, via PKC. Heterologous β2-AR phosphorylation correlated with 
receptor desensitisation and the reduction in maximal cyclic AMP accumulation.  
In this study, a prior incubation (15 minutes) of urethral tissues with noradrenaline, 
phenylephrine or A61603, at EC50 concentrations, induced a significant desensitisation of 
subsequent mAChR-mediated responses. Also, the potency of carbachol was reduced after 15 
minutes incubation with noradrenaline. The desensitisation induced by all three agonists was 
similar. This result confirms a heterologous type of desensitisation by phenylephrine, A61603 
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and noradrenaline between AR and mAChR.  Past studies on α1-ARs have revealed an α1-
AR-mediated heterologous desensitisation of mAChR-mediated responses in SH-SY5Y 
human neuroblastoma cells using noradrenaline (Bundey & Nahorski, 2001).  Although these 
authors showed that α1B-AR stimulation produced a heterologous desensitisation of mAChR-
mediated Gq/11 activation, they could not detect an increase in mAChR phosphorylation.   
In preceding chapters, we showed that the potency and efficacy of the α-AR agonist used 
affected the degree of desensitisation of α1-AR-mediated responses. This phenomenon 
suggests that increasing agonist-coupling efficiency primarily affects desensitisation. This 
may be by increasing the rate of phosphorylation of the ARs (January et al., 1997). However, 
this phenomenon seems not to apply to the heterologous desensitisation of mAChR by α1-AR 
stimulation, since noradrenaline, phenylephrine and A61603 induced a similar degree of 
heterologous desensitisation of mAChR-mediated responses, suggesting that the three 
agonists may be equi-effective in mediating heterologous desensitisation of mAChRs. The 
ability of the α-AR agonists to induce similar heterologous desensitisation may be associated 
with similar ability to activate second messenger-dependent kinases such as protein kinase A 
and PKC (Penn et al., 1998). In an earlier chapter we showed that A61603-induced 
contraction depends on PKC. In contrast, Roosen et al., (2008) showed a synergistic 
interaction between the mAChR and α1-AR system in the bladder. Electrical ﬁeld stimulation 
contractions of the guinea-pig trigone were enhanced by a mAChR agonist and an AR agonist, 
and activation of the α1-AR in the guinea-pig trigone augmented mAChR-mediated responses. 
This highlights tissue-specific differences in regions of the lower urinary tract. 
Upon investigating whether mAChR stimulation caused desensitisation of α1-AR-mediated 
responses we found that, prior incubation with carbachol did not desensitise urethral 
responses to noradrenaline. Instead, a non-significant potentiation was observed. An earlier 
report by Nagahama et al., (1998) has shown a similar report in the proximal urethra of the 
rabbit. Carbachol dose-dependently enhanced contraction of the proximal urethra region to 
noradrenaline. The potentiation may be the result of upregulation of α1-AR or its signalling in 
response to mAChR activation. For example, studies, in cardiac tissue (Benes et al., 2012; 
Dhein et al., 2013) and with cloned receptors in transfected cells (Budd et al., 1999; Lee and 
Fraser, 1993), showed that desensitization/down-regulation of mAChR or β-ARs can lead to 
sensitization/up-regulation of co-expressed receptors. Thus, in the present study activation or 
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desensitisation of the mAChR-mediated responses by carbachol may upregulate the 
noradrenaline-mediated responses in the urethral tissues by a similar mechanism. In the 
guinea pig trigone, Ca
2+
 sensitization was responsible for a synergistic potentiating effect 
between AR, mAChR, and purinergic receptor activation in the muscle of the superficial 
trigone (Roosen et al., 2008) mediated via PKC and Rho kinase. Thus, activation of PKC and 
Rho kinase may be responsible for the effect in this study. Either way, carbachol caused 
desensitisation of subsequent mAChR-mediated responses but not of subsequent α1-AR 
mediated responses, confirming a homologous form of desensitisation in the urethral smooth 
muscle.  
Does the urothelium/lamina propria affect the receptor-mediated 
desensitisation? 
In earlier chapters, we showed the inhibitory effect of the urothelium/LP on the underlying 
urethral smooth muscle responses, and showed that this effect was not associated with 
prostaglandins or NO. In this chapter, we investigated whether the urothelium/LP influences 
receptor interaction in the urethra.  
The presence of urothelium/LP did not affect the noradrenaline-induced desensitisation of 
mAChR-mediated responses. However, whilst carbachol was not able to desensitise α1-AR-
mediated responses in urethral tissues with urothelium/LP, it did desensitise α1-AR-mediated 
responses in those without urothelium/LP.  These results infer a post-junctional interaction 
dependent on the urothelium/LP.  Templeman et al., (2002) observed that urothelium derived 
factors mediated crosstalk among mAChR and AR systems in the porcine bladder.  However, 
Templeman et al., (2002) reported inhibition of noradrenaline-induced responses in the 
trigone of the porcine bladder with intact urothelium in the presence of carbachol, an 
observation we did not see in the urethra. The variation in results may be due to different 
lower urinary tract tissues. 
In the present study, we hypothesised that in the urethra carbachol might stimulate release of 
a factor from the urothelium that prevents or opposes desensitisation of noradrenaline 
responses. It is known that the urothelium releases factors in response to receptor stimulation 
(McLatchie et al., 2014; Sui et al., 2014). Stimulation of mAChRs increases ATP production, 
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and antagonising these receptors reduces ATP release in the bladder urothelial cells 
(McLatchie et al., 2014; Sui et al., 2014). Likewise, acetylcholine is released in response to 
mechanical stress (McLatchie et al., 2014; McLatchie & Fry, 2015). Less is known about 
urothelially released ATP and acetylcholine and other factors in the urethra. 
Prospective excitatory factors that may be released from the urothelium/LP include 
prostaglandins. Nile & Gillespie, (2012) have reported that cholinergic stimulation induces a 
concentration-dependent production of prostaglandin E2 in guinea pig bladder urothelium, 
which was inhibited in a dose-dependent manner by the selective M2 -mAChR antagonist. To 
our knowledge, no study has shown release of prostaglandins in the urothelium of urethra. 
However, expression of the prostaglandin E receptors, EP1, EP2, EP3, and EP4, and mRNA 
for EP2, EP3, and EP4 were reported in dog urethral urothelium (Ponglowhapan et al., 2010). 
In the human urethra, prostaglandin F2α mediates contraction (Andersson et al., 1977) as well 
as in rabbit urethral tissues (Morita et al., 1994). Thus prostaglandins are a possible 
modulator opposing desensitisation of the urethral tissues responses to noradrenaline. 
However, inhibition of cyclooxygenase with indomethacin (10μM) did not result in a 
desensitisation of noradrenaline-mediated responses ruling out prostaglandins. In addition, 
prior incubation with TTX (1μM) did not result in a desensitisation of noradrenaline-
mediated responses. This suggests that the neuronal release does not play a role.  
Thus although the urothelium opposes desensitisation, the precise mechanism remain to be 
elucidated. This study demonstrates post-junctional interaction between ARs and mAChRs in 
the urethra.  
Conclusions 
 Noradrenaline, phenylephrine and A61603 caused desensitisation of carbachol 
responses in urethral tissues. Desensitisation observed was similar for all agonists.  
 Desensitisation induced by noradrenaline was not urothelium/LP dependent.  
 Carbachol caused desensitisation of noradrenaline-mediated responses in the urethral 
tissues, although only in the absence of the urothelium/LP.  
 Masking of receptor-mediated desensitisation was not of neuronal origin and not due 
to cyclooxygenase activity.  
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CHAPTER 8 
 
Modified from Gordon & Nivatvongs, 2007. 
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8 NEUROTRANSMITTERS REGULATING 
CONTROL OF THE INTERNAL ANAL SPHINCTER 
SMOOTH MUSCLE 
8.1 BASAL TONE OF THE INTERNAL ANAL SPHINCTER 
The internal anal sphincter smooth muscle, which is a ring-shaped structure encircling the 
anorectum, exhibits basal tone and controls the passage of faecal contents through the 
anorectum (Zhang et al., 2016b). Healthy sphincters open transiently during faecal passage 
but, in the basal state, remain closed and therefore require perpetual force generation from the 
smooth muscle cells. The loss of this tone leads to disorders such as faecal incontinence, 
whilst the hypertonic IAS smooth muscle inhibits healing of anal fissure (Farouk et al., 
1994). A significant number of studies have indicated that the basal tone of IAS smooth 
muscle is independent of extrinsic nerve and hormone stimulation, but instead is an intrinsic 
property of the sphincter smooth muscle itself (Rattan, 2005). Zhang et al., (2016b) showed 
that intracellular Ca
2+
 is elevated via ryanodine receptors, L-Type Ca
2+
 channels and Ca
2+
-
activated Cl
-
 channels to mediate IAS basal tone in the mouse. The increase in intracellular 
Ca
2+
activates myosin light chain kinase and triggers the basal contractile tone. The Ca
2+
 
release from the opening of ryanodine receptors in the sarcoplasmic reticulum of the IAS is 
the initial signal for the generation and maintenance of IAS smooth muscle basal tone and 
this increased Ca
2+
 then activates Ca
2+
-activated Cl
-
 channels which activated the L-Type 
Ca
2+
 channels (Zhang et al., 2016b). Also, extracellular Ca
2+  
has been shown to contribute to 
the maintenance of basal tone of IAS in other animals (Cook et al., 1999a; Mundey et al., 
2000) and human (Cook et al., 1999b). Specifically, the Ca
2+ 
influx via the L-type Ca
2+
 
channels contributes to the basal tone of IAS (Cook et al., 1999a, b). 
Rho kinase is also important in the maintenance of IAS smooth muscle basal tone in animals 
(Patel & Rattan, 2006; 2007; Rattan et al., 2006) and human (Rattan & Singh, 2012; Rattan et 
al., 2015). Patel & Rattan, (2006) examined the molecular basis for the basal myogenic tone 
in the IAS and compared it to rectal smooth muscle (a mixture of phasic and tonic), and 
anococcygeus smooth muscle (phasic muscle) in the rat. The levels of RhoA/Rho kinase were 
higher at the cell membrane in the IAS compared with those from the rectal smooth muscle 
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and anococcygeus smooth muscle and C3 exoenzyme (RhoA inhibitor) and Y27632 (Rho 
kinase inhibitor) caused concentration-dependent relaxations of the IAS. In addition, active 
Rho kinase-II was shown to cause further shortening of the IAS. Singh et al., (2014; 2015) 
have shown that an age-associated decrease in IAS tone is due to oxidative stress-mediated 
decreases in Rho kinase signal transduction in the rat. The decrease in tone was associated 
with a decrease in RhoA/Rho kinase expression at the transcriptional and translational levels 
(Singh et al., 2014). Singh et al., (2014) thereby concluded that an increase in oxidative stress 
plays a major role in the ageing-associated decrease in IAS tone in the aged and may be one 
of the underlying mechanisms of recto-anal incontinence in certain ageing patients. 
Furthermore, Singh et al., (2015) showed that reactive oxygen species produced a bimodal 
effect on IAS smooth muscle tone of the rat. Higher concentrations of reactive oxygen 
species produced a decline in IAS tone, while lower concentrations of reactive oxygen 
species induced an increase in RhoA/Rho kinase activity and IAS tone.  All these results 
suggest a contribution by RhoA/Rho kinase to basal tone of the IAS smooth muscle and that 
altered activity is seen during ageing, leading to anorectum pathological conditions such as 
faecal incontinence. 
The rectoanal region is the final site for controlling the storage, transport and evacuation of 
faecal materials. The IAS is usually closed and maintains continence, while during the 
defecation reflex it briefly relaxes to allow the passage of faecal materials. The activity of the 
IAS is modulated by the innervation of the smooth muscle which is elucidated below. 
8.2 INNERVATION OF THE INTERNAL ANAL SPHINCTER  
As in other parts of the gastrointestinal tract, contraction and relaxation of the IAS smooth 
muscle are regulated by enteric and autonomic neurones and by the actions of other cell types, 
including ICC and fibroblast-like cells (Cobine et al., 2011).  
Excitatory motor innervation to the IAS is almost exclusively sympathetic, since it is blocked 
by guanethidine (inhibits the release of noradrenaline) and is inhibited by α1-AR antagonists 
(Cobine et al., 2007; 2010; Glavind et al., 1997; Tichenor et al., 2002). Guanethidine 
treatment leads to almost complete blockade of the EFS-induced response in the IAS of dog 
(Tichenor et al., 2002). Also, both prazosin (α1-AR antagonist) and yohimbine (α2-AR 
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antagonist) significantly reduce responses to EFS, but prazosin produces a significantly 
greater inhibition than yohimbine (Tichenor et al., 2002). However, in the proximal rectum, 
excitatory motor innervation is mediated by both cholinergic and tachykinergic mechanisms 
(Tichenor et al., 2002). Thus, extrinsic sympathetic nerves play an important role in 
regulating sphincter function. 
Neurotransmitters, such as NO, play a major role in the inhibitory neurotransmission of the 
IAS (Rattan et al., 1992; Rattan & Chakder, 1992). However, inhibitory neurotransmission in 
the IAS may involve other neurotransmitter such as vasoactive intestinal polypeptide (VIP) 
(Keef et al., 2013; Raghavan et al., 2010; 2011;  2014), carbon monoxide (CO) (Rattan & 
Chakder, 1993; Watkins et al., 2004) and purines (Acheson et al., 2009; Duffy et al., 2012).  
Excitatory inputs 
Initial in vitro studies by Parks et al., (1969) demonstrated that the sympathetic 
neurotransmitter noradrenaline causes a contraction of the IAS smooth muscle that could be 
blocked by the addition of the α-AR antagonist phenoxybenzamine. Yamato & Rattan (1990) 
demonstrated that stimulation of α1-AR causes an increase in resting pressure developed by 
the sphincter without affecting the anal pressure response to rectal distension. Alpha-AR-
mediated responses have been shown in the IAS smooth muscle of animals (Mills et al., 2008; 
Rayment et al., 2010) and humans (Owaki et al., 2015). In addition, Speakman et al., (1990; 
1993) showed that in vitro contractile responses of the human IAS to noradrenaline are 
decreased in incontinence. Using EFS, Cobine et al., (2007) showed that the excitatory motor 
innervation to the IAS of the monkey was noradrenergic, and the frequency-dependent 
contractions were abolished by guanethidine. In the sheep IAS, endogenous noradrenaline 
acts via postjunctional α-AR to antagonise neurogenic relaxations that are largely mediated 
by NO (Acheson et al., 2009). Thus, noradrenaline acting via the α-AR is excitatory in the 
IAS (Table ‎8.1). 
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 Inhibitory inputs 
In terms of the inhibitory control of the IAS smooth muscle studies have suggested that 
nNOS and eNOS isoforms of NOS modulate distinct components of IAS function (Banwait 
& Rattan, 2003; Evers, et al., 2013). Neuronal NOS was observed in the myenteric plexus of 
canine gastrointestinal neurones using NADPH-diaphorase staining techniques (Ward et al., 
1992), and western blot studies revealed the presence of eNOS in the circular smooth muscle 
of the IAS of the opossum (Banwait & Rattan, 2003). Likewise, immunoreactivity for nNOS 
has been shown in the IAS of other animals (Cobine et al., 2011; Wang et al., 2013), and 
humans (Moszkowicz et al., 2012) and inhibition of nNOS by reactive oxygen species may 
contribute to pathological conditions of the IAS (Singh et al., 2015). Qu et al., (2008) showed 
that 90% of NOS-expressing neurones were inhibitory motor neurones to the IAS muscle (26% 
of all neurones) and 10% (3% of all neurones) were interneurons. Thus, it is clear that NO is 
the major non-adrenergic, non-cholinergic neurotransmitter mediating neurogenic relaxation 
of the IAS in animals (Jones et al., 2003a; Rae & Muir, 1996) and human (O’Kelly et al., 
1993b). 
There is substantial evidence that ICC participate in nitrergic neurotransmission in the 
gastrointestinal tract. Interstitial cells of Cajal make very close contacts with varicose 
terminals of enteric motor neurones (Daniel & Posey-Daniel, 1984), express guanylate 
cyclase (Lino et al., 2009), synthesise cyclic GMP (Shuttleworth et al., 1993), and generate 
hyperpolarization (Burns et al., 1996) in response to nitrergic stimulation. Imatinib, an 
inhibitor of Kit receptor tyrosine kinase (a marker for ICC), significantly reduced the tone 
and the spontaneous activity of the human IAS, which also stained positive for the c-kit 
protein. Interstitial cells of Cajal have been observed in the IAS of animals (Cobine et al., 
2010; 2011; 2014; Duffy et al., 2012) and humans (Lorenzi et al., 2014; Piotrowska et al., 
2003), and thus ICC may participate in nitrergic transmission in the IAS. 
The cascade underlying nitrergic neuromuscular transmission in the IAS comprises Ca
2+
-
activated NOS, as a generator of NO, and NO-sensitive guanylyl cyclase, as a generator of 
the second messenger cyclic GMP (Lies et al., 2014). An important receptor for NO in 
visceral muscle is soluble guanylate cyclase, which is a heterodimeric enzyme containing α 
and β subunits that convert GTP to cyclic GMP (Denninger & Marletta, 1999). Guanylate 
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cyclase has been shown to mediate the NO-mediated relaxation of IAS in the mouse (Cobine 
et al., 2014). The relay of the cyclic GMP signal in the gastrointestinal tract may involve 
several effector molecules such as cyclic GMP-dependent protein kinase, cyclic GMP-
regulated phosphodiesterases, and cyclic GMP-gated ion channels (Figure ‎8.1; Hofmann, 
2005).  
Moreover, NO mediates its effect via an important downstream mediator of cyclic GMP, 
cyclic GMP-dependent protein kinase I (cGKI), which is a serine/threonine kinase that exists 
in two isoforms, cGKIα and cGKIβ. Cyclic GKI has been shown to phosphorylate ion 
channels and other proteins responsible for regulating the contractile state of smooth muscles 
(Orstavik et al., 1997). The cGKI-independent pathway is also implicated in NO-mediated 
IAS relaxation as shown in the cGKI knockout mouse (Cobine et al., 2014).  
Clinically the inhibitory pathways of IAS may be a target for pharmacotherapy i.e. relaxation 
of the IAS for anal fissures or stop relaxation for faecal incontinence. A deficiency in NO 
may be associated with chronic anal fissure, since this condition is associated with hypertonia 
of the IAS which lower the local blood flow and prevents healing (Lund, 2006). Internal anal 
sphincter from patients with chronic anal fissure showed little NOS presence compared with 
controls (Lund, 2006).  
Adenosine triphosphate (ATP) 
In the mouse, McDonnell et al., (2008) showed that exogenous ATP relaxed the IAS.  Under 
non-adrenergic, non-cholinergic conditions, purinergic pathways contribute to EFS-induced 
inhibitory junction potentials and relaxation in addition to the nitrergic pathways of the 
mouse IAS (Duffy et al., 2012).  P2 receptor antagonists significantly reduced the fast 
inhibitory junction potential and relaxation, achieved by desensitisation of P2Y receptors 
with αβmATP and by the selective P2Y1 receptor blocker and K+ channels blocker 
(McDonnell et al., 2008). Thus, purinergic transmission significantly contributes to NOS-
independent neural inhibition in the mouse IAS.  
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Also, ATP has been shown to contribute to inhibitory junction potentials and relaxation in 
conjunction with NO in other animals such as rat (De Luca et al., 1999; Opazo et al., 2011), 
guinea-pig (Rae & Muir, 1996) and human (Burleigh et al., 1979). In the IAS of rats, ATP is 
co-released by inhibitory motor neurones with NO and VIP, where it could induce IAS 
relaxation (Opazo et al., 2011). In the gastrointestinal tract, activated purinergic receptors 
induce an increase in intracellular Ca
2+
, and the opening of small conductance Ca
2+
-activated 
K
+
 channels, with an ultimate effect of hyperpolarization and relaxation (Koh et al., 1997; 
Kong et al., 2000; Vogalis & Goyal, 1997).   
Carbon monoxide (CO) 
Carbon monoxide synthesis is catalysed by the heme oxygenase, which is the rate-limiting 
enzyme in the catabolism of heme. Heme oxygenase degrades heme, producing CO, 
biliverdin, and Fe2+ (Tenhunen et al., 1969). There are two isoforms of heme oxygenase 
(heme oxygenase-1 and heme oxygenase-2) of which heme oxygenase-1 is an inducible 
enzyme, whereas heme oxygenase-2 is constitutively expressed. 
Non-adrenergic, non-cholinergic neurotransmission is markedly decreased in the upper 
gastrointestinal tract of heme oxygenase knockout mouse, but can be restored by addition of 
exogenous CO (Xue et al., 2000). Moreover, CO and NO are thought to be co-transmitters in 
the gastrointestinal tract, since CO restores intestinal smooth muscle relaxation in heme 
oxygenase knockout mice (Xue et al., 2000). 
Carbon monoxide also induces activation of guanylate cyclase (Verma et al., 1993). The 
guanylate cyclase activated by CO induces production of cyclic GMP from GTP, the opening 
of K
+
 channels such as voltage-gated K
+
 channels (Kv), with hyperpolarisation resulting in 
smooth muscle relaxation (Figure ‎8.1; Farrugia et al., 1993). Carbon monoxide-releasing 
molecules, CO, as well as non-adrenergic, non-cholinergic nerve stimulation, produce IAS 
relaxation via guanylate cyclase/cGKI activation (Rattan et al., 2004). Moreover, CO-induced 
smooth muscle relaxation has been reported via a guanylate cyclase-independent pathway, a 
process by which CO opens K
+ 
channels to cause hyperpolarization and smooth muscle 
relaxation (Figure ‎8.1) (Rich et al., 1994; Wang & Wu, 1997; Wang et al., 1997).  
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Vasoactive intestinal polypeptide (VIP)  
Vasoactive intestinal polypeptide, originally isolated from pig intestinal extracts by Said & 
Mutt (1970), has also been shown to participate in non-adrenergic, non-cholinergic  
relaxation throughout the intestine, including the IAS of animal (Biancani et al., 1985; Keef 
et al., 2013) and human (Burleigh et al., 1979; Raghavan et al., 2011). Keef et al., (2013) 
showed that during longer EFS trains, a non-purinergic, non-nitrergic relaxation and 
hyperpolarization developed slowly and persisted for several minutes beyond the end of the 
stimulus train, which was abolished by a VIP receptor antagonist, was absent in VIP 
knockout mice and was mimicked by exogenous VIP.  Thus, suggesting the contribution of 
VIP in inhibitory neuromuscular transmission in the mouse IAS (Keef et al., 2013). Keef et 
al., (2013) suggested that in vivo the VIP pathway may be activated with greater rectal 
distensions, leading to a more prolonged period of anal relaxation. 
Using genetic knockout of the biosynthetic enzymes for CO and NO in mice, Watkins et al., 
(2004) showed that the physiologic effects of exogenous and endogenous VIP in the mouse 
IAS are mediated by heme oxygenase-2-synthesized CO (Watkins et al., 2004). 
Immunoantagonism of VIP blocked non-adrenergic, non-cholinergic  transmission in the 
lower esophageal sphincter of the opossum (Goyal et al., 1980), exogenous VIP mimicked 
non-adrenergic, non-cholinergic  transmission, and VIP is localized to myenteric plexus 
neurons that mediate non-adrenergic, non-cholinergic  transmission in the lower esophagus of 
cat and pig (Uddman et al., 1978). At the postsynaptic level, many studies support that VIP 
and NO are parallel co-transmitters, acting via the adenylate cyclase and guanylate cyclase 
pathways respectively. Based on results from gastrointestinal tract smooth muscle cells, VIP 
is thought to be the principal neurotransmitter, acting partly via a VIP receptor and the 
adenylate cyclase/cyclic AMP pathway and by induction of muscular NO production (Van 
Geldre & Lefebvre, 2004). In addition, the capacity of VIP to release NO from isolated 
smooth muscle cells is associated with the induction of iNOS in the cells (Van Geldre & 
Lefebvre, 2004). Thus, VIP may mediate relaxation of the IAS by a direct effect or via 
modulation of other non-adrenergic, non-cholinergic neurotransmitters such as NO and CO. 
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Hydrogen Sulphide (H2S) 
Hydrogen sulphide is the third known gasotransmitter and the most recent candidate to join 
the family of gasotransmitters. It is a small molecule; that is more soluble in a lipophilic 
solvent with high membrane permeability (Chen et al., 2007). Hydrogen sulphide is produced 
by non-adrenergic, non-cholinergic, nerves from L-cysteine by two enzymes; cystathionine-
β-synthethase and cystathionine-γ-lyase, although, a third enzyme (3-
mercaptosulfutransferase) has been associated with H2S synthesis in mammals (Hosoki et al., 
1997).  Expression of these enzymes is widespread throughout the body, but particularly in 
the liver and brain (Kabil et al., 2011). Hydrogen sulphide has been implicated in K
+
 channels 
opening and hyperpolarization. Among the K
+
 channels opened by H2S, SK, ATP-dependent 
K
+
 (KATP), voltage-dependent K
+
 (Kv) and inwardly rectifying K
+
 channels (Kir)  have been 
suggested (Kubo et al., 2007; Zhao et al., 2001; Pouokam & Diener, 2011; Takir et al., 2015). 
However, H2S relaxations could also be achieved without K
+
 channels opening and may 
involve modulation of Ca
2+
 sensitization as shown in the mouse distal colon (Dhaese et al., 
2010). 
Teague et al., (2002) reported that NaHS (H2S donor) relaxed isolated rabbit ileum and 
acetylcholine-mediated contraction of the isolated guinea-pig ileum. In mouse gastric fundus 
H2S causes relaxation partially via activation of myosin light chain phosphatase (Dhaese & 
Lefebvre, 2009). Using cystathionine-β-synthase knockout mice and immuno-technique, H2S 
has been shown to modulate gastric compliance (Xiao et al., 2015). In addition, both 
cystathionine-β-synthethase and cystathionine-γ-lyase have been localised along the length of 
rat and mouse colon (Gil et al., 2011; Martin et al., 2010). Linden et al., (2008) demonstrated 
the expression of messenger RNA and protein localisation for cystathionine-β-synthethase 
and cystathionine-γ-lyase in the mouse colon. No studies have yet investigated whether H2S 
is an inhibitory transmitter in the IAS, however, H2S may mediate the relaxation of IAS. 
Acetylcholine 
Acetylcholine which acts via the muscarinic receptors has been shown to be excitatory and 
inhibitory in the IAS smooth muscle. For example, excitatory neurotransmission due to 
acetylcholine was shown in the mouse (Duffy et al., 2012) and human (Somara et al., 2009) 
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IAS.  However, in the cat, acetylcholine induced relaxation of the IAS to a major extent via 
an activation of nitrergic, inhibitory motor neurones (Buntzen et al., 1996). In human, 
mAChR activation seems to mediate the release of inhibitory neurotransmitters, which are 
not prostaglandin, histamine, 5-hydroxytryptamine, or dopamine, but could be ATP or VIP 
(Burleigh et al., 1979). Thus, activation of mAChR may mediate the inhibitory junctional 
potentials and relaxation by mediating the release of relaxing neurotransmitters. The 
contractile effect to acetylcholine reported in mouse and human IAS may be due to the low 
amount of relaxing agent release in response to mAChR activation (Duffy et al., 2012; 
Somara et al., 2009). Thus, relaxation was masked by the contractile action. The 
neurotransmitters involve in the modulation of the IAS smooth muscle is summarised in 
Table ‎8.1. 
Thus, the literature concerning the neurotransmitters of the IAS is confusing. A number of 
contracting and relaxing transmitters have been proposed but even the response to the 
classical transmitters such as acetylcholine is unclear. The aim of this chapter is, therefore, to 
characterise the excitatory and inhibitory neurotransmitters involved in control of the porcine 
IAS. In particular, this study will examine whether a number of inhibitory neurotransmitters 
can be shown to be co-released in one species.  
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8.3 MATERIALS AND METHODS 
Strips of female pig IAS smooth muscle were set up in organ baths as described in chapter 
2. During the 60 minutes equilibration, a basal resting tone consistently developed in these 
tissues (Figure ‎8.2). Thus tension was adjusted over the 60 minutes period until stable at 2g. 
 
Figure ‎8.2 Recording illustrating the increase in the basal tone of the porcine internal anal sphincter 
strips during equilibration (1g= 100mN). 
Electrical field stimulation (EFS) 
The smooth muscle strips were electrically stimulated as described in chapter 2. Initial 
responses for each frequency were obtained followed by responses in the presence of one of 
the drugs which interfere with neurotransmission. Antagonists/inhibitors were equilibrated 
with tissues for 30 minutes before obtaining responses to EFS. Only one drug was tested in 
each tissue and control experiments confirmed responses to EFS did not change over this 
short time period. Guanethidine (10µM) was used to block transmitter release from the 
sympathetic nerves, atropine (1µM) to block mAChR and α, β-methylene-ATP (10µM) to 
desensitise P2X receptors. Also, L-NNA (100µM), indomethacin (5µM), PAG 
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(propargylglycine; 1mM), AOAA (aminooxyacetic acid; 30µM), PheLeu-VIP (100nM), 
ODQ (10µM), ZnPPIX (10µM), suramin (100µM), and 8-phenyltheophyline (10µM) were 
used to block NOS, cyclooxygenase, cystathionine-γ-lyase, cystathionine-β-synthethase, VIP 
receptor, guanylate cyclase, heme oxygenase, P2 receptor and P1 receptor respectively. 
Moreover, TTX (1μM), a potent neurotoxin and selective inhibitor of neuronal 
sodium channel conductance was used to confirm that the smooth muscles were not directly 
activated using these stimulation parameters.  
Statistical Methods 
Changes in developed tension were expressed and the responses seen in the presence of 
antagonist/inhibitor were compared as described in chapter 2. 
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8.4 RESULTS 
Stimulation of the IAS strips via EFS induced a biphasic response, a relaxation response 
followed by a contraction response, as shown in Figure ‎8.3A&B. At 5 Hz, the relaxation was 
fast, lasting 2-3 seconds, followed by a contraction of approximately 10 seconds duration 
(Figure ‎8.3A). Stimulation at a frequency of 10 Hz produced a contraction that was greatly 
increased in both size and duration (Figure ‎8.3C). The responses were neurogenic in origin, 
and the neurotoxin tetrodotoxin (1µM, n = 8) completely abolished contractions at both 
frequencies. Relaxations to EFS were also greatly reduced by tetrodotoxin (3 µM) by 78.3 ± 
2.8% and 91.5 ±1.6% at 5Hz and 10Hz respectively (both P < 0.001). 
Contractile Responses to EFS 
Removal of the adrenergic component with guanethidine (10µM) almost completely 
abolished the contraction of the IAS to electrical stimulation at both frequencies 
(Figure ‎8.3B). Guanethidine reduced the large contractile responses at 5Hz and 10 Hz to 
contractions that were superimposed on large relaxations and only recovered to 30% and 20% 
below the baseline respectively (n=7, p<0.01; Figure ‎8.3B; Table ‎8.2). The percentage 
decrease in contractile response after incubation with guanethidine was 130.7±47.2% and 
120.0±18.7% for 5Hz and 10Hz respectively. Contractile responses were also reduced 
following desensitisation of P2X receptors with the potent purinoceptor agonist α, β-mATP 
(10 µM) (Figure ‎8.3D; Table ‎8.2). Responses at both frequencies were reduced, but the effect 
was only statistically significant for responses at 5 Hz (n=4, p<0.01; Table ‎8.2). 
Desensitisation of ATP receptors with α, β-mATP, decreased the contractile response by 
44.8±5.0% and 20.4±15.1% at 5Hz and 10Hz respectively. In contrast, responses to electrical 
stimulation were not significantly altered by the presence of the mAChR antagonist atropine 
(1 µM, Table ‎8.2). 
Relaxation Responses to EFS 
The relaxation responses obtained after removing adrenergic, cholinergic and purinergic 
contractions with guanethidine, atropine and α, β-mATP were also examined in greater detail 
to determine which inhibitory neurotransmitters were involved and their relative importance. 
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Under these conditions, relaxations to EFS were unaffected by the cyclooxygenase inhibitor 
indomethacin (5µM, n = 14) or the VIP- receptor antagonist PheLeu-VIP (100nM, n =6; 
Table ‎8.3). However, in the presence of the NO synthase inhibitor L-NNA (100µM), 
relaxations were reduced by 40-50% (Figure ‎8.4; Table ‎8.3). Inhibition of guanylate cyclase 
with ODQ (10µM) produced a greater inhibition than L-NNA (IAS relaxation response by 
70.9 ±6.7% and 62.5±5.3% at 5Hz and 10Hz respectively; n=7-8, p<0.001), but a combined 
L-NNA/ODQ treatment did not produce a greater inhibition of relaxation than ODQ alone 
(Figure ‎8.4). 
In another series of experiments the non-nitrergic relaxation remaining in the presence of L-
NNA (100µM) was investigated further. As previously, these relaxation experiments were 
performed in the presence of guanethidine, atropine and α, β-mATP to remove contractile 
responses. The relaxations obtained in the additional presence of L-NNA (100µM) were not 
affected by either the adenosine receptor (P1) antagonist 8-phenyltheophyline (10µM, n = 5) 
nor the P2-purinoceptor antagonist suramin (100µM, n = 5). The possible contribution to 
relaxation by CO was examined using zinc protoporphyrin IX (ZnPPIX, 10µM), which 
inhibits the synthesis of CO by heme oxygenase, and the contribution to relaxation by H2S 
was examined using a combination of propargylglycine (PAG,1mM) and aminooxyacetic 
acid (AOAA, 30µM) to inhibit H2S synthesis. The inhibition of CO synthesis reduced 
relaxation of the IAS to EFS by 42.0±7.2 and 21.6±3.6% at 5Hz and 10Hz respectively 
(n=10-11, p<0.01, p<0.001) and H2S synthesis (relaxation of the IAS to EFS by 26.7±5.8% 
and 20.9±3.1% at 5Hz and 10Hz respectively) (Figure ‎8.5). The inhibition of guanylate 
cyclase with ODQ reduced relaxations by about 70% and removing H2S with PAG/AOAA 
further reduced relaxation responses producing greater inhibition than ODQ alone. In contrast, 
the effects of CO removal with ZnPPIX were not additive with ODQ, the combination of 
ZnPPIX/ODQ yielding the same reduction in relaxation to EFS as ODQ alone (Figure ‎8.5). 
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Figure ‎8.3 Representative responses of  internal anal sphincter strips to electrical field stimulation in the 
absence (A & C) or presence of the adrenergic neurone blocker guanethidine (10µM, B) or after 
desensitisation of P2 receptors with α, β-mATP (10µM, D) (1g= 100mN). 
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Figure ‎8.4 Relaxation responses to electrical field stimulation in the presence or absence of inhibitors of 
nitric oxide production (L-NNA) and guanylate cyclase (ODQ).  n=5-8. *** P<0.001 compared to control 
values in the absence of inhibitors (one way ANOVA with Tukey post-hoc test). 
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Figure ‎8.5 Relaxation responses to electrical field stimulation in the presence or absence of inhibitors of 
carbon monoxide (ZnPPIX), hydrogen sulphide production (PAG + AOAA) and guanylate cyclase (ODQ).  
n=5-11. *P<0.05, ** P<0.01, and *** P<0.001 compared to control values in the absence of inhibitors (one 
way ANOVA with Tukey post-hoc test).  
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8.5 DISCUSSION 
Which transmitters contribute to internal anal sphincter contraction to 
electrical field stimulation? 
Stimulation of the porcine IAS strips via EFS induced a relaxation response followed by a 
contraction response, and first, we investigated the contractile neurotransmitter responsible 
for the contractile component of the response. 
Electrical field stimulation produced initial contractions of the IAS, which were blocked by 
the α-AR antagonist in mouse (Cobine et al., 2007), sheep (Acheson et al., 2009) and humans 
(Speakman et al., 1990; 1993). Thus, it is known that there is an α-adrenergic excitatory 
component of the response to EFS in the IAS smooth muscle. Acetylcholine may also 
mediate the contractile function of the IAS as shown in the mouse (Duffy et al., 2012) and 
human (Somara et al., 2009). In the bladder, ATP activates P2X, as confirmed by organ bath 
experiments and immunostaining (Lee et al., 2000) and P2X1 knockout mice (Vial & Evans, 
2000).  There appear to be species-dependent differences in the innervation of the IAS as 
shown in the monkey, rabbit or mouse (Cobine et al., 2007). In the monkey, the IAS is 
functionally innervated by sympathetic nerves that contract the IAS via excitatory α-ARs. In 
contrast, no significant motor function was identified for sympathetic nerves in the mouse or 
rabbit IAS (Cobine et al., 2007). To our knowledge, no studies have shown the contractile 
neurotransmitters released by the IAS smooth muscle of the pig in response to EFS even 
though it is the most relevant model for human.  
In this study, guanethidine was used to investigate the role of noradrenaline in the contraction 
of the pig IAS smooth muscle. Guanethidine is a neurotoxin selective for adrenergic nerves 
and abolishes adrenergic nerve transmission completely at a concentration of 10μM (Cobine 
et al., 2007). Guanethidine depressed contractions completely from a large contraction above 
the baseline to one that failed to increase to the baseline level following the initial relaxation 
response, suggesting a prolonged relaxation mechanism. Thus, guanethidine inhibited 
contraction by >100%, which prevented an accurate calculation of the contribution of 
noradrenaline to contraction of the IAS. 
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Although the exact contribution of noradrenaline could not be calculated, it can be concluded 
that noradrenaline is the main excitatory neurotransmitter released in the IAS. The result of 
this study supports previous reports in the literature. Acheson et al., (2009) showed in the 
sheep IAS smooth muscle that noradrenaline acts via post-junctional α-AR to antagonise 
neurogenic relaxations. Also in the monkey, the IAS smooth muscle is functionally 
innervated by sympathetic nerves that contract the muscle via excitatory α-ARs (Cobine et al., 
2007). In human, there is an α-adrenergic excitatory component of the response to EFS of the 
intramural nerves which was blocked by an α-AR inhibitor (Speakman et al., 1990; 1993). In 
previous studies, our group has shown that these adrenergic responses are mediated via the 
α1A/L-AR in the porcine IAS (Mills et al., 2008). 
In the present study desensitisation of P2X receptors also depressed contractile responses to 
EFS indicating an excitatory role for ATP in this tissue. ATP is often released as a co-
transmitter from autonomic nerves and is released with noradrenaline in many tissues 
including the colon (Venkova & Krier, 1993) and vasculature (Racchi et al., 1999). These 
previous studies used the agonist α, β-mATP to desensitise P2X purinergic receptors and it 
was used in the present study to desensitise the purinergic receptors of the IAS. It depressed 
contractile responses to EFS, although the inhibition was significantly less than that produced 
by guanethidine. The decrease in contraction to EFS by α, β-mATP was greater at 5Hz 
stimulation than at 10Hz suggesting that ATP provides a greater contribution to contractions 
at lower frequencies of stimulation. This idea is supported by the report that the inhibition of 
ATP breakdown has a greater potentiating effect on the neurogenic responses of visceral and 
vascular smooth muscle at low frequencies compared to higher frequencies (Khurana et al., 
2004). Thus the present results suggest a role for ATP in the neurogenic contractions of the 
IAS smooth muscle via P2X receptors, at least at lower frequencies of stimulation. 
Surprisingly, previous studies have suggested that ATP is an inhibitory neurotransmitter in 
the IAS (Opazo et al., 2011; Rae & Muir, 1996; Rattan, 2005). ATP mediates inhibitory 
junction potentials and relaxations in the guinea-pig (Rae & Muir, 1996) and human 
(Burleigh et al., 1979) IAS.  Both ATP and adenosine have been shown to produce 
concentration-dependent relaxations of the guinea pig (Crema et al., 1983; Rae & Muir, 
1996), rabbit (Biancani et al., 1985), rat (Nissan et al., 1984; Opazo et al., 2011), mouse 
(Keef et al., 2013) and sheep (Acheson et al., 2009) IAS smooth muscle. The inhibitory 
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junction potentials mediated by ATP was through P2Y1 receptors in the rat (Opazo et al., 
2011), mouse (Keef et al., 2013) and sheep (Acheson et al., 2009) IAS. Thus, P2X receptors 
may mediate contractile responses of the IAS whilst the P2Y receptors may mediate the 
inhibitory junction potentials and relaxations (Acheson et al., 2009; Keef et al., 2013; Opazo 
et al., 2011). In other tissues such as the bladder, ATP can induce smooth muscle relaxation 
via three possible mechanisms (1) directly via P2Y receptors (2) indirectly by inducing NO 
release from epithelial cells and (3) indirectly via P1 receptors after being broken down to 
adenosine (Hernandez et al., 2009; McMurray et al., 1998; Vesela et al., 2012). However, in 
the current studies the mucosa had been removed before tissues were set up and neither the 
P2-receptor antagonist suramin nor the P1-receptor antagonist 8-phenyltheophyline had any 
effect on relaxations, thus ruling out a role for ATP in relaxation responses of this tissue.  
Which transmitters contribute to relaxation to EFS? 
Using EFS and pharmacological agents, several studies have shown that the inhibitory 
neurotransmission in the IAS is mainly via NO in animals (Cobine et al., 2014; Mundey et al., 
2000; Opazo et al., 2011; Ratan & Chakder, 1992) and human (O’Kelly et al., 1993b). 
Neurogenic relaxations of the IAS induced by EFS were significantly reduced in the presence 
of a NOS inhibitor suggesting the major involvement of NO as a neurotransmitter in the 
sheep (Acheson et al., 2009), and mouse (McDonnell et al., 2008). However, other 
neurotransmitters have been associated with the inhibitory junctional potential and relaxation 
of the IAS. For example, EFS produced a residual non-nitrergic, non-adrenergic, apamin-
sensitive relaxation which was inhibited by a P2Y(1) receptor antagonist suggesting that 
purinergic transmission significantly contributes to NOS-independent neural inhibition in the 
sheep (Acheson et al., 2009) and mouse IAS (McDonnell et al., 2008). Thus, we hypothesised 
that the NO might be the major inhibitory neurotransmitter in the porcine IAS. Moreover, 
other neurotransmitters may contribute to the inhibitory junctional potential and relaxation of 
the porcine IAS. To our knowledge, no study has yet analysed the relaxing neurotransmitter 
in the porcine IAS in response to EFS. 
In this study, after inhibition of the contractile responses, relaxation responses to EFS were 
greatly enhanced and the mechanisms involved were investigated in more detail. The NOS 
inhibitor L-NNA (100μM) reduced the relaxation induced by field stimulation by 
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approximately 40-60%, suggesting that NO is responsible for approximately half of the 
relaxation response of the sphincter to nerve stimulation. This result supports literature 
showing that inhibitory junctional potentials and relaxation of the IAS is mainly mediated by 
NO (Mundey et al., 2000; Opazo et al., 2011; Rattan & Chakder, 1992). In the opossum, NO 
caused a concentration-dependent fall in the resting tone of the IAS, and the inhibitory action 
of NO may also be exerted directly on the IAS smooth muscle since it was not modified by 
the neurotoxin tetrodotoxin, which abolished the neurally mediated decrease in the IAS 
tension (Ratan & Chakder, 1992).  In the human IAS, an exogenous donor of NO relaxed 
tissue strips in a concentration-dependent manner and in the presence of atropine and 
guanethidine, transmural field stimulation produced tetrodotoxin-sensitive relaxations, which 
were inhibited in a dose-dependent manner by inhibitors of NOS (O’Kelly et al., 1993b). In 
the mouse, nitrergic relaxation depended on cyclic GMP-dependent protein kinase I and 
inhibitors of NOS abolished responses which confirm an essential role for guanylate cyclase 
in NO-induced relaxation of the IAS (Cobine et al., 2014). Thus, the NO-dependent 
inhibitory junctional potentials and relaxation may be mediated via guanylate cyclase in the 
pig.  
The intramuscular ICC contribute to the electrical events underlying nitrergic neuromuscular 
transmission in the mouse IAS (Duffy et al., 2012) and ICCs have been observed in the IAS 
of mouse (Cobine et al., 2011; 2014; Duffy et al., 2012), monkey (Cobine et al., 2010) and 
humans (Lorenzi et al., 2014; Piotrowska et al., 2003). Thus, ICC may contribute to the NO-
induced inhibitory junctional potential and relaxation in the pig IAS. However, to our 
knowledge, ICC have not been reported in the porcine IAS.  
Other non-nitrergic inhibitory neurotransmitters proposed in the IAS include acetylcholine, 
VIP, CO, and H2S. For example, VIP has been shown to participate in the inhibitory 
neuromuscular transmission of the IAS of rabbit, mice (Biancani et al., 1985; Keef et al., 
2013) and human (Burleigh et al., 1979; Raghavan et al., 2011).  Also, CO directly relaxes 
the mouse IAS (Rattan et al., 2005). Using a heme oxygenase knockout mouse, Xue et al., 
(2000) showed that responses to EFS are nearly abolished in these animals despite persistent 
nNOS expression, whereas exogenous CO restores normal responses, indicating that the NO 
system might not function in the absence of CO generation. Carbon monoxide produced IAS 
relaxation via guanylate cyclase/cGKI activation in the rat IAS smooth muscle (Rattan et al., 
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2004). Also, H2S production has been demonstrated in the gastrointestinal tract, and both 
cystathionine-β-synthethase and cystathionine-γ-lyase have been localised along the rat and 
mouse intestine (Gil et al., 2011; Martin et al., 2010). To our knowledge expression of H₂S 
has not be shown in the IAS. Hydrogen sulphide is endogenously produced in the rat colon 
where it regulates colonic motility (Gil et al., 2011). Cystathionine-β-synthethase and 
cystathionine-γ-lyase enzymes have been detected immunohistochemically in rat colonic 
smooth muscle cells (Hennig & Diener, 2009). Linden et al., (2008) demonstrated the 
expression of messenger RNA and protein localisation for cystathionine-β-synthethase and 
cystathionine-γ-lyase in the colon, brain and liver. Moreover, they showed that expression 
levels of the enzymes vary between tissues and are differentially distributed.  
Previous studies have suggested that mAChR stimulation results in relaxation which appears 
to be mediated via the release of NO in the cat, monkey (Buntzen et al., 1996; Rayner, 1979) 
and human (Burleigh et al., 1979; O'Kelly et al., 1993a). In the present study mAChR 
stimulation with carbachol elicited contractions and no relaxation was observed. Furthermore, 
atropine had no effect on the excitatory responses to EFS, and the inhibitory responses were 
obtained in the presence of atropine, ruling out a contribution from acetylcholine. In other 
tissues, such as blood vessels mAChR stimulation of epithelial cells can release NO to induce 
relaxation (Khurana et al., 2004). Similarly, in the urinary bladder, mAChRs are responsible 
for direct smooth muscle contraction (Hegde, 2006), but they may also stimulate the release 
of NO from urothelial cells (Andersson et al., 2008; Kullmann et al., 2008a). In the present 
study experiments were performed on muscle strips with the mucosa removed to allow 
neurotransmission to be examined without the complication of epithelial influences and no 
relaxation responses were observed. 
To determine the other transmitters contributing to IAS relaxation, the non-nitrergic 
relaxation induced by EFS in the presence of L-NNA was also investigated. Neither the VIP 
receptor antagonist PheLeu-VIP nor the cyclooxygenase inhibitor indomethacin significantly 
reduce the non-nitrergic relaxation ruling out a role for VIP or prostaglandins in relaxation of 
the pig IAS, a conclusion also reached by Acheson et al., (2009) in the sheep IAS.  Also, 
Burleigh et al., (1979) discounted prostaglandin E2 and prostaglandin F2α as possible 
neurotransmitters of the non-cholinergic, non-adrenergic inhibitory nerves in the human IAS. 
However, the guanylate cyclase inhibitor ODQ (Dellabianca et al., 2007) did have a 
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significant effect, reducing relaxations by approximately 70%. Carbon monoxide, which 
mediates smooth muscle relaxation responses via cyclic GMP, is an inhibitory 
neurotransmitter that plays a role in the relaxation of the opossum sphincter (Rattan et al., 
2004). Carbon monoxide caused a concentration-dependent and tetrodotoxin-resistant fall in 
the resting tension of the opossum IAS and caused an increase in the tissue cyclic GMP levels 
(Rattan & Chakder, 1993). Also, the opossum IAS smooth muscle was found to have 
significant levels of basal heme oxygenase activity (Rattan & Chakder, 2000). Using 
immunocytochemistry in the same animal, the enzyme heme oxygenase, which produces CO, 
has been found to be present in the myenteric and submucosal neurones of the IAS as well as 
in the ICCs found in this tissue (Battish et al., 2000). The non-nitrergic relaxation of the pig 
IAS to field stimulation was greatly reduced by ODQ which suggests the involvement of CO 
in the relaxation of this tissue. This was confirmed using ZnPPIX an inhibitor of heme 
oxygenase which is responsible for the synthesis of CO. This inhibitor reduced IAS 
relaxation responses by about 20% and this effect was not additive with ODQ. These data 
suggest that the ODQ sensitive component of the relaxation is composed of predominantly 
NO (50%) but with a smaller contribution from CO (20%). 
In the presence of ODQ, the remaining small, non-NO, non-CO relaxation must be mediated 
via a neurotransmitter that is cyclic GMP-independent. It has been shown that the enzymes 
responsible for the production of H2S are present in the enteric nerves and the myenteric ICC 
(Schicho et al., 2006), both of which can be found in the IAS (Shafik et al., 2006). Inhibition 
of H2S synthesis with PAG/AOAA depressed relaxation responses to EFS and the depression 
was additive to that of ODQ and therefore independent of cyclic GMP indicating a small role 
for H2S in relaxation of the IAS to EFS. 
Conclusion 
 Contractile responses of the IAS to EFS are mediated by noradrenaline and ATP. 
 Relaxation responses of the IAS are mediated mainly by NO, but H2S and CO also 
contribute to the relaxation. 
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9 GENERAL DISCUSSION 
Stress urinary incontinence and faecal incontinence are associated with loss of tone in the 
circular smooth muscle of the urethra and IAS respectively. Thus, stress urinary incontinence 
and faecal incontinence could be treated with pharmacological agents that can increase tone 
of the circular smooth muscle. On the other hand, healing of anal fissures associated with 
hypertonia of the IAS (Farid et al., 2009; Mapel et al., 2014) may be aided by inhibition of 
the smooth muscle contraction. 
Several pharmacological agents have been produced in the past which target the α1A/L-ARs in 
urethral smooth muscle (Blue et al., 2004; Knepper et al., 1995; Obika et al., 1995) and IAS 
(Carapeti et al., 1999a; 2000a;b; Cheetham et al., 2001). However, none of the developed 
agents have progressed through to a clinically useful treatment.  For example the α1A-AR 
agonist Ro 115–1240 was discontinued due to undisclosed reasons. Failure to develop 
clinically useful α1A-AR agonists for stress urinary incontinence and anorectal disorders has 
been linked to cardiovascular adverse effects (Radley et al., 2001; Segev et al., 2015) and 
desensitisation (Akinaga et al., 2013; Perez-Aso et al., 2013). Segev et al., (2015) showed 
that phenylpropanolamine significantly increased systolic, diastolic and mean blood pressure 
following administration in dogs. Moreover, responses of the urethra after continuous 
administration of phenylpropanolamine in dogs decreased, with a recurrence of incontinence 
(Noel et al., 2010: White & Pomeroy, 1989). The development of new pharmacotherapy for 
these conditions will rely on in-depth knowledge of the urethral and anorectal physiology and 
pharmacology. 
This study investigated signalling pathways involved in urethral tissues and neurotransmitters 
associated with normal urethral and anorectal physiology. These tissues contract to α1A- AR 
agonists and our group has shown that contraction of these tissues is mediated by the α1A/L-
AR subtype (Bagot and Chess-Williams, 2006).  
The thesis was based on three hypotheses; 1) the urethral urothelium is a key modulator of 
the urethral tissue function.  2) The Rho kinase pathway is a key modulator of urethral tissue 
basal tone and contractile tone and 3) co-release of a number of neuronally-released 
transmitters modulate the IAS responses. The importance of the neurotransmitters and the 
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Rho kinase pathway in governing the basal tone and contractile responses may highlight them 
as a drug target for treatment of stress urinary incontinence, faecal incontinence and anal 
fissures. 
Effect of age, region and urothelium 
Since age is a risk factor for urinary incontinence (Komesu et al., 2016), in this study, the 
effect of age on the receptor-mediated responses in the proximal urethral of the pig was 
highlighted. Age did not affect the α1-AR-mediated responses of this tissue, which was 
consistent with previous reports in the bladder (Kolta et al., 1984; Lluel et al., 2003) and 
urethra (Bagi et al., 2002), and other studies reporting the finding that age does not affect 
urethral responses (Ahmed et al., 2000; Suzuki et al., 1999). Thus, other contributing factors 
such as changes in the urothelium may be responsible for development of stress urinary 
incontinence.  Similarly, the inhibitory effect of the urothelium/LP in this study was 
comparable between the young and the older porcine tissues. However, age did influence 
agonist-induced desensitisation of the urethra, with desensitisation of subsequent responses to 
phenylephrine in the older porcine urethral tissues being greater (67.2%) than those of the 
younger tissues (33.1%). Whether these findings reflect the human situation remains to be 
verified. However, if so, this may provide some insight for future drug development. 
The region of the urethra responsible for greatest contractility to α1-AR stimulation was also 
investigated. This study showed a regional variation in α1-AR-mediated responses with the 
proximal urethral showing the greatest α1-AR-mediated responses to agonists, which supports 
previous studies using pharmacological techniques (Walters et al., 2006) and 
cystometry/profilometry (Aagaard et al., 2014; Kirby et al., 2015), confirming the pig urethra 
as a suitable model for human.  
To our knowledge, this study shows for the first time that the urethral urothelium has an 
inhibitory effect on the underlying smooth muscle response. The literature has shown this 
previously only in the bladder (Hawthorn et al., 2000; Templeman et al., 2002). In this study, 
we showed that in response to activation of α1A-ARs, β-ARs and mAChRs, the underlying 
smooth muscle responses of the urethra were modulated by the presence of the urothelium/LP. 
In response to α1A-AR activation, NO or prostaglandins did not mediate the inhibitory effect 
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of the urothelium/LP, which supports reports in the bladder (Guan et al., 2014a; Hawthorn et 
al., 2000). In relation to β-AR-mediated response, the urothelium/LP reduced the β-AR-
mediated relaxation to isoprenaline. Although the nature of the urothelial factors in urethra 
was not elucidated in the present study, the findings do highlight that the role of the 
urothelium/LP needs to be considered in the future drug design and development and 
pharmacological treatments. 
Urethral tone 
In this study, we found that basal tone increased in isolated urethral tissues during the 
equilibration period, which fuelled our interest in finding factors and signalling pathways 
responsible for this effect. We found a significant contribution of Ca
2+
 influx via L-type Ca
2+ 
channels to this basal tone, whilst Ca
2+
 release from the sarcoplasmic reticulum does not 
contribute to basal tone. Inhibition of cyclooxygenase also confirmed a role for 
prostaglandins in urethral tone maintenance, and Rho kinase, but not PKC, contributes to 
urethral basal tone.  
In the bladder, prostaglandins are released from the urothelium in response to receptor 
activation (Nile et al., 2010; Nile & Gillespie, 2012), and have been shown to be involved in 
the regulation of detrusor smooth muscle contractility in both rodents and humans (Creed & 
Callahan, 1989; Klausner et al., 2011; Kobayter et al., 2012; McCafferty et al., 2008). 
Prostaglandins increased intracellular Ca
2+
 in guinea-pig bladder detrusor smooth muscle, 
and prostaglandin E2 led to an inhibition of the spontaneous transient Ca
2+
-activated K
+
 (BK) 
currents in guinea pig detrusor, elevation of intracellular Ca
2+
 levels in freshly-isolated 
detrusor smooth muscle cells, and augmentation of detrusor smooth muscle phasic 
contractions (Parajuli et al., 2014).  In mouse detrusor smooth muscle, prostaglandin E2 has 
been reported to cause cell membrane depolarization, to increase Ca
2+
 oscillations, and to 
potentiate phasic contractions in the mouse bladder (Kobayter et al., 2012). A link between 
prostaglandin and Rho kinase has been shown in the bladder using Rho kinase inhibitors and 
cyclooxygenase inhibitors, which affected spontaneous rhythmic contraction amplitude 
following a stretch of bladders of rabbits (Komari et al., 2013). Moreover, Rho kinase 
mediated contractile responses following activation of prostaglandin receptors in the 
mesenteric artery of the rat (Kobayashi et al., 2011) and guinea-pig aorta (Shum et al., 2003). 
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Thus, prostaglandins may induce an increase in intracellular Ca
2+ 
via the L-type Ca
2+
 
channels and activate Rho kinase in the urethra, thereby mediating basal tone. Thus, 
prostaglandins appear to play a role in urethral basal tone, via Rho kinase activation, and this 
pathway may be a potential target for drug development. 
Receptor-mediated responses of urethra 
The greatest α1-AR-mediated responses and potency was recorded for A61603 in the urethra 
tissue, compared to noradrenaline and phenylephrine. This supports reports in the literature, 
with A61603 referred to as a highly potent and selective α1A-AR (Argyle & McGrath, 2000; 
Knepper et al., 1995). The greater potency of A61603 may be due to its ability to more 
potently stimulate phosphoinositide hydrolysis (Knepper et al., 1995).  Thus, 
phosphoinositide hydrolysis could be targeted to pharmacologically achieve greater 
contraction of the urethral smooth muscle. Also, other intracellular pathways activated by 
A61603 may be responsible for this greater potency, and this is discussed later. 
Whilst the α1A-AR has been confirmed as the main receptor mediating urethral contractile 
responses, the underlying signalling pathways are yet known, and were investigated in the 
present study. At maximal contractile responses, sarcoplasmic reticulum-released Ca
2+
 
contributed most to elicit responses to phenylephrine; whilst Ca
2+
 influx via L-type Ca
2+
 
channels were more important for responses to noradrenaline and  PKC contributed greatly to 
A61603-induced contractions. The contribution of Ca
2+
-sensitisation to α1-AR-mediated 
responses was greatest for A61603 for all response levels examined, suggesting a correlation 
between the Ca
2+
-sensitisation pathway and higher potency and efficacy, in addition to the 
greater induction of phosphoinositide hydrolysis reported for A61603 by Knepper et al., 
(1995). Thus this result shows that the greatest response mediated by α1A-AR activation is 
due to activation of Ca
2+
-sensitisation/PKC pathway. 
The phenomenon of desensitisation of α1-AR-mediated responses was investigated in chapter 
6 where the maintenance of urethral tissue tone after α1-AR-activation with a single agonist 
concentration for 120 minutes was described. Tone maintenance was greatest for A61603-
contracted tissues and lowest for noradrenaline-contracted tissues, with tone relaxing below 
the basal level for noradrenaline. A possible explanation for the difference in desensitisation 
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observed is a difference in intracellular signalling pathways and the differing contribution of 
Rho kinase and PKC to Ca
2+
 sensitization, as well as Ca
2+
 sources. Moreover, the urothelium 
and its released factors may modulate the receptor-mediated responses. However, we 
confirmed that the urothelium/LP does not contribute to the maintenance of urethral tone 
following α1-AR activation and tone maintenance was not associated with Rho kinase or 
prostaglandins.  
Alpha1-ARs are known to be subject to phosphorylation and internalisation upon exposure to 
noradrenaline or phenylephrine (Vazquez-Prado et al., 2000). It is well established that α1A-
ARs are less phosphorylated and internalised on exposure to α1-AR-agonists such as 
noradrenaline or phenylephrine than are the α1B-AR and α1D –AR subtypes, at least in Rat-1 
fibroblasts (Vazquez-Prado et al., 2000). Since the α1A-AR mediates contraction of the 
urethra, this may be a therapeutic advantage and means that desensitisation will be less of a 
problem in the urethra. However, the α1A-AR still undergoes desensitisation. In chapter 6, it 
was also shown that prior incubation with an equipotent concentration of α1-AR-agonist such 
as phenylephrine and A61603, but not noradrenaline, desensitises subsequent contractions to 
the physiological agonist noradrenaline. The potency of the α1-AR-agonist was proportional 
to the degree of desensitisation. Such a relationship has previously been reported for β-AR 
agonists, where salmeterol (lower efficacy β-AR agonist) induced less desensitisation than 
formoterol (Moore et al., 2007; January et al., 1997; 1998) or isoprenaline (higher efficacy β-
AR agonists) in HEK-293 cells and human airway smooth muscle cells respectively. 
Furthermore, the low efficacy agonist (salmeterol) caused less β-AR phosphorylation and 
internalisation than the full agonist formoterol (January et al., 1997; 1998). In addition, 
salmeterol showed weak efficacy for recruitment of arrestin (Moore et al., 2007), activation 
of adenylyl cyclase (Tran et al., 2004), and activation of GRK (Tran et al., 2004). Salmeterol 
did not induce significant β2-AR internalisation or degradation in HEK-293 cells and was 
incapable of stimulating the translocation of arrestin (Moore et al., 2007). Thus, A61603 may 
be able to induce greater GRK/PKC activation than phenylephrine, which may be responsible 
for the greatest desensitisation by A61603. 
In this study, looking at the various time points, desensitisation of α1-ARs probably occurred 
within the first 15 minutes. Desensitisation and internalisation of α1-ARs in response to α1A-
AR agonist has been shown in HEK-293 cells to occur at 5 minutes after exposure to agonists 
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(Akinaga et al., 2013). They showed that the α1A-AR agonist induces GRK-dependent α1A-
AR phosphorylation, followed by rapid desensitisation and internalisation (∼40% 
internalisation after 5 minutes of stimulation). Short-term exposure to this agonist could 
induce a long-term desensitisation of the α1A-ARs. 
Why noradrenaline did not induce desensitisation to subsequent contractions of the urethral 
tissues to noradrenaline is not known. However, a similar observation has been reported in 
the rat tail artery and vas deferens, where noradrenaline did not induce desensitisation 
(Akinaga et al., 2013). It is possible that the intracellular signalling pathway activated by 
noradrenaline may differ from those induced by phenylephrine and A61603.  
In chapter 6 it was concluded that desensitisation due to phenylephrine is associated with 
changes in Rho kinase (100%), whilst that due to A61603 is associated with Ca
2+
 influx via 
L-type channels, Rho kinase and PKC. Another intriguing observation was that Rho kinase 
contributed to both phenylephrine and A61603-induced desensitisation. Rho kinase is usually 
associated with contraction and Ca
2+
-sensitisation in the urethra (Teixeira et al., 2007; Walsh 
et al., 2011). This may suggest a feedback mechanism by which Rho kinase prevents chronic 
activation of receptors by regulating receptor desensitisation, as suggested by Cario-
Toumaniantz et al., (2012).  
A post-junctional interaction between the adrenergic and muscarinic system in the urethra 
was investigated in chapter 7. We showed that prior incubation with α1-AR agonists induced 
desensitisation of carbachol-mediated responses, indicating a heterologous form of 
desensitisation involving desensitisation of unrelated receptors. Our results show that prior 
incubation with carbachol induced homologous desensitisation of carbachol-mediated 
responses in urethral smooth muscle (52.5%). However, desensitisation with carbachol of 
noradrenaline-induced responses in smooth muscle alone, but not in intact tissues with 
urothelium/LP, suggests that the urothelium/LP masks desensitisation to carbachol. This 
masking effect of the urothelium/LP on carbachol-induced desensitisation of noradrenaline-
mediated responses was not due to neuronal release of factors or prostaglandins. The clinical 
application of this result is as yet unknown. For noradrenaline, a different form of 
desensitisation was found, with a noradrenaline mediating desensitisation of mAChR-
mediated responses with no significant effect on α1A-AR responses. 
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In conclusion, responses of the urethra are a result of interactions between the urothelium/LP 
and underlying smooth muscle. Moreover, the signalling pathway controlling responses is 
Ca
2+ 
sensitization, as this pathway does not only modulate contraction but also regulates 
receptor activity by mediating desensitisation, which might involve the activation of kinases 
responsible for initiating phosphorylation, internalisation and degradation of receptor. It 
would be myopic or presumptive not to suggest that Rho kinase and PKC may have effects 
on gene expression in the urethra. Presently, the gene expression being modulated by Ca
2+
-
sensitization in the urethra is unknown, but this study foresees modulation of expression of 
proteins associated with contraction and desensitisation. To our knowledge, such interaction 
and the effects of Rho kinase/PKC on protein upregulation has not be shown in the urethra. 
However, in vascular smooth muscle cells of mouse and human, activated PKC and Rho 
kinase induced expression of contractile smooth muscle markers, which could be partially or 
completely repressed by inhibitors of L-type Ca
2+
 channels, PKC, and Rho kinase (Hien et al., 
2016). Activated Rho kinase has also been shown to upregulate other proteins such as 
fibronectin in resident mesangial cells (Peng et al., 2008). Rho kinase inhibition, RhoA 
siRNA and dominant-negative RhoA markedly attenuated fibronectin upregulation thus 
confirming Rho kinase mediated upregulation of fibronectin. Thus, Ca
2+ 
sensitization could 
upregulate proteins involve in smooth muscle contraction and desensitisation of receptor-
mediated responses in the urethra.  
Transmitters contributing to internal anal sphincter responses to electrical 
field stimulation 
In the pig internal anal sphincter, guanethidine (10 µM)  which is a neurotoxin selective for 
adrenergic nerves and abolishes adrenergic nerve transmission (Cobine et al., 2007), 
depressed contractions completely from a large contraction above the baseline to one that 
failed to increase to the baseline level following the initial relaxation response, suggesting a 
prolonged relaxation mechanism. Thus guanethidine inhibited contraction by > 100%. 
Moreover, desensitisation of P2X receptors also depressed responses to EFS indicating an 
excitatory neurotransmitter role for ATP in this tissue. The reduction of contraction to EFS 
by α,β-mATP was greater at 5 Hz stimulation than at 10Hz suggesting that ATP provides a 
greater contribution to contractions at lower frequencies of stimulation.  This idea is 
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supported by the report that the inhibition of ATP breakdown has a greater potentiating effect 
on the neurogenic responses of visceral and vascular smooth muscle at low frequencies 
compared to higher frequencies (Khurana et al., 2004). Thus the present results suggest a role 
for ATP in the neurogenic contractions of the anal sphincter via P2X receptors, at least at 
lower frequencies of stimulation.  
After inhibition of the contractile responses, relaxation responses to EFS were greatly 
enhanced. The NOS inhibitor L-NNA (100 μM) reduced the relaxation induced by field 
stimulation by approximately 40-60%, suggesting that NO is responsible for approximately 
half of the relaxation response of the sphincter to nerve stimulation.  The non-nitrergic 
relaxation induced by EFS in the presence of Phe-Leu-VIP or indomethacin, inhibitors of VIP 
receptor and cyclooxygenase respectively, was not affected thus ruling out VIP or 
cyclooxygenase product in relaxation of the pig IAS, a conclusion also reached by Acheson 
et al., (2009) in the sheep IAS. However, the relaxation responses were reduced by 
approximately 70% in the presence of guanylate cyclase inhibitor ODQ. ODQ did have a 
significant effect which suggests the involvement of CO in the relaxation of this tissue since 
CO mediates smooth muscle relaxation responses via cGMP as shown in the opossum 
sphincter (Rattan et al., 2004). Using immunocytochemistry in the same animal, the enzyme 
heme oxygenase, which produces CO, has been found to be present in the myenteric and 
submucosal neurones of the IAS as well as in the interstitial cells of Cajal found in this tissue 
(Battish et al., 2000). ZnPPIX, an inhibitor of heme oxygenase reduced IAS relaxation 
responses by about 20% and this effect was not additive with ODQ. These data suggest that 
the ODQ sensitive component of the relaxation is composed of predominantly NO (50%) but 
with a smaller contribution from CO (20%).   
In the presence of ODQ, the remaining small, non-NO, and non-CO relaxation was found to 
be H2S, mediating its effect via the cGMP-independent pathway. Inhibition of H2S synthesis 
with PAG/AOAA depressed relaxation responses to EFS and the depression was additive to 
that of ODQ and therefore via a cGMP-independent pathway, thus indicating a small role for 
H2S in relaxation of the porcine IAS to EFS.   
The neurogenic contraction of the porcine IAS can be attributed mainly to noradrenaline and 
ATP, with both neurotransmitters probably released from adrenergic nerves. 
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Neurotransmission, at least in the pig IAS, does not appear to involve ACh. The relaxations 
of the IAS to EFS appears to be mediated by the simultaneous release of all three 
gasotransmitters with relative contributions nitric oxide > carbon monoxide >H2S. Non-
adrenergic non-cholinergic relaxations of the IAS have been shown in other species, with an 
involvement of nitric oxide, carbon monoxide, and possibly H2S. However, this study 
demonstrates the simultaneous release of all three gasoneurotransmitters, and their combined 
contributions, in mediating relaxation of the porcine IAS.  All these transmitters represent 
possible targets for drug development where enhancing sphincter tone may aid the treatment 
of faecal incontinence or reductions in IAS tone can aid healing of anal fissures. 
Final Conclusion 
Ca
2+
 sensitization is a significant pathway involved in the mediation of urethral contractile 
responses and basal tone, as well as modulation of α1A-adrenoceptor desensitisation. Thus, 
the Ca
2+
 sensitization pathway stands out as a prospective drug target for the development of 
new treatments for lower urinary tract symptoms such as stress urinary incontinence.  
Further research is necessary to determine the relative contribution of the Ca
2+
 sensitization 
pathways in incontinence, as there is the possibility of a switch towards a reduced Ca
2+
 
sensitization mechanism, which could underlie stress urinary incontinence and faecal 
incontinence, whilst greater Ca
2+
 sensitization may underlie hypertonia of the internal anal 
sphincter and inhibition of healing of anal fissures. 
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11 APPENDIX 
11.1 DRUGS, CONCENTRATIONS AND SOLVENTS 
Drugs Concentration used Mwt Solvent 
8-phenylltheophylline 10μM 256.3 dH20 
AOA 30μM 109.3 dH20 
Atropine 1μM 676.8 dH20 
Calphostin C 1μM 790.76  70%  ethanol 
Corticosterone 1μM 346.47 70% ethanol 
Cyclopiazonic acid 10μM 336.4 DMSO 
Desipramine 1μM 302.84 dH20 
EDTA 3mM 292.24 dH20 
Fasudil 10μM 327.83 dH20 
Guanethidine 10μM 296.39 dH20 
Indomethacin 10μM 357.8 70%  ethanol 
KCl 60mM 74.55 dH20 
L-NNA 100μM 219.20 dH20 
Nifedipine 100nM-1μM 346.34 DMSO 
ODQ 10μM 187.16 70% ethanol 
PAG 1mM 113.11 70% ethanol 
Phe-Leu-VIP 100nM 3342.24 dH20 
Propranolol 1μM 295.8 dH20 
Suramin 100μM 1519.23 dH20 
TTX 1μM 319.27 dH20 
Y27632 10μM 320.26 dH20 
ZnPPIX 10μM 644.05 70% ethanol 
αβ-mATP 10μM 505.2 dH20 
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Abstract 
Background/Aims 
The internal anal sphincter (IAS) plays an important role in maintaining continence and a 
number of neurotransmitters are known to regulate IAS tone. The aim of this study was to 
determine the relative importance of the neurotransmitters involved in the relaxant and 
contractile responses of the porcine IAS. 
Methods 
Responses of isolated strips of IAS to electrical field stimulation (EFS) were obtained in the 
absence and presence of inhibitors of neurotransmitter systems. 
Results 
Contractile responses of the sphincter to EFS were unaffected by the muscarinic receptor 
antagonist atropine (1 μM), but were almost completely abolished by the adrenergic neuron 
blocker guanethidine (10 μM). Contractile responses were also reduced (by 45% at 5 Hz, P < 
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0.01) following desensitisation of purinergic receptors with α,β-methylene-ATP (10 μM). In 
the presence of guanethidine, atropine, and α,β-methylene-ATP, the remaining relaxatory 
responses to EFS were examined. These responses were not altered by the cyclooxygenase 
inhibitor indomethacin (5 μM), the vasoactive intestinal polypeptide receptor antagonist [D-p-
Cl-Phe
6
,Leu
17
]-vasoactive intestinal peptide (PheLeu-VIP; 100 nM), or the purinoceptor 
antagonists 8-phenyltheophyline (P1 receptors) or suramin (P2 receptors). However 
relaxation responses were reduced by Nω-nitro-L-arginine (L-NNA; 100 µM) an inhibitor of 
nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 µM) an inhibitor of 
carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 µM) and 
aminooxyacetic acid (30 µM), inhibitors of hydrogen sulphide synthesis (15-20% reduction). 
Conclusions 
Stimulation of IAS efferent nerves releases excitatory and inhibitory neurotransmitters: 
noradrenaline is the predominant contractile transmitter with a smaller component from ATP, 
whilst 3 gases mediate relaxation responses to EFS, with the combined contributions being 
nitric oxide > carbon monoxide > hydrogen sulfide. 
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Introduction 
The internal anal sphincter (IAS) plays an important role in maintaining continence 
contributing up to 85% of resting anal tension
1
 and thus it is a potential target for the drug 
treatment of both anal fissures and fecal incontinence. Fecal incontinence is the uncontrolled 
passing of fecal material and drugs that increase IAS contractile tone may potentially aid 
continence, whilst drugs that reduce anal pressure may increase anal blood flow and thereby 
aid healing of anal fissures.  
Both the autonomic and enteric nervous systems influence tone of the IAS. It has been 
shown histologically that the main autonomic input to the IAS originates in the inferior rectal 
branches of the pelvic plexus with both tyrosine hydroxylase staining fibers (sympathetic) 
and nitric oxide (NO) staining fibers (presumed to be parasympathetic) innervating the 
tissue.
2,3
 In functional experiments, noradrenaline is the only neurotransmitter that has been 
identified as eliciting an excitatory response in the sphincter,
4
 while inhibitory roles have 
been suggested for NO, carbon monoxide (CO) and vasoactive intestinal polypeptide (VIP). 
It has also been suggested that acetylcholine and adenosine 5’-triphosphate (ATP) may also 
have roles in the relaxation of the sphincter.
4
 Although these neurotransmitters are usually 
excitatory rather than inhibitory, O’Kelly et al5 has suggested that stimulation of muscarinic 
receptors by acetylcholine causes the release of NO and a subsequent relaxation of the IAS.  
Previous studies using electrical field stimulation of the IAS have demonstrated the 
involvement of several neurotransmitters in responses of this tissue. However most of these 
studies have focused on the relaxation of the sphincter and its relevance to anal fissures, 
whereas the contractile component, which could be a target for drug development relevant to 
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fecal incontinence, has yet to be explored to the same extent.  It is known that NO plays an 
important role as an inhibitory neurotransmitter in the IAS
6
 and that noradrenaline acting via 
α1-adrenoceptors is responsible for contracting the sphincter.
7-9
 Furthermore, the relative 
contribution of each neurotransmitter system to the responses of the IAS has not been 
established. The aim of the present study was to identify the neurotransmitters released 
during electrical field stimulation (EFS) of the porcine IAS and determine the relative 
contributions of each transmitter to the functional responses. 
Materials and Methods 
Female pig internal anal sphincter (IAS) muscle samples were obtained from a local 
abattoir. The tissues were immediately placed in Krebs-bicarbonate solution (composition in 
mmol/L: NaCl 118.4, NaHCO3 24.9, KCl 4.7, CaCl2 1.9, MgSO4 1.15, KH2PO4 1.15, and 
glucose 11.7) at 4ºC. The mucosa and submucosa were removed and the circular muscle of 
the sphincter, approximately 2.5 cm from the anal opening, was cut into strips (15 × 3 mm). 
The muscle strips were set up in EZ-Bath tissue baths (GlobalTown Microtechnology, 
Sarasota, FL, USA) containing Krebs-bicarbonate solution at 37ºC and gassed with 5% CO2 
in oxygen. The muscle strips were attached to isometric force transducers connected to a 
MacLab recording system (AD Instruments Ltd. Bella Vista, NSW Australia ) and the 
developed tension measured using “CHART” software. Tissues were mounted under 1g 
resting tension and allowed to equilibrate for 30 minutes during which time they were washed 
with fresh Krebs-bicarbonate solution every 15 minutes.  
At this point the smooth muscle strips were electrically stimulated (40 V and 1 
millisecond pulse-width) delivered as 5 second trains every 100 seconds, at a frequency of 5 
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Hz and then 10 Hz. Initial responses for each frequency were obtained followed by responses 
in the presence of one of the following drugs which interfere with neurotransmission: Nω-
nitro-L-arginine (L-NNA, 100 μM), a NO synthase inhibitor; guanethidine (10 μM), a 
neurotoxin selective for adrenergic nerves; atropine (1 μM), a muscarinic receptor antagonist; 
α,β-methylene ATP (10 μM), a potent purinergic agonist that desensitises P2X receptors; 
indomethacin (5 μM), an inhibitor of cyclooxygenase 1 and 2; 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ, 10 μM), an inhibitor of guanylate cyclase; and [D-p-Cl-
Phe
6
,Leu
17
]-vasoactive intestinal peptide (PheLeu-VIP, 100 nM), a vasoactive intestinal 
polypeptide receptor antagonist.  Responses to EFS were repeated in the presence of one of 
the above antagonists/inhibitors which were equilibrated with tissues for 30 minutes before 
obtaining responses to EFS. Only one drug was tested on each tissue and control experiments 
confirmed responses to EFS did not change over this short time period. 
1. Drugs Used 
Atropine (sulfate salt monohydrate), α,β-methylene ATP (lithium salt), L-NNA (Nω-
nitro-L-arginine), indomethacin (1-[p-Chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic 
acid), PAG (propargylglycine), AOAA (aminooxyacetic acid), methylene blue hydrate, 
guanethidine (1-[2-Guanidinoethyl]octahydroazocine monosulfate), PheLeu-VIP ([D-p-Cl-
Phe
6
,Leu
17
]-vasoactive intestinal peptide), ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one), and tetrodotoxin were obtained from Sigma (Illinois, USA). ZnPPIX (zinc 
protoporphyrin IX) was obtained from Tocris Bioscience (Ellisville, MO, USA). 
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2. Statistical Methods 
Changes in developed tension were represented as a percentage of the tone of the 
tissue at the time of stimulation and the mean ± SEM were calculated. The responses seen in 
the presence of antagonist/inhibitor were compared to the initial responses in the absence of 
antagonist/inhibitor from the same tissue strip using Student’s paired t test. A P-value of ≤ 
0.05 was considered statistically significant.   
Results 
1. Influence of Frequency of Stimulation 
The IAS responded to EFS with a relaxation followed by a frequency-dependent 
contraction (Fig. 1). At 5 Hz stimulation the relaxation was fast, lasting 2-3 seconds, followed 
by a contraction of approximately 10 seconds duration. Stimulation at a frequency of 10 Hz 
produced a contraction that was greatly increased in both size and duration and appeared to 
mask the relaxation. The responses were neurogenic in origin, and the neurotoxin 
tetrodotoxin (3 µM, n = 8) completely abolished contractions at both frequencies. Relaxations 
to EFS were also greatly reduced by tetrodotoxin (3 µM) by 78.3 ± 2.8% and 91.5 ± 1.6% at 
5 Hz and 10 Hz respectively (both P < 0.001). 
2. Contractile Responses to Electrical Field Stimulation 
Removal of the adrenergic component with guanethidine (10 µM) almost completely 
abolished the contraction of the IAS to electrical stimulation at both frequencies (Table 1). 
Guanethidine reduced the large contractile responses at 5Hz and 10 Hz to contractions that 
were superimposed on large relaxations and only recovered to 30% and 20% below the 
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baseline respectively (Fig. 1). Contractile responses were also reduced following 
desensitization of P2X receptors with the potent purinoceptor agonist α,β-mATP (10 µM). 
Responses at both frequencies were reduced, but the effect was only statistically significant 
for responses at 5 Hz (Table 1). In contrast, responses to electrical stimulation were not 
significantly altered by the presence of the muscarinic receptor antagonist atropine (1 µM; 
Table 1).   
3. Relaxation Responses of the Internal Anal Sphincter 
The relaxation responses obtained after removing adrenergic, cholinergic, and 
purinergic contractions with guanethidine (10 µM), atropine (1 µM), and a,β-mATP (10 µM) 
were also examined in greater detail to determine which inhibitory neurotransmitters were 
involved and their relative importance.  Under these conditions, relaxations to EFS were 
unaffected by the cyclooxygenase (COX1/2) inhibitor indomethacin (5 µM, n = 14) or the 
VIP-receptor antagonist PheLeu-VIP (100 nM, n = 6; Table 2).  However, in the presence of 
the NO synthase inhibitor L-NNA (100 µM), relaxations were reduced by 40-50% (Fig. 2). 
Inhibition of guanylate cyclase with ODQ (10 µM) produced a greater inhibition than L-NNA, 
but a combined L-NNA/ODQ treatment did not produce a greater inhibition of relaxation 
than ODQ alone (Fig. 2). 
In another series of experiments the non-nitrergic relaxation remaining in the presence 
of L-NNA (100 µM) was investigated further. As previously, these relaxation experiments 
were performed in the presence of guanethidine (10 µM), atropine (1 µM), and a,β-mATP 
(10 µM) to remove contractile responses. The relaxations obtained in the additional presence 
of L-NNA (100 µM) were not affected by either the adenosine receptor (P1) antagonist 8-
phenyltheophyline (10 µM, n = 5) nor the P2-purinoceptor antagonist suramin (100 µM, n = 
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5; data not shown). The possible contribution to relaxation by CO was examined using zinc 
protoporphyrin IX (ZnPPIX, 10 µM), which inhibits the synthesis of CO by heme oxygenase, 
and the contribution to relaxation by hydrogen sulfide (H2S) was examined using a 
combination of propargylglycine (PAG, 1 mM) and aminooxyacetic acid (AOAA, 30 µM) to 
inhibit H2S synthesis. The inhibition of either CO synthesis or H2S synthesis reduced 
relaxation to EFS by 20-40% and 15-20% respectively (Fig. 3). The inhibition of guanylate 
cyclase with ODQ reduced relaxations by about 70% and removing H2S with PAG/AOAA 
further reduced relaxation responses producing greater inhibition than ODQ alone. In contrast 
the effects of CO removal with ZnPPIX were not additive with ODQ, the combination of 
ZnPPIX/ODQ yielding the same reduction in relaxation to EFS as ODQ alone (Fig. 3). 
Discussion 
In the pig anal sphincter, guanethidine was used to investigate the role of 
noradrenaline in the contraction of this tissue. Guanethidine is a neurotoxin selective for 
adrenergic nerves and abolishes adrenergic nerve transmission completely at a concentration 
of 10μM.10 Guanethidine (10 µM) depressed contractions completely from a large contraction 
above the baseline to one that failed to increase to the baseline level following the initial 
relaxation response, suggesting a prolonged relaxation mechanism. Thus guanethidine 
inhibited contraction by > 100%, which prevented an accurate calculation of the contribution 
of noradrenaline to contraction of the IAS. Although the exact contribution of noradrenaline 
could not be calculated it can be concluded that noradrenaline is the main excitatory 
neurotransmitter released in the IAS.  In previous studies we have shown that these 
adrenergic responses are mediated via α1A/L-adrenoceptors.
 9
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In the present study desensitisation of P2X receptors also depressed responses to EFS 
indicating an excitatory neurotransmitter role for ATP in this tissue. ATP is often released as 
a co-transmitter from autonomic nerves and is released with noradrenaline in many tissues 
including the colon
11
 and vasculature.
12
 These previous studies used the agonist α,β-mATP to 
desensitize P2X purinergic receptors. This potent agonist was used to desensitise the 
purinergic receptors of the IAS and it depressed contractile responses to EFS, but the 
inhibition was significantly less than that produced by guanethidine. The reduction of 
contraction to EFS by α,β-mATP was greater at 5 Hz stimulation than at 10Hz suggesting 
that ATP provides a greater contribution to contractions at lower frequencies of stimulation.  
This idea is supported by the report that the inhibition of ATP breakdown has a greater 
potentiating effect on the neurogenic responses of visceral and vascular smooth muscle at low 
frequencies compared to higher frequencies (Kennedy et al., 1996). Thus the present results 
suggest a role for ATP in the neurogenic contractions of the anal sphincter via P2X receptors, 
at least at lower frequencies of stimulation. Surprisingly, a previous study suggested that ATP 
is an inhibitory neurotransmitter in the IAS.
4
 In other tissues such as the bladder, ATP is able 
to induce smooth muscle relaxation via 3 possible mechanisms: (1) directly via P2Y receptors, 
(2) indirectly by inducing NO release from epithelial cells, and (3) indirectly via P1 receptors 
after being broken down to adenosine.
13
 However, in the current studies the mucosa had been 
removed before tissues were set up and neither the P2-receptor antagonist suramin, nor the 
P1-receptor antagonist 8-phenyltheophyline had any effect on relaxations, thus ruling out a 
role for ATP in relaxation responses of this tissue. 
After inhibition of the contractile responses, relaxation responses to EFS were greatly 
enhanced and the mechanisms involved were investigated in more detail. The NO synthase 
inhibitor L-NNA (100 μM) reduced the relaxation induced by field stimulation by 
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approximately 40-60%, suggesting that NO is responsible for approximately half of the 
relaxation response of the sphincter to nerve stimulation.  Also a number of other non-
nitrergic inhibitory neurotransmitters have been proposed for the IAS including acetylcholine, 
VIP, CO, and H2S. Previous studies have suggested that muscarinic receptor stimulation 
results in relaxation which appears to be mediated via the release of NO.
5
 In the present study 
muscarinic receptor stimulation with carbachol elicited contractions and no relaxation was 
observed. Furthermore, atropine had no effect on the excitatory responses to EFS and the 
inhibitory responses were obtained in the presence of atropine, ruling out a contribution from 
acetylcholine. In other tissues, such as blood vessels muscarinic receptor stimulation of 
epithelial cells can release NO to induce relaxation.
14
 Similarly, in the urinary bladder, 
muscarinic receptors are responsible for direct smooth muscle contraction,
15
 but they may 
also stimulate release of NO from urothelial cells.
16-18
 In the present study experiments were 
performed on muscle strips with the mucosa removed to allow neurotransmission to be 
examined without the complication of epithelial influences and no  relaxation responses were 
observed. 
The non-nitrergic relaxation induced by EFS in the presence of L-NNA was also 
investigated.  Neither the VIP receptor antagonist PheLeu-VIP nor the COX1/2 inhibitor 
indomethacin significantly reduce the non-nitrergic relaxation ruling out a role for VIP or 
prostaglandins in relaxation of the pig IAS, a conclusion also reached by Acheson et al
19
 in 
the sheep IAS. However the guanylate cyclase inhibitor ODQ
20
 did have a significant effect, 
reducing relaxations by approximately 70%. CO, which mediates smooth muscle relaxation 
responses via cGMP, is an inhibitory neurotransmitter that plays a role in the relaxation of the 
opossum sphincter.
21
 Using immunocytochemistry in the same animal, the enzyme heme 
oxygenase (HO), which produces CO, has been found to be present in the myenteric and 
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submucosal neurones of the IAS as well as in the interstitial cells of Cajal (ICCs) found in 
this tissue.
22
 The non-nitrergic relaxation of the pig IAS to field stimulation was greatly 
reduced by ODQ which suggests the involvement of CO in the relaxation of this tissue.  This 
was confirmed using ZnPPIX an inhibitor of HO which is responsible for the synthesis of CO. 
This inhibitor reduced IAS relaxation responses by about 20% and this effect was not 
additive with ODQ. These data suggest that the ODQ sensitive component of the relaxation is 
composed of predominantly NO (50%) but with a smaller contribution from CO (20%).   
In the presence ODQ, the remaining small, non-NO, and non-CO relaxation must be 
mediated via a neurotransmitter that is cGMP independent. It has been shown that the 
enzymes responsible for the production of H2S are present in the enteric nerves and the 
myenteric ICCs,
23
 both of which can be found in the IAS.
8,24,25
 Inhibition of H2S synthesis 
with PAG/AOAA depressed relaxation responses to EFS and the depression was additive to 
that of ODQ and therefore independent of cGMP indicating a small role for H2S in relaxation 
of the IAS to EFS.   
In conclusion the neurogenic contraction of the porcine IAS can be attributed mainly 
to noradrenaline and ATP, with both neurotransmitters probably released from adrenergic 
nerves. The smooth muscle of the IAS responds with contraction to muscarinic receptor 
stimulation, but neurotransmission, at least in the pig IAS, does not appear to involve 
acetylcholine. The relaxations of the IAS to electrical stimulation appears to be mediated by 
the simultaneous release of all three gaseous transmitters with relative contributions NO > 
CO > H2S. Non-adrenergic non-cholinergic relaxations of the IAS have been shown in other 
species, with an involvement of NO, CO, and possibly H2S. However, this study 
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demonstrates the simultaneous release of all three gaseous neurotransmitters, and their 
combined contributions, in mediating relaxation of the porcine IAS. 
 All these transmitters represent possible targets for drug development where enhancing 
sphincter tone may aid the treatment of fecal incontinence or reductions in IAS tone can aid 
healing of anal fissures. 
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Figure legends 
 
Figure 1. Experimental traces of internal anal sphincter (IAS) responses to electrical field 
stimulation in the absence and presence of the adrenergic neurone blocker guanethidine (10 
µM; A, B) and after desensitisation of P2X receptors with α,β-mATP (10 µM; C, D). Both 
drugs reduced contractions and enhanced the relaxations. In the presence of guanethidine, 
contractions remained below the initial baseline tone.  
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Figure 2. Effects of L-NNA  (100 µM) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ; 10 µM), alone and in combination, on the relaxations induced by electrical field 
stimulation after removal of the adrenergic, cholinergic and purinergic contractile 
components of responses. Relaxations to electrical field stimulation (EFS) were examined at 
(A) 5 Hz and (B) 10 Hz. Mean responses (± SEM, n = 5-10) are expressed as a percentage of 
the control pre-drug response to EFS. **P < 0.01, ***P < 0.001 compared to control values 
in the absence of inhibitors. 
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Figure 3. Effects of inhibitors of carbon monoxide (CO) and hydrogen sulfide synthesis on 
relaxations of the internal anal sphincter. Relaxations to electrical field stimulation (EFS) 
were examined after removal of the contractile components of responses with guanethidine 
(10 µM), atropine (1 µM), and a,β-mATP (10 µM). Responses were obtained at (A) 5 Hz and 
(B) 10 Hz in the absence and presence of the HO inhibitor zinc protoporphyrin IX (Znppix, 
10 µM) and/or inhibitors of the hydrogen sulfide (H2S) synthesizing enzymes, 
propargylglycine (PAG, 1 mM), and aminooxyacetic acid (AOAA, 30 µM). Mean responses 
(± SEM, n = 5-10) are expressed as a percentage of the control pre-drug response to EFS.  
**P < 0.01, ***P < 0.001 compared to control values in the absence of inhibitors of CO and 
H2S synthesis. 
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Tables 
Table 1. Mean (± SEM) Contractions Developed by Yissues in Response to Electrical Field 
Stimulation.  
NSD, no significant difference. 
Responses are expressed as a percentage of the initial resting tone immediately prior to 
stimulation. In the presence of guanethidine only relaxation responses were observed 
(indicated by negative values). 
a
P < 0.01 compared to responses in the absence of drug.   
 
 
 
 Contraction (% of baseline) Inhibition (% of 
control response) Drug/frequency Absence of Drug Presence of Drug 
Guanethidine (10 
μM) n = 7 
5 Hz 21.5 ± 10.3 -9.0 ± 4.8
a
 130.7 ± 47.2 
10 Hz 55.7 ± 17.3 -8.2 ± 9.1
a
 120.0 ± 18.7 
 
Atropine 
(1 μM), n = 8 
5 Hz 36.1 ± 6.5 24.7 ± 7.9 NSD 
10 HZ 46.4 ± 9.2 35.3 ± 7.3 NSD 
 
α,β-mATP (10 μM), 
n = 4 
5 Hz 33.4 ± 9.6 19.2 ± 7.4
a
 44.8 ± 5.0 
10 Hz 42.5 ± 6.1 35.0 ± 7.8 NSD 
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Table 2. Relaxation Responses Expressed As a Percentage of the Tone of the Tissue at the 
Time of Stimulation.  
 Relaxation (% of baseline) Inhibition (% of 
control response) Drug/frequency Absence of drug Presence of drug 
L-NNA 
(100 μM), n = 26 
5 Hz 56.6 ± 2.2 32.8 ± 2.8
a
 42.6 ± 4.2 
10 Hz 45.4 ± 3.7 19.9 ± 2.9
a
 60.4 ± 4.9 
 
Indomethacin 
(5 µM), n = 14 
5 Hz 44.9 ± 3.7 44.0 ± 3.6 1.7 ± 2.7 
10 Hz 47.1 ± 4.2 45.4 ± 4.5 4.5 ± 4.1 
 
PheLeu-VIP 
(100 nM), n = 6 
5 Hz 50.0 ± 4.2 48.0 ± 3.9 3.5 ± 2.5 
10 Hz 52.6 ± 4.9 52.0 ± 4.3 0.7 ± 2.2 
PheLeu-VIP, [D-p-Cl-Phe
6
,Leu
17
]-vasoactive intestinal peptide. 
An increase in inhibition indicates that the drug did not reduce the relaxation, rather it 
increased the relaxation. 
a
P < 0.001 compared to response in the absence of drug. 
 
 
 
 
